<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="hwp">nnn</journal-id><journal-id journal-id-type="publisher-id">NEURIMMINFL</journal-id><journal-title-group><journal-title>Neurology&#xAE; Neuroimmunology &amp; Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">2332-7812</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40020214</article-id><article-id pub-id-type="pmc">11908449</article-id>
<article-id pub-id-type="publisher-id">NXI-2024-100036</article-id><article-id pub-id-type="doi">10.1212/NXI.0000000000200377</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>120</subject><subject>41</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis</article-title><subtitle>An Association With Disease Progression</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5761-5178</contrib-id><name><surname>Klistorner</surname><given-names>Samuel</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2156-8864</contrib-id><name><surname>Barnett</surname><given-names>Michael</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Parratt</surname><given-names>John D.E.</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Yiannikas</surname><given-names>Con</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chenyu</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Dongang</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Shieh</surname><given-names>Andy</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0361-6399</contrib-id><name><surname>Klistorner</surname><given-names>Alexander</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">*</xref></contrib><aff id="aff1"><label>1</label>Save Sight Institute, Sydney Medical School, University of Sydney, <country>Australia</country>;</aff><aff id="aff2"><label>2</label>Brain and Mind Centre, University of Sydney, <country>Australia</country>;</aff><aff id="aff3"><label>3</label>Sydney Neuroimaging Analysis Centre, Camperdown, <country>Australia</country>;</aff><aff id="aff4"><label>4</label>Royal Prince Alfred Hospital, Sydney, <country>Australia</country>; and</aff><aff id="aff5"><label>5</label>Royal North Shore Hospital, Sydney, <country>Australia</country>.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Mr. Klistorner <email>samuel.klistorner@sydney.edu.au</email></corresp><fn fn-type="other"><p>The Article Processing Charge was funded by the authors.</p></fn><fn fn-type="other"><p>Previously published at medRxiv (doi: 10.1101/2023.12.29.23300651).</p></fn><fn fn-type="other"><p>Submitted and externally peer reviewed. The handling editor was Associate Editor Friedemann Paul, MD.</p></fn><fn fn-type="equal" id="fn1"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>2</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>12</volume><issue>3</issue><elocation-id>e200377</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>03</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#xA9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NXI-2024-100036.pdf"/><abstract><sec><title>Background and Objectives</title><p>In this study, we examine the long-term changes in chronic lesion tissue (CLT) among patients with relapsing-remitting MS (RRMS), focusing on its impact on clinical and radiologic disease progression indicators.</p></sec><sec><title>Methods</title><p>The study involved 72 patients with multiple sclerosis with at least a 5-year follow-up. Annual assessments used 3D fluid-attenuated inversion recovery (FLAIR), precontrast and postcontrast 3D T1, and diffusion-weighted MRI. Lesion segmentation was conducted using iQ-MS software, while brain structures were segmented using AssemblyNet. Volumetric changes in CLT were tracked using a novel custom-designed pipeline that estimates longitudinal volumetric changes in CLT using serial MRI data.</p></sec><sec><title>Results</title><p>Throughout the follow-up period, the volume of CLT in the entire cohort increased continuously and steadily, averaging 7.75% &#xB1; 8.2% or 315 &#xB1; 465 mm&#xB3; per year. Patients with expanding CLT experienced significantly faster brain atrophy, affecting both white and gray matter, particularly in the brain's central area. Expanded CLT was also associated with higher and worsening Expanded Disability Status Scale (EDSS) scores, in contrast to the stable CLT group, where EDSS remained unchanged. Sample size calculation for a clinical trial investigating the effect of treatment on slow expansion of chronic lesions demonstrated that a relatively small cohort of patients with RRMS, ranging from 24 to 69 patients per arm, would be required.</p></sec><sec><title>Discussion</title><p>This study demonstrates that, over a period of up to 5 years, patient-specific enlargement of CLT, when present, progresses at a constant rate and significantly influences brain atrophy and disease progression. In addition, the study underscores CLT as a promising biomarker for RRMS progression and suggests the feasibility of smaller, targeted clinical trials to evaluate treatments aimed at reducing chronic lesion expansion.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Multiple sclerosis (MS) is a complex CNS disorder characterized by heterogeneous inflammatory and variably destructive white and gray matter lesions. Smoldering inflammation at the rim of a subset of chronic lesions not only signifies the progressive nature of MS but also plays an instrumental role in disability worsening in patients with established disease.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> This low-grade inflammatory activity and demyelination manifests as a slow expansion of chronic lesion tissue (CLT) over time, eventually leading to axonal transection, neurodegeneration, and disability progression.<sup><xref rid="R2" ref-type="bibr">2-6</xref></sup></p>
      <p>Despite the critical role that CLT enlargement plays in the MS narrative, some aspects of its longitudinal evolution are not fully understood. Questions regarding its duration, consistency over time, or patient-specific nature have not been adequately examined. Addressing these knowledge gaps could significantly improve our understanding of smoldering lesions, help refine patient selection criteria for future clinical trials of agents that putatively target chronic inflammation, and ultimately enhance our ability to treat and manage MS.</p>
      <p>Furthermore, while the enlargement of chronic lesions is increasingly used as a biomarker of smoldering inflammation&#x2014;referred to as slowly expanding lesions (SELs) or CLT expansion&#x2014;there remains considerable variation in the methodologies used to identify and monitor this enlargement. These variations pertain to how chronic expanding lesions are selected, specifically the threshold used to assign lesions to the slowly expanding lesion (SEL) category. In addition, variations are observed in how these lesions are measured, whether by counting the number of expanding lesions or by measuring the volume of chronic lesion enlargement. For example, the widely used Jacobean transformation&#x2013;based technique is useful for identifying and counting individual lesions that meet specific classification criteria for SELs. However, this method is not suitable for the longitudinal volumetric estimation of lesion expansion. On the other hand, assessing chronic lesion expansion through manual lesion segmentation, although likely more accurate in estimating the actual volume of expanded lesional tissue, is time-consuming and may have limited applicability in large cohorts or serial studies.</p>
      <p>Therefore, we introduced a novel pipeline that estimates longitudinal volumetric changes in CLT using serial MRI data, integrating artificial intelligence (AI)-assisted lesion segmentation. This algorithm extends our previous technique, transitioning from a two-time point approach to a multiple-point analysis. The method not only accounts for lesion shift due to brain atrophy between time points but also identifies and removes new and confluent lesions (which are presumably driven by conventional, acute inflammatory demyelination) that emerge during the study. It eliminates the need for chronic lesion classification.</p>
      <p>In this study, we applied this novel approach to investigate the long-term evolution of CLT and its impact on clinical and radiologic measures of disease progression. We conducted this analysis using data obtained from a cohort of patients with relapsing-remitting MS (RRMS) who were followed for up to 7 years. In addition, we developed an imaging protocol and calculated the required sample size for trials involving therapeutic agents aimed at reducing smoldering inflammation.</p>
    </sec>
    <sec sec-type="methods" id="s2">
      <title>Methods</title>
      <sec id="s2-1">
        <title>Subjects</title>
        <p>Consecutive patients with established RRMS who were enrolled in the Mechanism of Axonal Degeneration in MS study (National MS Society grant, G-1508-05946) and had reached 5 years of follow-up were included. MS was diagnosed according to the revised McDonald 2010 criteria. Patients underwent annual MRI scans and clinical assessment. Patients were relapse free, and their therapy did not change for at least 6 months prior to enrollment. In addition, no steroid treatment was administered for at least 6 months prior to enrollment.</p>
        <p>Disease-modifying therapy (DMT) was categorized into moderate-efficacy (injectables, such as interferon and glatiramer acetate, teriflunomide, dimethyl-fumarate, and fingolimod) and high-efficacy (natalizumab, alemtuzumab, and ocrelizumab) drugs.<sup><xref rid="R7" ref-type="bibr">7,8</xref></sup></p>
      </sec>
      <sec id="s2-2">
        <title>Standard Protocol Approvals, Registrations, and Patient Consents</title>
        <p>This study was approved by University of Sydney Human Research Ethics Committees and followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants.</p>
      </sec>
      <sec id="s2-3">
        <title>MRI Protocol and Analysis</title>
        <p>MRI was performed using a 3T GE Discovery MR750 scanner (GE Medical Systems, Milwaukee, WI). The following MRI sequences were acquired: precontrast and postcontrast (gadolinium) sagittal 3D T1, fluid-attenuated inversion recovery (FLAIR) CUBE, and diffusion-weighted MRI. Specific acquisition parameters and MRI image processing are presented in the eMethods.</p>
      </sec>
      <sec id="s2-4">
        <title>Lesion Analysis</title>
        <p>White matter lesions were segmented for each time point of each patient using an AI-based lesion segmentation algorithm (iQ-Solutions MS Report, hereafter referred to as iQ-MS software suite, Sydney Neuroimaging Analysis Centre, Sydney, Australia).<sup><xref rid="R9" ref-type="bibr">9</xref></sup> The segmentation was based on unprocessed T1 and FLAIR images. These lesion masks were then transformed to anterior commissure-posterior commissure line (ACPC) space using linear registration. Only lesions larger than 50 mm&#xB3; were included in the analysis.</p>
        <p>To verify the AI algorithm's ability to correctly identify and measure the longitudinal change of chronic lesion volume, manual lesion segmentation was also implemented in a subgroup of 25 patients, and the gradients of lesion expansion between automated and manual modes were compared. Manual segmentation was performed using JIM 9 software (Xinapse Systems, Essex, United Kingdom) on coregistered T2 FLAIR images.</p>
        <p>Because of continuous change in the morphology and intensity of individual lesions, which may result in the merging or separation of adjacent lesions on sequential scans, it is frequently impractical to track a single lesion over long-term serial MRIs.<sup><xref rid="R10" ref-type="bibr">10,11</xref></sup> Therefore, in this study, our focus was not on tracking the expansion of individual lesions but rather on estimating the total change in CLT volume at the patient level. To achieve this, we made significant modifications to the previously described lesion estimation and analysis pipeline.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p>
        <p>The main building block of the new pipeline was a pair of coregistered lesion masks from 2 sequential MRIs. The pipeline implemented the following steps.<list list-type="order"><list-item><p>Matching of individual lesions between MRIs obtained at time points 1 and 2.</p></list-item><list-item><p>Classification of all time point 2 lesions without a matched counterpart at time point 1 as new free-standing lesions, and excluding them from CLT analysis.</p></list-item><list-item><p>Spatial adjustment of remained lesions to account for brain atrophy through affine coregistration between the 2 masks, as described in 5.</p></list-item><list-item><p>Identification of new confluent lesions at time point 2 using a custom-designed algorithm that detects nonspherical areas of lesion expansion, and excluding them from CLT analysis, as described in 5.</p></list-item><list-item><p>Classification of gadolinium-enhancing lesions and lesions undergoing substantial shrinking as acute or post-acute lesions, respectively; and excluding them from CLT analysis (detailed description provided in Supplementary material, eMethods).</p></list-item><list-item><p>Calculation of the volume of all remaining lesion tissue for time points 1 and 2, with the difference specified as annual CLT change.</p></list-item></list></p>
        <p>Subsequently, a cumulative volume (or %-wise increase) of CLT expansion for each patient is computed by summing consecutive annual expansion values. This process constructs a patient-wise profile of CLT evolution (<xref rid="F1" ref-type="fig">Figure 1</xref>) based on the line of best fit.</p>
        <fig position="float" id="F1">
          <label>Figure 1</label>
          <caption>
            <title>Calculation of Cumulative Volume of Chronic Lesion Tissue (CLT) Expansion</title>
            <p>CLT change is measured between 2 sequential scans for each annual interval independently. The cumulative profile is calculated by summing consecutive annual CLT expansion values.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f1" position="float"/>
        </fig>
        <p>The degree of tissue damage within chronic lesions was assessed by mean diffusivity (MD), as previously proposed.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Progressive annual tissue damage in chronic lesions was measured as an increase of MD in the lesion core between 2 consecutive MRI scans. A cumulative MD change for each patient was computed by adding the annual change.</p>
      </sec>
      <sec id="s2-5">
        <title>Volumetric Brain Analysis and EDSS</title>
        <p>Volumetric measurements were performed using AssemblyNet, an AI brain segmentation tool,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> on T1 images coregistered to ACPC space. The following volume metrics were analyzed: total brain, white matter, gray matter, cortex and deep gray matter, and ventricular volume.<sup><xref rid="R14" ref-type="bibr">14,15</xref></sup> The cerebellum was excluded from the white and gray matter analysis. All volumes were scaled based on MNI template registration to account for head size variability.</p>
        <p>For longitudinal analysis, to minimize the impact of variation in segmentation, we used a volume change per year metric as a measure of atrophy. This involved calculating the annual change for each MRI measure and generating a line of best fit to represent the annual changes. The gradient of the line of best fit represented the annual volume change.</p>
        <p>Expanded Disability Status Scale (EDSS) was assessed at baseline and 5-year follow-up. Disability worsening for each patient was calculated as EDSS difference between follow-up and baseline time points. No adjustment for the severity of EDSS at baseline was performed.</p>
      </sec>
      <sec id="s2-6">
        <title>Statistics</title>
        <p>Continuous variables were assessed for normality using the Shapiro-Wilk normality test and described as mean and SD or median with interquartile range (IQR), as appropriate. &#x3C7;<sup>2</sup> statistic was used for sex comparison between groups. For EDSS and DMT at baseline, independent-samples Mann-Whitney <italic toggle="yes">U</italic> test was used to evaluate significant difference between groups.</p>
        <p>For longitudinal changes of EDSS, related-samples Wilcoxon signed rank test was used. Significance of age and disease duration between groups was determined using Student <italic toggle="yes">t</italic> test.</p>
        <p>Analysis of covariance was used to determine the significant difference of brain atrophy measures between groups. Baseline analysis was controlled for age and sex, while longitudinal analysis was also controlled for new lesion volume. <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p>
      </sec>
      <sec sec-type="data-availability" id="s2-7">
        <title>Data Availability</title>
        <p>Anonymized data not published within this article will be made available by request from any qualified investigator.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <p>Seventy-two consecutive patients with MS enrolled in a longitudinal study of MS, who reached 5 years of follow-up, were included in this study. Of these, 17 patients reached 7 years and were included in the subanalysis. Four patients were removed from the analysis because of the very low (&lt;100 mm<sup>3</sup>) volume of chronic lesions. Demographic data are presented in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Demographic Data</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">5-y follow-up group</td>
              <td rowspan="1" colspan="1">7-y follow-up group</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Total no. of patients</td>
              <td rowspan="1" colspan="1">68</td>
              <td rowspan="1" colspan="1">17</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Age at enrollment, y</td>
              <td rowspan="1" colspan="1">40.9 (&#xB1;9.8)</td>
              <td rowspan="1" colspan="1">42.4 (&#xB1;9.9)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sex</td>
              <td rowspan="1" colspan="1">25M 43F</td>
              <td rowspan="1" colspan="1">7M 10F</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Disease duration at enrollment, y</td>
              <td rowspan="1" colspan="1">6.2 (&#xB1;5.1)</td>
              <td rowspan="1" colspan="1">5.6 (&#xB1;3.4)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EDSS at baseline, median (range)</td>
              <td rowspan="1" colspan="1">1 (0&#x2013;3)</td>
              <td rowspan="1" colspan="1">1 (0&#x2013;3)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lesion volume at baseline, mm<sup>3</sup></td>
              <td rowspan="1" colspan="1">4,193 (&#xB1;4,669)</td>
              <td rowspan="1" colspan="1">4,039.0 (&#xB1;4,025.8)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>Abbreviation: EDSS = Expanded Disability Status Scale.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>At the start of the study, 23 patients were on moderate-efficacy treatment (injectables, such as interferon and glatiramer acetate, teriflunomide, dimethyl-fumarate, and fingolimod),<sup><xref rid="R8" ref-type="bibr">8</xref></sup> while 38 patients were receiving high-efficacy drugs (fingolimod, natalizumab, alemtuzumab, or ocrelizumab) and 7 patients were treatment free. During the study, 20 patients changed the treatment category. By the end of the study period, 12 patients remained on moderate-efficacy treatment and 48 patients were on high-efficacy drugs. The decision to modify the therapy was taken by the treating physician based on a combination of clinical and radiologic activity. Overall, 48 patients did not change the treatment category during the study.</p>
      <sec id="s3-1">
        <title>Manual vs iQ-MS Segmentation Comparison</title>
        <p>We observed a strong correlation between the gradients of CLT expansion obtained using manual and AI-based lesion segmentation (<italic toggle="yes">r</italic> = 0.96, <italic toggle="yes">p</italic> &lt; 0.001, eFigure 1). This confirms the suitability of iQ-MS AI-based segmentation for our data set and in-house pipeline, and we proceeded with iQ-MS segmentation for the remaining analysis.</p>
      </sec>
      <sec id="s3-2">
        <title>Progressive CLT Enlargement Is Constant During 7 Years of Follow-Up</title>
        <p>Upon visual examination of CLT enlargement profiles of individual patients, it became evident that subject-wise expansion is a relatively constant process, typically well approximated by a linear function. Examples of CLT expansion profiles in individual patients are presented in <xref rid="F2" ref-type="fig">Figure 2</xref>. To quantitatively assess the predictive accuracy of the linear model, we calculated the root mean square error (RMSE) of cumulative CLT enlargement rate for each patient. The RMSE values were generally low for most of the patients, with only 3 exceptions (median 4.9, IQR 3.3&#x2013;7.1), supporting our observation (eFigure 2). Therefore, the magnitude of CLT expansion for individual patients can be effectively described by the gradient of the linear function representing the degree of absolute (volumetric) or relative (%) CLT expansion per year. This gradient was subsequently used in further analyses, including comparisons with clinical and radiologic data.</p>
        <fig position="float" id="F2">
          <label>Figure 2</label>
          <caption>
            <title>Examples of CLT Expansion Profiles in Individual Patients</title>
            <p>Dotted lines represent best linear fit. CLT = chronic lesion tissue.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f2" position="float"/>
        </fig>
        <p>The average cumulative rate (%) of CLT enlargement in the entire cohort is depicted in <xref rid="F3" ref-type="fig">Figure 3A</xref>. The figure illustrates a continuous and steady increase in the relative volume of CLT throughout the entire follow-up period, with an average annual increase of 7.75% &#xB1; 8.2%. A similar linear trend was observed in the subgroup of patients who reached 84 months of follow-up (<xref rid="F3" ref-type="fig">Figure 3B</xref>).</p>
        <fig position="float" id="F3">
          <label>Figure 3</label>
          <caption>
            <title>CLT Expansion During Follow-Up</title>
            <p>CLT expansion in the entire patient cohort (A and C) and subgroup of patients who reached 7-year follow-up. Upper row represents a relative (%-wise) change of chronic lesion volume; lower row shows the absolute values of CLT change. CLT = chronic lesion tissue.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f3" position="float"/>
        </fig>
        <p>In cases with small baseline lesion volumes, however, even a significant percentage of CLT expansion is unlikely to result in clinically or radiologically meaningful progression. Therefore, to estimate the impact of CLT enlargement on disease evolution, we also examined the annual increase in the absolute volume of expansion. This analysis revealed a similar linear growth pattern for the entire cohort over 60 months of follow-up, with an average expansion of approximately 315 &#xB1; 465 mm&#xB3; per year (<xref rid="F3" ref-type="fig">Figure 3C</xref>). The linear nature of CLT increase was also observed in a smaller subgroup of patients who reached 7 years of follow-up (<xref rid="F3" ref-type="fig">Figure 3D</xref>).</p>
        <p>The gradient of CLT volume enlargement exhibited significant variation among individual patients, spanning from around zero to over 2,400 mm<sup>2</sup>/year. Ranking patients based on the values of patient-wise CLT gradients revealed a continuum of expansion magnitudes between individual patients, making it difficult to conclusively dichotomize them into CLT expanding or CLT stable groups (<xref rid="F4" ref-type="fig">Figure 4A</xref>).</p>
        <fig position="float" id="F4">
          <label>Figure 4</label>
          <caption>
            <title>Ranking of CLT Gradients</title>
            <p>A. Orange circles indicate the top CLT quartile (definitely enlarging group), and blue circles indicate the bottom quartile (definitely stable group). B. Annual CLT expansion in definitely enlarging (DE, orange) and definitely stable (DS, blue) groups. CLT = chronic lesion tissue.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f4" position="float"/>
        </fig>
        <p>Therefore, to examine the effect of chronic lesion activity on clinical and radiologic measures of disease progression, we divided patients into quartiles based on the extent of CLT enlargement. The top quartile (orange) and bottom quartile (blue) were designated as categorical extremes, forming the definitely expanding (DE) group and definitely stable (DS) group, respectively, with each group consisting of 17 patients. The effectiveness of this separation is evident in <xref rid="F4" ref-type="fig">Figure 4B</xref>, which illustrates a substantial and consistent annual increase in CLT volume in the DE group (970 &#xB1; 115 mm3), while showing no visible volume change in the DS group. Significant differences in the degree of CLT enlargement between the 2 groups became evident by the second year of follow-up (year 1: <italic toggle="yes">p</italic> = 0.19, year 2: <italic toggle="yes">p</italic> &lt; 0.001, <italic toggle="yes">t</italic> test), a critical factor in calculating the sample size for a potential clinical trial (see below).</p>
      </sec>
      <sec id="s3-3">
        <title>CLT Volume Enlargement Is Associated With Loss of (Predominantly Central) Brain Tissue and EDSS Progression</title>
        <p>There was a statistically significant difference between the groups in terms of age (<italic toggle="yes">p</italic> = 0.04, <italic toggle="yes">t</italic> test) and gender composition (3 times more male patients in the expanding group, <italic toggle="yes">p</italic> = 0.03, Fisher exact test). Consequently, all presented brain volumetric comparisons at baseline were adjusted for age and sex.</p>
        <p>Baseline brain volumetric data for the DE and DS groups are presented in <xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="F5" ref-type="fig">Figure 5</xref> (left column). Group-based analysis revealed a significantly smaller total brain volume, as well as white, gray, and deep gray matter volume, in the DE group compared with the DS group. By contrast, total and cortical gray matter did not differ between the 2 groups. The difference in ventricle volumes demonstrated borderline significance. The composition of DMT was not significantly different between the 2 groups at baseline (<italic toggle="yes">p</italic> = 0.074, Mann-Whitney <italic toggle="yes">U</italic> test).</p>
        <table-wrap position="float" id="T2">
          <label>Table 2</label>
          <caption>
            <p>Comparison of Baseline and Longitudinal Brain Volumetric Data Between the DE and DS Groups</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">DS group</td>
                <td rowspan="1" colspan="1">DE group</td>
                <td rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Age (mean &#xB1; SD), y</td>
                <td rowspan="1" colspan="1">37.2 (9.0)</td>
                <td rowspan="1" colspan="1">43.8 (8.5)</td>
                <td rowspan="1" colspan="1">0.041<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sex (M/F)</td>
                <td rowspan="1" colspan="1">3M 14F</td>
                <td rowspan="1" colspan="1">10M 7F</td>
                <td rowspan="1" colspan="1">0.034<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Disease duration (mean &#xB1; SD), y</td>
                <td rowspan="1" colspan="1">5.12 (5.23)</td>
                <td rowspan="1" colspan="1">6.8 (4.44)</td>
                <td rowspan="1" colspan="1">0.34</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Baseline values</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">1,604,625 (49,266)</td>
                <td rowspan="1" colspan="1">1,546,852 (29,757)</td>
                <td rowspan="1" colspan="1">0.007<sup>b</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ventricle volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">26,791 (12,141)</td>
                <td rowspan="1" colspan="1">35,460 (9,788)</td>
                <td rowspan="1" colspan="1">0.052</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;White matter volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">547,659 (29,803)</td>
                <td rowspan="1" colspan="1">510,816 (31,108)</td>
                <td rowspan="1" colspan="1">0.016<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Gray matter volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">851,416 (18,364)</td>
                <td rowspan="1" colspan="1">833,709 (11,937)</td>
                <td rowspan="1" colspan="1">0.005<sup>b</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Deep gray matter volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">59,086 (3,035)</td>
                <td rowspan="1" colspan="1">54,757 (3,376)</td>
                <td rowspan="1" colspan="1">0.011<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Cortex volume (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">792,329 (17,771)</td>
                <td rowspan="1" colspan="1">778,951 (13,108)</td>
                <td rowspan="1" colspan="1">0.021<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;EDSS (median [interquartile range])</td>
                <td rowspan="1" colspan="1">0 (0&#x2013;1)</td>
                <td rowspan="1" colspan="1">2 (0&#x2013;3)</td>
                <td rowspan="1" colspan="1">0.016<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Lesion MD &#x3BC;<sup>2</sup>/sec</td>
                <td rowspan="1" colspan="1">1.08 (0.09)</td>
                <td rowspan="1" colspan="1">1.20 (0.09)</td>
                <td rowspan="1" colspan="1">0.034<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Longitudinal change</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">&#x2212;485 (4,090)</td>
                <td rowspan="1" colspan="1">&#x2212;6,391 (3,611)</td>
                <td rowspan="1" colspan="1">0.002<sup>b</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ventricle volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">312 (356)</td>
                <td rowspan="1" colspan="1">1,343 (798)</td>
                <td rowspan="1" colspan="1">&lt;0.001<sup>c</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;White matter volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">&#x2212;919 (2,215)</td>
                <td rowspan="1" colspan="1">&#x2212;4,588 (2,844)</td>
                <td rowspan="1" colspan="1">0.004<sup>b</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Gray matter volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">228 (2,201)</td>
                <td rowspan="1" colspan="1">&#x2212;1,483 (1,503)</td>
                <td rowspan="1" colspan="1">0.055</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Deep gray matter volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">&#x2212;41 (232)</td>
                <td rowspan="1" colspan="1">&#x2212;432 (358)</td>
                <td rowspan="1" colspan="1">0.013<sup>a</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Cortex volume change (mean &#xB1; SD), mm<sup>3</sup></td>
                <td rowspan="1" colspan="1">270 (2093)</td>
                <td rowspan="1" colspan="1">&#x2212;1,051 (1,384)</td>
                <td rowspan="1" colspan="1">0.096</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;EDSS change (median [interquartile range])</td>
                <td rowspan="1" colspan="1">0 (0&#x2013;0)</td>
                <td rowspan="1" colspan="1">0.25 (0&#x2013;2.5)</td>
                <td rowspan="1" colspan="1">0.002<sup>b</sup></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Lesion MD change &#x3BC;<sup>2</sup>/sec</td>
                <td rowspan="1" colspan="1">0.034 (0.039)</td>
                <td rowspan="1" colspan="1">0.115 (0.054)</td>
                <td rowspan="1" colspan="1">&lt;0.001<sup>c</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Abbreviations: DE = definitely expanding; DS = definitely stable; EDSS = Expanded Disability Status Scale; MD = mean diffusivity.</p>
            </fn>
            <fn>
              <p><sup>a</sup> &lt;0.05.</p>
            </fn>
            <fn>
              <p><sup>b</sup> &lt;0.01.</p>
            </fn>
            <fn>
              <p><sup>c</sup> &lt;0.001.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" id="F5">
          <label>Figure 5</label>
          <caption>
            <title>Comparison of Brain Volumetrics and Lesion MD Between DE (Orange Graphs) and DS (Blue Graphs) Groups at Baseline (Left Column) and During Follow-Up (Right Column)</title>
            <p>Change of brain volumetrics during follow-up is estimated using annual gradients. Asterisks indicate statistical significance (* &lt;0.05, ** &lt;0.01, *** &lt;0.001). Dashed line&#x2014;median value, dotted line&#x2014;quartiles. A and B&#x2014;Whole brain. C and D&#x2014;White matter. E and F&#x2014;Gray matter. G and H&#x2014;Deep gray matter. I and J&#x2014;Lateral ventricles. K and L&#x2014;lesion mean diffusivity. DE = definitely expanding ; DS = definitely stable ; MD = mean diffusivity.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f5" position="float"/>
        </fig>
        <p>Longitudinal analysis of brain volumetrics revealed significantly faster brain atrophy in the DE group compared with the DS group during the follow-up period (<xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="F5" ref-type="fig">Figure 5B</xref>). This atrophy affected both total white and total gray matter (<xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="F5" ref-type="fig">Figure 5D</xref>) and was particularly pronounced in the central area of the brain, affecting both central brain atrophy (measured by an increase in ventricular size, <xref rid="F5" ref-type="fig">Figure 5J</xref>) and deep gray matter atrophy (<xref rid="F5" ref-type="fig">Figure 5H</xref>). However, no significant difference was observed between the groups in terms of cortical thinning. To account for the significantly larger volume of new lesions in the DE group on brain volumetrics, this parameter was included as a covariate in the longitudinal model.</p>
        <p>In the DE group, CLT exhibited a significantly higher MD value at baseline compared with the DS group (1.20 &#xB1; 0.09 and 1.08 &#xB1; 0.09, respectively, <italic toggle="yes">p</italic> = 0.034). In addition, the average increase in MD was significantly larger in the DE group than in the DS group (0.115 &#xB1; 0.054 and 0.034 &#xB1; 0.039, respectively, <italic toggle="yes">p</italic> &lt; 0.001). This indicates more extensive tissue damage within chronic lesions in the expanding group, both at baseline and during follow-up.</p>
        <p>EDSS was also significantly higher in the DE group at baseline (mean 1.6, median 2 vs mean 0.43, median 0, <italic toggle="yes">p</italic> = 0.016, independent-samples Mann-Whitney <italic toggle="yes">U</italic> test). During the study, EDSS significantly worsened in the expanding group (mean 1.6 vs 2.5, <italic toggle="yes">p</italic> = 0.04, related-samples Wilcoxon signed rank test), while remaining unchanged in the stable group (mean 0.43 vs 0.40), resulting in a more significant EDSS difference at the last follow-up (mean 2.5, median 2.5 vs mean 0.40 median 0, <italic toggle="yes">p</italic> = 0.002, independent-samples Mann-Whitney <italic toggle="yes">U</italic> test).</p>
      </sec>
      <sec id="s3-4">
        <title>Sample Size Calculation for a Clinical Trial Investigating the Effect of Treatment on Slow Expansion of Chronic Lesions</title>
        <p>The sample size calculation for a hypothetical placebo-controlled clinical trial to test the effect of treatment on slow expansion of chronic lesions was based on the average annual slope and SD of CLT expansion in the DE patient group. Considering that a reduction in the lesion expansion slope can occur only in cases with an established pattern of lesion expansion, it is essential to select only patients who have demonstrated a significant gradient of CLT expansion before the trial period. Based on our analysis, such patients constituted 1 quartile of the entire cohort.</p>
        <p>To identify patients suitable for such a trial, the MRI results from the 2 years preceding enrollment must be examined (because, as shown above, 2 years is sufficient to observe a statistical difference between 2 groups). A minimum of 3 pretrial MRI time points are needed to determine the expanding gradient. Because only a quarter of RRMS population with the highest expansion gradient is suitable for the study, MRI scans of a group 4 times the size of the required enrollment number must be screened. Inclusion also should be limited to patients whose pretrial scans were acquired with the same scanner/imaging protocol.</p>
        <p>Reduction of the CLT enlargement slope in the treated group is indicative of the potential treatment effect, as shown in <xref rid="F6" ref-type="fig">Figure 6A</xref> (arrow). <xref rid="F6" ref-type="fig">Figure 6B</xref> illustrates the sample size (per arm) required for a treatment effect ranging between 20% and 60%, which is best described by power function. For instance, to demonstrate a statistically significant (two-sided, <italic toggle="yes">p</italic> &lt; 0.05) reduction in lesion expansion with 80% power for a treatment effect of 50%, it would be sufficient to enroll 24 patients per arm. Consequently, to meet this requirement, the pretrial MRIs of (24 &#xD7; 4 &#xD7; 2 arms) = 192 patients would need to be screened.</p>
        <fig position="float" id="F6">
          <label>Figure 6</label>
          <caption>
            <title>Schematic Representation of Sample Size Estimation</title>
            <p>A. Pretrial trajectory of CLT expansion is estimated based on images acquired 2 years prior to enrollment (screening period). Arrow indicates potential treatment effect. B. Sample size (per arm) at various treatment effect levels. CLT = chronic lesion tissue.</p>
          </caption>
          <graphic xlink:href="NXI-2024-100036f6" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <p>This study investigated the long-term longitudinal dynamics of CLT expansion in patients with RRMS and its association with clinical and radiologic biomarkers of disease progression. We established that the slow expansion of CLT is a patient-specific process, which, when present, remains remarkably constant, at least within the time frame of this study (i.e., up to 7 years). Furthermore, we demonstrated a significant link between CLT expansion and clinically and radiologically measured disease progression. In addition, we observed a relatively higher prevalence of this expansion among male patients.</p>
      <p>These observations were facilitated by the relatively long study duration and the consistent use of the same imaging hardware and protocol. There are also 2 novel technical aspects of the study that enabled us to accurately estimate subtle longitudinal change in CLT volume, namely the utilization of AI-based lesion segmentation and the development of a new serial MRI pipeline for the identification and measurement of the volume of the slowly expanding component of chronic lesions.</p>
      <p>The potential benefits of AI, such as speed and consistency, make it an attractive alternative to manual or semiautomated techniques for estimating lesion expansion. Given that applying AI for this purpose is a novel approach, we sought to validate its accuracy and reliability. To achieve this, we compared the CLT expansion gradient between AI-based lesion segmentation and a thorough manual segmentation method in a representative patient's subgroup. This comparison revealed a very high level of concordance, confirming the suitability of using the AI-based technique for the entire cohort.</p>
      <p>The new pipeline offers several advantages for studying the expansion of CLT over multiple serial MRIs. In contrast to our previous methodology,<sup><xref rid="R5" ref-type="bibr">5,16,17</xref></sup> which was limited to the investigation of chronic lesion expansion between 2 MRI scans obtained several years apart, the current pipeline permits the incorporation of an extended series of MRI examinations.</p>
      <p>The dynamic nature of this pipeline also enables the integration of newly occurring lesions into the analysis throughout the study. Owing to its pair-based annual approach for analyzing expansion between 2 consecutive scans, newly formed lesions can be accurately identified at each annual interval. These lesions are then included in the analysis from the time they become chronic, namely at least 12 months after their initial appearance.</p>
      <p>Furthermore, because our analysis measures the entire volume of CLT expansion for the patient, rather than the number of expanding lesions, it eliminates the need for chronic lesion classification into slowly expanding lesions (SELs) and non&#x2013;slowly expanding lesions categories. Rather than requiring individual lesions to demonstrate constant enlargement across at least 3 time points based on heuristically determined thresholds, the current algorithm directly estimates the actual volume of expanded CLT in individual patients. However, we still applied a criterion for asphericity of lesion growth to identify (and exclude) new confluent lesion activity.</p>
      <p>Using the new pipeline, we established that, on average, the volume of CLT in our cohort of patients with RRMS increased gradually and constantly over the course of the study, i.e., up to 7 years. We also demonstrated that the gradient of CLT expansion varied widely between patients, ranging from stable to extensively expanding.</p>
      <p>However, in individual patients, the annual change of CLT enlargement remained relatively constant throughout the entire observation period (as supported by low RMSE values). This is also confirmed by the group analysis of patients who do experience CLT expansion, which demonstrates the remarkable stability of the expansion gradient. Therefore, CLT expansion appears to be a patient-specific process; expansion of chronic lesions does occur (to varying degrees) in some patients, while others do not experience it.</p>
      <p>Currently, the reason why some patients experience the growth of CLT while others do not remains unclear. Numerous studies have linked smoldering inflammation at the rim of chronic lesions (and lesion expansion as its imaging equivalent) with microglial activation and low-grade inflammatory demyelination.<sup><xref rid="R3" ref-type="bibr">3,18-20</xref></sup> In light of this, recent publications suggesting that patient-specific factors are more likely to influence microglial response and oligodendroglial pathology in MS are particularly noteworthy. These individual factors (or more likely combination of factors<sup><xref rid="R21" ref-type="bibr">21</xref></sup>) may include age, sex, disease stage, lesion location, genetic heterogeneity, susceptibility to de/remyelination, gut dysbiosis, vitamin D levels, or even lifestyle or comorbid conditions.<sup><xref rid="R3" ref-type="bibr">3,16,22-24</xref></sup></p>
      <p>Indeed, our findings show a higher prevalence of male patients in the DE group, which might be a contributing factor to the CLT expansion and associated neurodegeneration (as suggested by our earlier studies<sup><xref rid="R12" ref-type="bibr">12,25</xref></sup>). This aligns with the well-known observation that male patients with MS tend to have a more aggressive disease course.<sup><xref rid="R26" ref-type="bibr">26,27</xref></sup> Patients in the DE group were also significantly older compared with the stable group, and their immune response may, therefore, be shifted from an adaptive to a compartmentalized, innate phenotype (and associated microglial activation).<sup><xref rid="R27" ref-type="bibr">27</xref></sup></p>
      <p>Another patient-specific factor that may potentially influence the severity of smoldering inflammation at the lesion rim, and consequently, the rate of CLT expansion, is the type of treatment a patient receives. It has recently been demonstrated that natalizumab treatment decreases the prevalence of slowly expanding lesions in patients with secondary progressive MS (SPMS)<sup><xref rid="R28" ref-type="bibr">28,29</xref></sup> likely by reducing microglial activation at the rim of chronic lesions.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Ocrelizumab was also reported to reduce the relative volume of slowly expanding lesions (but, surprisingly, not other measures of smoldering inflammation, such as a decrease in T1 signal intensity and an increase in T1 hypointense lesion load) in patients with primary progressive MS (PPMS).<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Although our sample size is too small to reliably estimate the potential effect of individual therapies, the proportion of patients receiving first and second-line therapies at baseline was similar between the DE and DS groups. Furthermore, most (10/17) of the patients in the DE group were already on high-efficacy therapy at the beginning of the study. In addition, a further 5 patients in this group changed treatment from a less effective option to a more effective one without any visible effect on the gradient of CLT expansion. However, this question remains open, and the potential effect of therapy would be best assessed in the context of a treatment-specific clinical trial.</p>
      <p>Expansion of CLT is linked to brain tissue loss, predominantly in the central regions, and to disease progression. Ranking patients based on the degree of CLT expansion did not reveal a clear dichotomy. Instead, it demonstrated a continuum of change in the expansion gradient.</p>
      <p>Hence, to examine the effect of CLT expansion on disease progression, we used quartiles rather than choosing a threshold to classify patients into expanding and nonexpanding categories. This approach identified the most expanding and most stable cases, designating them as the DE and DS groups, respectively.</p>
      <p>The longitudinal examination of CLT expansion in these groups affirmed the static nature of chronic lesion volume in the DS group and the ongoing growth in the DE group. Notably, in the DE group, the average cumulative rate of lesion expansion displayed a remarkably consistent linear trend across multiple time points during the entire follow-up. Throughout this period, there was no evidence of either regression or acceleration of the annual expansion gradient.</p>
      <p>Group analysis revealed a more prominent loss of brain tissue at baseline in the DE group. More importantly, there was also a faster rate of brain atrophy during the follow-up period in patients with definite expansion, compared with those in the stable group. The difference between the 2 groups remained highly significant after adjusting the analysis for the volume of new lesions, indicating a considerable contribution of CLT expansion to brain tissue loss. It is understood that smoldering inflammatory demyelination at the rim of chronic lesions leads to the transection of axons traversing the inflamed lesion rim. This results in both retrograde and anterograde (Wallerian) axonal degeneration, negatively affecting anatomically interconnected brain areas and contributing to accelerated brain atrophy.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p>
      <p>This trend was particularly evident in the central brain, as indicated by ventricular enlargement and deep gray matter atrophy, which showed the largest statistical differences between the groups. By contrast, the difference in longitudinal changes of cortical volume between the groups was nonsignificant. The prevalence of central brain tissue damage in patients with chronic lesion expansion is likely linked to the predominantly periventricular location of the expanding lesions.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p>
      <p>The link between lesion expansion and axonal damage is further strengthened by the more significant rarefaction of CLT (as measured by an increase in MD inside the lesions<sup><xref rid="R5" ref-type="bibr">5</xref></sup>) in the DE group compared with the stable patients. This difference was observed both at baseline and during follow-up. Elevated MD in chronic white matter MS lesions reflects enlargement of the extracellular space,<sup><xref rid="R31" ref-type="bibr">30-33</xref></sup> which is caused by a combination of ongoing tissue loss and the relatively rigid structure of chronic lesion.<sup><xref rid="R35" ref-type="bibr">34</xref></sup> Therefore, the significantly higher MD at baseline and the larger increase in MD during follow-up observed in the DE group suggest that ongoing smoldering inflammation at the lesion edge, as evidenced by CLT expansion, promotes progressive axonal damage.</p>
      <p>The debilitating effect of chronic lesion expansion on the progression of MS is further evidenced by observed differences in patient's physical disability and its evolution over time. The DE group demonstrated a higher EDSS at baseline, which notably increased during the study period. By contrast, EDSS in the DS group remained stable. This disparity suggests that chronic lesion expansion, along with associated neurodegeneration, significantly contributes to physical decline in patients with MS. These findings are consistent with our previous work.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Moreover, the correlation between chronic lesion activity and physical disability has been similarly demonstrated in patients with PPMS<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and SPMS.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p>
      <p>In parallel with improved understanding of the role of smoldering inflammation (and associated lesion expansion) in disease progression, there is a growing interest in developing therapies to mitigate this process. We therefore performed sample size estimation for a hypothetical clinical trial focusing on reducing the rate of chronic lesion expansion. Our calculations suggest that, to observe a reasonable treatment effect of 30%&#x2013;50%, a relatively small cohort of patients with RRMS, ranging from 24 to 69 patients per arm, would be required.</p>
      <p>However, because only patients with an established trend of lesion expansion are suitable for the trial, a thorough pretrial screening process is necessary. This process involves the collection and analysis of multiple MRI compatible scans, which may not always be available.</p>
      <p>Our study has several limitations. First, our analysis was based on a relatively small sample of patients with RRMS, particularly when group analysis was involved. Larger studies are necessary to confirm these findings.</p>
      <p>Second, while we acknowledge that different treatment options may exert varying effects on smoldering inflammation and associated lesion expansion, heterogeneity of treatment at baseline in our study and changes in medication during the follow-up period limit our ability to comprehensively assess their impact on our observations. Nevertheless, considering the consistent nature of the chronic lesion expansion process observed in this study and the tendency for treatment alterations to involve a shift toward more potent drugs, it is likely that even currently available highly effective therapies, which primarily target the adaptive immune response, have a limited influence on this process.</p>
      <p>Third, no longitudinal analysis of individual lesions was performed in this study. However, because of temporal changes in lesion morphology in relation to merging of lesions or the development of new confluent lesions, the MRI time series analysis implemented here is more appropriately suited for estimating lesion expansion on a patient-wise basis, rather than focusing on individual lesions. Of note, MS therapy targets the patient, rather than specific, individual lesions.</p>
      <p>In conclusion, our data show that, over a 7-year period, patient-specific enlargement of CLT, where present, evolves at a constant rate and significantly contributes to disease progression.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="contributions">
      <title>Author Contributions</title>
      <p content-type="contributions">S. Klistorner: drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data. M. Barnett: major role in the acquisition of data; analysis or interpretation of data. J.D.E. Parratt: major role in the acquisition of data. C. Yiannikas: major role in the acquisition of data. C. Wang: analysis or interpretation of data. D. Wang: analysis or interpretation of data. A. Shieh: analysis or interpretation of data. A. Klistorner: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data.</p>
    </sec>
    <sec sec-type="funding">
      <title>Study Funding</title>
      <p content-type="funding">The authors report no targeted funding.</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Disclosure</title>
      <p>The authors report no relevant disclosures. Go to <ext-link xlink:href="https://n.neurology.org/lookup/doi/10.1212/NXI.0000000000200377" ext-link-type="uri">Neurology.org/NN</ext-link> for full disclosures.</p>
    </sec>
    <glossary>
      <title>Glossary</title>
      <def-list>
        <def-item>
          <term id="G1">CLT</term>
          <def>
            <p>chronic lesion tissue</p>
          </def>
        </def-item>
        <def-item>
          <term id="G2">DE</term>
          <def>
            <p>definitely expanding group</p>
          </def>
        </def-item>
        <def-item>
          <term id="G3">DMT</term>
          <def>
            <p>disease-modifying therapy</p>
          </def>
        </def-item>
        <def-item>
          <term id="G4">DS</term>
          <def>
            <p>definitely stable group</p>
          </def>
        </def-item>
        <def-item>
          <term id="G5">EDSS</term>
          <def>
            <p>Expanded Disability Status Scale</p>
          </def>
        </def-item>
        <def-item>
          <term id="G6">IQR</term>
          <def>
            <p>interquartile range</p>
          </def>
        </def-item>
        <def-item>
          <term id="G7">MD</term>
          <def>
            <p>mean diffusivity</p>
          </def>
        </def-item>
        <def-item>
          <term id="G8">MS</term>
          <def>
            <p>multiple sclerosis</p>
          </def>
        </def-item>
        <def-item>
          <term id="G9">PPMS</term>
          <def>
            <p>primary progressive MS</p>
          </def>
        </def-item>
        <def-item>
          <term id="G10">RMSE</term>
          <def>
            <p>root mean square error</p>
          </def>
        </def-item>
        <def-item>
          <term id="G11">RRMS</term>
          <def>
            <p>relapsing-remitting MS</p>
          </def>
        </def-item>
        <def-item>
          <term id="G12">SPMS</term>
          <def>
            <p>econdary progressive MS</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prineas</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Wright</surname>
<given-names>RG</given-names></string-name></person-group>. <article-title>Immunipathology of secondary-progressive multiple sclerosis</article-title>. <source>Ann Neurol</source>. <year>2001</year>;<volume>50</volume>:<fpage>646</fpage>-<lpage>657</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.1255</pub-id>.<pub-id pub-id-type="pmid">11706971</pub-id>
</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calvi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carrasco</surname>
<given-names>FP</given-names></string-name>, <string-name><surname>Tur</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>17</issue>):<fpage>e1783</fpage>-<lpage>e1793</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000200144</pub-id><pub-id pub-id-type="pmid">35277438</pub-id>
</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dal-Bianco</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Grabner</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kronnerwetter</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging</article-title>. <source>Acta Neuropathol</source>. <year>2017</year>;<volume>133</volume>(<issue>1</issue>):<fpage>25</fpage>-<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-016-1636-z</pub-id><pub-id pub-id-type="pmid">27796537</pub-id>
</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elliott</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Belachew</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wolinsky</surname>
<given-names>JS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis</article-title>. <source>Brain</source>. <year>2019</year>;<volume>142</volume>(<issue>9</issue>):<fpage>2787</fpage>-<lpage>2799</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz212</pub-id><pub-id pub-id-type="pmid">31497864</pub-id>
</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klistorner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Yiannikas</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Expansion of chronic lesions is linked to disease progression in relapsing&#x2013;remitting multiple sclerosis patients</article-title>. <source>Mult Scler</source>. <year>2021</year>;<volume>27</volume>(<issue>10</issue>):<fpage>1533</fpage>-<lpage>1542</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1352458520974357</pub-id><pub-id pub-id-type="pmid">33215557</pub-id>
</mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elliott</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wolinsky</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Hauser</surname>
<given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions</article-title>. <source>Mult Scler</source>. <year>2019</year>;<volume>25</volume>(<issue>14</issue>):<fpage>1915</fpage>-<lpage>1925</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1352458518814117</pub-id><pub-id pub-id-type="pmid">30566027</pub-id>
</mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samjoo</surname>
<given-names>IA</given-names></string-name>, <string-name><surname>Worthington</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Drudge</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Efficacy classification of modern therapies in multiple sclerosis</article-title>. <source>J Comp Eff Res</source>. <year>2021</year>;<volume>10</volume>(<issue>6</issue>):<fpage>495</fpage>-<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.2217/cer-2020-0267</pub-id><pub-id pub-id-type="pmid">33620251</pub-id>
</mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scolding</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Barnes</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Cader</surname>
<given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis</article-title>. <source>Pract Neurol</source>. <year>2015</year>;<volume>15</volume>(<issue>4</issue>):<fpage>273</fpage>-<lpage>279</lpage>. doi:<pub-id pub-id-type="doi">10.1136/practneurol-2015-001139</pub-id><pub-id pub-id-type="pmid">26101071</pub-id>
</mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barnett</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Beadnall</surname>
<given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis</article-title>. <source>NPJ Digit Med</source>. <year>2023</year>;<volume>6</volume>(<issue>1</issue>):<fpage>196</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41746-023-00940-6</pub-id><pub-id pub-id-type="pmid">37857813</pub-id>
</mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pongratz</surname>
<given-names>V</given-names></string-name>, <string-name><surname>K&#xFC;ster</surname>
<given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging</article-title>. <source>Neuroimage Clin</source>. <year>2019</year>;<volume>23</volume>(<issue>May</issue>):<fpage>101849</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2019.101849</pub-id><pub-id pub-id-type="pmid">31085465</pub-id>
</mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>K&#xF6;hler</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wahl</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ziemssen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Linn</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kitzler</surname>
<given-names>HH</given-names></string-name></person-group>. <article-title>Exploring individual multiple sclerosis lesion volume change over time: development of an algorithm for the analyses of longitudinal quantitative MRI measures</article-title>. <source>Neuroimage Clin</source>. <year>2019</year>;<volume>21</volume>(<issue>November 2018</issue>):<fpage>101623</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2018.101623</pub-id><pub-id pub-id-type="pmid">30545687</pub-id>
</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klistorner</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yiannikas</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evidence of progressive tissue loss in the core of chronic MS lesions: a longitudinal DTI study</article-title>. <source>Neuroimage Clin</source>. <year>2018</year>;<volume>17</volume>:<fpage>1028</fpage>-<lpage>1035</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2017.12.010</pub-id><pub-id pub-id-type="pmid">29387524</pub-id>
</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coup&#xE9;</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mansencal</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Cl&#xE9;ment</surname>
<given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>AssemblyNet: a large ensemble of CNNs for 3D whole brain MRI segmentation</article-title>. <source>Neuroimage</source>. <year>2020</year>;<volume>219</volume>:<fpage>117026</fpage>-<lpage>117126</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117026</pub-id><pub-id pub-id-type="pmid">32522665</pub-id>
</mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dwyer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bergsland</surname>
<given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis</article-title>. <source>Neuroimage Clin</source>. <year>2017</year>;<volume>15</volume>:<fpage>769</fpage>-<lpage>779</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2017.06.022</pub-id><pub-id pub-id-type="pmid">28706852</pub-id>
</mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kalkers</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vrenken</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Uitdehaag</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Polman</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Barkhof</surname>
<given-names>F</given-names></string-name></person-group>. <article-title>Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue</article-title>. <source>Mult Scler</source>. <year>2002</year>;<volume>8</volume>(<issue>5</issue>):<fpage>410</fpage>-<lpage>414</lpage>. doi:<pub-id pub-id-type="doi">10.1191/1352458502ms833oa</pub-id>.<pub-id pub-id-type="pmid">12356208</pub-id>
</mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klistorner</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Graham</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Klistorner</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>The expansion and severity of chronic MS lesions follows a periventricular gradient</article-title>. <source>Mult Scler</source>. <year>2022</year>;<volume>28</volume>(<issue>10</issue>):<fpage>1504</fpage>-<lpage>1514</lpage>. doi:<pub-id pub-id-type="doi">10.1177/13524585221080667</pub-id><pub-id pub-id-type="pmid">35296170</pub-id>
</mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klistorner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Klistorner</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Mechanisms of central brain atrophy in multiple sclerosis</article-title>. <source>Mult Scler</source>. <year>2022</year>;<volume>28</volume>(<issue>13</issue>):<fpage>2038</fpage>-<lpage>2045</lpage>. doi:<pub-id pub-id-type="doi">10.1177/13524585221111684</pub-id><pub-id pub-id-type="pmid">35861244</pub-id>
</mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>J&#xE4;ckle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Zeis</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Schaeren-Wiemers</surname>
<given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Molecular signature of slowly expanding lesions in progressive multiple sclerosis</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>(<issue>7</issue>):<fpage>2073</fpage>-<lpage>2088</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa158</pub-id><pub-id pub-id-type="pmid">32577755</pub-id>
</mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Absinta</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maric</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gharagozloo</surname>
<given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A lymphocyte&#x2013;microglia&#x2013;astrocyte axis in chronic active multiple sclerosis</article-title>. <source>Nature</source>. <year>20212020</year>;<volume>597</volume>(<issue>7878</issue>):<fpage>709</fpage>-<lpage>714</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-03892-7</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhlmann</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Moccia</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Coetzee</surname>
<given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Multiple sclerosis progression: time for a new mechanism-driven framework</article-title>. <source>Lancet Neurol</source>. <year>2023</year>;<volume>22</volume>(<issue>1</issue>):<fpage>78</fpage>-<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(22)00289-7</pub-id><pub-id pub-id-type="pmid">36410373</pub-id>
</mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pitt</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lo</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Gauthier</surname>
<given-names>SA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Toward precision phenotyping of multiple sclerosis</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. <year>2022</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e200025</fpage>-<lpage>e200027</lpage>. doi:<pub-id pub-id-type="doi">10.1212/NXI.0000000000200025</pub-id><pub-id pub-id-type="pmid">36041861</pub-id>
</mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Macnair</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Calini</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Agirre</surname>
<given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Single nuclei RNAseq stratifies multiple sclerosis patients into three distinct white matter glia responses</article-title>. <source>bioRxiv</source>. <year>2022</year>. doi:<pub-id pub-id-type="doi">10.1101/2022.04.06.487263</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kessler</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Thomas</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kuhlmann</surname>
<given-names>T</given-names></string-name></person-group>. <article-title>Microglia activation in periplaque white matter in multiple sclerosis depends on age and lesion type, but does not correlate with oligodendroglial loss</article-title>. <source>Acta Neuropathol</source>. <year>2023</year>;<volume>146</volume>(<issue>6</issue>):<fpage>817</fpage>-<lpage>828</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-023-02645-2</pub-id><pub-id pub-id-type="pmid">37897549</pub-id>
</mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhlmann</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ludwin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Prat</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Antel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Br&#xFC;ck</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Lassmann</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>An updated histological classification system for multiple sclerosis lesions</article-title>. <source>Acta Neuropathol</source>. <year>2017</year>;<volume>133</volume>(<issue>1</issue>):<fpage>13</fpage>-<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-016-1653-y</pub-id><pub-id pub-id-type="pmid">27988845</pub-id>
</mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klistorner</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yiannikas</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Graham</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Parratt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>MH</given-names></string-name></person-group>. <article-title>Progressive injury in chronic multiple sclerosis lesions is gender-specific: a DTI study</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>2</issue>):<fpage>01492455</fpage>-<lpage>e149311</lpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0149245</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shirani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kingwell</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rieckmann</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tremlett</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009)</article-title>. <source>Mult Scler</source>. <year>2012</year>;<volume>18</volume>(<issue>4</issue>):<fpage>442</fpage>-<lpage>450</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1352458511422097</pub-id>.<pub-id pub-id-type="pmid">21952097</pub-id>
</mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ribbons</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>McElduff</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Boz</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e0122686</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0122686</pub-id>.<pub-id pub-id-type="pmid">26046348</pub-id>
</mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beynon</surname>
<given-names>V</given-names></string-name>, <string-name><surname>George</surname>
<given-names>IC</given-names></string-name>, <string-name><surname>Elliott</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chronic lesion activity and disability progression in secondary progressive multiple sclerosis</article-title>. <source>BMJ Neurol Open</source>. <year>2022</year>;<volume>4</volume>:<fpage>0002400</fpage>-<lpage>e311</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjno-2021-000240</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sucksdorff</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tuisku</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Matilainen</surname>
<given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Natalizumab treatment reduces microglial activation in the white matter of the MS brain</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. <year>2019</year>;<volume>6</volume>(<issue>4</issue>):<fpage>5744</fpage>-<lpage>e610</lpage>. doi:<pub-id pub-id-type="doi">10.1212/NXI.0000000000000574</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scanderbeg</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Tomaiuolo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Sabatini</surname>
<given-names>U</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Demyelinating plaques in relapsing-remitting and secondary-progressive multiple sclerosis: assessment with diffusion MR imaging</article-title>. <source>Am J Neuroradiol</source>. <year>2000</year>;<volume>21</volume>(<issue>5</issue>):<fpage>862</fpage>-<lpage>868</lpage>.<pub-id pub-id-type="pmid">10815661</pub-id>
</mixed-citation>
      </ref>
      <ref id="R32">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Filippi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Iannucci</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cercignani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Assunta Rocca</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pratesi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Comi</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging</article-title>. <source>Arch Neurol</source>. <year>2000</year>;<volume>57</volume>(<issue>7</issue>):<fpage>1017</fpage>-<lpage>1021</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.57.7.1017</pub-id>.<pub-id pub-id-type="pmid">10891984</pub-id>
</mixed-citation>
      </ref>
      <ref id="R33">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Droogan</surname>
<given-names>AG</given-names></string-name>, <string-name><surname>Clark</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Werring</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Barker</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>WI</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>DH</given-names></string-name></person-group>. <article-title>Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging</article-title>. <source>Magn Reson Imaging</source>. <year>1999</year>;<volume>17</volume>(<issue>5</issue>):<fpage>653</fpage>-<lpage>661</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0730-725x(99)00011-9</pub-id><pub-id pub-id-type="pmid">10372518</pub-id>
</mixed-citation>
      </ref>
      <ref id="R34">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Barnett</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Yiannikas</surname>
<given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. <year>2019</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e593</fpage>-<lpage>e599</lpage>. doi:<pub-id pub-id-type="doi">10.1212/NXI.0000000000000593</pub-id><pub-id pub-id-type="pmid">31454773</pub-id>
</mixed-citation>
      </ref>
      <ref id="R35">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Barkhof</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Frank</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Parker</surname>
<given-names>GJM</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>AJ</given-names></string-name></person-group>. <article-title>Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance</article-title>. <source>Brain</source>. <year>2002</year>;<volume>125</volume>(<issue>Pt 8</issue>):<fpage>1676</fpage>-<lpage>1695</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awf177</pub-id><pub-id pub-id-type="pmid">12135961</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title-group><journal-title>bioRxiv</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40093050</article-id><article-id pub-id-type="pmc">11908256</article-id>
<article-id pub-id-type="doi">10.1101/2025.03.05.641682</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Biophysical basis for brain folding and misfolding patterns in ferrets and humans</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5407-9111</contrib-id><name><surname>Choi</surname><given-names>Gary P. T.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3469-3904</contrib-id><name><surname>Liu</surname><given-names>Chunzi</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0296-3981</contrib-id><name><surname>Yin</surname><given-names>Sifan</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4633-2700</contrib-id><name><surname>S&#xE9;journ&#xE9;</surname><given-names>Gabrielle</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1937-6529</contrib-id><name><surname>Smith</surname><given-names>Richard S.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0156-2238</contrib-id><name><surname>Walsh</surname><given-names>Christopher A.</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5114-0519</contrib-id><name><surname>Mahadevan</surname><given-names>L.</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Mathematics, The Chinese University of Hong Kong, Hong Kong</aff><aff id="A2"><label>2</label>School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA</aff><aff id="A3"><label>3</label>Department of Cell Biology, Duke University, Durham, NC, USA</aff><aff id="A4"><label>4</label>Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA</aff><aff id="A5"><label>5</label>Departments of Neurology and Pediatrics, Harvard Medical School, Boston, MA, USA</aff><aff id="A6"><label>6</label>Division of Genetics and Genomics, Manton Center for Orphan Disease, and Howard Hughes Medical Institute, Boston Children&#x2019;s Hospital, Boston, MA, USA</aff><aff id="A7"><label>7</label>Departments of Physics, and Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions</p><p id="P2">L.M. conceived of the project and designed research. G.P.T.C. carried out the computations, C.L. and G.S. carried out the gel swelling experiments, S.Y. carried out the morphometric analysis, R.S.S. and C.W. carried out the genetic mutation experiments. G.P.T.C. and L.M. wrote the paper with input from all authors, and all authors edited the paper.</p></fn><corresp id="CR1"><label>*</label>To whom correspondence should be addressed; <email>lmahadev@g.harvard.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>3</month><year>2025</year></pub-date><elocation-id>2025.03.05.641682</elocation-id><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</ext-link>, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.</license-p></license></permissions><self-uri content-type="pdf">nihpp-2025.03.05.641682.pdf</self-uri><abstract id="ABS1"><p id="P3">A mechanistic understanding of neurodevelopment requires us to follow the multiscale processes that connect molecular genetic processes to macroscopic cerebral cortical formations and thence to neurological function. Using magnetic resonance imaging of the brain of the ferret, a model organism for studying cortical morphogenesis, we create <italic toggle="yes">in vitro</italic> physical gel models and <italic toggle="yes">in silico</italic> numerical simulations of normal brain gyrification. Using observations of genetically manipulated animal models, we identify cerebral cortical thickness and cortical expansion rate as the primary drivers of dysmorphogenesis and demonstrate that <italic toggle="yes">in silico</italic> models allow us to examine the causes of aberrations in morphology and developmental processes at various stages of cortical ontogenesis. Finally, we explain analogous cortical malformations in human brains, with comparisons with human phenotypes induced by the same genetic defects, providing a unified perspective on brain morphogenesis that is driven proximally by genetic causes and affected mechanically via variations in the geometry of the brain and differential growth of the cortex.</p></abstract></article-meta></front>
  <body>
    <p id="P4">Understanding the growth and form of normal and abnormal cortical convolutions (gyri and sulci) is important for the study of human neurodevelopmental diseases (<xref rid="R1" ref-type="bibr">1</xref>&#x2013;<xref rid="R5" ref-type="bibr">5</xref>). During early brain development, the cortical plate expands tangentially relative to the underlying white matter (<xref rid="R6" ref-type="bibr">6</xref>). This pattern of growth is the central cause of gyrification; indeed tangential cortical expansion creates compressive forces on the faster-growing outer layer of the cortex and tensile forces on the attached slower-growing inner layer, and the relative-growth induced forces cause cortical folding as suggested more than a century ago (<xref rid="R7" ref-type="bibr">7</xref>) and first quantitatively elucidated nearly fifty years ago (<xref rid="R8" ref-type="bibr">8</xref>). At a molecular and cellular level, neurogenesis, neuronal migration, and neuronal differentiation all contribute to the tangential growth of the developing cortex via processes such as an increase in either the number or size of cells (<xref rid="R9" ref-type="bibr">9</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref>). Recent models that take these facts into account attempt to explain gyrification in terms of a simple mechanical instability, termed sulcification (<xref rid="R13" ref-type="bibr">13</xref>), that when iterated with variations (<xref rid="R14" ref-type="bibr">14</xref>) shows that tangential expansion of the gray matter constrained by the white matter can explain a range of different morphologies seen in the brains of different organisms (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>). Furthermore, when deployed over developmental time to simulate normal human cortical convolution, the results can capture a substantial range of features seen in normal human fetal brain morphogenesis (<xref rid="R17" ref-type="bibr">17</xref>). However, these and other similar studies (<xref rid="R18" ref-type="bibr">18</xref>&#x2013;<xref rid="R29" ref-type="bibr">29</xref>) do not allow us to understand malformations of cortical development (MCD) owing to our inability to probe the development of the human fetal brain <italic toggle="yes">in utero</italic>.</p>
    <p id="P5">An alternative strategy is to turn to model organisms to study the developmental trajectory of MCDs. Since commonly used animal models such as the mouse and rat have lissencephalic cortices, the ferret, a gyrencephalic non-primate, has been favored as an experimentally tractable laboratory organism that demonstrates cortical folding patterns that are roughly similar to that observed in the human (<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R30" ref-type="bibr">30</xref>&#x2013;<xref rid="R33" ref-type="bibr">33</xref>). Furthermore, since the process of cortical folding in the ferret is almost exclusively postnatal, with the progressive development of cortical gyri and sulci from postnatal day 0 (P0) to adolescence (<xref rid="F1" ref-type="fig">Fig. 1</xref>), it is more easily observable. Finally, the ability to perform region-specific genetic manipulation of the ferret brain through <italic toggle="yes">in utero</italic> electroporation (<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>) makes the ferret an ideal system for modeling normal and abnormal neurodevelopmental processes.</p>
    <p id="P6">Inspired by our previous studies using physical experiments with swelling gels and computational models of brain growth (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R36" ref-type="bibr">36</xref>), we model the folding of a normal ferret brain using a physical gel model and a computational model based on the principle of constrained cortical expansion and compare the simulation results with the real brain development using various geometric morphometric approaches. We then use the computational and physical models to reproduce defective developmental processes of the ferret brain and show that they are consistent with biological experiments that manipulate different molecular drivers of neurogenesis, neuronal migration and cell growth in the cortex that underlie its relative thickness and expansion rate. Taken together, our studies provide a mesoscopic approach to brain morphogenesis that combines computational <italic toggle="yes">in silico</italic> and physical gel <italic toggle="yes">in vitro</italic> models with morphological and molecular analysis of ferret cortical disease models, and shed light on analogous MCDs in human brains.</p>
    <sec id="S1">
      <title>Physical gel model</title>
      <p id="P7">Inspired by the observation that soft physical gels swell and fold superficially when immersed in solvents, we constructed a physical simulacrum of ferret brain folding following our previous protocols (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>). Specifically, we produced two-layer PDMS gel models of the ferret brain at various ages based on surfaces reconstructed from MR Images (see SI Section S1 for details). We then immersed the two-layer gel brain model in n-hexane, which led to folding patterns by solvent-driven swelling of the outer layers (<xref rid="F2" ref-type="fig">Fig. 2a</xref>).</p>
      <p id="P8"><xref rid="F2" ref-type="fig">Fig. 2b</xref> shows the experimental results for a P8 gel brain; it swells nonuniformly and folds progressively from an initial state that has invaginations corresponding to the cruciate sulcus (crs), the coronal sulcus (cns), and the suprasylvian sulcus (sss). The post-swelling state shows the development of sulci corresponding in location and self-contacting nature to the crs, cns, sss, and the formation of rhinal sulcus (rs), the pseudosylvian sulcus (pss), and lateral sulcus (ls), and ansate sulcus (as) observed in real ferrets aged P21 and older. <xref rid="F2" ref-type="fig">Fig. 2c</xref> shows another swelling experiment with a starting shape corresponding to the P16 gel brain, from which we observe a similar progression in the folding patterns. We see that our minimal physical model can capture the qualitative aspects of the folding transitions in the ferret brain (see also SI Section S1 and Video S1&#x2013;S2).</p>
    </sec>
    <sec id="S2">
      <title>Computational model</title>
      <p id="P9">To complement our physical experiments with quantitative simulations of ferret brain development, we followed the approach in (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>) and considered a neo-Hookean material model for the brain cortex consisting of a layer of gray matter on top of a deep layer of white matter with volumetric strain energy density
<disp-formula id="FD1">
<label>(1)</label>
<mml:math id="M1" display="block"><mml:mi>W</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>&#x3BC;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold">F</mml:mi><mml:mi mathvariant="bold">F</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>2</mml:mn><mml:mo>/</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo>&#x2212;</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:mi>J</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math>
</disp-formula>
where <inline-formula><mml:math id="M2" display="inline"><mml:mi mathvariant="bold">F</mml:mi></mml:math></inline-formula> is the deformation gradient, <inline-formula><mml:math id="M3" display="inline"><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">F</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, <inline-formula><mml:math id="M4" display="inline"><mml:mi>&#x3BC;</mml:mi></mml:math></inline-formula> is the shear modulus and <inline-formula><mml:math id="M5" display="inline"><mml:mi>K</mml:mi></mml:math></inline-formula> is the bulk modulus. We assume that <inline-formula><mml:math id="M6" display="inline"><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mi>&#x3BC;</mml:mi></mml:math></inline-formula> for a modestly compressible material. Computer simulations were then performed on tetrahedral meshes of ferret brains to model the gyrification (see SI Section S2 for more details).</p>
      <p id="P10">We considered both simulations that modeled the changes in brain morphology from P0 to P32 as one continuous process (<xref rid="F3" ref-type="fig">Fig. 3a</xref>, see also SI Movie S3) and stepwise simulations that considered the growth process in stages, i.e. from P0 to P4, from P4 to P8, from P8 to P16 and from P16 to P32 (<xref rid="F3" ref-type="fig">Fig. 3b</xref>, see also SI Movie S4). In both sets of simulations, the emergence of cortical folding can be observed. In the continuous simulation approach, we observed the appearance of multiple minor folds since the continuous simulations only depend on the P0 initial brain, so that the effect of minor features in the P0 brain on the brain growth may accumulate over time. By contrast, in the stepwise simulation approach which focuses on multiple shorter growth periods, and thus reduces the accumulation of shape variations over time. Comparing the P16 results of stepwise numerical simulation, the gel experiment and the P16 real brain, we observe that the folding patterns are visually very similar (<xref rid="F4" ref-type="fig">Fig. 4a</xref>). For a more quantitative comparison, we applied a method based on aligning landmarks using spherical mapping termed FLASH (Fast Landmark Aligned Spherical Harmonic Parameterization) (<xref rid="R37" ref-type="bibr">37</xref>) to parameterize the simulated P16 ferret brain and the P16 brain surface generated from the MRI scans onto the unit sphere using landmark-aligned optimized conformal mappings, with the coronal sulcus (cns), suprasylvian sulcus (sss), presylvian sulcus (prs), and pseudosylvian sulcus (pss) on both the left and right hemispheres used as landmarks (see <xref rid="F4" ref-type="fig">Fig. 4a</xref>, and SI Section S3 for more details). We then assessed the geometric similarity of the two brain surfaces on the spherical domain in terms of their shape index (<xref rid="R38" ref-type="bibr">38</xref>), which is a surface measure defined based on the surface mean curvature and Gaussian curvature. The similarity of the two shape indices suggests that the folding pattern produced by our simulation is close to the actual folding pattern (see SI Section S3 and (<xref rid="R39" ref-type="bibr">39</xref>) for more details of the morphometric method). We further utilized spherical harmonic-based representations of the two brains, which also shows that the two brains have consistent geometric similarities (see SI Section S3).</p>
    </sec>
    <sec id="S3">
      <title>Neurology of ferret and human cortical malformations</title>
      <p id="P11">The effectiveness of our differential growth-based model in quantifying the normative development of normal ferret brains begs the question of whether we can use the same framework to study malformations of cortical development (MCD). For instance, <italic toggle="yes">SCN3A</italic> encodes a sodium channel and specific missense mutations of it are associated with the MCD polymicrogyria (PMG) (<xref rid="R40" ref-type="bibr">40</xref>), while genetic manipulations of <italic toggle="yes">ASPM</italic> have also been shown to produce severe microcephaly in human and ferret brains (<xref rid="R32" ref-type="bibr">32</xref>), while disrupting <italic toggle="yes">TMEM161B</italic> leads to cortical malformations in humans and ferrets (<xref rid="R41" ref-type="bibr">41</xref>). In these and other examples, various genetic causes lead to variations in the cortical thickness ratio <italic toggle="yes">h/R</italic> and/or the tangential growth ratio <italic toggle="yes">g</italic> in space and time, that we know to be critical geometric parameters that change the physical nature of the sulcification instability driving cortical folding.</p>
      <p id="P12">In <xref rid="F5" ref-type="fig">Fig. 5a</xref>, we show a control human brain MRI (top), a wild-type P16 ferret brain MRI (middle), and the stepwise numerical simulation result under the normal parameter setup (bottom). In <xref rid="F5" ref-type="fig">Fig. 5b</xref>, (top) we show the MCD polymicrogyria (PMG) phenotype in humans associated with over-expression of a mutated <italic toggle="yes">SCN3A</italic> gene. In <xref rid="F5" ref-type="fig">Fig. 5b</xref> (middle), we show that the same mutation in ferrets leads to an increased number of tightly packed folds in the perisylvian region. To model this cortical malformation, we performed a modified numerical simulation with the cortical thickness reduced to 1<italic toggle="yes">/</italic>4 of the original thickness at a localized zone around the perisylvian region of the P8 brain model. From the modified numerical simulation result (<xref rid="F5" ref-type="fig">Fig. 5b</xref>, bottom), we can see that our model can qualitatively capture perisylvian PMG.</p>
      <p id="P13">In <xref rid="F5" ref-type="fig">Fig. 5c</xref> (top) and <xref rid="F5" ref-type="fig">Fig. 5c</xref> (middle) (<xref rid="R32" ref-type="bibr">32</xref>) we show that <italic toggle="yes">ASPM</italic> mutants produce severe microcephaly in human and ferret brains (<xref rid="R32" ref-type="bibr">32</xref>), because the cortical surface area is reduced while there is no significant change in the cortical thickness. To reproduce this malformation we consider a modified computational experiment with a reduction of the growth rate to 1<italic toggle="yes">/</italic>4 of the original rate. In <xref rid="F5" ref-type="fig">Fig. 5c</xref> (bottom), we show the results of numerical simulations that lead to less prominent folding when compared to the normal brain, consistent with observations in human and ferret brains.</p>
      <p id="P14">Finally, in <xref rid="F5" ref-type="fig">Fig. 5d</xref> (top) and <xref rid="F5" ref-type="fig">Fig. 5d</xref> (middle) (<xref rid="R41" ref-type="bibr">41</xref>), we show that disrupting <italic toggle="yes">TMEM161B</italic> also leads to cortical malformations in human and ferret brains, with shallower sulci. Modifying the morphogenetic simulations with a reduction of the growth rate to 3<italic toggle="yes">/</italic>4 of the original rate and an increase of the cortical thickness to 1.5 times the original thickness leads to results shown in <xref rid="F5" ref-type="fig">Fig. 5d</xref> (bottom) that matches the experimentally observed malformation patterns qualitatively.</p>
      <p id="P15">In SI Section S4, we present additional physical gel and computational experiments to demonstrate the effect of different combinations of the growth rate and cortical thickness parameters on the cortical malformation results.</p>
    </sec>
    <sec id="S4">
      <title>Discussion</title>
      <p id="P16">Understanding the growth and form of the cerebral cortex is a fundamental question in neurobiology, and the experimentally accessible progressive postnatal development of the ferret brain makes it an ideal system for analysis. Here, we have used a combination of physical and computational models based on differential growth to show how ferret brain morphologies arise. By modifying the scaled cortical layer thickness and the tangential growth profile in our model, we have qualitatively reproduced various cortical malformations and shown how developmental mechanisms lead to morphological manifestations with potential functional implications. All together, our study elucidates the normal and abnormal folding in the ferret brain as a function of its genetic antecedents that lead to changes in the geometry of the cortex and thence to different physical folding patterns with functional consequences. A computational and physical-gel brain study informed by detailed MRI of ferret and human fetal brains allows us to move towards a synthesis of the genetic, physical and morphological basis for cortical malformations.</p>
      <p id="P17">While this work has focused on the morphogenesis and dysmorphogenesis of the ferret brain, one may also use the physical and computational models to understand how folding occurs across organisms as in our complementary study (<xref rid="R39" ref-type="bibr">39</xref>), where we investigate how modifying the cortical layer thickness and the tangential growth rate would lead to abnormal folding in different species.</p>
    </sec>
    <sec id="S5">
      <title>Methods</title>
      <sec id="S6">
        <title>Physical gel model for ferret brain folding</title>
        <p id="P18">Beginning with T2-weighted motion-corrected anatomical MR images of ferret brains of various ages (<xref rid="R42" ref-type="bibr">42</xref>), we recreated digital maps of the surfaces of pre-swelling brain states. Then, we followed our prior experimental approach (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>) and produced two-layer PDMS gel models of the ferret brain at various ages based on the reconstructed brain surfaces. Specifically, we first generated a negative rubber mold with Ecofl ex 00&#x2013;30 from a 3D-printed brain plastic model and then the core gel with SYLGARD 184 at a 1:45 crosslinker:base ratio. To mimic the cortical layer, we surface-coated 4 layers of PDMS gel at a 1:35 crosslinker:base ratio onto the core layer. Finally, tangential cortical growth was mimicked by immersing the two-layer gel brain model in n-hexane for 1.5 hours, which resulted in solvent-driven swelling of the outer layers, leading to folding patterns. See SI Section S1 for details.</p>
      </sec>
      <sec id="S7">
        <title>Computational model for ferret brain folding</title>
        <p id="P19">Three geometrical parameters of the 3D brain models control its morphogenesis: the average brain size <inline-formula><mml:math id="M7" display="inline"><mml:mi>R</mml:mi></mml:math></inline-formula> (determined for example by its volume), the average cortical thickness <inline-formula><mml:math id="M8" display="inline"><mml:mi>T</mml:mi></mml:math></inline-formula> and the average tangential expansion ratio of the cortex relative to the white matter, <inline-formula><mml:math id="M9" display="inline"><mml:msup><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. To characterize brain development in the ferret, we followed the empirical scaling laws for gray-matter volume to thickness described in (<xref rid="R15" ref-type="bibr">15</xref>) and set <inline-formula><mml:math id="M10" display="inline"><mml:mi>R</mml:mi><mml:mo>/</mml:mo><mml:mi>T</mml:mi><mml:mo>&#x2248;</mml:mo><mml:mn>10</mml:mn></mml:math></inline-formula> with the tangential expansion ratio <inline-formula><mml:math id="M11" display="inline"><mml:mi>g</mml:mi><mml:mo>&#x2248;</mml:mo><mml:mn>1.9</mml:mn></mml:math></inline-formula>, along with an indicator function <inline-formula><mml:math id="M12" display="inline"><mml:mi>&#x3B8;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mi>y</mml:mi><mml:mo>/</mml:mo><mml:mi>T</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, with <inline-formula><mml:math id="M13" display="inline"><mml:mi>y</mml:mi></mml:math></inline-formula> the distance from surface in a material reference frame used to distinguish between the cortical gray matter layer (with <inline-formula><mml:math id="M14" display="inline"><mml:mi>&#x3B8;</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>) from the deeper white matter (with <inline-formula><mml:math id="M15" display="inline"><mml:mi>&#x3B8;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>).</p>
        <p id="P20">Using MRIs of ferret brains, we created a computational model of the initial brain size and shape, that was discretized using tetrahedral meshes with over one million tetrahedral elements using Netgen (<xref rid="R43" ref-type="bibr">43</xref>). Using a finite element method implemented using a discretized version of the energy of the system (1), we minimized the energy by quasistatic equilibration using an explicit solver (<xref rid="R17" ref-type="bibr">17</xref>), while growth was applied incrementally using the form described earlier by expanding the tetrahedral elements with inversion handling (<xref rid="R44" ref-type="bibr">44</xref>) and a nodal pressure formulation (<xref rid="R45" ref-type="bibr">45</xref>). Self-avoidance of the surface was handled using the penalty-based vertex-triangle contact processing (<xref rid="R46" ref-type="bibr">46</xref>). We also enforce the condition that there is no growth in the central part as well as in the bottom part of the brain to better simulate the development of ferret brains. See SI Section S2 for more details.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack id="S8">
      <title>Acknowledgments</title>
      <p id="P21">We thank Jun Young Chung and James Weaver for their help with preliminary experiments. This work is supported in part by the Harvard Quantitative Biology Initiative and the NSF-Simons Center for Mathematical and Statistical Analysis of Biology at Harvard, award no. 1764269 (to G.P.T.C. and L.M.), the Simons Foundation and the Henri Seydoux Fund (to L.M.). G.P.T.C. is also supported by the CUHK Faculty of Science Direct Grant Direct Grant for Research (Project Code 4053650). C.A.W. is supported by the NINDS through R01NS032457 and R01NS035129, the Templeton Foundation, and by the Allen Discovery Center for Human Brain Evolution. C.A.W. is an Investigator of the Howard Hughes Medical Institute. R.S.S was supported by R00NS112604.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement" id="FN2">
        <p id="P23">Competing interests</p>
        <p id="P24">The authors declare no conflict of interest.</p>
      </fn>
    </fn-group>
    <sec sec-type="data-availability" id="S9">
      <title>Data availability</title>
      <p id="P22">Newborn ferret brain surfaces will be made available upon request. All other data are included in the article and/or supplementary material.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Lui</surname><given-names>J. H.</given-names></name>, <name><surname>Hansen</surname><given-names>D. V.</given-names></name>, and <name><surname>Kriegstein</surname><given-names>A. R.</given-names></name>, &#x201C;<article-title>Development and evolution of the human neocortex</article-title>,&#x201D; <source>Cell</source>, vol. <volume>146</volume>, no. <issue>1</issue>, pp. <fpage>18</fpage>&#x2013;<lpage>36</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21729779</pub-id>
</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Geschwind</surname><given-names>D. H.</given-names></name> and <name><surname>Rakic</surname><given-names>P.</given-names></name>, &#x201C;<article-title>Cortical evolution: judge the brain by its cover</article-title>,&#x201D; <source>Neuron</source>, vol. <volume>80</volume>, no. <issue>3</issue>, pp. <fpage>633</fpage>&#x2013;<lpage>647</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">24183016</pub-id>
</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Moln&#xE1;r</surname><given-names>Z.</given-names></name>, <name><surname>Clowry</surname><given-names>G. J.</given-names></name>, <name><surname>&#x160;estan</surname><given-names>N.</given-names></name>, <name><surname>Alzu&#x2019;bi</surname><given-names>A.</given-names></name>, <name><surname>Bakken</surname><given-names>T.</given-names></name>, <name><surname>Hevner</surname><given-names>R. F.</given-names></name>, <name><surname>H&#xFC;ppi</surname><given-names>P. S.</given-names></name>, <name><surname>Kostovi&#x107;</surname><given-names>I.</given-names></name>, <name><surname>Rakic</surname><given-names>P.</given-names></name>, <name><surname>Anton</surname><given-names>E.</given-names></name>, <etal/>, &#x201C;<article-title>New insights into the development of the human cerebral cortex</article-title>,&#x201D; <source>J. Anat.</source>, vol. <volume>235</volume>, no. <issue>3</issue>, pp. <fpage>432</fpage>&#x2013;<lpage>451</lpage>, <year>2019</year>.<pub-id pub-id-type="pmid">31373394</pub-id>
</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Del-Valle-Anton</surname><given-names>L.</given-names></name> and <name><surname>Borrell</surname><given-names>V.</given-names></name>, &#x201C;<article-title>Folding brains: from development to disease modeling</article-title>,&#x201D; <source>Physiol. Rev.</source>, vol. <volume>102</volume>, no. <issue>2</issue>, pp. <fpage>511</fpage>&#x2013;<lpage>550</lpage>, <year>2022</year>.<pub-id pub-id-type="pmid">34632805</pub-id>
</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><name><surname>Akula</surname><given-names>S. K.</given-names></name>, <name><surname>Exposito-Alonso</surname><given-names>D.</given-names></name>, and <name><surname>Walsh</surname><given-names>C. A.</given-names></name>, &#x201C;<article-title>Shaping the brain: The emergence of cortical structure and folding</article-title>,&#x201D; <source>Dev. Cell</source>, vol. <volume>58</volume>, no. <issue>24</issue>, pp. <fpage>2836</fpage>&#x2013;<lpage>2849</lpage>, <year>2023</year>.<pub-id pub-id-type="pmid">38113850</pub-id>
</mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="book"><name><surname>Welker</surname><given-names>W.</given-names></name>, &#x201C;<part-title>Why does the cortex fissure and fold: a review of determinants of gyri and sulci</part-title>,&#x201D; in <source>Cerebral Cortex</source> (<name><surname>Jones</surname><given-names>EG</given-names></name>, <name><surname>Peters</surname><given-names>A</given-names></name>, eds), pp. <fpage>3</fpage>&#x2013;<lpage>136</lpage>, <publisher-name>Plenum Press</publisher-name>
<publisher-loc>New York, NY</publisher-loc>, <year>1990</year>.</mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="book"><name><surname>His</surname><given-names>W.</given-names></name>, <source>Untersuchungen &#xFC;ber die erste Anlage des Wirbelthierleibes: die erste Entwickelung des H&#xFC;hnchens im Ei</source>, vol. <volume>1</volume>. <publisher-name>FCW Vogel</publisher-name>, <year>1868</year>.</mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Richman</surname><given-names>D. P.</given-names></name>, <name><surname>Stewart</surname><given-names>R. M.</given-names></name>, <name><surname>Hutchinson</surname><given-names>J. W.</given-names></name>, and <name><surname>Caviness</surname><given-names>V. S.</given-names></name>, &#x201C;<article-title>Mechanical model of brain convolutional development</article-title>,&#x201D; <source>Science</source>, vol. <volume>189</volume>, no. <issue>4196</issue>, pp. <fpage>18</fpage>&#x2013;<lpage>21</lpage>, <year>1975</year>.<pub-id pub-id-type="pmid">1135626</pub-id>
</mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><name><surname>Fietz</surname><given-names>S. A.</given-names></name>, <name><surname>Kelava</surname><given-names>I.</given-names></name>, <name><surname>Vogt</surname><given-names>J.</given-names></name>, <name><surname>Wilsch-Br&#xE4;uninger</surname><given-names>M.</given-names></name>, <name><surname>Stenzel</surname><given-names>D.</given-names></name>, <name><surname>Fish</surname><given-names>J. L.</given-names></name>, <name><surname>Corbeil</surname><given-names>D.</given-names></name>, <name><surname>Riehn</surname><given-names>A.</given-names></name>, <name><surname>Distler</surname><given-names>W.</given-names></name>, <name><surname>Nitsch</surname><given-names>R.</given-names></name>, <etal/>, &#x201C;<article-title>OSVZ progenitors of human and ferret neocortex are epithelial-like and expand by integrin signaling</article-title>,&#x201D; <source>Nat. Neurosci.</source>, vol. <volume>13</volume>, no. <issue>6</issue>, pp. <fpage>690</fpage>&#x2013;<lpage>699</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20436478</pub-id>
</mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>D. V.</given-names></name>, <name><surname>Lui</surname><given-names>J. H.</given-names></name>, <name><surname>Parker</surname><given-names>P. R. L.</given-names></name>, and <name><surname>Kriegstein</surname><given-names>A. R.</given-names></name>, &#x201C;<article-title>Neurogenic radial glia in the outer subventricular zone of human neocortex</article-title>,&#x201D; <source>Nature</source>, vol. <volume>464</volume>, no. <issue>7288</issue>, pp. <fpage>554</fpage>&#x2013;<lpage>561</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20154730</pub-id>
</mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Borrell</surname><given-names>V.</given-names></name>, &#x201C;<article-title>How cells fold the cerebral cortex</article-title>,&#x201D; <source>J. Neurosci.</source>, vol. <volume>38</volume>, no. <issue>4</issue>, pp. <fpage>776</fpage>&#x2013;<lpage>783</lpage>, <year>2018</year>.<pub-id pub-id-type="pmid">29367288</pub-id>
</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="book"><name><surname>Van Essen</surname><given-names>D. C.</given-names></name>, &#x201C;<part-title>Biomechanical models and mechanisms of cellular morphogenesis and cerebral cortical expansion and folding</part-title>,&#x201D; in <source>Seminars in Cell &amp; Developmental Biology</source>, <publisher-name>Elsevier</publisher-name>, <year>2022</year>.</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Hohlfeld</surname><given-names>E.</given-names></name> and <name><surname>Mahadevan</surname><given-names>L.</given-names></name>, &#x201C;<article-title>Unfolding the sulcus</article-title>,&#x201D; <source>Phys. Rev. Lett.</source>, vol. <volume>106</volume>, no. <issue>10</issue>, p. <fpage>105702</fpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21469809</pub-id>
</mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Tallinen</surname><given-names>T.</given-names></name>, <name><surname>Biggins</surname><given-names>J. S.</given-names></name>, and <name><surname>Mahadevan</surname><given-names>L.</given-names></name>, &#x201C;<article-title>Surface sulci in squeezed soft solids</article-title>,&#x201D; <source>Phys. Rev. Lett.</source>, vol. <volume>110</volume>, no. <issue>2</issue>, p. <fpage>024302</fpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23383906</pub-id>
</mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><name><surname>Tallinen</surname><given-names>T.</given-names></name>, <name><surname>Chung</surname><given-names>J. Y.</given-names></name>, <name><surname>Biggins</surname><given-names>J. S.</given-names></name>, and <name><surname>Mahadevan</surname><given-names>L.</given-names></name>, &#x201C;<article-title>Gyrification from constrained cortical expansion</article-title>,&#x201D; <source>Proc. Natl. Acad. Sci.</source>, vol. <volume>111</volume>, no. <issue>35</issue>, pp. <fpage>12667</fpage>&#x2013;<lpage>12672</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">25136099</pub-id>
</mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><name><surname>Kroenke</surname><given-names>C. D.</given-names></name> and <name><surname>Bayly</surname><given-names>P. V.</given-names></name>, &#x201C;<article-title>How forces fold the cerebral cortex</article-title>,&#x201D; <source>J. Neurosci.</source>, vol. <volume>38</volume>, no. <issue>4</issue>, pp. <fpage>767</fpage>&#x2013;<lpage>775</lpage>, <year>2018</year>.<pub-id pub-id-type="pmid">29367287</pub-id>
</mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><name><surname>Tallinen</surname><given-names>T.</given-names></name>, <name><surname>Chung</surname><given-names>J. Y.</given-names></name>, <name><surname>Rousseau</surname><given-names>F.</given-names></name>, <name><surname>Girard</surname><given-names>N.</given-names></name>, <name><surname>Lef&#xE8;vre</surname><given-names>J.</given-names></name>, and <name><surname>Mahadevan</surname><given-names>L.</given-names></name>, &#x201C;<article-title>On the growth and form of cortical convolutions</article-title>,&#x201D; <source>Nat. Phys.</source>, vol. <volume>12</volume>, no. <issue>6</issue>, pp. <fpage>588</fpage>&#x2013;<lpage>593</lpage>, <year>2016</year>.</mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><name><surname>Toro</surname><given-names>R.</given-names></name> and <name><surname>Burnod</surname><given-names>Y.</given-names></name>, &#x201C;<article-title>A morphogenetic model for the development of cortical convolutions</article-title>,&#x201D; <source>Cereb. Cortex</source>, vol. <volume>15</volume>, no. <issue>12</issue>, pp. <fpage>1900</fpage>&#x2013;<lpage>1913</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">15758198</pub-id>
</mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><name><surname>Toro</surname><given-names>R.</given-names></name>, <name><surname>Perron</surname><given-names>M.</given-names></name>, <name><surname>Pike</surname><given-names>B.</given-names></name>, <name><surname>Richer</surname><given-names>L.</given-names></name>, <name><surname>Veillette</surname><given-names>S.</given-names></name>, <name><surname>Pausova</surname><given-names>Z.</given-names></name>, and <name><surname>Paus</surname><given-names>T.</given-names></name>, &#x201C;<article-title>Brain size and folding of the human cerebral cortex</article-title>,&#x201D; <source>Cereb. Cortex</source>, vol. <volume>18</volume>, no. <issue>10</issue>, pp. <fpage>2352</fpage>&#x2013;<lpage>2357</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">18267953</pub-id>
</mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><name><surname>Herculano-Houzel</surname><given-names>S.</given-names></name>, &#x201C;<article-title>The human brain in numbers: a linearly scaled-up primate brain</article-title>,&#x201D; <source>Front. Hum. Neurosci.</source>, vol. <volume>3</volume>, p. <fpage>857</fpage>, <lpage>2009</lpage>.</mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><name><surname>Azevedo</surname><given-names>F. A. C.</given-names></name>, <name><surname>Carvalho</surname><given-names>L. R. B.</given-names></name>, <name><surname>Grinberg</surname><given-names>L. T.</given-names></name>, <name><surname>Farfel</surname><given-names>J. M.</given-names></name>, <name><surname>Ferretti</surname><given-names>R. E. L.</given-names></name>, <name><surname>Leite</surname><given-names>R. E. P.</given-names></name>, <name><surname>Filho</surname><given-names>W. J.</given-names></name>, <name><surname>Lent</surname><given-names>R.</given-names></name>, and <name><surname>Herculano-Houzel</surname><given-names>S.</given-names></name>, &#x201C;<article-title>Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain</article-title>,&#x201D; <source>J. Comp. Neurol.</source>, vol. <volume>513</volume>, no. <issue>5</issue>, pp. <fpage>532</fpage>&#x2013;<lpage>541</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19226510</pub-id>
</mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><name><surname>Hutton</surname><given-names>C.</given-names></name>, <name><surname>Draganski</surname><given-names>B.</given-names></name>, <name><surname>Ashburner</surname><given-names>J.</given-names></name>, and <name><surname>Weiskopf</surname><given-names>N.</given-names></name>, &#x201C;<article-title>A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging</article-title>,&#x201D; <source>Neuroimage</source>, vol. <volume>48</volume>, no. <issue>2</issue>, pp. <fpage>371</fpage>&#x2013;<lpage>380</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19559801</pub-id>
</mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><name><surname>Nie</surname><given-names>J.</given-names></name>, <name><surname>Guo</surname><given-names>L.</given-names></name>, <name><surname>Li</surname><given-names>G.</given-names></name>, <name><surname>Faraco</surname><given-names>C.</given-names></name>, <name><surname>Miller</surname><given-names>L. S.</given-names></name>, and <name><surname>Liu</surname><given-names>T.</given-names></name>, &#x201C;<article-title>A computational model of cerebral cortex folding</article-title>,&#x201D; <source>J. Theor. Biol.</source>, vol. <volume>264</volume>, no. <issue>2</issue>, pp. <fpage>467</fpage>&#x2013;<lpage>478</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20167224</pub-id>
</mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><name><surname>Bayly</surname><given-names>P.</given-names></name>, <name><surname>Okamoto</surname><given-names>R.</given-names></name>, <name><surname>Xu</surname><given-names>G.</given-names></name>, <name><surname>Shi</surname><given-names>Y.</given-names></name>, and <name><surname>Taber</surname><given-names>L.</given-names></name>, &#x201C;<article-title>A cortical folding model incorporating stress-dependent growth explains gyral wavelengths and stress patterns in the developing brain</article-title>,&#x201D; <source>Phys. Biol.</source>, vol. <volume>10</volume>, no. <issue>1</issue>, p. <fpage>016005</fpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23357794</pub-id>
</mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><name><surname>Budday</surname><given-names>S.</given-names></name>, <name><surname>Raybaud</surname><given-names>C.</given-names></name>, and <name><surname>Kuhl</surname><given-names>E.</given-names></name>, &#x201C;<article-title>A mechanical model predicts morphological abnormalities in the developing human brain</article-title>,&#x201D; <source>Sci. Rep.</source>, vol. <volume>4</volume>, p. <fpage>5644</fpage>, <lpage>2014</lpage>.<pub-id pub-id-type="pmid">25008163</pub-id>
</mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><name><surname>Garcia</surname><given-names>K. E.</given-names></name>, <name><surname>Wang</surname><given-names>X.</given-names></name>, and <name><surname>Kroenke</surname><given-names>C. D.</given-names></name>, &#x201C;<article-title>A model of tension-induced fiber growth predicts white matter organization during brain folding</article-title>,&#x201D; <source>Nat. Commun.</source>, vol. <volume>12</volume>, no. <issue>1</issue>, p. <fpage>6681</fpage>, <year>2021</year>.<pub-id pub-id-type="pmid">34795256</pub-id>
</mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><name><surname>Heuer</surname><given-names>K.</given-names></name>, <name><surname>Traut</surname><given-names>N.</given-names></name>, <name><surname>de Sousa</surname><given-names>A. A.</given-names></name>, <name><surname>Valk</surname><given-names>S. L.</given-names></name>, <name><surname>Clavel</surname><given-names>J.</given-names></name>, and <name><surname>Toro</surname><given-names>R.</given-names></name>, &#x201C;<article-title>Diversity and evolution of cerebellar folding in mammals</article-title>,&#x201D; <source>Elife</source>, vol. <volume>12</volume>, p. <fpage>e85907</fpage>, <lpage>2023</lpage>.<pub-id pub-id-type="pmid">37737580</pub-id>
</mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><name><surname>Pang</surname><given-names>J. C.</given-names></name>, <name><surname>Aquino</surname><given-names>K. M.</given-names></name>, <name><surname>Oldehinkel</surname><given-names>M.</given-names></name>, <name><surname>Robinson</surname><given-names>P. A.</given-names></name>, <name><surname>Fulcher</surname><given-names>B. D.</given-names></name>, <name><surname>Breakspear</surname><given-names>M.</given-names></name>, and <name><surname>Fornito</surname><given-names>A.</given-names></name>, &#x201C;<article-title>Geometric constraints on human brain function</article-title>,&#x201D; <source>Nature</source>, vol. <volume>618</volume>, no. <issue>7965</issue>, pp. <fpage>566</fpage>&#x2013;<lpage>574</lpage>, <year>2023</year>.<pub-id pub-id-type="pmid">37258669</pub-id>
</mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><name><surname>Schwartz</surname><given-names>E.</given-names></name>, <name><surname>Nenning</surname><given-names>K.-H.</given-names></name>, <name><surname>Heuer</surname><given-names>K.</given-names></name>, <name><surname>Jeffery</surname><given-names>N.</given-names></name>, <name><surname>Bertrand</surname><given-names>O. C.</given-names></name>, <name><surname>Toro</surname><given-names>R.</given-names></name>, <name><surname>Kasprian</surname><given-names>G.</given-names></name>, <name><surname>Prayer</surname><given-names>D.</given-names></name>, and <name><surname>Langs</surname><given-names>G.</given-names></name>, &#x201C;<article-title>Evolution of cortical geometry and its link to function, behaviour and ecology</article-title>,&#x201D; <source>Nat. Commun.</source>, vol. <volume>14</volume>, no. <issue>1</issue>, p. <fpage>2252</fpage>, <year>2023</year>.<pub-id pub-id-type="pmid">37080952</pub-id>
</mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><name><surname>Neal</surname><given-names>J.</given-names></name>, <name><surname>Takahashi</surname><given-names>M.</given-names></name>, <name><surname>Silva</surname><given-names>M.</given-names></name>, <name><surname>Tiao</surname><given-names>G.</given-names></name>, <name><surname>Walsh</surname><given-names>C. A.</given-names></name>, and <name><surname>Sheen</surname><given-names>V. L.</given-names></name>, &#x201C;<article-title>Insights into the gyrification of developing ferret brain by magnetic resonance imaging</article-title>,&#x201D; <source>J. Anat.</source>, vol. <volume>210</volume>, no. <issue>1</issue>, pp. <fpage>66</fpage>&#x2013;<lpage>77</lpage>, <year>2007</year>.<pub-id pub-id-type="pmid">17229284</pub-id>
</mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><name><surname>Sawada</surname><given-names>K.</given-names></name> and <name><surname>Watanabe</surname><given-names>M.</given-names></name>, &#x201C;<article-title>Development of cerebral sulci and gyri in ferrets (mustela putorius)</article-title>,&#x201D; <source>Congenit. Anom</source>., vol. <volume>52</volume>, no. <issue>3</issue>, pp. <fpage>168</fpage>&#x2013;<lpage>175</lpage>, <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>M. B.</given-names></name>, <name><surname>Sun</surname><given-names>X.</given-names></name>, <name><surname>Kodani</surname><given-names>A.</given-names></name>, <name><surname>Borges-Monroy</surname><given-names>R.</given-names></name>, <name><surname>Girskis</surname><given-names>K. M.</given-names></name>, <name><surname>Ryu</surname><given-names>S. C.</given-names></name>, <name><surname>Wang</surname><given-names>P. P.</given-names></name>, <name><surname>Patel</surname><given-names>K.</given-names></name>, <name><surname>Gonzalez</surname><given-names>D. M.</given-names></name>, <name><surname>Woo</surname><given-names>Y. M.</given-names></name>, <etal/>, &#x201C;<article-title>Aspm knockout ferret reveals an evolutionary mechanism governing cerebral cortical size</article-title>,&#x201D; <source>Nature</source>, vol. <volume>556</volume>, no. <issue>7701</issue>, pp. <fpage>370</fpage>&#x2013;<lpage>375</lpage>, <year>2018</year>.<pub-id pub-id-type="pmid">29643508</pub-id>
</mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><name><surname>Gilardi</surname><given-names>C.</given-names></name> and <name><surname>Kalebic</surname><given-names>N.</given-names></name>, &#x201C;<article-title>The ferret as a model system for neocortex development and evolution</article-title>,&#x201D; <source>Front. Cell Dev. Biol.</source>, vol. <volume>9</volume>, p. <fpage>661759</fpage>, <lpage>2021</lpage>.</mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><name><surname>Masuda</surname><given-names>K.</given-names></name>, <name><surname>Toda</surname><given-names>T.</given-names></name>, <name><surname>Shinmyo</surname><given-names>Y.</given-names></name>, <name><surname>Ebisu</surname><given-names>H.</given-names></name>, <name><surname>Hoshiba</surname><given-names>Y.</given-names></name>, <name><surname>Wakimoto</surname><given-names>M.</given-names></name>, <name><surname>Ichikawa</surname><given-names>Y.</given-names></name>, and <name><surname>Kawasaki</surname><given-names>H.</given-names></name>, &#x201C;<article-title>Pathophysiological analyses of cortical malformation using gyrencephalic mammals</article-title>,&#x201D; <source>Sci. Rep.</source>, vol. <volume>5</volume>, no. <issue>1</issue>, pp. <fpage>1</fpage>&#x2013;<lpage>15</lpage>, <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><name><surname>Tabata</surname><given-names>H.</given-names></name> and <name><surname>Nakajima</surname><given-names>K.</given-names></name>, &#x201C;<article-title>Efficient in utero gene transfer system to the developing mouse brain using electroporation: visualization of neuronal migration in the developing cortex</article-title>,&#x201D; <source>Neuroscience</source>, vol. <volume>103</volume>, no. <issue>4</issue>, pp. <fpage>865</fpage>&#x2013;<lpage>872</lpage>, <year>2001</year>.<pub-id pub-id-type="pmid">11301197</pub-id>
</mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><name><surname>Tallinen</surname><given-names>T.</given-names></name> and <name><surname>Biggins</surname><given-names>J. S.</given-names></name>, &#x201C;<article-title>Mechanics of invagination and folding: Hybridized instabilities when one soft tissue grows on another</article-title>,&#x201D; <source>Phys. Rev. E</source>, vol. <volume>92</volume>, no. <issue>2</issue>, p. <fpage>022720</fpage>, <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>P. T.</given-names></name>, <name><surname>Lam</surname><given-names>K. C.</given-names></name>, and <name><surname>Lui</surname><given-names>L. M.</given-names></name>, &#x201C;<article-title>FLASH: Fast landmark aligned spherical harmonic parameterization for genus-0 closed brain surfaces</article-title>,&#x201D; <source>SIAM J. Imaging Sci.</source>, vol. <volume>8</volume>, no. <issue>1</issue>, pp. <fpage>67</fpage>&#x2013;<lpage>94</lpage>, <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><name><surname>Koenderink</surname><given-names>J. J.</given-names></name> and <name><surname>van Doorn</surname><given-names>A. J.</given-names></name>, &#x201C;<article-title>Surface shape and curvature scales</article-title>,&#x201D; <source>Image Vis. Comput.</source>, vol. <volume>10</volume>, no. <issue>8</issue>, pp. <fpage>557</fpage>&#x2013;<lpage>564</lpage>, <year>1992</year>.</mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><name><surname>Yin</surname><given-names>S.</given-names></name>, <name><surname>Liu</surname><given-names>C.</given-names></name>, <name><surname>Jung</surname><given-names>Y.</given-names></name>, <name><surname>Choi</surname><given-names>G. P. T.</given-names></name>, <name><surname>Toro</surname><given-names>R.</given-names></name>, <name><surname>Heuer</surname><given-names>K.</given-names></name>, and <name><surname>Mahadevan</surname><given-names>L.</given-names></name>, &#x201C;<article-title>Morphogenesis and morphometry of brain folding patterns across species</article-title>,&#x201D; <source>Preprint</source>, <year>2025</year>.</mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>R. S.</given-names></name>, <name><surname>Kenny</surname><given-names>C. J.</given-names></name>, <name><surname>Ganesh</surname><given-names>V.</given-names></name>, <name><surname>Jang</surname><given-names>A.</given-names></name>, <name><surname>Borges-Monroy</surname><given-names>R.</given-names></name>, <name><surname>Partlow</surname><given-names>J. N.</given-names></name>, <name><surname>Hill</surname><given-names>R. S.</given-names></name>, <name><surname>Shin</surname><given-names>T.</given-names></name>, <name><surname>Chen</surname><given-names>A. Y.</given-names></name>, <name><surname>Doan</surname><given-names>R. N.</given-names></name>, <etal/>, &#x201C;<article-title>Sodium channel SCN3A (NaV1. 3) regulation of human cerebral cortical folding and oral motor development</article-title>,&#x201D; <source>Neuron</source>, vol. <volume>99</volume>, no. <issue>5</issue>, pp. <fpage>905</fpage>&#x2013;<lpage>913</lpage>, <year>2018</year>.<pub-id pub-id-type="pmid">30146301</pub-id>
</mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><name><surname>Akula</surname><given-names>S. K.</given-names></name>, <name><surname>Marciano</surname><given-names>J. H.</given-names></name>, <name><surname>Lim</surname><given-names>Y.</given-names></name>, <name><surname>Exposito-Alonso</surname><given-names>D.</given-names></name>, <name><surname>Hylton</surname><given-names>N. K.</given-names></name>, <name><surname>Hwang</surname><given-names>G. H.</given-names></name>, <name><surname>Neil</surname><given-names>J. E.</given-names></name>, <name><surname>Dominado</surname><given-names>N.</given-names></name>, <name><surname>Bunton-Stasyshyn</surname><given-names>R. K.</given-names></name>, <name><surname>Song</surname><given-names>J. H. T.</given-names></name>, <etal/>, &#x201C;<article-title>TMEM161B regulates cerebral cortical gyration, sonic hedgehog signaling, and ciliary structure in the developing central nervous system</article-title>,&#x201D; <source>Proc. Natl. Acad. Sci.</source>, vol. <volume>120</volume>, no. <issue>4</issue>, p. <fpage>e2209964120</fpage>, <year>2023</year>.<pub-id pub-id-type="pmid">36669111</pub-id>
</mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="webpage">&#x201C;<source>FIIND: Ferret interactive integrated neuro development atlas</source>.&#x201D; <comment><ext-link xlink:href="https://neuroanatomy.github.io/fiind/" ext-link-type="uri">https://neuroanatomy.github.io/fiind/</ext-link></comment>, <year>2018</year>.</mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="webpage">&#x201C;<source>NetGen</source>.&#x201D; <comment><ext-link xlink:href="https://ngsolve.org/" ext-link-type="uri">https://ngsolve.org/</ext-link></comment>, <year>2019</year>.</mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="confproc"><name><surname>Stomakhin</surname><given-names>A.</given-names></name>, <name><surname>Howes</surname><given-names>R.</given-names></name>, <name><surname>Schroeder</surname><given-names>C.</given-names></name>, and <name><surname>Teran</surname><given-names>J. M.</given-names></name>, &#x201C;<source>Energetically consistent invertible elasticity</source>,&#x201D; in <conf-name>Proceedings of the 11th ACM SIGGRAPH/Eurographics conference on Computer Animation</conf-name>, pp. <fpage>25</fpage>&#x2013;<lpage>32</lpage>, <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><name><surname>Bonet</surname><given-names>J.</given-names></name> and <name><surname>Burton</surname><given-names>A.</given-names></name>, &#x201C;<article-title>A simple average nodal pressure tetrahedral element for incompressible and nearly incompressible dynamic explicit applications</article-title>,&#x201D; <source>Comm. Numer. Meth. Eng.</source>, vol. <volume>14</volume>, no. <issue>5</issue>, pp. <fpage>437</fpage>&#x2013;<lpage>449</lpage>, <year>1998</year>.</mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="book"><name><surname>Ericson</surname><given-names>C.</given-names></name>, <source>Real-time collision detection</source>. <publisher-name>CRC Press</publisher-name>, <year>2004</year>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="F1">
      <label>Figure 1:</label>
      <caption>
        <title>Time course of ferret brain morphogenesis.</title>
        <p id="P25"><bold>a</bold>, Whole brain samples from ferrets of various ages show progressive development of cortical gyri and sulci. <bold>b</bold>, Ferret brains show an increase in complexity of sulcal pattern and in sulcal depth throughout development. The rhinal sulcus (rs), cruciate sulcus (crs), coronal sulcus (cns), suprasylvian sulcus (sss), pseudosylvian sulcus (pss), lateral sulcus (ls), and ansate sulcus (as) are labelled. Schematic by G. S&#xE9;journ&#xE9;.</p>
      </caption>
      <graphic xlink:href="nihpp-2025.03.05.641682v1-f0001" position="float"/>
    </fig>
    <fig position="float" id="F2">
      <label>Figure 2:</label>
      <caption>
        <title>Physical gel model of ferret brain morphogenesis.</title>
        <p id="P26"><bold>a</bold>, Schematic of the gel experiment. We first produced a two-layer gel model of a ferret brain from MRI scans as previously described (<xref rid="R17" ref-type="bibr">17</xref>). We then immersed the gel model in n-hexane for 1.5 hours, which induced the outer layer to swell by absorbing the solvent over time, resulting in the development of cortical gyri and sulci. <bold>b</bold>, The swelling experiment for the P8 ferret model, in which it can be observed that the swelling of the cortical layer produces sulcal patterns and characteristics comparable to the real ferret brain. <bold>c</bold>, The swelling experiment for the P16 gel model. Scale bar = 1cm. Notation guide: cruciate sulcus (crs), coronal sulcus (cns), suprasylvian sulcus (sss), rhinal sulcus (rs), pseudosylvian sulcus (pss), lateral sulcus (ls), ansate sulcus (as).</p>
      </caption>
      <graphic xlink:href="nihpp-2025.03.05.641682v1-f0002" position="float"/>
    </fig>
    <fig position="float" id="F3">
      <label>Figure 3:</label>
      <caption>
        <title>Numerical model of ferret brain morphogenesis.</title>
        <p id="P27"><bold>a</bold>, Continuous growth simulation from P0 to adolescence. The P0 brain tetrahedral mesh was used as the input for the numerical simulation. <bold>b</bold>, Stepwise growth simulation from P0 to P4, P4 to P8, P8 to P16, and P16 to P32. For different growth intervals, we use different brain tetrahedral meshes as the input for the numerical simulation. Different views of the input P0 brain and the simulated P16 brain are provided.</p>
      </caption>
      <graphic xlink:href="nihpp-2025.03.05.641682v1-f0003" position="float"/>
    </fig>
    <fig position="float" id="F4">
      <label>Figure 4:</label>
      <caption>
        <title>Comparison of cortical folding in real and simulated ferret brain models.</title>
        <p id="P28"><bold>a</bold>, The top row shows the increase in complexity of sulcal pattern and in sulcal depth of ferret brains from P8 to P16. The middle row shows a numerical model of a P8 brain and its deformed state mimicking progression to P16. The bottom row shows a physical gel model of P8 and its post-swelling state mimicking progression to P16 (scale bar = 1cm). The P8 initial states have invaginations corresponding to the cruciate sulcus (crs), coronal sulcus (cns) and suprasylvian sulcus (sss), and both the numerical deformed state and the physical post-swelling state have sulci corresponding in location and self-contacting nature to the crs, cns, sss, lateral sulcus (ls), and ansate sulcus (as) observed in P16 real ferrets. <bold>b</bold>, The real P16 brain reconstructed from MRI scans, the simulated P16 brain, and their respective landmark-aligned spherical mappings obtained by the FLASH algorithm (<xref rid="R37" ref-type="bibr">37</xref>), each color-coded with the shape index (<xref rid="R38" ref-type="bibr">38</xref>) of the brain.</p>
      </caption>
      <graphic xlink:href="nihpp-2025.03.05.641682v1-f0004" position="float"/>
    </fig>
    <fig position="float" id="F5">
      <label>Figure 5:</label>
      <caption>
        <title>Modeling malformations of cortical development (MCD) using our model.</title>
        <p id="P29"><bold>a</bold>, Control. <bold>b</bold>, <italic toggle="yes">SCN3A</italic>. <bold>c</bold>, <italic toggle="yes">ASPM</italic>. <bold>d</bold>, <italic toggle="yes">TMEM161B</italic>. For each example, we show human (top) and ferret (middle) brain MRIs. We then perform a modified numerical brain simulation on the P8 model with different tangential growth rate and cortical thickness parameters, including (<bold>a</bold>) the original growth rate and cortical thickness, (<bold>b</bold>) a reduction of the cortical thickness at a localized zone, (<bold>c</bold>) a reduction of the growth rate globally, and (<bold>d</bold>) a reduction of the growth rate and an increase of the cortical thickness globally. All numerical simulation results (bottom) qualitatively capture the cortical malformations.</p>
      </caption>
      <graphic xlink:href="nihpp-2025.03.05.641682v1-f0005" position="float"/>
    </fig>
  </floats-group>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40082771</article-id><article-id pub-id-type="pmc">11907912</article-id>
<article-id pub-id-type="publisher-id">3745</article-id><article-id pub-id-type="doi">10.1186/s12876-025-03745-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Colitis can reduce the cingulate cortex neuronal density in rats</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Amlashi</surname><given-names>Fazel Isapanah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Besharat</surname><given-names>Sima</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Jahanshahi</surname><given-names>Mehrdad</given-names></name><address><email>mejahanshahi@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Shirzad-Aski</surname><given-names>Hesamaddin</given-names></name><address><email>Shirzad.hessam1364@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Torshizi</surname><given-names>Fatemeh Nassaj</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mcx2558</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution>Golestan Research Center of Gastroenterology and Hepatology, </institution><institution>GolestanUniversity of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mcx2558</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution>Neuroscience Research Center, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mcx2558</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution>Infectious Diseases Research Center, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, 49178-67439 Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mcx2558</institution-id><institution-id institution-id-type="GRID">grid.411747.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0418 0096</institution-id><institution>Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, </institution><institution>Golestan University of Medical Sciences, </institution></institution-wrap>Gorgan, Iran </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>171</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and aim</title><p id="Par1">Hyperalgesia and hypersensitivity in patients with Inflammatory Bowel Disease (IBD) can be related to central nervous system (CNS) changes, particularly in the pain pathways. The objective of this study was to examine the neuronal density of the cingulate cortex area (CC) and amygdala in an animal model of colitis.</p></sec><sec><title>Materials and methods</title><p id="Par2">In this experiment, 13 male Wistar rats were subjected to study. Colitis was induced in the rats by transrectally administering 1&#xA0;cc of acetic acid 3% under sedation with xylazine 10% (5&#xA0;mg/kg). After 14 days of colitis, the rats were euthanized under high doses of anesthesia with ketamine (50&#xA0;mg/kg), xylazine (10&#xA0;mg/kg), and diazepam (2.5&#xA0;mg/kg). Their brains were then removed surgically. Six-micrometer-thick brain slices were stained with <italic>cresyl violet</italic>, and the neuronal density of the amygdala, area 1 of the cingulate cortex area (CC1), and area 2 of the cingulate cortex area (CC2) was assessed via microscopic imaging.</p></sec><sec><title>Results</title><p id="Par3">The mean&#x2009;&#xB1;&#x2009;standard deviation (SD) of the neuronal density in CC1 was significantly decreased in rats with colitis compared to the control group in both the right CC1 (43.53&#x2009;&#xB1;&#x2009;9.63 vs. 62.7&#x2009;&#xB1;&#x2009;11.89; p-value &#x2C2; 0.001), and left CC1 (41.19&#x2009;&#xB1;&#x2009;9.05 and 63.1&#x2009;&#xB1;&#x2009;7.44; p-value &#x2C2; 0.001). Additionally, the neuronal density of CC2 in the colitis group was found to be significantly lower than that of the controls in both the right CC2 (57.8&#x2009;&#xB1;&#x2009;13.23 vs. 87.95&#x2009;&#xB1;&#x2009;8.76; p-value &#x2C2; 0.001), and left CC2 (55.42&#x2009;&#xB1;&#x2009;11.3 vs. 98&#x2009;&#xB1;&#x2009;8.99; p-value &#x2C2; 0.001). Furthermore, the amygdala had a lower neuronal density in both hemispheres in rats with colitis in comparison to the controls bilaterally: right hemisphere (24.51&#x2009;&#xB1;&#x2009;5.49 and 36.3&#x2009;&#xB1;&#x2009;7.44; p-value&#x2009;=&#x2009;0.360), and left hemisphere (24.52&#x2009;&#xB1;&#x2009;5.53 VS. 35.25&#x2009;&#xB1;&#x2009;5.6; P-value&#x2009;=&#x2009;0.869).</p></sec><sec><title>Conclusion</title><p id="Par4">This study showed that colitis can reduce the neuronal density within cortical areas and amygdala of both hemispheres. Considering the cingulate cortex&#x2019;s role in suppressing pain perception, any harm inflicted upon this region of the brain can has the ability to impact the cognitive and sensory aspects of pain.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12876-025-03745-x.</p></sec></abstract><abstract id="Abs2" abstract-type="Key Message"><title>Key message</title><p id="Par5">&#x2022; What is already known?</p><p id="Par6">Inflammatory Bowel Disease (IBD) can be related to central nervous system (CNS) changes.</p><p id="Par7">
&#x2022; What is new here?</p><p id="Par8">A reduction rate in the density of neurons in the cingulate cortex and amygdala area of the brain was observed in rats with colitis.</p><p id="Par9">
&#x2022; How can this study help patient care?</p><p id="Par10">The neuronal damage in the pain matrix can result in the alteration of pain perception in patients with IBD.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12876-025-03745-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colitis</kwd><kwd>Inflammatory bowel disease</kwd><kwd>Acetic acid</kwd><kwd>Gyrus cinguli</kwd><kwd>Amygdala</kwd><kwd>Chronic inflammation</kwd><kwd>Animal model</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par11">Inflammatory bowel disease (IBD) is a long-term immune-mediated disorder that triggers ongoing inflammation in the gastrointestinal (GI) tract. It is primarily categorized into two types: Crohn&#x2019;s disease (CD) and ulcerative colitis (UC) [<xref ref-type="bibr" rid="CR1">1</xref>]. While IBD predominantly affects the GI tract, patients may also experience a range of symptoms affecting other systems, including pulmonary, cardiovascular, ocular, dermatological, musculoskeletal, urinary, and neurologic systems [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. This multi-organ involvement s in IBD stems from systemic inflammation resulting from an imbalance between pro-inflammatory and anti-inflammatory substances in the body.</p>
      <p id="Par12">The central nervous system (CNS) is often underestimated aspect that can be influenced by IBD, leading to various psychiatric, cognitive, or neurological symptoms [<xref ref-type="bibr" rid="CR5">5</xref>]. Injury or inflammation of the GI tract can result in heightened sensitivity and pain in the intestine [<xref ref-type="bibr" rid="CR6">6</xref>]. Additionally,, those with IBD frequently encounter other pain-related conditions, such as fibromyalgia, polymyalgia rheumatica, chronic pain syndrome, abdominal discomfort, myalgia, and arthralgia [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. Various proposed mechanisms indicate an alteration in the functioning of the pain neuromatrix. These include persistent hyperexcitability in the viscerosensory nuclei of the brainstem and thalamus, hypothalamus, amygdala, hippocampus, anterior insula, and anterior cingulate cortical [<xref ref-type="bibr" rid="CR10">10</xref>]. This amplified sensitivity to pain is largely attributed to neuroplastic alterations in the spinal cord and brain that arise from GI tract pathologies.</p>
      <p id="Par13">Melzack and Casey introducee the neuromatrix theory of pain to demonstrate the interconnectedness of various pain components, including cognitive, sensory, and affective elements. They suggested that various areas of the brain work together to create the overall experience of pain [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. A key player in this pain neuromatrix is the cingulate cortex (CC), which is essential for modulating pain-related behaviors and influencing activity in the spinal dorsal horn [<xref ref-type="bibr" rid="CR13">13</xref>]. Research has shown that damage to the CC can significantly enhance nociceptive responses in animal models [<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, studies have revealed that patients with IBD often exhibit a reduction in grey matter volume and alterations in various cortical regions of the brain [<xref ref-type="bibr" rid="CR15">15</xref>]. As a result, injuries in the areas of the brain responsible for processing pain can interfere with the system&#x2019;s typical functioning, leading to alterations in the pain experiences of those affected by IBD.</p>
      <p id="Par14">The concept of the gut-brain axis (GBA) refers to the interaction between the brain and the GI tract in both normal and abnormal circumstances [<xref ref-type="bibr" rid="CR16">16</xref>]. A growing body of evidence suggests that the GBA establishes direct links between the limbic system and the enteric nervous system of the GI tract [<xref ref-type="bibr" rid="CR17">17</xref>]. The Amygdala, a vital element of the GBA, plays a crucial role in the two-way communication that occurs among GI functions, gut microbiota, and emotional response [<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, the amygdala is implicated in pain perception and related behaviors, as part of the pain neuromatrix [<xref ref-type="bibr" rid="CR18">18</xref>]. Studies using functional magnetic resonance imaging (fMRI) have shown that the amygdala is impacted in patients with IBD [<xref ref-type="bibr" rid="CR17">17</xref>]. This observation suggests that alterations in the CNS may play a role in heightened pain sensitivity experienced by IBD patients.</p>
      <p id="Par15">We proposed that the onset of systemic inflammation associated with IBD could result in neuronal damage within the brain. Such damage may affect the pain pathways in the CNS, particularly in areas like CC and amygdala, potentially altering how pain is processed.</p>
      <p id="Par16">Therefore, in this study we aimed to evaluate the neuronal population in CC and amygdala in both hemispheres of rats with colitis induced by the 3% acetic acid solution enema; then compare the neuronal density in rats with IBD and healthy group.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Animals</title>
        <p id="Par17">In the present study, 13 male Wistar rats aged between 12 and 15 weeks, with an average weight of 250&#x2009;&#xB1;&#x2009;25&#xA0;g, were employed. The animals were purchased from a branch of the Institute Pasteur of Tehran, Iran, which is responsible for the production and sale of animals for research, located in the north of Iran. Following their relocation to the animal center of Golestan University of Medical Sciences (GOUMS) in Iran, the rats were subjected to standard conditions. The adaptation period to the new environment was 14 days. The animals were housed in plastic cages that provided an enriched environment. A 12-hour light-dark cycle and an ambient temperature of 22 to 24&#xA0;&#xB0;C were maintained for their continued care. Furthermore, the rats were provided with unrestricted access to both food and water. Before induction of colitis, the rats had only access to water for 24&#xA0;h and their food was limited [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
        <p id="Par18">The study protocol has been approved by the local ethical committee of Golestan University of Medical Sciences (ID: IR.GOUMS.REC.1401.081). The experiments reported herein were precisely in accordance with the principles given by the National Committee for Research Ethics in Science and Technology, Guide for the Care and Use of Laboratory Animals in Iran and the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Design of the experiment</title>
        <p id="Par19">The colitis group consisted of nine rats (20% possible percentage decrease), which were administered 2&#xA0;ml of a 3% acetic acid solution via transrectal injection on the first day of the experiment. This was done under sedation conditions, with the rats receiving an intraperitoneal (IP) injection of xylazine 2% (5&#xA0;mg/kg; Alfasan, the Netherlands). The control group consisted of four rats that appeared healthy. They were treated with distilled water in the same manner as the group with colitis.</p>
      </sec>
      <sec id="Sec5">
        <title>Inclusion and exclusion criteria</title>
        <p id="Par20">After adaptation of the animals, all apparently healthy animals with a weight range of 225&#x2013;275 gr were included in the experiment into two groups. Furthermore, animals were remained in the colitis group if the colitis model induced successfully.</p>
        <p id="Par21">If the rats lost more than 30% of their initial body weight during the experiment or fever was detected in them, they were excluded from the study because of the increasing risk of death [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Colitis induction</title>
        <p id="Par22">To prepare the 3% acetic acid solution, a mixture of absolute glacial acetic acid (CAS-Nummer:64-19-7, Merck, Germany) and distilled water was utilized. Each rat was then administered 2&#xA0;ml of this solution via transrectal administration using a feeding tube with a diameter of 1.5&#xA0;mm under conditions of animal sedation (xylazine 2% (10&#xA0;mg/kg)). The tube was inserted into the rectum to a depth of approximately 8&#xA0;cm, ensuring that it reached the splenic flexure of the colon. The solution was infused at a slow rate in the Trendelenburg position, and the rats were kept for one minute to prevent leakage [<xref ref-type="bibr" rid="CR22">22</xref>]. After induction, the animals were observed by a veterinarian (H.S.) for one hour.</p>
        <p id="Par23">Each group of rats were kept in separate cages for 14 days [<xref ref-type="bibr" rid="CR23">23</xref>] and have been monitored daily regards their weights and disease activity index as described in the next section. Following 14 days of colitis, all rats were euthanized and their brains and colons were collected for analysis, as described in Sects.&#xA0;<xref rid="Sec2" ref-type="sec">2</xref>&#x2013;<xref rid="Sec15" ref-type="sec">5</xref> and <xref rid="Sec2" ref-type="sec">2</xref>&#x2013;6.</p>
      </sec>
      <sec id="Sec7">
        <title>Disease activity index (DAI)</title>
        <p id="Par24">The severity and activity of colitis were assessed by the Disease Activity Index (DAI). The DAI assessed aspects such as weight loss, stool consistency, and rectal bleeding [<xref ref-type="bibr" rid="CR24">24</xref>]. To measure the DAI, a checklist was used daily. The checklist included the following items:</p>
        <p id="Par25">
<list list-type="order"><list-item><p id="Par26">Stool trait: It was rated as normal (0), soft (2), or diarrhea (4).</p></list-item><list-item><p id="Par27">Weight loss: It was categorized as none (0), 1&#x2013;5% (1), 6&#x2013;10% (2), 11&#x2013;20% (3), or more than 20% (4).</p></list-item><list-item><p id="Par28">Rectal bleeding: It was rated determined as negative (0), positive occult blood test (2), and visible bleeding (4).</p></list-item></list>
</p>
      </sec>
      <sec id="Sec700">
        <title>Colon evaluation</title>
        <p id="Par29">One day following the administration of acetic acid, one rat from the colitis group was placed in a carbon dioxide (CO<sub>2</sub>) gas chamber for the purpose of sacrifice. Its intestine (colon portion) was then surgically removed. Upon examination, the colon exhibited significant inflammation (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The colon displayed complete involvement with hyperemia, inflammation, and ulcers, which can be indicative of colitis [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
        <p id="Par30">
<fig id="Fig1"><label>Fig. 1</label><caption><p>The macroscopic evaluation of colon in rats with acetic acid-induced colitis. <bold>A</bold> and <bold>B</bold>: after one day of colitis induction, the colon was completely hyperemic and inflamed; <bold>C</bold> and <bold>D</bold>: 14 days later, the inflammation seemed to be decreased but large ulcers were seen</p></caption><graphic xlink:href="12876_2025_3745_Fig1_HTML" id="d33e432"/></fig>
</p>
        <p id="Par31">On the 14th day after the acetic acid enema, the colon of one other rat was surgically removed (euthanized as before in the CO<sub>2</sub> tank) and appeared non-hyperemic, but exhibited a 2-cm long ulcer, with very mild inflammation. Imaging studies depicted a severe and acute onset of colitis in the initial days; followed by a gradual reduction in its severity over time. Considering the evidence, it can be concluded that the induction of chronic colitis was successful in the colitis group.</p>
      </sec>
      <sec id="Sec8">
        <title>Histological procedures</title>
        <p id="Par32">The other rats were first administered an intra-peritoneal (IP) injection of a cocktail including ketamine 10% (50&#xA0;mg/kg; Alfasan, the Netherlands), xylazine 2% (10&#xA0;mg/kg), and diazepam hydrochloride (2.5&#xA0;mg/kg; Darupakhsh, Iran) drugs [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], followed by decapitation to remove their brains from the skull [<xref ref-type="bibr" rid="CR23">23</xref>]. The brains were then preserved in a solution containing 4% paraformaldehyde (DR Mojallali, Iran) for a duration of 14 days. Afterward, the brain tissues underwent preparation using a tissue processor (D2 2080/H, Iran), involving dehydration using alcohol and clarification using xylol (DR Mojallali, Iran) [<xref ref-type="bibr" rid="CR26">26</xref>]. Subsequently, the paraffin blocks of the brain were sectioned to 6&#xA0;&#x3BC;m thickness sagittal planes serial approach using a rotary microtome (Pooyan MK 1110, Iran) [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title><italic>Cresyl Violet</italic> staining</title>
        <p id="Par33">Deparafinized brain slices were rehydrated in a graded ethanol series and rinsed in distilled water. The brain sections&#x2019; slides were then stained with the 0.02% <italic>cresyl violet</italic> (Sigma, USA) for 5&#xA0;min [<xref ref-type="bibr" rid="CR27">27</xref>], then dipped in distilled water (3 times), and dehydrated in a graded ethanol series (Merck, Germany), and finally washed out in xylene (DR Mojallali, Iran) and coverslipped with entellan (Merck, Germany).</p>
      </sec>
      <sec id="Sec10">
        <title>Brain areas</title>
        <p id="Par34">The brain areas within the CC and amygdala are defined based on the Paxinos and Watson <italic>The Rat Brain atlas</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. The CC is composed of two distinct areas, namely CC area 1 (CC1) and area 2 (CC2), which are situated adjacent to the midline. To locate the amygdala, one can trace the internal capsule on the lower section of the brain in both hemispheres.</p>
      </sec>
      <sec id="Sec11">
        <title>Morphometry of neurons</title>
        <p id="Par35">To evaluate the density of neurons, a microscope (BX51, Olympus, Japan) along with a DP 12 digital camera was employed to capture an image from each location in both hemispheres. The images, magnified at 400&#xD7;, were subsequently transferred to a computer for morphometric analysis [<xref ref-type="bibr" rid="CR29">29</xref>]. The OLYSIA Autobioreport software was utilized to overlay suitable grids onto the images. On each image, a randomly selected area of 30,000 &#xB5;m<sup>2</sup> was chosen [<xref ref-type="bibr" rid="CR30">30</xref>]. As neuronal density refers to numerical density of neurons per unit area, our definition of neuronal density was the ratio between the sum of area covered by neurons divided by the whole frame surface. An operator, who remained unaware of the condition, manually counted the neurons, considering only those with distinctive cell bodies and/or nuclei.</p>
      </sec>
      <sec id="Sec12">
        <title>Statistical analysis</title>
        <p id="Par36">The mean and standard deviation (SD) of CC1, CC2, and amygdala variables were calculated. The normality of the data was checked using the Shapiro-Wilk test and then, they were compared using the Welch t-test, student t-test, and Mann-Whitney u-test. The significance level of the tests was considered to be 0.05. Data were analyzed using SPSS 25 software.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Results</title>
      <p id="Par37">The group of rats with colitis showed a higher DAI compared to the control groups. The mean&#x2009;&#xB1;&#x2009;SD of DAI was 2&#x2009;&#xB1;&#x2009;1.08 in rats with colitis, whereas it was 0.33&#x2009;&#xB1;&#x2009;0.27 in the control group (p-value&#x2009;=&#x2009;0.024). As it was expected, the colitis group had a higher DAI compared to control group. The neuronal density in Cingulate Cortex (CC) was found to be lower on both sides in rats with colitis compared to the control group (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).</p>
      <p id="Par38">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Comparison of the neuronal density of cingulate cortex (CC) and amygdala in colitis and control group. <bold>A</bold>: CC area 1 in the right hemisphere; <bold>B</bold>: CC area 1 in the left hemisphere; <bold>C</bold>: CC area 2 in the right hemisphere; <bold>D</bold>: CC area 2 in the left hemisphere; <bold>E</bold>: amygdala in the right hemisphere; <bold>F</bold>: amygdala in the left hemisphere. *p-value &#x2C2; 0.001; ** p-value&#x2009;&gt;&#x2009;0.05</p></caption><graphic xlink:href="12876_2025_3745_Fig2_HTML" id="d33e532"/></fig>
</p>
      <p id="Par39">In the right CC1, the mean&#x2009;&#xB1;&#x2009;SD of neuronal density in the colitis group was 43.53&#x2009;&#xB1;&#x2009;9.63, whereas it was 62.7&#x2009;&#xB1;&#x2009;11.89 in the control group, showing a significant difference (p-value &#x2C2; 0.001), which is detectable in image B comparing to image D in Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>. Similarly, in the left CC1, the mean&#x2009;&#xB1;&#x2009;SD of neuronal density in the colitis group was 41.19&#x2009;&#xB1;&#x2009;9.05, while it was 63.1&#x2009;&#xB1;&#x2009;7.44 in the control group, again demonstrating a significant difference (p-value &#x2C2; 0.001). Also, the image A showed lower population of neurons in CC compared to image C in Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>. The neuronal density of CC1 between hemispheres was not significantly different in the colitis group (p-value&#x2009;=&#x2009;0.333). However, in the control group, the neuronal density of CC1 in the left hemisphere was significantly higher than in the right hemisphere (p-value&#x2009;=&#x2009;001). Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref> shows the microscopic image of CC1 in both hemispheres.</p>
      <p id="Par40">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Microscopic images (400 X magnification) of cingulate cortex area 1 (CC1) in rats with acid acetic-induced colitis shows a significant decrease level of neuron density compared to the control group. <bold>A</bold>: Left CC1 in colitis rats; <bold>B</bold>: Right CC1 in colitis rats; <bold>C</bold>: Left CC1 in control rats; <bold>D</bold>: Right CC1 in control rats</p></caption><graphic xlink:href="12876_2025_3745_Fig3_HTML" id="d33e566"/></fig>
</p>
      <p id="Par41">In the colitis group, the neuronal density in the right CC2 was significantly lower compared to the control group (57.8&#x2009;&#xB1;&#x2009;13.23 VS. 87.95&#x2009;&#xB1;&#x2009;8.76, respectively; p-value &#x2C2; 0.001), which is detectable in image B and D in Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>. Similarly, the mean&#x2009;&#xB1;&#x2009;SD of neuronal density in the left CC2 was 55.42&#x2009;&#xB1;&#x2009;11.3 in the colitis group and 98&#x2009;&#xB1;&#x2009;8.99 in the control group, showing a significant difference (p-value &#x2C2; 0.001), as showed in the image A and C in Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>. There was no significant difference in the neuronal density of CC2 between the hemispheres in rats with colitis (p-value&#x2009;=&#x2009;0.056). Additionally, this measure was not significant in the control group either (p-value&#x2009;=&#x2009;0.932). In Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref> the microscopic images of this area are presented.</p>
      <p id="Par42">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Microscopic images (400&#x22C5; magnification) of cingulate cortex area 2 (CC2) in rats with acid acetic-induced colitis shows a significant decrease level of neuron density compared to the control group. <bold>A</bold>: Left CC2 in rats with colitis; <bold>B</bold>: Right CC2 in rats with colitis; <bold>C</bold>: Left CC2 in control rats; <bold>D</bold>: Right CC2 in control rats</p></caption><graphic xlink:href="12876_2025_3745_Fig4_HTML" id="d33e600"/></fig>
</p>
      <p id="Par43">In both the left and right hemispheres, the density of the amygdala was observed to be lower in the colitis group compared to the control group (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Specifically, in the right amygdala (image B and D in Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>), the mean&#x2009;&#xB1;&#x2009;SD neuronal density in the colitis group was 24.51&#x2009;&#xB1;&#x2009;5.49, while in the control group, it was 36.3&#x2009;&#xB1;&#x2009;7.44. However, there was no significant difference in the neuronal density between these groups (p-value&#x2009;=&#x2009;0.360). Similarly, the neuronal density in the left amygdala was found to be lower in the colitis group compared to the control group (Image A and C in Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>), but this difference was not statistically significant (24.52&#x2009;&#xB1;&#x2009;5.53 VS. 35.25&#x2009;&#xB1;&#x2009;5.6; p-value&#x2009;=&#x2009;0.869). The microscopic images of the amygdala in both hemispheres are presented in Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>.</p>
      <p id="Par44">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Microscopic images (400&#x22C5; magnification) of the amygdala in rats with acid acetic-induced colitis shows decrease level of neuron density compared to control rats. <bold>A</bold>: Left amygdala in rat with colitis; <bold>B</bold>: Right amygdala in rat with colitis; <bold>C</bold>: Left amygdala in control rats; <bold>D</bold>: Right amygdala in control rats</p></caption><graphic xlink:href="12876_2025_3745_Fig5_HTML" id="d33e637"/></fig>
</p>
    </sec>
    <sec id="Sec14">
      <title>Discussion</title>
      <p id="Par45">The current research revealed a notable decline in neuronal density within the pain neuromatrix of the brain (specifically in CC areas 1 and 2) in rats with colitis induced by acid-acetic compared to the control group. However, the decrease in neuronal density observed in the amygdala did not reach statistical significance. These findings imply that colitis could negatively impact neurons in brain regions linked to pain perception.</p>
      <p id="Par46">Zikou et al. found comparable findings concerning alteration in the brain among IBD patients [<xref ref-type="bibr" rid="CR15">15</xref>]. Using magnetic resonance imaging (MRI), they showed a decrease in gray matter volume across several brain regions in IBD patients including the inferior temporal gyrus, right precentral gyrus, right supplementary motor area, right middle frontal gyrus, and left superior parietal gyrus. In contrast to our observations, their results displayed a noticeable lateralization, while we identified a symmetrical decline in the population of cortical neurons. This suggests that the impact of colitis on the brain may be more widespread that previously understand.</p>
      <p id="Par47">The potential mechanisms underlying the neuronal damages associated with colitis primarily involve the GBA. Vasculitis of the small cerebral vessels, arises due to vascular blockage, increased coagulability, inflammation, and alteration in the muscle tone of the vessels, plus decreased oxygen supply to brain tissues can lead to valerian degeneration in neurons [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, three to four times greater risk of thrombosis and intravascular coagulation have been seen in UC compared to the normal population [<xref ref-type="bibr" rid="CR32">32</xref>]. These findings strongly suggest a contribution of vasculitis to the decline in neuronal density in rats with colitis, that would better to be investigated in further studies.</p>
      <p id="Par48">Another study conducted by Agostini et al. [<xref ref-type="bibr" rid="CR17">17</xref>] used fMRI images in UC patients, identified a significant reduction in blood oxygen level-dependent (BOLD) activity in the amygdala, thalamic regions, and cerebellar area in IBD patients compared to controls in absence of volume difference. Our results also indicated nonsignificant changes in neuronal density of amygdala. But considering Agostini&#x2019;s investigation, the effect of IBD on the brain is not limited to neuronal deaths merely and can result in functional changes of such a brain area. These studies together highlight the substantial impact of IBD on various brain regions in affected individuals, which aligns with our findings.</p>
      <p id="Par49">Systemic inflammation caused by colitis has the potential to spread inflammation to the brain, resulting in neuroinflammation [<xref ref-type="bibr" rid="CR33">33</xref>]. This fact is observed in different animal colitis models. In rats with colitis induced by Tri-Nitrobenzene Sulfonic Acid (TNBS) the expression level of pro-inflammatory cytokines such as interleukin 6 (IL-6) increases, in both colon and brain tissue (<xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR34">34</xref>). Tumor necrosis factor &#x3B1; (TNF-&#x3B1;), involved in the colitis pathology [<xref ref-type="bibr" rid="CR1">1</xref>], was also found to be significantly increased in Dextran sulfate sodium (DSS)-induced colitis model [<xref ref-type="bibr" rid="CR34">34</xref>]. Additionally, the number of monocyte-derived macrophages was increased during colitis leading to significant changes in microglial activities [<xref ref-type="bibr" rid="CR35">35</xref>]. These findings demonstrated how peripheral inflammation can result in neuroinflammation in the colitis animal model by altering the production of cytokines and inflammatory cells. These could somehow be the underlying reasons for decreased neuron density in the studied areas, although it would be better to investigate the changes in neuroinflammatory markers in further studies.</p>
      <p id="Par50">A noteworthy finding of this study was the insignificant decrease in neuronal density observed in the amygdala of rats with colitis, as compared to the control group. The activation of the hypothalamic-pituitary-adrenal (HPA) axis and the presence of inflammatory markers are additional factors contributing to neuroinflammation in an animal model of colitis. Rise in the levels of cortisol, corticosterone, and C-reactive protein (CRP), glial fibrillary acidic protein (GFAP) and cyclooxygenase 2 (COX-2) up regulation in the hippocampus and hypothalamus [<xref ref-type="bibr" rid="CR36">36</xref>&#x2013;<xref ref-type="bibr" rid="CR38">38</xref>], increase brain-derived neurotrophic factor (BDNF), in the hypothalamic regions of mice with colitis, and down regulate COX-2 and BDNF in the amygdala of mice with colitis [<xref ref-type="bibr" rid="CR36">36</xref>]. These findings may show that the amygdala exhibits a greater resistance to inflammatory changes when compared to cortical areas. Consequently, it is evident that colitis can induce inflammation in the brain through a bottom-up pathway.</p>
      <p id="Par51">The blood-brain barrier (BBB) can be disrupted as a result of peripheral inflammation, leading to changes in the normal condition of the central nervous system (CNS) by interrupting intercellular tight junctions (TJs). In the rodent model of colitis, the TJ protein expressions, including occludin and claudin-5, were significantly downregulated in specific regions of the brain, such as the cortex and hippocampus [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>] On the other hand, Colitis can alter the permeability of the colon, allowing the release of the bacterial endotoxins into the bloodstream [<xref ref-type="bibr" rid="CR41">41</xref>] and altering the composition of the gut microbiota and elevating levels of lipopolysaccharides [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The leakage of endotoxins could potentially serve as another mechanism through which inflammation can spread to the CNS [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      <p id="Par52">The question at hand pertains to the implications of a decrease in the density of neurons in the CC on the pain process that could be focused in humane and clinical studies in future. The CC plays a dual role in the pain process: directly inhibiting pain and exerting inhibitory effects on other brain regions involved in pain [<xref ref-type="bibr" rid="CR13">13</xref>]. Activation of CC has been linked to a reduction in pain-related behavior in animal models [<xref ref-type="bibr" rid="CR44">44</xref>]. Conversely, lesions in this area increase nociceptive responses [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Electrophysiological investigations have revealed a larger population of inhibitory neurons compared to excitatory neurons in the CC [<xref ref-type="bibr" rid="CR46">46</xref>]. Presence of GABAergic neurons and opioid receptors in the CC can lead to inhibitory role in pain perception [<xref ref-type="bibr" rid="CR14">14</xref>]. The CC can alleviate pain by influencing other CNS regions such as the supra-spinal pain suppressor system, located at the level of the Periaqueductal gray (PAG) and inhibiting neurons in the dorsal horn of the spinal cord that respond to mechanical pain stimuli. (<xref ref-type="bibr" rid="CR47">47</xref>&#x2013;<xref ref-type="bibr" rid="CR48">48</xref>). Therefore, it can be inferred that a decrease in the neuronal density of CC diminishes its inhibitory roles in the pain neuromatrix and perception of pain.</p>
      <p id="Par53">The study had a few constraints that can provide valuable insights for future researchers in their upcoming projects. Firstly, it would have been beneficial to include a larger number of animals to yield more reliable and conclusive outcomes. However, it is important to acknowledge that reducing the number of animals is a fundamental principle of bioethics in working with laboratory animals. Secondly, the study lacked access to animal imaging devices such as brain MRI, or fMRI for functional and volume evaluations. Lastly, this study did not evaluate inflammatory markers in the blood and brain. Assessing these markers would have been advantageous in elucidating the effects of colitis on the central nervous system. Therefore, it is suggested that future studies incorporate the assessment of inflammatory markers to gain further clarity in this regard.</p>
    </sec>
    <sec id="Sec15">
      <title>Conclusion</title>
      <p id="Par54">As the results showed, colitis could reduce the density of neurons in the CC region of the brain in comparison to the control group. Considering the role of CC in suppressing pain perception, further studies on different parts of the brain are required to delve into the precise mechanisms underlying CNS damage in colitis.</p>
    </sec>
    <sec id="Sec16" sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <p>Below is the link to the electronic supplementary material.</p>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12876_2025_3745_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Fazel Isapanah Amlashi and Sima Besharat equally contributed as the first authors.</p>
      </fn>
      <fn>
        <p>Mehrdad Jahanshahi and Hesamaddin Shirzad-Aski equally contributed as the Corresponding authors.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This paper was extracted from the thesis dedicated to achieving an MD degree from Golestan University of Medical Sciences. Also, the authors appreciate the kind help and technical support received from Dr. Emsegol Nikmahzar, Dr. Masoumeh Khalili, and Dr. Amir Alborzi.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>FA: Study concept and design,; acquisition of data; analysis and interpretation of the data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; All authors approved the final version of the manuscript. SB: study concept and design; acquisition of data; critical revision of the manuscript for important intellectual content; drafting of the manuscript; administrative, technical, and material support; study supervision; All authors approved the final version of the manuscript. MJ: study concept and design; critical revision of the manuscript for important intellectual content; drafting of the manuscript; study supervision; All authors approved the final version of the manuscript. HSH: study concept and design; critical revision of the manuscript for important intellectual content; drafting of the manuscript; administrative, technical, and material support; All authors approved the final version of the manuscript. FN: analysis and interpretation of the data; drafting of the manuscript; statistical analysis. All authors approved the final version of the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>The research deputy of Golestan University of Medical Sciences provided all financial support for this study (code: IR.GOUMS.PAJOOHESHYAR.112708).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>Data are available on request from the corresponding author.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar1">
        <title>Ethics approval and consent to participate</title>
        <p id="Par55">The study protocol has been approved by the local ethical committee of Golestan University of Medical Sciences (ID: IR.GOUMS.REC.1401.081). The experiments reported herein were precisely in accordance with the principles given by the National Committee for Research Ethics in Science and Technology, Guide for the Care and Use of Laboratory Animals and ARRIVE guidelines. It should be noted that these animals did not belong to any other private company.</p>
      </notes>
      <notes id="FPar2">
        <title>Consent for publication</title>
        <p id="Par56">Not applicable.</p>
      </notes>
      <notes id="FPar3" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par57">The authors declare no competing interests.</p>
      </notes>
    </notes>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CNS</term>
          <def>
            <p id="Par58">Central Nervous System</p>
          </def>
        </def-item>
        <def-item>
          <term>CC</term>
          <def>
            <p id="Par59">Cingulate Cortex Area</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p id="Par60">Standard Deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>IBD</term>
          <def>
            <p id="Par61">Inflammatory Bowel Disease</p>
          </def>
        </def-item>
        <def-item>
          <term>CD</term>
          <def>
            <p id="Par62">Crohn&#x2019;s Disease</p>
          </def>
        </def-item>
        <def-item>
          <term>UC</term>
          <def>
            <p id="Par63">Ulcerative Colitis</p>
          </def>
        </def-item>
        <def-item>
          <term>GBA</term>
          <def>
            <p id="Par64">Gut-Brain Axis</p>
          </def>
        </def-item>
        <def-item>
          <term>GI</term>
          <def>
            <p id="Par65">Gastrointestinal</p>
          </def>
        </def-item>
        <def-item>
          <term>fMRI</term>
          <def>
            <p id="Par66">Functional Magnetic Resonance Imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>GOUMS</term>
          <def>
            <p id="Par67">Golestan University of Medical Sciences</p>
          </def>
        </def-item>
        <def-item>
          <term>ARRIVE</term>
          <def>
            <p id="Par68">Animal Research: Reporting of In Vivo Experiments</p>
          </def>
        </def-item>
        <def-item>
          <term>DAI</term>
          <def>
            <p id="Par69">Disease Activity Index</p>
          </def>
        </def-item>
        <def-item>
          <term>CO<sub>2</sub></term>
          <def>
            <p id="Par70">Carbon Dioxide</p>
          </def>
        </def-item>
        <def-item>
          <term>IP</term>
          <def>
            <p id="Par71">Intra-Peritoneal</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p id="Par72">Magnetic Resonance Imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>WMHIs</term>
          <def>
            <p id="Par73">White-Matter Hyperintensities</p>
          </def>
        </def-item>
        <def-item>
          <term>BOLD</term>
          <def>
            <p id="Par74">Blood Oxygen Level-Dependent</p>
          </def>
        </def-item>
        <def-item>
          <term>TNBS</term>
          <def>
            <p id="Par75">Tri-Nitrobenzene Sulfonic Acid</p>
          </def>
        </def-item>
        <def-item>
          <term>IL-6</term>
          <def>
            <p id="Par76">Interleukin 6</p>
          </def>
        </def-item>
        <def-item>
          <term>TNF-&#x3B1;</term>
          <def>
            <p id="Par77">Tumor Necrosis Factor&#x3B1;</p>
          </def>
        </def-item>
        <def-item>
          <term>DSS</term>
          <def>
            <p id="Par78">Dextran Sulfate Sodium</p>
          </def>
        </def-item>
        <def-item>
          <term>CD86</term>
          <def>
            <p id="Par79">Cluster Of Differentiation 86</p>
          </def>
        </def-item>
        <def-item>
          <term>HPA</term>
          <def>
            <p id="Par80">Hypothalamic-Pituitary-Adrenal</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p id="Par81">C-Reactive Protein</p>
          </def>
        </def-item>
        <def-item>
          <term>GFAP</term>
          <def>
            <p id="Par82">Glial Fibrillary Acidic Protein</p>
          </def>
        </def-item>
        <def-item>
          <term>COX-2</term>
          <def>
            <p id="Par83">Cyclooxygenase 2</p>
          </def>
        </def-item>
        <def-item>
          <term>BDNF</term>
          <def>
            <p id="Par84">Brain-Derived Neurotrophic Factor</p>
          </def>
        </def-item>
        <def-item>
          <term>BBB</term>
          <def>
            <p id="Par85">Blood-Brain Barrier</p>
          </def>
        </def-item>
        <def-item>
          <term>TJs</term>
          <def>
            <p id="Par86">Tight Junctions</p>
          </def>
        </def-item>
        <def-item>
          <term>PAG</term>
          <def>
            <p id="Par87">Periaqueductal Gray</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name><name><surname>Eisenhut</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>JI</given-names></name></person-group><article-title>IBD Immunopathogenesis: a comprehensive review of inflammatory molecules</article-title><source>Autoimmun Rev</source><year>2017</year><volume>16</volume><issue>4</issue><fpage>416</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2017.02.013</pub-id><pub-id pub-id-type="pmid">28212924</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD Immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16(4):416&#x2013;26.<pub-id pub-id-type="pmid">28212924</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Annese</surname><given-names>V</given-names></name></person-group><article-title>A review of extraintestinal manifestations and complications of inflammatory bowel disease</article-title><source>Saudi J Med Med Sci</source><year>2019</year><volume>7</volume><issue>2</issue><fpage>66</fpage><pub-id pub-id-type="doi">10.4103/sjmms.sjmms_81_18</pub-id><pub-id pub-id-type="pmid">31080385</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Annese V. A review of extraintestinal manifestations and complications of inflammatory bowel disease. Saudi J Med Med Sci. 2019;7(2):66.<pub-id pub-id-type="pmid">31080385</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Jose</surname><given-names>FA</given-names></name><name><surname>Garnett</surname><given-names>EA</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Ferry</surname><given-names>GD</given-names></name><name><surname>Winter</surname><given-names>HS</given-names></name><name><surname>Baldassano</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2009</year><volume>15</volume><issue>1</issue><fpage>63</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/ibd.20604</pub-id><pub-id pub-id-type="pmid">18626963</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(1):63&#x2013;8.<pub-id pub-id-type="pmid">18626963</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>C</given-names></name><name><surname>Sch&#xF6;lmerich</surname><given-names>J</given-names></name></person-group><article-title>Extraintestinal manifestations and complications in IBD</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2013</year><volume>10</volume><issue>10</issue><fpage>585</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2013.117</pub-id><pub-id pub-id-type="pmid">23835489</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Ott C, Sch&#xF6;lmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585&#x2013;95.<pub-id pub-id-type="pmid">23835489</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>R</given-names></name><name><surname>Teich</surname><given-names>N</given-names></name></person-group><article-title>Neurologic manifestations of ulcerative colitis</article-title><source>Eur J Neurol</source><year>2007</year><volume>14</volume><issue>5</issue><fpage>483</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2007.01718.x</pub-id><pub-id pub-id-type="pmid">17437605</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Scheid R, Teich N. Neurologic manifestations of ulcerative colitis. Eur J Neurol. 2007;14(5):483&#x2013;93.<pub-id pub-id-type="pmid">17437605</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>B</given-names></name></person-group><article-title>Inflammatory bowel disease: perspectives from cingulate cortex in the first brain</article-title><source>Neurogastroenterol Motil</source><year>2013</year><volume>25</volume><issue>2</issue><fpage>93</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/nmo.12067</pub-id><pub-id pub-id-type="pmid">23336589</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Vogt B. Inflammatory bowel disease: perspectives from cingulate cortex in the first brain. Neurogastroenterol Motil. 2013;25(2):93&#x2013;8.<pub-id pub-id-type="pmid">23336589</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bakshi</surname><given-names>N</given-names></name><name><surname>Hart</surname><given-names>AL</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Williams</surname><given-names>ACC</given-names></name><name><surname>Lackner</surname><given-names>JM</given-names></name><name><surname>Norton</surname><given-names>C</given-names></name><name><surname>Croft</surname><given-names>P</given-names></name></person-group><article-title>Chronic pain in patients with inflammatory bowel disease</article-title><source>Pain</source><year>2021</year><volume>162</volume><issue>10</issue><fpage>2466</fpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000002304</pub-id><pub-id pub-id-type="pmid">34534174</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain. 2021;162(10):2466.<pub-id pub-id-type="pmid">34534174</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Bejerano</surname><given-names>C</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Gonz&#xE1;lez-Vela</surname><given-names>C</given-names></name><name><surname>P&#xE9;rez-Mart&#xED;n</surname><given-names>I</given-names></name><name><surname>Martinez-Rodriguez</surname><given-names>I</given-names></name><name><surname>Jimenez-Bonilla</surname><given-names>J</given-names></name><name><surname>Gonz&#xE1;lez-Gay</surname><given-names>M</given-names></name></person-group><article-title>Case report polymyalgia rheumatica as presenting manifestation of vasculitis involving the lower extremities in a patient with ulcerative colitis</article-title><source>Clin Exp Rheumatol</source><year>2012</year><volume>30</volume><issue>70</issue><fpage>S110</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">22640654</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Bejerano C, Blanco R, Gonz&#xE1;lez-Vela C, P&#xE9;rez-Mart&#xED;n I, Martinez-Rodriguez I, Jimenez-Bonilla J, Gonz&#xE1;lez-Gay M. Case report polymyalgia rheumatica as presenting manifestation of vasculitis involving the lower extremities in a patient with ulcerative colitis. Clin Exp Rheumatol. 2012;30(70):S110&#x2013;3.<pub-id pub-id-type="pmid">22640654</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>G</given-names></name><name><surname>Van Langenberg</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>S</given-names></name><name><surname>Gibson</surname><given-names>PR</given-names></name></person-group><article-title>Chronic pain in inflammatory bowel disease: characteristics and associations of a hospital-based cohort</article-title><source>Inflamm Bowel Dis</source><year>2013</year><volume>19</volume><issue>6</issue><fpage>1210</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/MIB.0b013e318280e729</pub-id><pub-id pub-id-type="pmid">23524595</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Morrison G, Van Langenberg D, Gibson S, Gibson PR. Chronic pain in inflammatory bowel disease: characteristics and associations of a hospital-based cohort. Inflamm Bowel Dis. 2013;19(6):1210&#x2013;7.<pub-id pub-id-type="pmid">23524595</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Okauchi</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Shigeta</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pain matrix shift in the rat brain following persistent colonic inflammation revealed by voxel-based statistical analysis</article-title><source>Mol Pain</source><year>2019</year><volume>15</volume><fpage>1744806919891327</fpage><pub-id pub-id-type="doi">10.1177/1744806919891327</pub-id><pub-id pub-id-type="pmid">31709891</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Huang T, Okauchi T, Hu D, Shigeta M, Wu Y, Wada Y, et al. Pain matrix shift in the rat brain following persistent colonic inflammation revealed by voxel-based statistical analysis. Mol Pain. 2019;15:1744806919891327.<pub-id pub-id-type="pmid">31709891</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Melzack</surname><given-names>R</given-names></name></person-group><article-title>Pain and the neuromatrix in the brain</article-title><source>J Dent Educ</source><year>2001</year><volume>65</volume><issue>12</issue><fpage>1378</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/j.0022-0337.2001.65.12.tb03497.x</pub-id><pub-id pub-id-type="pmid">11780656</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Melzack R. Pain and the neuromatrix in the brain. J Dent Educ. 2001;65(12):1378&#x2013;82.<pub-id pub-id-type="pmid">11780656</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Melzack</surname><given-names>R</given-names></name></person-group><article-title>Evolution of the neuromatrix theory of pain. The prithvi Raj lecture: presented at the third world Congress of world Institute of pain, Barcelona 2004</article-title><source>Pain Pract</source><year>2005</year><volume>5</volume><issue>2</issue><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/j.1533-2500.2005.05203.x</pub-id><pub-id pub-id-type="pmid">17177754</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Melzack R. Evolution of the neuromatrix theory of pain. The prithvi Raj lecture: presented at the third world Congress of world Institute of pain, Barcelona 2004. Pain Pract. 2005;5(2):85&#x2013;94.<pub-id pub-id-type="pmid">17177754</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>PN</given-names></name><name><surname>Peng</surname><given-names>YB</given-names></name><name><surname>Boyette-Davis</surname><given-names>JA</given-names></name><name><surname>Uhelski</surname><given-names>ML</given-names></name></person-group><article-title>The anterior cingulate cortex and pain processing</article-title><source>Front Integr Neurosci</source><year>2014</year><volume>8</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.3389/fnint.2014.00035</pub-id><pub-id pub-id-type="pmid">24829554</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Fuchs PN, Peng YB, Boyette-Davis JA, Uhelski ML. The anterior cingulate cortex and pain processing. Front Integr Neurosci. 2014;8:35.<pub-id pub-id-type="pmid">24829554</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Uhelski</surname><given-names>ML</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Romero-Ortega</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>Y-t</given-names></name><name><surname>Fuchs</surname><given-names>PN</given-names></name><name><surname>Mohanty</surname><given-names>SK</given-names></name></person-group><article-title>Pain Inhibition by optogenetic activation of specific anterior cingulate cortical neurons</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>e0117746</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0117746</pub-id><pub-id pub-id-type="pmid">25714399</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Gu L, Uhelski ML, Anand S, Romero-Ortega M, Kim Y-t, Fuchs PN, Mohanty SK. Pain Inhibition by optogenetic activation of specific anterior cingulate cortical neurons. PLoS ONE. 2015;10(2):e0117746.<pub-id pub-id-type="pmid">25714399</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zikou</surname><given-names>AK</given-names></name><name><surname>Kosmidou</surname><given-names>M</given-names></name><name><surname>Astrakas</surname><given-names>LG</given-names></name><name><surname>Tzarouchi</surname><given-names>LC</given-names></name><name><surname>Tsianos</surname><given-names>E</given-names></name><name><surname>Argyropoulou</surname><given-names>MI</given-names></name></person-group><article-title>Brain involvement in patients with inflammatory bowel disease: a voxel-based morphometry and diffusion tensor imaging study</article-title><source>Eur Radiol</source><year>2014</year><volume>24</volume><fpage>2499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s00330-014-3242-6</pub-id><pub-id pub-id-type="pmid">25001084</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Zikou AK, Kosmidou M, Astrakas LG, Tzarouchi LC, Tsianos E, Argyropoulou MI. Brain involvement in patients with inflammatory bowel disease: a voxel-based morphometry and diffusion tensor imaging study. Eur Radiol. 2014;24:2499&#x2013;506.<pub-id pub-id-type="pmid">25001084</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Konturek</surname><given-names>S</given-names></name><name><surname>Konturek</surname><given-names>P</given-names></name><name><surname>Pawlik</surname><given-names>T</given-names></name><name><surname>Brzozowski</surname><given-names>T</given-names></name></person-group><article-title>Brain-gut axis and its role in the control of food intake</article-title><source>J Physiol Pharmacol</source><year>2004</year><volume>55</volume><issue>2</issue><fpage>137</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15082874</pub-id>
</element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Konturek S, Konturek P, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol. 2004;55(2):137&#x2013;54.<pub-id pub-id-type="pmid">15082874</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>A</given-names></name><name><surname>Filippini</surname><given-names>N</given-names></name><name><surname>Cevolani</surname><given-names>D</given-names></name><name><surname>Agati</surname><given-names>R</given-names></name><name><surname>Leoni</surname><given-names>C</given-names></name><name><surname>Tambasco</surname><given-names>R</given-names></name><etal/></person-group><article-title>Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing</article-title><source>Inflamm Bowel Dis</source><year>2011</year><volume>17</volume><issue>8</issue><fpage>1769</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1002/ibd.21549</pub-id><pub-id pub-id-type="pmid">21744432</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Agostini A, Filippini N, Cevolani D, Agati R, Leoni C, Tambasco R, et al. Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing. Inflamm Bowel Dis. 2011;17(8):1769&#x2013;77.<pub-id pub-id-type="pmid">21744432</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cowan</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hoban</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ventura-Silva</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Dinan</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cryan</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Gutsy moves: the amygdala as a critical node in microbiota to brain signaling</article-title>
            <source>BioEssays</source>
            <year>2018</year>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>1700172</fpage>
            <pub-id pub-id-type="doi">10.1002/bies.201700172</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Cowan CS, Hoban AE, Ventura-Silva AP, Dinan TG, Clarke G, Cryan JF. Gutsy moves: the amygdala as a critical node in microbiota to brain signaling. BioEssays. 2018;40(1):1700172.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Hagar</surname><given-names>HH</given-names></name><name><surname>El Medany</surname><given-names>A</given-names></name><name><surname>El Eter</surname><given-names>E</given-names></name><name><surname>Arafa</surname><given-names>M</given-names></name></person-group><article-title>Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats</article-title><source>Eur J Pharmacol</source><year>2007</year><volume>554</volume><issue>1</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.09.066</pub-id><pub-id pub-id-type="pmid">17112501</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Hagar HH, El Medany A, El Eter E, Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol. 2007;554(1):69&#x2013;77.<pub-id pub-id-type="pmid">17112501</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The ARRIVE guidelines animal research: reporting in vivo experiments</article-title><source>PLoS Biol</source><year>2010</year><volume>8</volume><issue>6</issue><fpage>e1000412</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000412</pub-id><pub-id pub-id-type="pmid">20613859</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. The ARRIVE guidelines animal research: reporting in vivo experiments. PLoS Biol. 2010;8(6):e1000412.<pub-id pub-id-type="pmid">20613859</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ahmadi-Noorbakhsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mirabzadeh Ardakani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sadighi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aldavood</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Farajli Abbasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farzad-Mohajeri</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Guideline for the care and use of laboratory animals in Iran</article-title>
            <source>Lab Anim</source>
            <year>2021</year>
            <volume>50</volume>
            <issue>11</issue>
            <fpage>303</fpage>
            <lpage>5</lpage>
            <pub-id pub-id-type="doi">10.1038/s41684-021-00871-3</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Ahmadi-Noorbakhsh S, Mirabzadeh Ardakani E, Sadighi J, Aldavood SJ, Farajli Abbasi M, Farzad-Mohajeri S, et al. Guideline for the care and use of laboratory animals in Iran. Lab Anim. 2021;50(11):303&#x2013;5.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Qelliny</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>UF</given-names>
              </name>
              <name>
                <surname>Elgarhy</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Khaled</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Budesonide-loaded Eudragit S 100 nanocapsules for the treatment of acetic acid-induced colitis in animal model</article-title>
            <source>AAPS PharmSciTech</source>
            <year>2019</year>
            <volume>20</volume>
            <fpage>1</fpage>
            <lpage>17</lpage>
            <pub-id pub-id-type="doi">10.1208/s12249-019-1453-5</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Qelliny MR, Aly UF, Elgarhy OH, Khaled KA. Budesonide-loaded Eudragit S 100 nanocapsules for the treatment of acetic acid-induced colitis in animal model. AAPS PharmSciTech. 2019;20:1&#x2013;17.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Sayyahi</surname><given-names>A</given-names></name><name><surname>Jahanshahi</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>H</given-names></name><name><surname>Sepehri</surname><given-names>H</given-names></name></person-group><article-title>Vitamin E can compensate the density of M1 receptors in the hippocampus of scopolamine-treated rats</article-title><source>Folia Neuropathol</source><year>2018</year><volume>56</volume><issue>3</issue><fpage>215</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.5114/fn.2018.78703</pub-id><pub-id pub-id-type="pmid">30509043</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Sayyahi A, Jahanshahi M, Amini H, Sepehri H. Vitamin E can compensate the density of M1 receptors in the hippocampus of scopolamine-treated rats. Folia Neuropathol. 2018;56(3):215&#x2013;28.<pub-id pub-id-type="pmid">30509043</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Protective effect of methane-rich saline on acetic acid-induced ulcerative colitis via blocking the TLR4/NF-&#x3BA;B/MAPK pathway and promoting IL-10/JAK1/STAT3-mediated anti-inflammatory response</article-title><source>Oxid Med Cell Longev</source><year>2019</year><volume>2019</volume><fpage>7850324</fpage><pub-id pub-id-type="pmid">31182999</pub-id>
</element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Wang G, Xu B, Shi F, Du M, Li Y, Yu T, Chen L. Protective effect of methane-rich saline on acetic acid-induced ulcerative colitis via blocking the TLR4/NF-&#x3BA;B/MAPK pathway and promoting IL-10/JAK1/STAT3-mediated anti-inflammatory response. Oxid Med Cell Longev. 2019;2019:7850324.<pub-id pub-id-type="pmid">31182999</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi-Noorbakhsh</surname><given-names>S</given-names></name><name><surname>Farajli Abbasi</surname><given-names>M</given-names></name><name><surname>Ghasemi</surname><given-names>M</given-names></name><name><surname>Bayat</surname><given-names>G</given-names></name><name><surname>Davoodian</surname><given-names>N</given-names></name><name><surname>Sharif-Paghaleh</surname><given-names>E</given-names></name><etal/></person-group><article-title>Anesthesia and analgesia for common research models of adult mice</article-title><source>Lab Anim Res</source><year>2022</year><volume>38</volume><issue>1</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s42826-022-00150-3</pub-id><pub-id pub-id-type="pmid">36514128</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Ahmadi-Noorbakhsh S, Farajli Abbasi M, Ghasemi M, Bayat G, Davoodian N, Sharif-Paghaleh E, et al. Anesthesia and analgesia for common research models of adult mice. Lab Anim Res. 2022;38(1):40.<pub-id pub-id-type="pmid">36514128</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Nikmahzar E, Jahanshahi M, Babakordi F. Ginkgo biloba Extract Decreases Scopolamine-Induced Congophilic Amyloid Plaques Accumulation in Male Rat&#x2019;s Brain. Jundishapur J Nat Pharm Prod. 2018;13(4).</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>W-H</given-names></name><name><surname>Roh</surname><given-names>GS</given-names></name></person-group><article-title>A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates Kainic acid-induced hippocampal cell death</article-title><source>BMC Neurosci</source><year>2016</year><volume>17</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12868-016-0270-y</pub-id><pub-id pub-id-type="pmid">26728069</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Kim H, Lee JY, Park KJ, Kim W-H, Roh GS. A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates Kainic acid-induced hippocampal cell death. BMC Neurosci. 2016;17:1&#x2013;10.<pub-id pub-id-type="pmid">26728069</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover edition. Elsevier; 2006.</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Seifhosseini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jahanshahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moghimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aazami</surname>
                <given-names>N-S</given-names>
              </name>
            </person-group>
            <article-title>The effect of scopolamine on avoidance memory and hippocampal neurons in male Wistar rats</article-title>
            <source>Basic Clin Neurosci</source>
            <year>2011</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <lpage>15</lpage>
          </element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Seifhosseini S, Jahanshahi M, Moghimi A, Aazami N-S. The effect of scopolamine on avoidance memory and hippocampal neurons in male Wistar rats. Basic Clin Neurosci. 2011;3(1):9&#x2013;15.</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Jahanshahi</surname><given-names>M</given-names></name><name><surname>Nickmahzar</surname><given-names>E</given-names></name><name><surname>Babakordi</surname><given-names>F</given-names></name></person-group><article-title>The effect of Ginkgo biloba extract on scopolamine-induced apoptosis in the hippocampus of rats</article-title><source>Anat Sci Int</source><year>2013</year><volume>88</volume><fpage>217</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s12565-013-0188-8</pub-id><pub-id pub-id-type="pmid">23828103</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Jahanshahi M, Nickmahzar E, Babakordi F. The effect of Ginkgo biloba extract on scopolamine-induced apoptosis in the hippocampus of rats. Anat Sci Int. 2013;88:217&#x2013;22.<pub-id pub-id-type="pmid">23828103</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzarouchi</surname><given-names>LC</given-names></name><name><surname>Tsifetaki</surname><given-names>N</given-names></name><name><surname>Konitsiotis</surname><given-names>S</given-names></name><name><surname>Zikou</surname><given-names>A</given-names></name><name><surname>Astrakas</surname><given-names>L</given-names></name><name><surname>Drosos</surname><given-names>A</given-names></name><name><surname>Argyropoulou</surname><given-names>MI</given-names></name></person-group><article-title>CNS involvement in primary Sj&#xF6;gren syndrome: assessment of Gray and white matter changes with MRI and voxel-based morphometry</article-title><source>Am J Roentgenol</source><year>2011</year><volume>197</volume><issue>5</issue><fpage>1207</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2214/AJR.10.5984</pub-id><pub-id pub-id-type="pmid">22021516</pub-id>
</element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">Tzarouchi LC, Tsifetaki N, Konitsiotis S, Zikou A, Astrakas L, Drosos A, Argyropoulou MI. CNS involvement in primary Sj&#xF6;gren syndrome: assessment of Gray and white matter changes with MRI and voxel-based morphometry. Am J Roentgenol. 2011;197(5):1207&#x2013;12.<pub-id pub-id-type="pmid">22021516</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Diakou</surname><given-names>M</given-names></name><name><surname>Kostadima</surname><given-names>V</given-names></name><name><surname>Giannopoulos</surname><given-names>S</given-names></name><name><surname>Zikou</surname><given-names>AK</given-names></name><name><surname>Argyropoulou</surname><given-names>MI</given-names></name><name><surname>Kyritsis</surname><given-names>AP</given-names></name></person-group><article-title>Cerebral venous thrombosis in an adolescent with ulcerative colitis</article-title><source>Brain Dev</source><year>2011</year><volume>33</volume><issue>1</issue><fpage>49</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2010.04.006</pub-id><pub-id pub-id-type="pmid">20472378</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Diakou M, Kostadima V, Giannopoulos S, Zikou AK, Argyropoulou MI, Kyritsis AP. Cerebral venous thrombosis in an adolescent with ulcerative colitis. Brain Dev. 2011;33(1):49&#x2013;51.<pub-id pub-id-type="pmid">20472378</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>C-P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Z-Q</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Mu</surname><given-names>L-Z</given-names></name><etal/></person-group><article-title>Expression of Interleukin 6 in brain and colon of rats with TNBS-induced colitis</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><issue>18</issue><fpage>2252</fpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i18.2252</pub-id><pub-id pub-id-type="pmid">20458762</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Wang K, Yuan C-P, Wang W, Yang Z-Q, Cui W, Mu L-Z, et al. Expression of Interleukin 6 in brain and colon of rats with TNBS-induced colitis. World J Gastroenterol. 2010;16(18):2252.<pub-id pub-id-type="pmid">20458762</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>S-H</given-names></name><name><surname>Zhao</surname><given-names>Y-Q</given-names></name><etal/></person-group><article-title>Cortical inflammation is increased in a DSS-induced colitis mouse model</article-title><source>Neurosci Bull</source><year>2018</year><volume>34</volume><fpage>1058</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s12264-018-0288-5</pub-id><pub-id pub-id-type="pmid">30225764</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Han Y, Zhao T, Cheng X, Zhao M, Gong S-H, Zhao Y-Q, et al. Cortical inflammation is increased in a DSS-induced colitis mouse model. Neurosci Bull. 2018;34:1058&#x2013;66.<pub-id pub-id-type="pmid">30225764</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Sroor</surname><given-names>HM</given-names></name><name><surname>Hassan</surname><given-names>AM</given-names></name><name><surname>Zenz</surname><given-names>G</given-names></name><name><surname>Valadez-Cosmes</surname><given-names>P</given-names></name><name><surname>Farzi</surname><given-names>A</given-names></name><name><surname>Holzer</surname><given-names>P</given-names></name><etal/></person-group><article-title>Experimental colitis reduces microglial cell activation in the mouse brain without affecting microglial cell numbers</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>20217</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56859-0</pub-id><pub-id pub-id-type="pmid">31882991</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Sroor HM, Hassan AM, Zenz G, Valadez-Cosmes P, Farzi A, Holzer P, et al. Experimental colitis reduces microglial cell activation in the mouse brain without affecting microglial cell numbers. Sci Rep. 2019;9(1):20217.<pub-id pub-id-type="pmid">31882991</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>J</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name></person-group><article-title>From gut to brain: alteration in inflammation markers in the brain of dextran sodium sulfate-induced colitis model mice</article-title><source>Clin Psychopharmacol Neurosci</source><year>2018</year><volume>16</volume><issue>4</issue><fpage>422</fpage><pub-id pub-id-type="doi">10.9758/cpn.2018.16.4.422</pub-id><pub-id pub-id-type="pmid">30466215</pub-id>
</element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">Do J, Woo J. From gut to brain: alteration in inflammation markers in the brain of dextran sodium sulfate-induced colitis model mice. Clin Psychopharmacol Neurosci. 2018;16(4):422.<pub-id pub-id-type="pmid">30466215</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Font-Nieves</surname><given-names>M</given-names></name><name><surname>Sans-Fons</surname><given-names>MG</given-names></name><name><surname>Gorina</surname><given-names>R</given-names></name><name><surname>Bonfill-Teixidor</surname><given-names>E</given-names></name><name><surname>Salas-P&#xE9;rdomo</surname><given-names>A</given-names></name><name><surname>M&#xE1;rquez-Kisinousky</surname><given-names>L</given-names></name><etal/></person-group><article-title>Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>9</issue><fpage>6454</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.327874</pub-id><pub-id pub-id-type="pmid">22219191</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Font-Nieves M, Sans-Fons MG, Gorina R, Bonfill-Teixidor E, Salas-P&#xE9;rdomo A, M&#xE1;rquez-Kisinousky L, et al. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J Biol Chem. 2012;287(9):6454&#x2013;68.<pub-id pub-id-type="pmid">22219191</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>KK</given-names></name></person-group><article-title>Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker</article-title><source>Trends Neurosci</source><year>2015</year><volume>38</volume><issue>6</issue><fpage>364</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2015.04.003</pub-id><pub-id pub-id-type="pmid">25975510</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364&#x2013;74.<pub-id pub-id-type="pmid">25975510</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Natah</surname><given-names>SS</given-names></name><name><surname>Mouihate</surname><given-names>A</given-names></name><name><surname>Pittman</surname><given-names>QJ</given-names></name><name><surname>Sharkey</surname><given-names>KA</given-names></name></person-group><article-title>Disruption of the blood&#x2013;brain barrier during TNBS colitis</article-title><source>Neurogastroenterol Motil</source><year>2005</year><volume>17</volume><issue>3</issue><fpage>433</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2005.00654.x</pub-id><pub-id pub-id-type="pmid">15916631</pub-id>
</element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Natah SS, Mouihate A, Pittman QJ, Sharkey KA. Disruption of the blood&#x2013;brain barrier during TNBS colitis. Neurogastroenterol Motil. 2005;17(3):433&#x2013;46.<pub-id pub-id-type="pmid">15916631</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Villar&#xE1;n</surname><given-names>RF</given-names></name><name><surname>Espinosa-Oliva</surname><given-names>AM</given-names></name><name><surname>Sarmiento</surname><given-names>M</given-names></name><name><surname>De Pablos</surname><given-names>RM</given-names></name><name><surname>Arg&#xFC;elles</surname><given-names>S</given-names></name><name><surname>Delgado&#x2010;Cort&#xE9;s</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Ulcerative colitis exacerbates lipopolysaccharide&#x2010;induced damage to the nigral dopaminergic system: potential risk factor in parkinsons disease</article-title><source>J Neurochem</source><year>2010</year><volume>114</volume><issue>6</issue><fpage>1687</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06879.x</pub-id><pub-id pub-id-type="pmid">20584104</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Villar&#xE1;n RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arg&#xFC;elles S, Delgado&#x2010;Cort&#xE9;s MJ, et al. Ulcerative colitis exacerbates lipopolysaccharide&#x2010;induced damage to the nigral dopaminergic system: potential risk factor in parkinsons disease. J Neurochem. 2010;114(6):1687&#x2013;700.<pub-id pub-id-type="pmid">20584104</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation-alternatives>
          <element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>LGd</surname><given-names>OLIVEIRA</given-names></name><name><surname>ALd</surname><given-names>CUNHA</given-names></name><name><surname>Duarte</surname><given-names>AC</given-names></name><name><surname>Casta&#xF1;on</surname><given-names>MCMN</given-names></name><name><surname>Chebli</surname><given-names>JMF</given-names></name><collab>AGUIAR JAKd</collab></person-group><article-title>Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis</article-title><source>Arq Gastroenterol</source><year>2014</year><volume>51</volume><fpage>107</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1590/S0004-28032014000200007</pub-id><pub-id pub-id-type="pmid">25003261</pub-id>
</element-citation>
          <mixed-citation id="mc-CR41" publication-type="journal">LGd OLIVEIRA, ALd CUNHA, Duarte AC, Casta&#xF1;on MCMN, Chebli JMF, AGUIAR JAKd. Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis. Arq Gastroenterol. 2014;51:107&#x2013;12.<pub-id pub-id-type="pmid">25003261</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation-alternatives>
          <element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Caradonna</surname><given-names>L</given-names></name><name><surname>Amati</surname><given-names>L</given-names></name><name><surname>Magrone</surname><given-names>T</given-names></name><name><surname>Pellegrino</surname><given-names>NM</given-names></name><name><surname>Jirillo</surname><given-names>E</given-names></name><name><surname>Caccavo</surname><given-names>D</given-names></name></person-group><article-title>Invited review: enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance</article-title><source>J Endotoxin Res</source><year>2000</year><volume>6</volume><issue>3</issue><fpage>205</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11052175</pub-id>
</element-citation>
          <mixed-citation id="mc-CR42" publication-type="journal">Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Invited review: enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000;6(3):205&#x2013;14.<pub-id pub-id-type="pmid">11052175</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation-alternatives>
          <element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Jeong</surname><given-names>J</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice</article-title><source>Mucosal Immunol</source><year>2018</year><volume>11</volume><issue>2</issue><fpage>369</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/mi.2017.49</pub-id><pub-id pub-id-type="pmid">28612842</pub-id>
</element-citation>
          <mixed-citation id="mc-CR43" publication-type="journal">Jang S, Lim S, Jeong J, Jang H, Lee H, Han M, Kim D. Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice. Mucosal Immunol. 2018;11(2):369&#x2013;79.<pub-id pub-id-type="pmid">28612842</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation-alternatives>
          <element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>LaGraize</surname><given-names>SC</given-names></name><name><surname>Labuda</surname><given-names>CJ</given-names></name><name><surname>Rutledge</surname><given-names>MA</given-names></name><name><surname>Jackson</surname><given-names>RL</given-names></name><name><surname>Fuchs</surname><given-names>PN</given-names></name></person-group><article-title>Differential effect of anterior cingulate cortex lesion on mechanical hypersensitivity and escape/avoidance behavior in an animal model of neuropathic pain</article-title><source>Exp Neurol</source><year>2004</year><volume>188</volume><issue>1</issue><fpage>139</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.04.003</pub-id><pub-id pub-id-type="pmid">15191810</pub-id>
</element-citation>
          <mixed-citation id="mc-CR44" publication-type="journal">LaGraize SC, Labuda CJ, Rutledge MA, Jackson RL, Fuchs PN. Differential effect of anterior cingulate cortex lesion on mechanical hypersensitivity and escape/avoidance behavior in an animal model of neuropathic pain. Exp Neurol. 2004;188(1):139&#x2013;48.<pub-id pub-id-type="pmid">15191810</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation-alternatives>
          <element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms of pain in the anterior cingulate cortex</article-title><source>J Neurosci Res</source><year>2006</year><volume>84</volume><issue>5</issue><fpage>927</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/jnr.21003</pub-id><pub-id pub-id-type="pmid">16862566</pub-id>
</element-citation>
          <mixed-citation id="mc-CR45" publication-type="journal">Zhuo M. Molecular mechanisms of pain in the anterior cingulate cortex. J Neurosci Res. 2006;84(5):927&#x2013;33.<pub-id pub-id-type="pmid">16862566</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation-alternatives>
          <element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>SM</given-names></name><name><surname>Pfister</surname><given-names>J-P</given-names></name><name><surname>Santello</surname><given-names>M</given-names></name><name><surname>Senn</surname><given-names>W</given-names></name><name><surname>Nevian</surname><given-names>T</given-names></name></person-group><article-title>Nerve injury-induced neuropathic pain causes disinhibition of the anterior cingulate cortex</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><issue>17</issue><fpage>5754</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3667-13.2014</pub-id><pub-id pub-id-type="pmid">24760836</pub-id>
</element-citation>
          <mixed-citation id="mc-CR46" publication-type="journal">Blom SM, Pfister J-P, Santello M, Senn W, Nevian T. Nerve injury-induced neuropathic pain causes disinhibition of the anterior cingulate cortex. J Neurosci. 2014;34(17):5754&#x2013;64.<pub-id pub-id-type="pmid">24760836</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation-alternatives>
          <element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>BA</given-names></name><name><surname>Wiley</surname><given-names>RG</given-names></name><name><surname>Jensen</surname><given-names>EL</given-names></name></person-group><article-title>Localization of mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of mu regulation</article-title><source>Exp Neurol</source><year>1995</year><volume>135</volume><issue>2</issue><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1006/exnr.1995.1069</pub-id><pub-id pub-id-type="pmid">7589327</pub-id>
</element-citation>
          <mixed-citation id="mc-CR47" publication-type="journal">Vogt BA, Wiley RG, Jensen EL. Localization of mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of mu regulation. Exp Neurol. 1995;135(2):83&#x2013;92.<pub-id pub-id-type="pmid">7589327</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation-alternatives>
          <element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J-H</given-names></name><name><surname>Xiao</surname><given-names>T-H</given-names></name><name><surname>Chang</surname><given-names>C-W</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X-L</given-names></name><name><surname>Gao</surname><given-names>G-D</given-names></name><name><surname>Yu</surname><given-names>Y-Q</given-names></name></person-group><article-title>Activation of anterior cingulate cortex produces inhibitory effects on noxious mechanical and electrical stimuli-evoked responses in rat spinal WDR neurons</article-title><source>Eur J Pain</source><year>2011</year><volume>15</volume><issue>9</issue><fpage>895</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2011.04.003</pub-id><pub-id pub-id-type="pmid">21600816</pub-id>
</element-citation>
          <mixed-citation id="mc-CR48" publication-type="journal">Ma J-H, Xiao T-H, Chang C-W, Gao L, Wang X-L, Gao G-D, Yu Y-Q. Activation of anterior cingulate cortex produces inhibitory effects on noxious mechanical and electrical stimuli-evoked responses in rat spinal WDR neurons. Eur J Pain. 2011;15(9):895&#x2013;9.<pub-id pub-id-type="pmid">21600816</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40082706</article-id><article-id pub-id-type="pmc">11906772</article-id><article-id pub-id-type="publisher-id">93708</article-id><article-id pub-id-type="doi">10.1038/s41598-025-93708-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>First insights and future research perspectives from the sarcoidosis registry at the Medical University of Vienna</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Guttmann-Ducke</surname><given-names>Claudia</given-names></name><address><email>claudia.guttmann-ducke@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lutnik</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gysan</surname><given-names>Maximilian Robert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sarova</surname><given-names>Pavla</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Milacek</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bal</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graninger</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Prosch</surname><given-names>Helmut</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gompelmann</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Idzko</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Pneumology, University Hospital Vienna, </institution><institution> Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Clinical Pharmacology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05r0e4p82</institution-id><institution-id institution-id-type="GRID">grid.487248.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 9340 1179</institution-id><institution>Karl Landsteiner Institut f&#xFC;r Infektiologie, </institution></institution-wrap>St. P&#xF6;lten, Austria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Biomedical Imaging and Image-Guided Therapy, Vienna General Hospital, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>8644</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">
Sarcoidosis is a systemic granulomatous disease that may differ in clinical presentation, organ involvement and severity among different populations. The primary objective was to evaluate demographic characteristics, disease stage, diagnostic work-up and treatment of patients with sarcoidosis. The sarcoidosis registry was founded in 2022 at the Medical University of Vienna and is intended to record patients from all over Austria who were diagnosed with sarcoidosis. All relevant information was collected at the time of the initial presentation and then on an ongoing basis every 6 months thereafter. Data was available for 199 sarcoidosis patients who were treated at the Medical University of Vienna between 2022 and 2023. The mean age of all patients was 52&#x2009;&#xB1;&#x2009;13 years. At 57.5%, women were significantly more represented than men were. Of these patients, 44.5% were smokers, and significantly more of them were men (63.8%). Chest X-ray revealed sarcoidosis in lung stages 1, 2, 3 and 4 in 34. 5%, 46%, 9.5% and 6% respectively. Overall, 37.5% (male: 33 (38.8%)) of all patients received oral corticosteroid therapy (OCS) during their illness, the mean duration of treatment with OCS (years, median, IQR) was 5 (3; 7.5). Most patients who received OCS for their disease were in pulmonary stage 4 with 81.8%. Patients were on average overweight with a mean BMI of 28.3&#xA0;kg/m2 (&#xB1;&#x2009;6.5). This study is the first characterization of sarcoidosis patients in Austria.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-93708-9.</p></sec></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Respiratory tract diseases</kwd><kwd>Epidemiology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par8">Sarcoidosis is an inflammatory granulomatous multisystemic disease of unknown etiology that affects all individuals regardless of sex, race, and age, with a prevalence of about 4.7&#x2013;64/100,000 people and an incidence of 1&#x2013;35.5/100,000 people per year worldwide<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>.</p>
      <p id="Par9">The lungs (lymph nodes and lung parenchyma) are involved in most patients, followed by the skin, liver, and eyes. Pulmonary involvement varies from radiographic abnormalities in asymptomatic individuals to a progressive pulmonary disorder causing lung fibrosis and respiratory failure. While dyspnea and cough are the most common organ-related symptoms of sarcoidosis, fatigue is the most common symptom in patients with sarcoidosis, with a broad variety of other constitutional symptoms<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref></sup>. It was originally assumed that young people aged between 20 and 40 were the age group most affected<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. However, there is now evidence that sarcoidosis can be present in older people regardless of gender<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
      <p id="Par10">Several studies have been published demonstrating the differences in age at diagnosis, clinical presentation and organ involvement &#x2013; including in the US<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref></sup>, UK<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, Denmark<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, Korea<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and Sweden<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The sarcoidosis registry of the Medical University of Vienna was launched to collect long-term follow-up data from a large cohort of patients with sarcoidosis. The overall aim was to present the clinical picture of sarcoidosis, also known as the chameleon of internal medicine due to the disease&#x2019;s ability to mimic other clinical pictures, in its entirety. In addition, it seems important to be able to follow the course of sarcoidosis, to detect multi-organ involvement in this disease and to characterise the care of patients with proven sarcoidosis.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Registry</title>
        <p id="Par11">The Sarcoidosis Registry of the Medical University of Vienna was founded in 2022 and enrolls patients from all over Austria at the Department of Pulmonology at Medical University of Vienna with a suspected or confirmed diagnosis of sarcoidosis from February 2022 to March 2023. All patients with confirmed sarcoidosis who were treated at the Department of Pulmonology at Medical University of Vienna from 1 March 2022 onwards were included in this sarcoidosis registry. All patients gave written informed consent before participating in the registry. Patient characteristics are collected on an ongoing basis. This study presents the basic characteristics of the patients with sarcoidosis. In addition, a series of analyses were carried out on these basic data to determine correlations between these characteristics and the course of sarcoidosis. This registry has been approved by the Ethics Committee of the Medical University of Vienna (Ethics Committee Number EK 2246/2021) and was conducted in accordance with the Declaration of Helsinki.</p>
      </sec>
      <sec id="Sec4">
        <title>Data collection</title>
        <p id="Par12">Socio-demographic data (age, gender, body mass index (BMI)) and information on concomitant diseases were recorded for all patients at the time of diagnosis and inclusion in this registry. Medical management data including pulmonary function tests (PFT), lung diffusion capacity, chest CT, cerebral MRI, MRI of the heart and diagnostic procedures with biopsies were collected from all patients enrolled in this registry. Patients with cardiac symptoms underwent cardiac MRI. Late enhancement on cardiac MRI was defined as cardiac involvement. Patients with neurological symptoms underwent brain MRI. If pathological changes on MRI were compatible with the presence of neurosarcoidosis and corresponding clinical symptoms, neurological involvement was assumed. Moreover, pharmacological and non-pharmacological therapies, hospitalizations, exacerbations and deaths were recorded to gain a better understanding of the clinical presentation, disease severity, and response to treatment, disease course and mortality. Missing data were not replaced and are addressed when necessary.</p>
      </sec>
      <sec id="Sec5">
        <title>Statistical analysis</title>
        <p id="Par13">For categorical parameters, descriptive statistics include relative and absolute frequencies. For metric parameters, the mean and standard deviation, or the median, range and interquartile range (IQR) were calculated. Furthermore, subgroup analyses were conducted to compare characteristics between patients treated with oral corticosteroids and those who were corticosteroid-na&#xEF;ve, and between different stages of pulmonary involvement. Group comparisons were assessed using t-tests or Mann-Whitney-U tests for metric parameters and Chi-square tests for categorical parameters. ANOVA was employed to compare the characteristics between different stages of sarcoid lung involvement. Differences were considered significant if the p-value was less than 0.05. All statistical analyses were conducted using GraphPad Prism version 9 (GraphPad Software, MA, USA).</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <sec id="Sec7">
        <title>Clinical characteristics, comorbidities and pulmonary function test</title>
        <p id="Par14">Data were available for 199 Austrian sarcoidosis patients from 2022 to 2023. Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> provides an overview of the baseline data. At the time of diagnosis, the median age was 46 years (IQR: 36; 55). Women are more likely to be diagnosed with sarcoidosis than men (men 42.5% vs. women 57.5%, <italic>p</italic>&#x2009;=&#x2009;0.0036, <italic>x</italic><sup>2</sup> test). Patients were on average overweight with a median BMI of 27.76&#xA0;kg/m<sup>2</sup> (24.14&#x2013;31.64). Almost half of the patients were former or current smokers (44.5%), of whom 63.8% were men (men 63.8% vs. women 34.8%, <italic>p</italic>&#x2009;=&#x2009;0.0006, <italic>x</italic><sup>2</sup> test). Allergies, not specified, were reported as the most common comorbidity in 20% (<italic>n</italic>&#x2009;=&#x2009;40), followed by cancer as the second most common comorbidity in 11.5% (<italic>n</italic>&#x2009;=&#x2009;23). The most common existing malignancies (<italic>n</italic>&#x2009;=&#x2009;23) at the time of inclusion in the registry were gynecological cancers (<italic>n</italic>&#x2009;=&#x2009;9), urological cancers (<italic>n</italic>&#x2009;=&#x2009;3) and neuroendocrine tumors (<italic>n</italic>&#x2009;=&#x2009;3). A total of 15.6% of women had a history of cancer, compared with 7.2% of men. Other comorbidities were diabetes mellitus type 2 (T2DM) in 7.5% and asthma in 5.5%. Clinical features of sarcoidosis are presented in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.</p>
        <p id="Par15">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Baseline characteristics</th><th align="left">Total</th><th align="left">Male</th><th align="left">Female</th><th align="left"><italic>p</italic> -value</th></tr></thead><tbody><tr><td align="left" colspan="5">Clinical characteristics</td></tr><tr><td align="left">&#xA0;Patients (n, %)</td><td align="left">199</td><td align="left">85 (42.5)</td><td align="left">109 (57.5)</td><td char="." align="char">
<bold>0.0036</bold>
</td></tr><tr><td align="left">&#xA0;Age (yrs, mean, SD)</td><td align="left">52 (13)</td><td align="left">52 (12)</td><td align="left">55 (14)</td><td char="." align="char">0.2408</td></tr><tr><td align="left">&#xA0;Age at time of diagnosis (yrs, median, IQR)</td><td align="left">46 (36; 55)</td><td align="left">40 (35; 50)</td><td align="left">50 (37; 57)</td><td char="." align="char">0.0601</td></tr><tr><td align="left">&#xA0;BMI (kg/m&#xB2;, median, IQR)</td><td align="left">27.76 (24.14; 31.64)</td><td align="left">28.7 (26.05; 31.62)</td><td align="left">25.63 (23.05; 32.39)</td><td char="." align="char">0.5915</td></tr><tr><td align="left">&#xA0;Smoker (%)</td><td align="left">89 (44.5)</td><td align="left">50 (63.8)</td><td align="left">38 (34.8)</td><td char="." align="char">
<bold>0.0006</bold>
</td></tr><tr><td align="left">&#xA0;Pack years (yrs, median, IQR)</td><td align="left">0 (0; 10)</td><td align="left">10 (0; 19)</td><td align="left">0 (0; 7)</td><td char="." align="char">0.4975</td></tr><tr><td align="left" colspan="5">Comorbidities</td></tr><tr><td align="left">&#xA0;Allergies (n, %)</td><td align="left">40 (20.0)</td><td align="left">20 (24.1)</td><td align="left">20 (18.3)</td><td char="." align="char">0.2739</td></tr><tr><td align="left">&#xA0;Arterial hypertension (n, %)</td><td align="left">9 (4.5)</td><td align="left">4 (4.8)</td><td align="left">5 (4.6)</td><td char="." align="char">0.9399</td></tr><tr><td align="left">&#xA0;COPD (n, %)</td><td align="left">5 (2.5)</td><td align="left">2 (2.4)</td><td align="left">3 (1.8)</td><td char="." align="char">0.8826</td></tr><tr><td align="left">&#xA0;Asthma (n, %)</td><td align="left">11 (5.5)</td><td align="left">5 (6.0)</td><td align="left">6 (5.5)</td><td char="." align="char">0.4445</td></tr><tr><td align="left">&#xA0;Cancer (n, %)</td><td align="left">23 (11.5)</td><td align="left">6 (7.2)</td><td align="left">17 (15.6)</td><td char="." align="char">0.0769</td></tr><tr><td align="left">&#xA0;Diabetes mellitus type 2 (n, %)</td><td align="left">15 (7.5)</td><td align="left">7 (8.2)</td><td align="left">8 (7.0)</td><td char="." align="char">0.7475</td></tr><tr><td align="left">&#xA0;Pulmonary hypertension (n, %)</td><td align="left">4 (2.0)</td><td align="left">2 (2.4)</td><td align="left">2 (1.8)</td><td char="." align="char">0.7824</td></tr><tr><td align="left" colspan="5">Pulmonary function test (PFT)</td></tr><tr><td align="left">&#xA0;FEV<sub>1</sub> predicted (%, median, IQR)</td><td align="left">91.5 (77.0; 101.0)</td><td align="left">88.0 (74.0; 101.0)</td><td align="left">81.5 (67.5; 93.0)</td><td char="." align="char">0.0506</td></tr><tr><td align="left">&#xA0;FEV<sub>1</sub> (mL, median, IQR)</td><td align="left">2790 (2228 ;3558)</td><td align="left">3710 (2580; 4410)</td><td align="left">2070 (1530; 2735)</td><td char="." align="char">
<bold>&lt;&#x2009;0.001</bold>
</td></tr><tr><td align="left">&#xA0;FEV<sub>1</sub>/FVC ratio (median, IQR)</td><td align="left">0.97 (0.92; 1.03)</td><td align="left">0.96 (0.92; 1.04)</td><td align="left">0.96 (0.92; 1.00)</td><td char="." align="char">0.9999</td></tr><tr><td align="left">&#xA0;TLC (mL, median, IQR)</td><td align="left">5595 (4865; 6903)</td><td align="left">7145 (5700; 7780)</td><td align="left">4830 (4100; 5390)</td><td char="." align="char">
<bold>&lt;&#x2009;0.001</bold>
</td></tr><tr><td align="left">&#xA0;KCO/SB (%, median, IQR)</td><td align="left">89.3 (77.6; 101.3)</td><td align="left">98.7 (88.9; 106.2)</td><td align="left">82.9 (74.8; 94.3)</td><td char="." align="char">
<bold>&lt;&#x2009;0.001</bold>
</td></tr><tr><td align="left">&#xA0;DLCO/VA (%, median, IQR)</td><td align="left">88.6 (79.4; 95.5)</td><td align="left">86.3 (69.5; 90.3)</td><td align="left">87.8 (74.6; 93.4)</td><td char="." align="char">0.2512</td></tr><tr><td align="left" colspan="5">Clinical features</td></tr><tr><td align="left">&#xA0;Arthralgia (n, %)</td><td align="left">4 (2.0)</td><td align="left">2 (2.4)</td><td align="left">2 (1.8)</td><td align="left"/></tr><tr><td align="left">&#xA0;Chest pain (n, %)</td><td align="left">3 (1.5)</td><td align="left">2 (2.4)</td><td align="left">1 (0.9)</td><td align="left"/></tr><tr><td align="left">&#xA0;Cough (n, %)</td><td align="left">8 (4.0)</td><td align="left">3 (3.5)</td><td align="left">5 (4.4)</td><td align="left"/></tr><tr><td align="left">&#xA0;Dyspnea (n, %)</td><td align="left">25 (12.5)</td><td align="left">15 (17.6)</td><td align="left">10 (8.8)</td><td align="left"/></tr><tr><td align="left">&#xA0;Fatigue (n, %)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#xA0;Myalgia (n, %)</td><td align="left">5 (2.5)</td><td align="left">2 (2.4)</td><td align="left">3 (2.6)</td><td align="left"/></tr><tr><td align="left">&#xA0;Palpitations (n, %)</td><td align="left">11 (5.5)</td><td align="left">7 (8.3)</td><td align="left">4 (3.5)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Significance level <italic>p</italic>&lt;0,05 are in bold.</p><p>Baseline characteristics of the registry population at time of inclusion; group comparisons were assessed using t-tests for metric parameters and chi-square tests for categorical parameters; BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1&#xA0;s; TLC: total lung capacity; DLCO/VA: diffusing capacity of the lung for carbon monoxide divided by alveolar volume; KCO: carbon monoxide transfer coefficient; yrs: years.</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par16">PFT was performed at baseline in 93.5% (<italic>n</italic>&#x2009;=&#x2009;186) patients. Airflow obstruction, defined as FEV1/FVC&#x2009;&lt;&#x2009;70%<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> was seen in 26% (<italic>n</italic>&#x2009;=&#x2009;52) of patients. Restrictive lung disease, defined by an FVC below under limit of normal (LLN) was found in 8.5% of all patients (<italic>n</italic>&#x2009;=&#x2009;17). A diffusion disorder, defined by a DLCO&#x2009;&lt;&#x2009;70%, was found in 11.5% (<italic>n</italic>&#x2009;=&#x2009;23) of all patients in whom a DLCO measurement was performed (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). KCO was significantly lower in women compared to men (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) (mean KCO/SB men: 98% vs. women 82%, <italic>p</italic>&#x2009;&lt;&#x2009;0.0001, t-test). Allergic comorbidities at the beginning of the study were present in 40 patients (20%). Median IgE as an expression of a possible allergic component was on average 35.8 U/mL (IQR 11.6; 109.0). The median FeNO was found to be 21 ppb (parts per billion) (IQR 10; 32) (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).</p>
        <p id="Par170">
<fig id="Fig1"><label>Fig. 1</label><caption><p>DLCO/VA [%] and KCO/SB [%] of sarcoidosis patients, where available in total, white (<italic>n</italic>&#x2009;=&#x2009;181); men, blue (<italic>n</italic>&#x2009;=&#x2009;81) and women, red (<italic>n</italic>&#x2009;=&#x2009;100); <italic>p</italic>&#x2009;&lt;&#x2009;0.0001, t- test, data presented as percentage (median and 5&#x2013;95 percentile);</p></caption><graphic xlink:href="41598_2025_93708_Fig1_HTML" id="d33e855"/></fig>
</p>
        <p id="Par18">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Diagnostic results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Laboratory tests</th></tr></thead><tbody><tr><td align="left">Interleukin 2 receptor (U/mL, median, IQR)</td><td align="left">600 (414; 9311)</td></tr><tr><td align="left">Neopterin (U/mL, median, IQR)</td><td align="left">5.7 (4.7; 8.8)</td></tr><tr><td align="left">ACE (U/mL, median, IQR)</td><td align="left">40.1 (27.5; 57.5)</td></tr><tr><td align="left">IgE (U/mL, median, IQR)</td><td align="left">35.8 (11.6; 109.0)</td></tr><tr><td align="left">EOS rel. (%, median, IQR)</td><td align="left">2.6 (1.4; 4.5)</td></tr><tr><td align="left">pBNP (pg/mL, median, IQR)</td><td align="left">59.9 (35.6; 35000)</td></tr><tr><td align="left">FeNO (ppb, median, IQR)</td><td align="left">21; (10; 32)</td></tr><tr><td align="left" colspan="2">BAL (Bronchoalveolar lavage)</td></tr><tr><td align="left">&#xA0;Lymphocyte count (percentage, median, IQR)</td><td align="left">21 (8; 41)</td></tr></tbody></table><table-wrap-foot><p> Presentation of diagnostic results of registry population at time of inclusion; laboratory results were assessed from serum samples; BAL was performed in 101 patients; ACE: angiotensin converting enzyme; IgE: immune Globulin E; pBNP: pro &#x2013; brain natriuretic peptide; EOS: eosinophil lymphocyte; FeNO: exhaled nitric oxide.</p></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="Sec8">
        <title>Histological work-up</title>
        <p id="Par19">A total of 99.4% (<italic>n</italic>&#x2009;=&#x2009;198) of patients had a histologically confirmed diagnosis of sarcoidosis, of which 76.65% (<italic>n</italic>&#x2009;=&#x2009;151) were diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and 6.6% (<italic>n</italic>&#x2009;=&#x2009;13) by transbronchial biopsy. In 16.75% (<italic>n</italic>&#x2009;=&#x2009;33) of all patients, the diagnosis of sarcoidosis was made by biopsy of other tissue, mainly the skin.</p>
        <p id="Par20">Bronchoalveolar lavage (BAL) underwent 50.5% (<italic>n</italic>&#x2009;=&#x2009;101) of patients, which revealed a median lymphocyte count 21% (IQR 8; 41) (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Characteristic BAL findings in sarcoidosis may include a normal or slightly elevated total cell count with lymphocytosis<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p>
      </sec>
      <sec id="Sec9">
        <title>Organ involvement and disease staging</title>
        <p id="Par21">The lungs (mediastinal and hilar lymph nodes and lung parenchyma) were most frequently affected at 96.5%. Radiological assessment with chest CT revealed stage 1, 2, 3 and 4 sarcoidosis in 34.5% (male <italic>n</italic>&#x2009;=&#x2009;23 (27.1%)), 46% (male <italic>n</italic>&#x2009;=&#x2009;44 (51.8%)), 9.5% (male <italic>n</italic>&#x2009;=&#x2009;7 (8.2%)) and 6% (male <italic>n</italic>&#x2009;=&#x2009;9 (10.6%)) respectively. In 6% (<italic>n</italic>&#x2009;=&#x2009;7) of the patients, no pulmonary involvement could be detected (pulmonary stage 0). Women were more frequently affected in pulmonary stages 0&#x2013;3 (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Only in stage 4 disease, men were significantly more affected (men 10.6% vs. women 2.6%, <italic>p</italic>&#x2009;=&#x2009;0.0197, <italic>x</italic><sup>2</sup> test). The prevalence of skin manifestations was 24% and of ocular manifestation 14%. At the time of enrolment in the sarcoidosis registry, 66.5% of patients underwent MRI of the heart to rule out possible involvement. In 5.5%, late enhancement was a sign of organ involvement. A total of 59% of the patients underwent cerebral MRI that showed cerebral manifestation in 9%. Organ involvement is presented in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>.</p>
        <p id="Par22">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Organ manifestations and disease stage.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Organ involvement and disease stage</th><th align="left">Total</th><th align="left">Male</th><th align="left">Female</th><th align="left"><italic>p</italic> -value</th></tr></thead><tbody><tr><td align="left">Lung (n,%)</td><td char="." align="char">193 (96.5)</td><td char="." align="char">83 (97.6)</td><td char="." align="char">110 (96.5)</td><td align="left"/></tr><tr><td align="left">&#xA0;Stage 0 (n, %)</td><td char="." align="char">7 (4.0)</td><td char="." align="char">2 (2.4)</td><td char="." align="char">5 (4.4)</td><td char="." align="char">0.4413</td></tr><tr><td align="left">&#xA0;Stage 1 (n, %)</td><td char="." align="char">69 (34.5)</td><td char="." align="char">23 (27.1)</td><td char="." align="char">46 (40.4)</td><td char="." align="char">0.0513</td></tr><tr><td align="left">&#xA0;Stage 2 (n, %)</td><td char="." align="char">92 (46.0)</td><td char="." align="char">44 (51.8)</td><td char="." align="char">48 (42.1)</td><td char="." align="char">0.1764</td></tr><tr><td align="left">&#xA0;Stage 3 (n, %)</td><td char="." align="char">19 (9.5)</td><td char="." align="char">7 (8.2)</td><td char="." align="char">12 (10.5)</td><td char="." align="char">0.5864</td></tr><tr><td align="left">&#xA0;Stage 4 (n, %)</td><td char="." align="char">12 (6.0)</td><td char="." align="char">9 (10.6)</td><td char="." align="char">3 (2.6)</td><td char="." align="char">
<bold>0.0197</bold>
</td></tr><tr><td align="left">Other manifestations</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#xA0;Skin (n, %)</td><td char="." align="char">48 (24.0)</td><td char="." align="char">18 (21.2)</td><td char="." align="char">30 (26.3)</td><td char="." align="char">0.4019</td></tr><tr><td align="left">&#xA0;Eye (n, %)</td><td char="." align="char">28 (14.0)</td><td char="." align="char">9 (10.6)</td><td char="." align="char">19 (16.7)</td><td char="." align="char">0.2225</td></tr><tr><td align="left">&#xA0;Brain (n, %)</td><td char="." align="char">18 (9.0)</td><td char="." align="char">7 (8.2)</td><td char="." align="char">11 (9.6)</td><td char="." align="char">0.7309</td></tr><tr><td align="left">&#xA0;Liver (n, %)</td><td char="." align="char">17 (8.5)</td><td char="." align="char">11 (13.0)</td><td char="." align="char">6 (5.3)</td><td char="." align="char">0.0533</td></tr><tr><td align="left">&#xA0;Kidney (n, %)</td><td char="." align="char">10 (5.0)</td><td char="." align="char">8 (9.4)</td><td char="." align="char">2 (1.8)</td><td char="." align="char">
<bold>0.0144</bold>
</td></tr><tr><td align="left">&#xA0;Heart (n, %)</td><td char="." align="char">11 (5.5)</td><td char="." align="char">6 (7.1)</td><td char="." align="char">5 (4.4)</td><td char="." align="char">0.5339</td></tr></tbody></table><table-wrap-foot><p>Presentation of organ involvement of the registry population at time of inclusion; group comparisons were assessed using chi-square tests; disease stages are defined as radiologically determined sarcoidosis stages (0&#x2013;4) using CT scan; total 199 patients.</p><p>Significance level <italic>p</italic>&lt;0,05 are in bold.</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par230">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Comparison of frequencies of sarcoidosis stages between male, blue (<italic>n</italic>&#x2009;=&#x2009;85) (blue) and female, red (<italic>n</italic>&#x2009;=&#x2009;114), percentages are reported. (<italic>p</italic>&#x2009;=&#x2009;0,0244, x<sup>2</sup> Test)</p></caption><graphic xlink:href="41598_2025_93708_Fig2_HTML" id="d33e1186"/></fig>
</p>
      </sec>
      <sec id="Sec10">
        <title>Laboratory tests</title>
        <p id="Par24">Results from laboratory tests and bronchoalveolar lavage are presented in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>. Comparing laboratory results of ACE, IL2 and neopterin between sarcoidosis stages, no significant differences using ANOVA testing were found. Furthermore, no significant differences were found using ANOVA testing in the vital capacity, diffusions capacity and FeNO (a marker of T2 inflammation). Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref> visualizes diagnostic results of sarcoidosis stages.</p>
        <p id="Par25">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Visualization of selected diagnostic results in patients with histological confirmed sarcoidosis stage (<italic>n</italic>&#x2009;=&#x2009;188); stage 0 (<italic>n</italic>&#x2009;=&#x2009;7 (6%)); stage 1 (<italic>n</italic>&#x2009;=&#x2009;68 (34.0%)); stage 2 (<italic>n</italic>&#x2009;=&#x2009;92 (46.0%)); stage 3 (<italic>n</italic>&#x2009;=&#x2009;17 (8.5%)); stage 4 (<italic>n</italic>&#x2009;=&#x2009;11 (5.5%)); Displayed are results of laboratory and pulmonary function: IL 2 receptor [U/mL]; ACE [U/mL]; Neopterin [U/mL]; VC [%]; TLCO/VA; FeNO [pbb]; Values are reported as median and range;</p></caption><graphic xlink:href="41598_2025_93708_Fig3_HTML" id="d33e1226"/></fig>
</p>
        <p id="Par26">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Comparison of laboratory results and disease activity markers between patients with single organ involvement (SO) (<italic>n</italic>&#x2009;=&#x2009;94) and multi organ involvement (MO) (<italic>n</italic>&#x2009;=&#x2009;105); IL 2 receptor [U/mL]; ACE [U/mL]; Neopterin [U/mL]; * Spearman, <italic>p</italic>&#x2009;=&#x2009;0.031.</p></caption><graphic xlink:href="41598_2025_93708_Fig4_HTML" id="d33e1246"/></fig>
</p>
        <p id="Par27">Figure <xref rid="Fig4" ref-type="fig">4</xref> shows the comparison between single and multi-organ involvement in sarcoidosis in correlation with activity parameters (IL2 receptor, neopterin, ACE). A significant correlation was found between neopterin and multi-organ involvement (Spearman, <italic>p</italic>&#x2009;=&#x2009;0.031).</p>
        <p id="Par28">In the comparison between single-organ and multi-organ involvement in sarcoidosis, no correlation was found for IL2 receptor and ACE.</p>
      </sec>
      <sec id="Sec11">
        <title>Treatment</title>
        <p id="Par29">Overall, 37.5% (male: 33 (38.8%)) of all patients received OCS while their illness, the median duration of treatment was 5 years (IQR 3; 7.5). (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>)</p>
        <p id="Par30">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Overview of treatment with oral corticosteroids (OCS) and differences in selected characteristics between OCS treated patients and OCS naive patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Steroid treatment</th><th align="left">Total</th><th align="left">Male</th><th align="left">Female</th></tr></thead><tbody><tr><td align="left">OCS (n, %)</td><td align="left">75 (37.5)</td><td align="left">33 (38.8)</td><td align="left">42 (36.8)</td></tr><tr><td align="left">Duration OCS therapy (yrs, median)</td><td align="left">5 (3; 7.5)</td><td align="left">5 (3; 8)</td><td align="left">5 (3; 7)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">With OCS</th><th align="left">No OCS</th><th align="left"/></tr></thead><tbody><tr><td align="left">BMI, (mean, SD)</td><td align="left">28.3 (&#xB1;&#x2009;5.6)</td><td align="left">28.5 (&#xB1;&#x2009;6.3)</td><td align="left"/></tr><tr><td align="left">Smoker, (n, %)</td><td align="left">39 (52.0%)</td><td align="left">50 (66.6%)</td><td align="left"/></tr><tr><td align="left">DLCO/VA, (mean, SD)</td><td align="left">86.7 (&#xB1;&#x2009;18.8)</td><td align="left">91.1 (&#xB1;&#x2009;16.7)</td><td align="left"/></tr><tr><td align="left">Diabetes mellitus Type 2 (n, %)</td><td align="left">7 (9.2%)</td><td align="left">8 (10.6%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Comparison of clinically relevant selected characteristics of registry patients with (<italic>n</italic>&#x2009;=&#x2009;75; 37.5%) and without (<italic>n</italic>&#x2009;=&#x2009;124) oral corticosteroid (OCS) therapy at time of inclusion in registry.</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par31">Most patients who received OCS for their disease were in pulmonary stage 4 with 81.8%. (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>) There were no significant differences in baseline characteristics between OCS treated and OCS naive patients. (Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref>) Among the baseline data such as BMI and nicotine abuse, no significant differences were found between the patients with oral corticosteroid therapy and those without therapy. Similarly, no significant difference in diffusion capacity was found between the two patient groups.</p>
        <p id="Par32">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Comparison of percentage of patients taking oral corticosteroids (<italic>n</italic>&#x2009;=&#x2009;75) between sarcoidosis stages (0&#x2013;4) at time of inclusion in registry.</p></caption><graphic xlink:href="41598_2025_93708_Fig5_HTML" id="d33e1382"/></fig>
</p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Discussion</title>
      <p id="Par33">Several registries for sarcoidosis exist including the United States of America, Great Britain and Sweden, but they differ immensely in design and data collection, so that direct comparisons are only possible to a limited extent (Supplementary Table 1). This study is the first characterization of sarcoidosis patients in Austria.</p>
      <sec id="Sec13">
        <title>Sex aspects and diagnosis</title>
        <p id="Par35">The US Optum health care database identified a total of 29372 adult patients with sarcoidosis, 14700 (55%) of them were over 55 years of age at the time of diagnosis<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Women were two times more likely to have sarcoidosis, the highest prevalence for sarcoidosis was noted in African American women (178.5)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The data from the sarcoidosis register of the Medical University of Vienna also show a significantly higher number of women (57, 5%) suffering from sarcoidosis. Median age at diagnosis was 46 (IQR 36; 55) and overall median age was 52 (IQR 42; 62).</p>
        <p id="Par36">Data from the Swedish National Patient Register, the British Thoracic Society Sarcoidosis Registry and the Danish National Patient Register (DNPR) showed a slight male predominance with 55%, 58% and 56% respectively<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Regarding at the age of diagnosis, 55% of the sarcoidosis patients registered in the US Optum health care database were over 55 years of age and the Swedish National Patient Register found a mean age at diagnosis of 50 years. The National Health Service database identified 6376 individuals with a primary diagnosis of sarcoidosis between 2003 and 2015<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, with a mean age of 48.8 years. NHLBI-sponsored US studies (ACCESS, A Case Control Etiologic Study of Sarcoidosis and Nurses&#x2019; Health Study) have shown that a significant number of patients develop sarcoidosis after the age of 50, which is consistent with previous observations that the incidence may be biphasic<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref></sup>. Data from the Sarcoidosis Register of the Medical University of Vienna, Austria, showed a median age at diagnosis of 46 (36&#x2013;55) years, significantly younger than the US cohort. In a large multi- center study investigating how demographic differences affect the manifestation of sarcoidosis using the WASOG tool, 1445 patients with sarcoidosis were prospectively reviewed and showed that the median age at diagnosis was 46 years and 61% of patients were female<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. However, in the Worldwide Sarcoidosis Research Study (WISE), the median age of more than 1500 patients with was found to be 43 years<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p>
      </sec>
      <sec id="Sec14">
        <title>Therapy</title>
        <p id="Par38">Systemic corticosteroids remain the standard of care. No clear protocol for dose and duration has been validated<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Analyses from an U.S. national health care database showed that the most used treatment for sarcoidosis was prednisone. This is consistent with evidence-based recommendations for the use of glucocorticoids as first-line therapy for symptomatic disease<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>.</p>
        <p id="Par39">About one third (37.5%) of the sarcoidosis patients in this study were treated for the disease. In contrast, in most previously published U.S. studies, researchers have reported that about half of patients achieved steroids<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR28">28</xref></sup>. In a Danish National Patient Register (DNPR), more than half of the patients did not receive systemic corticosteroids<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. At the time of presentation to the British Thoracic Society Sarcoidosis Registry, 39% of all patients were being treated with oral corticosteroids<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p>
        <p id="Par40">Data from the Sarcoidosis Register of the Medical University of Vienna showed that 37.5% of all patients (males: 33, 38.8%) received OCS during the entire course of the disease. This figure also includes data on medical history. Other immunomodulatory drugs were not included in this data collection. The median duration of corticosteroid therapy was 5 years (IQR 3; 7). Most patients who received corticosteroid therapy were in pulmonary stage 4 disease (81.8%). Among the baseline data such as BMI and smoking history, no significant differences were found between the patients with oral corticosteroid therapy and those without therapy. Similarly, no significant difference in diffusion capacity was found between the two patient groups. Corticosteroid therapy has not been shown to have a significant effect on diabetes. A large prospective multi-center study investigating the demographic differences that affect the manifestations of sarcoidosis using the WASOG tool, including 1445 patients with sarcoidosis, 18% of patients did not receive any systemic treatment for sarcoidosis<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The Rheumatology Informatics System for Effectiveness (RISE) registry, which included 3276 patients with sarcoidosis, showed that 59.3% of patients were prescribed glucocorticoids and 24.7% received long-term glucocorticoid therapy<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p>
      </sec>
      <sec id="Sec15">
        <title>Organ involvement and disease staging</title>
        <p id="Par42">Data from the British Thoracic Society Sarcoidosis Registry show pulmonary sarcoidosis in stages 0 (8%), 1 (24%), 2 (29%), 3 (11%), 4 (14%)<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, slightly different from our data with 34.5% of patients in radiologically confirmed pulmonary stage 1, 46% of all patients in stage 2, only 9.5% patients of the Austrian cohort were in stage 3 and 6% patients in stage 4. Only 4% (<italic>n</italic>&#x2009;=&#x2009;7) of all patients had no radiologically detectable pulmonary manifestation of sarcoidosis. Peculiarities in the gender distribution of pulmonary sarcoidosis stages showed a significant male predominance in stage 4 disease (10.6%). A large prospective multicenter study investigating demographic differences affecting manifestations of sarcoidosis using the WASOG tool in 1445 patients with sarcoidosis showed that women were more likely to have eye or skin involvement, men were more likely to have cardiac involvement<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. A US and web-based self-reported questionnaire providing data on demographics, diagnosis, organ involvement and treatment modalities of sarcoidosis included 3835 respondents and compared Hispanic patients with non-Hispanic patients<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. The most common organs involved were lung, central and peripheral lymph nodes. Hispanics reported more peripheral nerve and peripheral lymph node involvement than non-Hispanics<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
        <p id="Par43">In the registry of the Medical University of Vienna, the lungs were also the most frequently affected organ (96.5%), the skin was the second most frequently affected organ, significant gender-specific differences in favor of men (<italic>n</italic>&#x2009;=&#x2009;8(9.4%)) were only seen in kidney involvement in sarcoidosis, which affected 5% of all patients.</p>
        <p id="Par44">Sarcoidosis was histologically confirmed in 99.4% of patients (<italic>n</italic>&#x2009;=&#x2009;198) in the baseline analysis. BAL was performed in 50.5% (<italic>n</italic>&#x2009;=&#x2009;101) of all patients (males: 41 (41.4%)) for initial diagnosis. The lymphocyte count in BAL was 21% (IQR 8; 41). The prognostic value of lymphocytes in BAL is questionable. Laviolette M. et al. have already discussed this<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Among the comorbidities examined, 5% of all patients (<italic>n</italic>&#x2009;=&#x2009;11) had a history of asthma and allergic comorbidities (requiring a specific IgE, a marker of T2 inflammation) was present in 40 patients (20%) with a specific IgE 35.8 U/mL (IQR 11.6; 109.0). Blood Eosinophils were 2.6% (IQR 1.4; 4.5). FeNO was 21 ppb (IQR 10; 32), so there was no proof of T2 inflammation (eosinophils and FeNO).</p>
        <p id="Par45">FeNO and blood-eosinophils were not elevated on average. The study by Cameli et al. showed that exhaled nitric oxide is not a useful biomarker in the treatment of patients with pulmonary sarcoidosis<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Significant associations between the laboratory parameters neopterin, ACE and s IL2 receptor and pulmonary sarcoidosis stages could not be observed in our study. As expected, the most common manifestation was lung involvement. (96.5%). The most common comorbidities were allergic comorbidities (20%), oncological diseases (11.5%) and diabetes mellitus type 2 (7.5%). Obstructive lung disease was known to be associated with COPD in 2.5% of patients and with asthma in 5.5% of patients. Lung function tests showed airflow obstruction in 26%, restrictive lung disease in 8.5% and diffusion disorder in 11.5%. KCO was significant impaired in women, FEV1 and TLC were significantly lower in women than in men.</p>
        <p id="Par46">In conclusion, the available data and the different approaches to data collection in the different registries, as well as the different case numbers in the international comparison, do not allow any valid statement to be made about relevant differences or correlations. Patients in the Austrian cohort had a different staging distribution than countries such as Great Britain, but the age differences at diagnosis as well as the general average age as well as the general dominance of the female sex did not show any significant differences to the existing data of other registries.</p>
        <p id="Par47">Given the long-term follow-up nature of the registry, future analyses could potentially establish new correlations and help to decipher the still unexplained aetiology of sarcoidosis. As the data originate from standard clinical assessments, a particular challenge (as with all purely observational, non-interventional studies) is the lack of data especially for suitable laboratory and clinical markers for risk assessment.</p>
        <p id="Par48">The initial situation and the various analyses once again illustrate the heterogeneity of sarcoidosis with its many different manifestations, which underlines the importance of a personalised approach to disease management. It is hoped that comparative studies and the observation of a large cohort will overcome the current limitations caused by the small number of cases in individual centres, which have so far made it difficult to draw conclusions about the success of therapy and to determine the dose of the immunomodulatory therapy to be planned in combination with appropriate imaging (PET-CT versus CT/MRI) and serological follow-up examinations. Future research will focus on understanding the causes of sarcoidosis, relevant biomarkers and new effective and targeted therapies for patients with previously refractory sarcoidosis and pulmonary fibrosis.</p>
      </sec>
    </sec>
    <sec id="Sec16">
      <title>Strengths and limitations</title>
      <p id="Par50">This is the first register, assessing sarcoidosis patients in central Europe, and offers a decent population size and real-world data. A limiting factor is the small number of patients compared to other registries and the fact that it is an analysis of a single center. Due to the circumstance of the single center and the recruitment modality of the hospital outpatient clinic by means of referrals from the extramural area, there is a not insignificant possibility that sarcoidosis patients remain undetected. Due to the nature of a registry and retrospective observation as well as the fact that real-life data are involved, incomplete data and irregular patient appointments are a limitation that must be considered.</p>
    </sec>
    <sec id="Sec17">
      <title>Conclusion</title>
      <p id="Par51">
This study is the first characterization of sarcoidosis patients in Austria. It offers new insights in characteristics of this special patient cohort. Based on the data collected, the cohort is characterized by a heterogeneous appearance; in the preliminary analysis of the available baseline characteristics, the basic laboratory values and the lung function, no correlations could be identified regarding clinical severity and diagnostic findings.</p>
      <p id="Par52">
The present study is hypothesis-generating and clearly demonstrates the need for further clinical research, particularly in conjunction with radiological findings. The planned long-term follow-up of patients in the sarcoidosis registry at the Medical University of Vienna will show whether the treatment of sarcoidosis can be optimized.</p>
    </sec>
    <sec id="Sec19" sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <p>Below is the link to the electronic supplementary material.</p>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2025_93708_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ACE</term>
          <def>
            <p id="Par100">Angiotensin converting enzyme</p>
          </def>
        </def-item>
        <def-item>
          <term>BAL</term>
          <def>
            <p id="Par110">Bronchoalveolar lavage</p>
          </def>
        </def-item>
        <def-item>
          <term>BMI</term>
          <def>
            <p id="Par120">Body mass index</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p id="Par130">Computer tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>DLCO or TLCO</term>
          <def>
            <p id="Par140">Diffusing capacity for carbon monoxide</p>
          </def>
        </def-item>
        <def-item>
          <term>EOS</term>
          <def>
            <p id="Par150">Eosinophil lymphocyte</p>
          </def>
        </def-item>
        <def-item>
          <term>FeNO</term>
          <def>
            <p id="Par160">Exhaled nitric oxide</p>
          </def>
        </def-item>
        <def-item>
          <term>FEV</term>
          <def>
            <p id="Par17">Forced expiratory volume</p>
          </def>
        </def-item>
        <def-item>
          <term>FVC</term>
          <def>
            <p id="Par180">Forced vital capacity</p>
          </def>
        </def-item>
        <def-item>
          <term>IgE</term>
          <def>
            <p id="Par190">Immunoglobulin E</p>
          </def>
        </def-item>
        <def-item>
          <term>IL2</term>
          <def>
            <p id="Par200">Interleukin 2 receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>KCO</term>
          <def>
            <p id="Par210">Carbon monoxide transfer coefficient</p>
          </def>
        </def-item>
        <def-item>
          <term>LLN</term>
          <def>
            <p id="Par220">Lower limit of normal</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p id="Par23">Magnet resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>OCS</term>
          <def>
            <p id="Par240">Oral corticosteroid</p>
          </def>
        </def-item>
        <def-item>
          <term>pBNP</term>
          <def>
            <p id="Par250">Pro brain natriuretic peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>PFT</term>
          <def>
            <p id="Par260">Pulmonary function test</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p id="Par270">Standard deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>T2DM</term>
          <def>
            <p id="Par280">Diabetes mellitus type 2</p>
          </def>
        </def-item>
        <def-item>
          <term>TLC</term>
          <def>
            <p id="Par290">Total lung capacity</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>Claudia Guttmann-Ducke and Martin Lutnik contributed equally to this work and share first authorship.</p>
      </fn>
    </fn-group>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>C.G.-D.: Conceptualization, Data curation, Formal analysis, Methodology, Visualization, Project administration, Writing original draft &amp; editing. M.L.: Data curation, Formal analysis, Methodology, Visualization; M.R.G.: review &amp; editing, P.S.: review &amp; editing, C.M.: review &amp; editing , C.B.: review &amp; editing, W.G.: Writing&#x2014;review &amp; editing, H.P.: Writing&#x2014;review &amp; editing, D.G.: Conceptualization, Investigation, Project administration, Writing&#x2014;review &amp; editing, M.I.: Conceptualization, Investigation, Project administration, Writing&#x2014;review &amp; editing;</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>No special funds were provided for this study.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The datasets generated and analyzed during the current study are availablefrom the corresponding author on reasonable request.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par57">
First insights and future research perspectives from the sarcoidosis registry at the Medical University of ViennaC Guttmann-Ducke, M Lutnik, MR Gysan, P Sarova, C Milacek, C Bal, W Graninger, H Prosch, D Gompelmann and M Idzko. The authors declare following conflicts of interest: Claudia Guttmann- Ducke: Speaker Fees Boehringer Ingelheim all outside the submitted work, Marco Idzko: lecture fees from AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Menarini, MSD, Novartis, Roche, Sanofi, and Thermofischer; and advisory board fees from Alk-Pharma, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Novartis, and Sanofi, all outside the submitted work; Daniela Gompelmann: lecture and travel fees from Olympus, Pulmonx, Astra Zeneca, Boehriger Ingelheim, Erbe, Berlin Chemie, Chiesi, MSD all outside the submitted work. Martin Lutnik: no conflict of interest; Christopher Milacek: no conflict of interest; Pavla Sarova: no conflict of interest; Maximilian Robert Gysan: Fees Boehringer Ingelheim all outside the submitted work. Wolfgang Graninger: no conflict of interest. Helmut Prosch: Fees from AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Merck Sharp &amp; Dohme, Novartis, Roche/Intermune, Sanofi, Siemens Healthcare, and Takeda; and research support from AstraZeneca, Boehringer, Siemens, and EU4Healthall outside the submitted work. Christina Bal: Fees Olympus all outside the submitted work.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Wijsenbeek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung diseases</article-title>
            <source>Lancet Lond. Engl.</source>
            <year>2022</year>
            <volume>400</volume>
            <issue>10354</issue>
            <fpage>769</fpage>
            <lpage>786</lpage>
            <pub-id pub-id-type="doi">10.1016/S0140-6736(22)01052-2</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Wijsenbeek, M., Suzuki, A. &amp; Maher, T. M. Interstitial lung diseases. <italic>Lancet Lond. Engl.</italic><bold>400</bold> (10354), 769&#x2013;786 (2022).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uzunhan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brillet</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <source>M&#xFC;ller-Quernheim J. Sarcoidosis Lancet Lond. Engl.</source>
            <year>2014</year>
            <volume>383</volume>
            <issue>9923</issue>
            <fpage>1155</fpage>
            <lpage>1167</lpage>
          </element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y. &amp; Brillet, P. Y. <italic>M&#xFC;ller-Quernheim J. Sarcoidosis Lancet Lond. Engl.</italic><bold>383</bold>(9923), 1155&#x2013;1167 (2014).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Jayakrishnan</surname><given-names>B</given-names></name><name><surname>Al-Busaidi</surname><given-names>N</given-names></name><name><surname>Al-Mubaihsi</surname><given-names>S</given-names></name><name><surname>Al-Rawas</surname><given-names>OA</given-names></name></person-group><article-title>Sarcoidosis in the middle East</article-title><source>Ann. Thorac. Med.</source><year>2019</year><volume>14</volume><issue>2</issue><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.4103/atm.ATM_227_18</pub-id><pub-id pub-id-type="pmid">31007761</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Jayakrishnan, B., Al-Busaidi, N., Al-Mubaihsi, S. &amp; Al-Rawas, O. A. Sarcoidosis in the middle East. <italic>Ann. Thorac. Med.</italic><bold>14</bold>(2), 106&#x2013;115 (2019).<pub-id pub-id-type="pmid">31007761</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Mihailovic-Vucinic</surname><given-names>V</given-names></name><name><surname>Jovanovic</surname><given-names>D</given-names></name></person-group><article-title>Pulmonary sarcoidosis</article-title><source>Clin. Chest Med.</source><year>2008</year><volume>29</volume><issue>3</issue><fpage>459</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2008.03.002</pub-id><pub-id pub-id-type="pmid">18539238</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Mihailovic-Vucinic, V. &amp; Jovanovic, D. Pulmonary sarcoidosis. <italic>Clin. Chest Med.</italic><bold>29</bold>(3), 459&#x2013;473 (2008).<pub-id pub-id-type="pmid">18539238</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>S&#xE8;ve</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sarcoidosis: A clinical overview from symptoms to diagnosis</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>766</fpage><pub-id pub-id-type="doi">10.3390/cells10040766</pub-id><pub-id pub-id-type="pmid">33807303</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">S&#xE8;ve, P. et al. Sarcoidosis: A clinical overview from symptoms to diagnosis. <italic>Cells</italic><bold>10</bold>(4), 766 (2021).<pub-id pub-id-type="pmid">33807303</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Rybicki</surname><given-names>BA</given-names></name><name><surname>Major</surname><given-names>M</given-names></name><name><surname>Popovich</surname><given-names>J</given-names></name><name><surname>Maliarik</surname><given-names>MJ</given-names></name><name><surname>Iannuzzi</surname><given-names>MC</given-names></name></person-group><article-title>Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization</article-title><source>Am. J. Epidemiol.</source><year>1997</year><volume>145</volume><issue>3</issue><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a009096</pub-id><pub-id pub-id-type="pmid">9012596</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Rybicki, B. A., Major, M., Popovich, J., Maliarik, M. J. &amp; Iannuzzi, M. C. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. <italic>Am. J. Epidemiol.</italic><bold>145</bold>(3), 234&#x2013;241 (1997).<pub-id pub-id-type="pmid">9012596</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Sawahata</surname><given-names>M</given-names></name><etal/></person-group><article-title>Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan</article-title><source>Respir Med.</source><year>2015</year><volume>109</volume><issue>2</issue><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2014.12.012</pub-id><pub-id pub-id-type="pmid">25613109</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Sawahata, M. et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. <italic>Respir Med.</italic><bold>109</bold>(2), 272&#x2013;278 (2015).<pub-id pub-id-type="pmid">25613109</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ungprasert</surname><given-names>P</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Matteson</surname><given-names>EL</given-names></name></person-group><article-title>Influence of gender on epidemiology and clinical manifestations of sarcoidosis: A population-based retrospective cohort study 1976&#x2013;2013</article-title><source>Lung</source><year>2017</year><volume>195</volume><issue>1</issue><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/s00408-016-9952-6</pub-id><pub-id pub-id-type="pmid">27709291</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Ungprasert, P., Crowson, C. S. &amp; Matteson, E. L. Influence of gender on epidemiology and clinical manifestations of sarcoidosis: A population-based retrospective cohort study 1976&#x2013;2013. <italic>Lung</italic><bold>195</bold>(1), 87&#x2013;91 (2017).<pub-id pub-id-type="pmid">27709291</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Sarcoidosis in America. Analysis based on health care use</article-title><source>Ann. Am. Thorac. Soc.</source><year>2016</year><volume>13</volume><issue>8</issue><fpage>1244</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201511-760OC</pub-id><pub-id pub-id-type="pmid">27509154</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Baughman, R. P. et al. Sarcoidosis in America. Analysis based on health care use. <italic>Ann. Am. Thorac. Soc.</italic><bold>13</bold>(8), 1244&#x2013;1252 (2016).<pub-id pub-id-type="pmid">27509154</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study</article-title><source>Respir Med.</source><year>2021</year><volume>187</volume><fpage>106564</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2021.106564</pub-id><pub-id pub-id-type="pmid">34391118</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Zhou, Y. et al. The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <italic>Respir Med.</italic><bold>187</bold>, 106564 (2021).<pub-id pub-id-type="pmid">34391118</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Innabi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sarcoidosis among US Hispanics in a nationwide registry</article-title><source>Respir Med.</source><year>2021</year><volume>190</volume><fpage>106682</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2021.106682</pub-id><pub-id pub-id-type="pmid">34788736</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Innabi, A. et al. Sarcoidosis among US Hispanics in a nationwide registry. <italic>Respir Med.</italic><bold>190</bold>, 106682 (2021).<pub-id pub-id-type="pmid">34788736</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hammam</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Treatment of sarcoidosis in US rheumatology practices: Data from the American college of rheumatology&#x2019;s rheumatology informatics system for effectiveness (RISE) registry</article-title>
            <source>Arthritis Care Res.</source>
            <year>2022</year>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <lpage>376</lpage>
            <pub-id pub-id-type="doi">10.1002/acr.24496</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Hammam, N. et al. Treatment of sarcoidosis in US rheumatology practices: Data from the American college of rheumatology&#x2019;s rheumatology informatics system for effectiveness (RISE) registry. <italic>Arthritis Care Res.</italic><bold>74</bold>(3), 371&#x2013;376 (2022).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Thillai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sarcoidosis in the UK: Insights from British thoracic society registry data</article-title><source>BMJ Open. Respir Res.</source><year>2019</year><volume>6</volume><issue>1</issue><fpage>e000357</fpage><pub-id pub-id-type="doi">10.1136/bmjresp-2018-000357</pub-id><pub-id pub-id-type="pmid">30956798</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Thillai, M. et al. Sarcoidosis in the UK: Insights from British thoracic society registry data. <italic>BMJ Open. Respir Res.</italic><bold>6</bold>(1), e000357 (2019).<pub-id pub-id-type="pmid">30956798</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Sikj&#xE6;r</surname><given-names>MG</given-names></name><name><surname>Hilberg</surname><given-names>O</given-names></name><name><surname>Ibsen</surname><given-names>R</given-names></name><name><surname>L&#xF8;kke</surname><given-names>A</given-names></name><name><surname>Sarcoidosis</surname></name></person-group><article-title>A nationwide registry-based study of incidence, prevalence and diagnostic work-up</article-title><source>Respir Med.</source><year>2021</year><volume>187</volume><fpage>106548</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2021.106548</pub-id><pub-id pub-id-type="pmid">34352562</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Sikj&#xE6;r, M. G., Hilberg, O., Ibsen, R., L&#xF8;kke, A. &amp; Sarcoidosis A nationwide registry-based study of incidence, prevalence and diagnostic work-up. <italic>Respir Med.</italic><bold>187</bold>, 106548 (2021).<pub-id pub-id-type="pmid">34352562</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003&#x2013;2015: A nationwide population-based study</article-title><source>Respir Med.</source><year>2018</year><volume>144S</volume><fpage>S28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2018.03.028</pub-id><pub-id pub-id-type="pmid">29631888</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Park, J. E. et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003&#x2013;2015: A nationwide population-based study. <italic>Respir Med.</italic><bold>144S</bold>, S28&#x2013;34 (2018).<pub-id pub-id-type="pmid">29631888</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation-alternatives>
          <element-citation id="ec-CR16" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cameli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbagli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rottoli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Exhaled nitric oxide is not increased in pulmonary sarcoidosis</article-title>
            <source>Sarcoidosis Vasc. Diffuse Lung Dis. Off J. WASOG</source>
            <year>2016</year>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <lpage>40</lpage>
          </element-citation>
          <mixed-citation id="mc-CR16" publication-type="journal">Cameli, P., Barbagli, E. &amp; Rottoli, P. Exhaled nitric oxide is not increased in pulmonary sarcoidosis. <italic>Sarcoidosis Vasc. Diffuse Lung Dis. Off J. WASOG</italic><bold>33</bold>(1), 39&#x2013;40 (2016).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019</article-title><source>Eur. Respir J.</source><year>2019</year><volume>53</volume><issue>5</issue><fpage>1900164</fpage><pub-id pub-id-type="doi">10.1183/13993003.00164-2019</pub-id><pub-id pub-id-type="pmid">30846476</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Singh, D. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. <italic>Eur. Respir J.</italic><bold>53</bold>(5), 1900164 (2019).<pub-id pub-id-type="pmid">30846476</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Drent</surname><given-names>M</given-names></name><name><surname>Mansour</surname><given-names>K</given-names></name><name><surname>Linssen</surname><given-names>C</given-names></name></person-group><article-title>Bronchoalveolar lavage in sarcoidosis</article-title><source>Semin Respir Crit. Care Med.</source><year>2007</year><volume>28</volume><issue>5</issue><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1055/s-2007-991521</pub-id><pub-id pub-id-type="pmid">17975776</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Drent, M., Mansour, K. &amp; Linssen, C. Bronchoalveolar lavage in sarcoidosis. <italic>Semin Respir Crit. Care Med.</italic><bold>28</bold>(5), 486&#x2013;495 (2007).<pub-id pub-id-type="pmid">17975776</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Cozier</surname><given-names>YC</given-names></name></person-group><article-title>Assessing the worldwide epidemiology of sarcoidosis: Challenges and future directions</article-title><source>Eur. Respir J.</source><year>2016</year><volume>48</volume><issue>6</issue><fpage>1545</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1183/13993003.01819-2016</pub-id><pub-id pub-id-type="pmid">27903684</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Cozier, Y. C. Assessing the worldwide epidemiology of sarcoidosis: Challenges and future directions. <italic>Eur. Respir J.</italic><bold>48</bold>(6), 1545&#x2013;1548 (2016).<pub-id pub-id-type="pmid">27903684</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Anantham</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sarcoidosis in Singapore: Epidemiology, clinical presentation and ethnic differences</article-title>
            <source>Respirol. Carlton Vic.</source>
            <year>2007</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>355</fpage>
            <lpage>360</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1440-1843.2007.01074.x</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Anantham, D. et al. Sarcoidosis in Singapore: epidemiology, clinical presentation and ethnic differences. <italic>Respirol. Carlton Vic.</italic><bold>12</bold>(3), 355&#x2013;360 (2007).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Byg</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Milman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis in Denmark 1980&#x2013;1994. A registry-based incidence study comprising 5536 patients</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis. Off J. WASOG</source>
            <year>2003</year>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <lpage>52</lpage>
          </element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Byg, K. E., Milman, N. &amp; Hansen, S. Sarcoidosis in Denmark 1980&#x2013;1994. A registry-based incidence study comprising 5536 patients. <italic>Sarcoidosis Vasc. Diffuse Lung Dis. Off J. WASOG</italic>. <bold>20</bold>(1), 46&#x2013;52 (2003).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>O</given-names></name><name><surname>Abramovitz</surname><given-names>L</given-names></name><name><surname>Wiley</surname><given-names>AS</given-names></name><name><surname>Cozier</surname><given-names>YC</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names></name></person-group><article-title>Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women</article-title><source>Ann. Am. Thorac. Soc.</source><year>2016</year><volume>13</volume><issue>1</issue><fpage>67</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201508-568BC</pub-id><pub-id pub-id-type="pmid">26501211</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Dumas, O., Abramovitz, L., Wiley, A. S., Cozier, Y. C. &amp; Camargo, C. A. Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women. <italic>Ann. Am. Thorac. Soc.</italic><bold>13</bold>(1), 67&#x2013;71 (2016).<pub-id pub-id-type="pmid">26501211</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Epidemiology of sarcoidosis in Japan</article-title><source>Eur. Respir J.</source><year>2008</year><volume>31</volume><issue>2</issue><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1183/09031936.00075307</pub-id><pub-id pub-id-type="pmid">17959635</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Morimoto, T. et al. Epidemiology of sarcoidosis in Japan. <italic>Eur. Respir J.</italic><bold>31</bold>(2), 372&#x2013;379 (2008).<pub-id pub-id-type="pmid">17959635</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation-alternatives>
          <element-citation id="ec-CR24" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yigla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badarna-Abu-Ria</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goralnik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>AHE</given-names>
              </name>
              <name>
                <surname>Weiler-Ravell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis in residents of Northern Israel of Arabic and Jewish origin: A comparative study</article-title>
            <source>Respirol. Carlton Vic.</source>
            <year>2006</year>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>586</fpage>
            <lpage>591</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1440-1843.2006.00891.x</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR24" publication-type="journal">Yigla, M., Badarna-Abu-Ria, N., Goralnik, L., Rubin, A. H. E. &amp; Weiler-Ravell, D. Sarcoidosis in residents of Northern Israel of Arabic and Jewish origin: A comparative study. <italic>Respirol. Carlton Vic.</italic><bold>11</bold>(5), 586&#x2013;591 (2006).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gerke</surname><given-names>AK</given-names></name><name><surname>Judson</surname><given-names>MA</given-names></name><name><surname>Cozier</surname><given-names>YC</given-names></name><name><surname>Culver</surname><given-names>DA</given-names></name><name><surname>Koth</surname><given-names>LL</given-names></name></person-group><article-title>Disease burden and variability in sarcoidosis</article-title><source>Ann. Am. Thorac. Soc.</source><year>2017</year><volume>14</volume><issue>Supplement_6</issue><fpage>S421</fpage><lpage>S428</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.201707-564OT</pub-id><pub-id pub-id-type="pmid">29087725</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Gerke, A. K., Judson, M. A., Cozier, Y. C., Culver, D. A. &amp; Koth, L. L. Disease burden and variability in sarcoidosis. <italic>Ann. Am. Thorac. Soc.</italic><bold>14</bold>(Supplement_6), S421&#x2013;S428 (2017).<pub-id pub-id-type="pmid">29087725</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Baughman</surname>
                <given-names>RP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Presenting characteristics as predictors of duration of treatment in sarcoidosis</article-title>
            <source>QJM Mon J. Assoc. Phys.</source>
            <year>2006</year>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <lpage>315</lpage>
          </element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Baughman, R. P. et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. <italic>QJM Mon J. Assoc. Phys.</italic><bold>99</bold>(5), 307&#x2013;315 (2006).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Clinical characteristics of patients in a case control study of sarcoidosis</article-title><source>Am. J. Respir Crit. Care Med.</source><year>2001</year><volume>164</volume><issue>10 Pt 1</issue><fpage>1885</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.164.10.2104046</pub-id><pub-id pub-id-type="pmid">11734441</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Baughman, R. P. et al. Clinical characteristics of patients in a case control study of sarcoidosis. <italic>Am. J. Respir Crit. Care Med.</italic><bold>164</bold>(10 Pt 1), 1885&#x2013;1889 (2001).<pub-id pub-id-type="pmid">11734441</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>JE</given-names></name><name><surname>Israel</surname><given-names>HL</given-names></name><name><surname>Steiner</surname><given-names>RM</given-names></name><name><surname>Triolo</surname><given-names>J</given-names></name><name><surname>Patrick</surname><given-names>H</given-names></name></person-group><article-title>Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy</article-title><source>Chest</source><year>1997</year><volume>111</volume><issue>3</issue><fpage>623</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1378/chest.111.3.623</pub-id><pub-id pub-id-type="pmid">9118698</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Gottlieb, J. E., Israel, H. L., Steiner, R. M., Triolo, J. &amp; Patrick, H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. <italic>Chest</italic><bold>111</bold>(3), 623&#x2013;631 (1997).<pub-id pub-id-type="pmid">9118698</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Genet</journal-id><journal-id journal-id-type="iso-abbrev">Nat Genet</journal-id><journal-title-group><journal-title>Nature Genetics</journal-title></journal-title-group><issn pub-type="ppub">1061-4036</issn><issn pub-type="epub">1546-1718</issn><publisher><publisher-name>Nature Publishing Group US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000831</article-id><article-id pub-id-type="pmc">11906363</article-id>
<article-id pub-id-type="publisher-id">2097</article-id><article-id pub-id-type="doi">10.1038/s41588-025-02097-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Cancer-independent somatic mutation of the wild-type <italic>NF1</italic> allele in normal tissues in neurofibromatosis type 1</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4306-0102</contrib-id><name><surname>Oliver</surname><given-names>Thomas R. W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3592-1005</contrib-id><name><surname>Lawson</surname><given-names>Andrew R. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4831-8088</contrib-id><name><surname>Lee-Six</surname><given-names>Henry</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tollit</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Hyunchul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hooks</surname><given-names>Yvette</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7703-9216</contrib-id><name><surname>Sanghvi</surname><given-names>Rashesh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0937-5290</contrib-id><name><surname>Young</surname><given-names>Matthew D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5803-1035</contrib-id><name><surname>Butler</surname><given-names>Timothy M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nicola</surname><given-names>Pantelis A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Treger</surname><given-names>Taryn D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lensing</surname><given-names>Stefanie V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2671-9972</contrib-id><name><surname>Burke</surname><given-names>G. A. Amos</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Aquilina</surname><given-names>Kristian</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>L&#xF6;bel</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2036-494X</contrib-id><name><surname>Cortes-Ciriano</surname><given-names>Isidro</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hargrave</surname><given-names>Darren</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Jorgensen</surname><given-names>Mette</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jessop</surname><given-names>Flora A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5826-3554</contrib-id><name><surname>Coorens</surname><given-names>Tim H. H.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2832-1303</contrib-id><name><surname>Flanagan</surname><given-names>Adrienne M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0779-7337</contrib-id><name><surname>Allinson</surname><given-names>Kieren</given-names></name><address><email>kallinson@nhs.net</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1122-4416</contrib-id><name><surname>Martincorena</surname><given-names>Inigo</given-names></name><address><email>im3@sanger.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7833-2158</contrib-id><name><surname>Jacques</surname><given-names>Thomas S.</given-names></name><address><email>t.jacques@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6600-7665</contrib-id><name><surname>Behjati</surname><given-names>Sam</given-names></name><address><email>sb31@sanger.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cy4wa09</institution-id><institution-id institution-id-type="GRID">grid.10306.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0606 5382</institution-id><institution>Wellcome Sanger Institute, </institution></institution-wrap>Hinxton, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04v54gj93</institution-id><institution-id institution-id-type="GRID">grid.24029.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0383 8386</institution-id><institution>Cambridge University Hospitals NHS Foundation Trust, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Research Department of Pathology, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013meh722</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2188 5934</institution-id><institution>Department of Paediatrics, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03angcq70</institution-id><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Cancer Research UK Clinical Trials Unit, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zydm450</institution-id><institution-id institution-id-type="GRID">grid.424537.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 5902 9895</institution-id><institution>Great Ormond Street Hospital for Children NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02catss52</institution-id><institution-id institution-id-type="GRID">grid.225360.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9709 7726</institution-id><institution>European Molecular Biology Laboratory, </institution><institution>European Bioinformatics Institute (EMBL-EBI), </institution></institution-wrap>Cambridge, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>UCL Great Ormond Street Institute of Child Health, </institution></institution-wrap>London, UK </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05a0ya142</institution-id><institution-id institution-id-type="GRID">grid.66859.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0546 1623</institution-id><institution>Broad Institute of MIT and Harvard, </institution></institution-wrap>Cambridge, MA USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dx46b94</institution-id><institution-id institution-id-type="GRID">grid.412945.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0467 5857</institution-id><institution>Department of Histopathology, </institution><institution>Royal National Orthopaedic Hospital NHS Trust, </institution></institution-wrap>Middlesex, UK </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>57</volume><issue>3</issue><fpage>515</fpage><lpage>521</lpage><history><date date-type="received"><day>21</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Cancer predisposition syndromes mediated by recessive cancer genes generate tumors via somatic variants (second hits) in the unaffected allele. Second hits may or may not be sufficient for neoplastic transformation. Here we performed whole-genome and whole-exome sequencing on 479 tissue biopsies from a child with neurofibromatosis type 1, a multisystem cancer-predisposing syndrome mediated by constitutive monoallelic <italic>NF1</italic> inactivation. We identified multiple independent <italic>NF1</italic> driver variants in histologically normal tissues, but not in 610 biopsies from two nonpredisposed children. We corroborated this finding using targeted duplex sequencing, including a further nine adults with the same syndrome. Overall, truncating <italic>NF1</italic> mutations were under positive selection in normal tissues from individuals with neurofibromatosis type 1. We demonstrate that normal tissues in neurofibromatosis type 1 commonly harbor second hits in <italic>NF1</italic>, the extent and pattern of which may underpin the syndrome&#x2019;s cancer phenotype.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">Histologically normal tissues of individuals with a germline <italic>NF1</italic> mutation exhibited multiple second <italic>NF1</italic> hits, unrelated to their tumors, that conferred a selective advantage.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>DNA sequencing</kwd><kwd>CNS cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust (Wellcome)</institution></institution-wrap></funding-source><award-id>206194</award-id><award-id>223135/Z/21/Z</award-id><award-id>108413/A/15/D</award-id><principal-award-recipient><name><surname>Oliver</surname><given-names>Thomas R. W.</given-names></name><name><surname>Behjati</surname><given-names>Sam</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>This study was funded by the Wellcome Trust (institutional grant; personal fellowships to T.R.W.O. and S.B.; grant number 206194, 108413/A/15/D &amp; 223135/Z/21/Z). T.S.J. is grateful to the Brain Tumour Charity (including the Everest Centre for Low-Grade Paediatric Brain Tumours (GN-000382 &amp; GN-000707) and the INSTINCT programme), Great Ormond Street Hospital Children's Charity, Children with Cancer UK, the Olivia Hodson Cancer Fund, Cancer Research UK and the National Institute for Health Research for funding. This research was supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre and the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. Additional funding was received from The Royal National Orthopaedic Research and Development Department (A.M.F.) and The Bone Cancer Research Trust (A.M.F.). We thank the CCLG Tissue Bank, the CCLG centres and the ECMC Paediatric Network for the collection and provision of tissue samples (project number 2016 BS 05). The CCLG Tissue Bank is funded by Cancer Research UK and CCLG. A.M.F. is also separately supported by the National Institute for Health Research, Sarcoma UK, the UCLH Biomedical Research Centre and the UCL Experimental Cancer Centre. Funding from these institutions supported the work of the Biobank where the samples from the adult cohort were stored.</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002203</institution-id><institution>Brain Tumour Charity</institution></institution-wrap></funding-source><award-id>GN-000382</award-id><award-id>GN-000707</award-id><principal-award-recipient><name><surname>Jacques</surname><given-names>Thomas S.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Nature America, Inc. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Main</title>
      <p id="Par3">In recessive tumor predisposition syndromes, one allele is mutated in the zygote (or, rarely, in early embryogenesis), while the second allele is inactivated by subsequent somatic mutation (second hit; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Although a second hit would ordinarily be expected to lead to neoplasia, it is possible that some cells remain phenotypically normal in the presence of biallelic mutation, just as oncogenic mutations have been reported within healthy tissues. Recent studies of normal adult tissues have revealed bona fide cancer-causing (driver) mutations that accumulate with age and exposure to environmental mutagens, primarily in exposed epithelial tissues<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref></sup>. The acquisition of mutations in normal tissues may be accelerated by germline mutations perturbing the fidelity of DNA replication, as seen in normal intestinal crypts of patients with a mutant DNA polymerase<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Furthermore, in children with malignant rhabdoid tumors (cancers driven by biallelic inactivation of <italic>SMARCB1</italic>), we have observed normal tissues that share a genetic ancestor with the nearby tumor and harbor the same somatic <italic>SMARCB1</italic> hit, without an elevated mutation rate<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). We therefore speculated that second hits may occur in normal tissues of predisposed individuals that are unrelated to tumor lineages or affected by hypermutation, which we set out to investigate here (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Concepts and experimental approach.</title><p><bold>a</bold>, The second mutation in a recessive tumor predisposition syndrome is typically thought to lead to neoplasia. <bold>b</bold>, Some second hits may be found in the adjacent normal tissue to a childhood cancer, indicating that their presence is insufficient for neoplastic transformation. <bold>c</bold>, The possibility remains that second hits may be sustained in normal tissues that are independent of the cancer cell lineage. <bold>d</bold>, Histological images of three illustrative microdissected tissues are shown. The layers of the cerebellar cortex are annotated on the uppermost image. The light blue outlines with yellow arrowheads on the images are representative regions microdissected. Scale bars&#x2009;=&#x2009;500, 250 and 250&#x2009;&#xB5;m (top to bottom). <bold>e</bold>, Experiment overview, detailing the number of bulk- and LCM-derived sequences generated per anatomical region per child. Please note that this includes all biopsies, irrespective of tumor involvement. A version of this table, limited to the tumor biopsies used in the high-grade glioma driver mutation identification, is provided as Supplementary Table <xref rid="MOESM4" ref-type="media">2</xref>. ML, molecular layer; PL, Purkinje layer; GL, granular layer; WM, white matter; CNS, central nervous system; PNS, peripheral nervous system; LCM, laser capture microdissection.</p></caption><graphic xlink:href="41588_2025_2097_Fig1_HTML" id="d33e502"/></fig></p>
      <p id="Par4">Neurofibromatosis type 1 is a complex multisystem disorder that predisposes to neoplasia. It is caused by germline mutation in the <italic>NF1</italic> gene, a tumor suppressor gene that encodes neurofibromin, a negative regulator of intracellular RAS/MAPK signaling. The syndrome&#x2019;s neoplastic phenotype is variable and tends to affect neuroectodermal lineages, although tissues derived from other germ layers also have an increased risk of cancer. An essential diagnostic feature of neurofibromatosis type 1 is the caf&#xE9; au lait spot, a macroscopically visible clonal expansion of melanocytes<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Other neoplastic manifestations, which exhibit variable penetrance, include neurofibromas, skeletal dysplasias, leukemias, malignant peripheral nerve sheath tumors and gliomas<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref></sup>. In all these lesions, <italic>NF1</italic>, as a recessive cancer gene, exhibits a second mutation, not infrequently as the sole detected somatic driver event<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, consistent with Knudson&#x2019;s two-hit hypothesis<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
      <p id="Par5">We performed a postmortem study of three children aged &lt;10 years old with high-grade midline gliomas&#x2014;two (PD50297 and PD51123) with sporadic tumors (<italic>H3F3A</italic> K27M mutant) and one with neurofibromatosis type 1 with a pathogenic truncating <italic>NF1</italic> (c.3113&#x2009;+&#x2009;1G&gt;A) germline mutation. Our key question was whether normal tissues across the body harbored driver events, in particular in the predisposed child. We extensively sampled normal tissues and neoplasms (Supplementary Tables <xref rid="MOESM4" ref-type="media">1</xref> and <xref rid="MOESM4" ref-type="media">2</xref>), which, in the case of the child with neurofibromatosis, included a brain tumor, a subcutaneous spindle cell lesion (Extended Data Fig. <xref rid="Fig4" ref-type="fig">1</xref>) and a caf&#xE9; au lait spot. Guided by parental wishes, we surveyed central nervous system (CNS) tissues in all three children and extracranial tissues in two of them, including the predisposed child. None of the children had been pretreated with cytotoxic chemotherapy. Radiotherapy was given to the two children with sporadic tumors.</p>
      <p id="Par6">In total, we performed whole-genome sequencing (WGS) on 838 microdissected groups of cells (median coverage 28&#xD7;), using an established approach that we and others have pursued in the study of normal tissue genomes<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1d,e</xref>). We supplemented this with additional bulk tissue WGS (<italic>n</italic>&#x2009;=&#x2009;71) and whole-exome sequencing (WES) of other microdissected tissues (<italic>n</italic>&#x2009;=&#x2009;180; Fig. <xref rid="Fig1" ref-type="fig">1e</xref>). We assembled catalogs of all classes of mutations (substitutions<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, insertions and deletions (InDels), rearrangements and copy number changes; Supplementary Tables <xref rid="MOESM4" ref-type="media">3</xref>&#x2013;<xref rid="MOESM4" ref-type="media">8</xref> and <xref rid="MOESM1" ref-type="media">Supplementary Note</xref>) using a validated variant calling pipeline (<xref rid="Sec2" ref-type="sec">Methods</xref>; <xref rid="MOESM1" ref-type="media">Supplementary Note</xref>). To exclude low-level tumor contamination of normal tissues, we quantified the extent of tumor infiltration in each sample (including samples distant from the tumor) by searching for the mutations assigned to the tumor&#x2019;s phylogenetic trunk (<xref rid="MOESM1" ref-type="media">Supplementary Note</xref> and Supplementary Tables <xref rid="MOESM4" ref-type="media">3</xref> and <xref rid="MOESM4" ref-type="media">9</xref>).</p>
      <p id="Par7">We identified somatic driver variants in both neoplastic and normal tissues (Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Tables <xref rid="MOESM4" ref-type="media">10</xref>&#x2013;<xref rid="MOESM4" ref-type="media">14</xref>). Gliomas exhibited a multitude of driver mutations in cancer genes known to operate in gliomagenesis<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. The normal tissues of the two nonpredisposed children bore comparatively few cancer-associated mutations, yielding only a <italic>CREBBP</italic> frameshift mutation (p.Q2199fs*99) within a single colonic crypt (PD50297g_lo0012) by our standard pipeline. Further inspection of the copy number data revealed one more putative driver, chromosome 11p loss of heterozygosity (LOH; Extended Data Fig. <xref rid="Fig5" ref-type="fig">2</xref>) in a nerve (PD51123t_lo0028), a variant commonly reported in Wilms tumor, rhabdomyosarcoma and hepatoblastoma<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.<fig id="Fig2"><label>Fig. 2</label><caption><title><italic>NF1</italic> mutations and driver events identified by sequencing bulk tissues or microdissections.</title><p>Individual driver variants can be found in the lists of mutations provided in Supplementary Tables <xref rid="MOESM4" ref-type="media">10</xref>&#x2013;<xref rid="MOESM4" ref-type="media">14</xref>. A single asterisk indicates that the identification of the LOH event was only possible because we could phase parental alleles (<xref rid="Sec2" ref-type="sec">Methods</xref>). The low cell fraction of many of these meant that it was not possible to determine the breakpoint. When counting LOH events, those called from sequences derived from the same original bulk biopsy are treated as the same event, and those from different biopsies are treated as unique. These events should not be considered when comparing mutations against the other two children because their SNP alleles on chromosome 17 could not be phased. Double asterisks indicate that in sequences from the high-grade glioma, we only considered mutations in genes recognized in a large meta-analysis to be drivers of these neoplasms (<xref rid="Sec2" ref-type="sec">Methods</xref>). Triple asterisks indicate that one additional <italic>MSH6</italic> frameshift mutation (p.F1088fs*2) was noted in the spinal cord (PD51122v_lo0008) and spleen (PD51122z_lo0017) of the child with neurofibromatosis type 1; this, however, remained heterozygous without evidence of hypermutation and did not co-occur with somatic <italic>NF1</italic> mutation, making it of uncertain significance. Four asterisks indicate that chromosome 11p LOH was identified in a single sample after manual inspection of the copy number output, although it was too low a fraction to be detected by the copy number caller. Del, deletion; Inv, inversion.</p></caption><graphic xlink:href="41588_2025_2097_Fig2_HTML" id="d33e661"/></fig></p>
      <p id="Par8">By contrast, in the child with neurofibromatosis type 1, we found bona fide somatic <italic>NF1</italic> driver point mutations (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) that either truncated the gene (p.R304*, p.K233fs*48 and p.I679fs*21) or were likely oncogenic based on recurrence, in silico predictions, correlation between genotype and phenotype and functional studies (p.Y489C)<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. These mutations were detected by a combination of WGS and WES of microdissections or bulk tissues. They occurred in anatomically distant regions of the CNS (left parietal cortex, cerebellar hemisphere or spinal cord). The affected tissues appeared macroscopically and microscopically normal and were not correlated with focal areas of signal intensity on imaging (a feature often found in the brains of children with neurofibromatosis type 1 (ref. <sup><xref ref-type="bibr" rid="CR22">22</xref></sup>; Extended Data Figs. <xref rid="Fig6" ref-type="fig">3</xref> and <xref rid="Fig7" ref-type="fig">4</xref>). The variant allele frequencies (VAFs) of second <italic>NF1</italic> hits indicated clone sizes as large as 56% of cells (clone size&#x2009;=&#x2009;2&#x2009;&#xD7;&#x2009;VAF) in a microdissection (hundreds of cells) and 19% in a bulk tissue (a macroscopic piece of tissue). <italic>NF1</italic> second hits were independent of those found in the clonal lesions (glioma, spindle cell lesion and caf&#xE9; au lait spot; Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). In particular, as both copies of <italic>NF1</italic> in the glioma were already inactivated, there should be no selection pressure for further loss-of-function mutations in <italic>NF1</italic> in tumor cells. Given this and our ability to detect tumor contamination accurately (<xref rid="MOESM1" ref-type="media">Supplementary Note</xref>), the <italic>NF1</italic> mutations in normal tissues are not the result of tumor cells infiltrating normal tissues. The mutation burden of <italic>NF1</italic> null normal tissues was inconsistent with a recent clonal expansion (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>; <xref rid="Sec2" ref-type="sec">Methods</xref>). Like the spindle cell lesion and caf&#xE9; au lait spot, no additional driver mutations were identified in the <italic>NF1</italic> null histologically normal tissues.<fig id="Fig3"><label>Fig. 3</label><caption><title><italic>NF1</italic> null clones pervade the normal tissues of individuals with neurofibromatosis type 1.</title><p><bold>a</bold>, Loss of the wild-type <italic>NF1</italic> allele is an independent event in each of the three neoplasms in PD51122. The allele frequency (<italic>y</italic> axis) represents a rolling window of 50 SNPs. Gridlines are present for matching to coordinates. <bold>b</bold>, The substitution count and median VAF in normal brain, color-coded by the presence of biallelic <italic>NF1</italic> mutation. <bold>c</bold>, Schematic representation of the brain and spinal cord outlining the location of each somatic <italic>NF1</italic> mutation in normal tissue from PD51122 discovered by different sequencing methods (before genotyping). The VAF of each mutation is shown in the table (2sf). The figure is created with BioRender.com. <bold>d</bold>, Distribution of somatic <italic>NF1</italic> mutations across tissues from PD51122 (above the locus-specific error rate; <xref rid="Sec2" ref-type="sec">Methods</xref>). The number within the box indicates the number of mutated samples from that tissue (red if &gt;0). <bold>e</bold>, Pairwise comparison of the number of substitutions shared between whole-genome sequences of normal biopsies, according to whether they possess the same <italic>NF1</italic> second hit. The black line represents the interquartile range. The black dot is the median. <italic>P</italic> values were generated using one-sided permutation tests (<xref rid="Sec2" ref-type="sec">Methods</xref>). &#x2018;<italic>n</italic>&#x2019; refers to the number of pairwise comparisons, not samples. The CNS and MES groups exclude normal tissues with a second <italic>NF1</italic> hit. <bold>f</bold>, The d<italic>N</italic>/d<italic>S</italic> ratios for truncating variants, according to germ layer and <italic>NF1</italic> germline mutation status. The dot represents the maximum likelihood estimate, and the lines represent the 95% credible interval. When the lower bound of the credible interval is above 1 (red line), there is a statistically significant positive selection. Credible intervals falling below the boundary of the plot are terminated with slanted double lines. <bold>g</bold>, Normal tissues from adults with neurofibromatosis type 1 are grouped by tissue type and evaluated for an excess of nonsynonymous variants in <italic>NF1</italic> and compared with the index children. Top, d<italic>N</italic>/d<italic>S</italic> ratios for truncating mutations (the dot represents the maximum likelihood estimate, and the lines represent the 95% credible interval); middle, counts of variants in <italic>NF1</italic>; bottom, total duplex coverage (<xref rid="Sec2" ref-type="sec">Methods</xref>; <xref rid="MOESM1" ref-type="media">Supplementary Note</xref>) over <italic>NF1</italic> in each group. R, right; L, left; MES, mesoderm; WT, wild type.</p></caption><graphic xlink:href="41588_2025_2097_Fig3_HTML" id="d33e821"/></fig></p>
      <p id="Par9">To expand the breadth and depth of <italic>NF1</italic> mutations detected within the normal tissues of the predisposed child, we used two strategies. First, we re-examined all the child&#x2019;s sequencing data for evidence of LOH of the <italic>NF1</italic> locus (chromosome 17q). As this child&#x2019;s glioma harbored complete LOH of chromosome 17 (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>), we were able to increase the sensitivity to detect allelic shift by obtaining definitive chromosome 17 haplotypes from phasing allele-specific single nucleotide polymorphisms (<xref rid="Sec2" ref-type="sec">Methods</xref>; Supplementary Tables <xref rid="MOESM4" ref-type="media">3</xref> and <xref rid="MOESM4" ref-type="media">4</xref> and Extended Data Fig. <xref rid="Fig8" ref-type="fig">5</xref>). This haplotype-resolved copy number calling revealed six instances of LOH in normal tissues (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), of which at least two were demarcated by distinct breakpoints consistent with independent events (Extended Data Fig. <xref rid="Fig8" ref-type="fig">5</xref>). We captured LOH-driven <italic>NF1</italic> null clone sizes as small as 2% (PD51122b; cerebellum) and up to 13% (PD51122h_lo0012; occipital cortex), and no second <italic>NF1</italic> hit was related to a neoplasm. Curiously, while this approach did not yield any <italic>NF1</italic> null clones in any non-neuroectodermal lineage, it did identify rare examples where the germline mutant allele was lost in microdissections of tissues derived from other germ layers (bladder muscle (PD51122s_lo0012) and a renal tubule (PD51122u_lo0009); Extended Data Fig. <xref rid="Fig9" ref-type="fig">6</xref>). All <italic>NF1</italic> second hits identified thus far are shown in Fig. <xref rid="Fig3" ref-type="fig">3c</xref>.</p>
      <p id="Par10">Second, to deepen our search for <italic>NF1</italic> null normal cells, we assessed all samples for evidence of <italic>NF1</italic> point mutations that had been previously called in normal tissues. Three variants (p.R304*, p.I679fs*21 and p.Y489C) were detectable in more than one biopsy above the locus-specific error rate (<xref rid="Sec2" ref-type="sec">Methods</xref>; Fig. <xref rid="Fig3" ref-type="fig">3d</xref> and Supplementary Table <xref rid="MOESM4" ref-type="media">15</xref>). There were the following two possible explanations: either the shared variants arose before the seeding of the anatomical areas in which the mutations were found, or mutations appeared independently in different tissues. We could establish which scenario was more likely by comparing the total number of mutations across the genome that were shared between affected tissues&#x2014;those with a common developmental root would possess more. For <italic>NF1</italic> mutations that spanned only regions of the brain (p.R304* and p.I679fs*21), affected tissues shared significantly more mutations with each other than unaffected brain regions did (<italic>P</italic>&#x2009;&lt;&#x2009;0.001 for both mutations, one-sided permutation test; Fig. <xref rid="Fig3" ref-type="fig">3e</xref>; <xref rid="Sec2" ref-type="sec">Methods</xref>), implicating a common ancestor in their development, although convergent evolution with shared selection pressures between developmentally related tissues is also possible. The same could not be said for the <italic>NF1</italic> mutation found in both the brain and spleen when compared to normal tissues of the CNS and mesoderm (p.Y489C; <italic>P</italic>&#x2009;=&#x2009;0.373, one-sided permutation test; Fig. <xref rid="Fig3" ref-type="fig">3d</xref>), meaning that they likely developed independently.</p>
      <p id="Par11">Taken together, the multiple lines of inquiry we had pursued thus far pointed toward the enrichment of <italic>NF1</italic> nonsynonymous mutations within the normal tissues of a predisposed individual but not wild-type individuals, at least within the brain and spinal cord. It seems likely that this pattern of <italic>NF1</italic> mutation has emerged as a consequence of positive selective pressure, given the absence of the concomitant silent and intronic <italic>NF1</italic> variants (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) that would be expected under a neutral model.</p>
      <p id="Par12">To establish statistically whether there is a positive selection for nonsynonymous variants in <italic>NF1</italic> in predisposed normal tissues, we re-interrogated 60 normal tissue samples (21 from the predisposed child and 39 from the unaffected children) by duplex sequencing of the <italic>NF1</italic> gene<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. Duplex sequencing, through barcode tagging of both strands of DNA molecules, enables highly sensitive and specific mutation calling, which may deliver sufficient variants for formal statistical assessment of selection through the nonsynonymous to synonymous variant ratio (d<italic>N</italic>/d<italic>S</italic>)<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Duplex sequencing yielded a total of 29 nonsynonymous (21 truncating; eight missense or in-frame) and two synonymous <italic>NF1</italic> mutations in the predisposed child (Supplementary Table <xref rid="MOESM4" ref-type="media">16</xref>). By contrast, in the normal tissues of the two children without neurofibromatosis, we detected nine nonsynonymous (four truncating; five missense or in-frame) and five synonymous <italic>NF1</italic> mutations (Supplementary Table <xref rid="MOESM4" ref-type="media">16</xref>). Calculation of the d<italic>N</italic>/d<italic>S</italic> ratio provided strong evidence of positive selection for truncating <italic>NF1</italic> variants in normal tissues from the child with a germline predisposition (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). Interestingly, the spleen had a particularly high proportion of truncating variants, and, when analyzed separately from other tissues, it had the highest d<italic>N</italic>/d<italic>S</italic> ratio (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). This finding was of interest given that neurofibromatosis type 1 predisposes to juvenile myelomonocytic leukemia, which always (as per the diagnostic definition) involves the spleen<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, whether through entrapment of leukemic cells or as their organ of origin.</p>
      <p id="Par13">Next, we extended our analysis into normal tissue from adults with neurofibromatosis type 1 (Supplementary Table <xref rid="MOESM4" ref-type="media">17</xref>). We were able to obtain normal peripheral nerves, muscle tissue or blood from nine individuals who underwent extensive surgical resections for sarcoma. The principal cellular material of peripheral nerves is made up of Schwann cells that are derived from the neuroectoderm, whereas muscle and blood develop from mesoderm. Consistent with the pattern of mutation we observed in pediatric tissues, we found, by duplex sequencing, a stark excess of truncating <italic>NF1</italic> mutations in peripheral nerves, indicative of positive selection (Fig. <xref rid="Fig3" ref-type="fig">3g</xref>).</p>
      <p id="Par14">In this study of <italic>NF1</italic> mutations in individuals with neurofibromatosis type 1, we observed independent second <italic>NF1</italic> hits in macroscopically and histologically normal pediatric and adult tissues. Multiple lines of evidence arrive at the same conclusion: in neurofibromatosis type 1, nonsynonymous second somatic mutations of <italic>NF1</italic> are selected for in histologically normal tissues. Although <italic>NF1</italic> is a ubiquitously expressed gene, the tissue distribution of neoplasms associated with neurofibromatosis type 1 is not random, showing a predilection for neuroectodermal lineages<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, which is mirrored in the distribution of second <italic>NF1</italic> hits we identified. Unlike our study, though, where these mutations pervaded the CNS, most brain tumors that arise in children with neurofibromatosis type 1 are localized to the optic pathway and brainstem<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Our findings may thus explain some, but not all, of the cancer phenotypes associated with neurofibromatosis type 1.</p>
      <p id="Par15">Three factors, unrelated to the germline mutation status of <italic>NF1</italic>, may also have contributed to the number of nonsynonymous mutations we observed. The first is age, as neutral mutations accrue with time, and the second is the size of the <italic>NF1</italic> gene. <italic>NF1</italic> has one of the largest footprints of any gene (8,520&#x2009;bp coding sequence compared to a median length across human genes of 1,257&#x2009;bp (ref. <sup><xref ref-type="bibr" rid="CR28">28</xref></sup>)), meaning there are simply more sites to mutate. Hypermutation is a third factor that might augment the rate of driver mutation acquisition, but our comprehensive study of the index case found no evidence to support that here. Notably, all these factors are accounted for by our model of selection (d<italic>N</italic>/d<italic>S</italic>), meaning that they cannot explain our data. We can assume, then, that the strength of the signal we see in the carriers compared to unaffected children is the result of selective pressure specifically for second hits. The fact that this is so readily apparent in the extensively studied child suggests that this occurs from an early age, possibly even during development (Fig. <xref rid="Fig3" ref-type="fig">3be</xref>). Given the extent to which we observed <italic>NF1</italic> loss-of-function variants in normal tissues, it seems reasonable to propose that although in certain contexts second hits may be sufficient to cause neoplasia<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>, as suggested by our case&#x2019;s caf&#xE9; au lait spot and spindle cell lesion, transformation to a discernible tumor is an uncommon immediate outcome of biallelic <italic>NF1</italic> loss.</p>
      <p id="Par16">This finding may represent a fundamental principle of <italic>NF1</italic> mutation in neurofibromatosis type 1, of which determining the precise nuances and clinical implications will require extensive surveys in human tissues<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Consistent with our data, mouse models support a complex relationship between cellular genotype and phenotype in neurofibromatosis type 1&#x2014;the genetic background of the mouse, the identity of the cell in which <italic>NF1</italic> is inactivated, the presence of cooperating somatic mutations and the status of <italic>NF1</italic> function in neighboring cells, all appear to affect tumor development<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. From a practical, clinical point of view, it is conceivable that the extent of second <italic>NF1</italic> hits in normal tissues represents a quantifiable link between germline genotype and cancer risk. In the broader context of recessive cancer predispositions, our findings call for systematic investigations to establish whether second hits occur commonly in such predispositions or delineate a particular group of syndromes.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Sample collection</title>
        <p id="Par17">This study complies with all relevant ethical regulations. Written and informed consent was given for all samples. The study of the discovery cohort of three children was approved by National Health Service (NHS) research ethics committees (PD50297&#x2014;HRA East Midlands Derby REC, 08/H0405/22+5; PD51122 and PD51123&#x2014;London Brent REC, 16/LO/0960). Each autopsy was undertaken at the child&#x2019;s local neuropathology unit, with parental consent, 1&#x2013;7&#x2009;days following death. Samples were snap-frozen at the point of sampling, with adjacent brain tissue taken for immediate formalin fixation and processing in the local diagnostic laboratory. A full list of the samples taken is provided in Supplementary Table <xref rid="MOESM4" ref-type="media">1</xref>.</p>
        <p id="Par18">The study of the validation cohort of adults with neurofibromatosis type 1 was approved by NHS research ethics committees (20/YH/0088, IRAS 272816, NHS Yorkshire and the Humber&#x2014;Leeds East Research Ethics Committee). Patients with a diagnosis of neurofibromatosis type 1 who were undergoing resection for sarcoma consented to the use in research of normal tissue removed as part of the resection but distant from the lesion or of blood samples. Solid tissue samples were immediately frozen in liquid nitrogen. Blood samples were centrifuged, and plasma and cellular fractions were separated before freezing.</p>
      </sec>
      <sec id="Sec4">
        <title>Statistics and reproducibility</title>
        <p id="Par19">The study was designed in two phases. In the first phase, a discovery cohort of three children, of whom one had neurofibromatosis type 1 and two did not, was investigated. In the second phase, a validation cohort of ten adults, all of whom had neurofibromatosis type 1, was investigated.</p>
        <p id="Par20">The sample size in each case was determined by tissue availability. No statistical method was used to determine sample size. Lethal high-grade midline gliomas are rare in children&#x2014;we studied all cases at collaborating centers over the study period (of approximately 2&#x2009;years) in which consent for research was given. Of these, only one had neurofibromatosis type 1. For our validation cohort, all cases of patients with neurofibromatosis type 1 and tissue available at our collaborating center were studied. One patient from the validation cohort was excluded as no <italic>NF1</italic> germline variant was identified. The experiments were not randomized, and the investigators were not blinded to whether patients had neurofibromatosis type 1 during the experiments and outcome assessment.</p>
      </sec>
      <sec id="Sec5">
        <title>Preparation of samples for sequencing: tissue processing and DNA extraction</title>
        <p id="Par21">A subset of the bulk samples in the discovery cohort underwent bulk DNA extraction using either the DNeasy Blood &amp; Tissue Kit (Qiagen), AllPrep DNA/RNA Mini Kit (Qiagen) or the Gentra Puregene Blood Kit (Qiagen). The choice of samples to undergo bulk DNA extraction was guided by a prior understanding of the clonal architecture of the tissue. For example, intestinal biopsies were not subject to bulk DNA extraction. This is because their clonality meant that pseudo-single-cell genome readouts, rather than a single polyclonal amalgamation, could be achieved by microdissection of individual crypts instead<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Similarly, bulk DNA extraction was not performed for samples taken from the interface of the tumor and normal as it was hoped microdissection would better isolate the tumor and normal tissue compartments.</p>
        <p id="Par22">The remaining tissue from solid organ biopsies in the discovery cohort was fixed in PAXgene (PreAnalytiX), according to the manufacturer&#x2019;s instructions, and processed in preparation for laser capture microdissection using an established protocol<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. To ensure correct feature labeling of nervous system structures during microdissection, reference slides were generated using 4-micron-thick sections mounted on SuperFrost Plus slides (VWR International) and reviewed by the neuropathologist who performed the autopsy. The sections subject to microdissection were 16 microns thick and mounted on polyethylene naphthalate membrane slides (Leica Microsystems). The microdissected tissue then underwent lysis and further DNA extraction<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. For duplex sequencing of samples from the first three children, curls of paraffin-embedded tissues were deparaffinized with xylene and ethanol 100% washes, followed by lysis with Arcturus PicoPure (Thermo Fisher Scientific) and DNA extraction using the DNA Micro Kit (Qiagen) according to the manufacturer&#x2019;s protocol save for a double elution and the use of EB as an elution buffer rather than AE.</p>
        <p id="Par23">DNA was extracted from solid tissues from the adult cohort using the DNeasy Blood &amp; Tissue Kit (Qiagen) and from blood using the Gentra Puregene Blood Kit (Qiagen).</p>
      </sec>
      <sec id="Sec6">
        <title>Preparation of samples for sequencing: library preparation for WGS and WES</title>
        <p id="Par24">In the discovery cohort, the NEBNext Ultra II DNA Library Prep Kit (New England Biolabs) was used for the preparation of DNA extracted from the bulk samples, while the protocol for microdissected tissue used the NEBNext Ultra II DNA FS Library Prep Kit (New England Biolabs) instead. For the microdissected libraries subject to WES, the SureSelect Human All Exon V5 bait set (Agilent Technologies) was used. A full list of the successfully generated whole-genome and whole-exome sequences can be found in Supplementary Tables <xref rid="MOESM4" ref-type="media">3</xref> and <xref rid="MOESM4" ref-type="media">4</xref>, respectively.</p>
      </sec>
      <sec id="Sec7">
        <title>Preparation of samples for sequencing: library preparation for duplex sequencing of the <italic>NF1</italic> gene</title>
        <p id="Par25">Libraries were prepared using a version of the protocol for nanorate sequencing<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> that has been adapted to be compatible with targeted sequencing<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. DNA was sheared to an average size of 450&#x2009;bp by focused ultrasonication using the Covaris 644 LE220 instrument (Covaris) in 120&#x2009;&#x3BC;l. It was purified using a 0.8&#xD7; soluble-phase reversible immobilization (SPRI) bead ratio and eluted in 30&#x2009;&#x3BC;l nuclease-free water (NFW). DNA fragments were blunted in a final reaction volume of 30&#x2009;&#x3BC;l, including 3&#x2009;&#x3BC;l (10&#xD7;) mung bean buffer (Takara Bio, 2420A), 0.125&#x2009;&#x3BC;l mung bean nuclease (Takara Bio, 2420A), 1.875&#x2009;&#x3BC;l of NFW and 25&#x2009;&#x3BC;l DNA. The reaction was incubated at 37&#x2009;&#xB0;C for 10&#x2009;min with the lid tracking 5&#x2009;&#xB0;C above. Samples were purified using 2.5&#xD7; SPRI beads and eluted in 15&#x2009;&#x3BC;l NFW. In total, 10&#x2009;&#x3BC;l was used as input into an A-tailing reaction, containing 1.5&#x2009;&#x3BC;l T4 DNA ligase buffer (New England Biolabs, B0202S), 1.5&#x2009;&#x3BC;l (1&#x2009;mM) dATP/ddBTP (New England Biolabs, N0440S; GE HealthCare, 27204501), 1.5&#x2009;&#x3BC;l Klenow fragment (3&#x2032;&#x2013;5&#x2032; exo-; New England Biolabs, M0212L) and 0.5&#x2009;&#x3BC;l T4 polynucleotide kinase (New England Biolabs, M0201). The reaction was incubated at 37&#x2009;&#xB0;C for 30&#x2009;min with the lid tracking 15&#x2009;&#xB0;C above. The whole sample of 15&#x2009;&#x3BC;l was taken into the ligation reaction mix, which consisted of 30&#x2009;&#x3BC;l Ultra II Ligation MM (New England Biolabs, E7595L), 1&#x2009;&#x3BC;l Ultra II ligation enhancer (New England Biolabs, E7595L), 1.25&#x2009;&#x3BC;l xGen Duplex Seq Adapters (Integrated DNA Technologies, 1080799) and 12.75&#x2009;&#x3BC;l NFW. The reaction was incubated at 20&#x2009;&#xB0;C for 20&#x2009;min, with the lid temperature off. Ligated DNA was cleaned up using SPRI beads and eluted in 40&#x2009;&#x3BC;l NFW.</p>
        <p id="Par26">DNA was quantified by qPCR using a KAPA library quantification kit (Kapa Biosystems, KK4835). The supplied primer premix was first added to the supplied KAPA SYBR FAST master mix. In addition, 20&#x2009;&#x3BC;l of 100&#x2009;&#x3BC;M NanoqPCR1 primer (HPLC, 5&#x2032;-ACACTCTTTCCCTACACGAC-3&#x2032;) and 20&#x2009;&#x3BC;l of 100&#x2009;&#x3BC;M NanoqPCR2 primer (HPLC, 5&#x2032;-GTGACTGGAGTTCAGACGTG-3&#x2032;) were added to the KAPA SYBR FAST master mix. Samples were diluted 1:500 using NFW, and reactions were set up in a 10&#x2009;&#x3BC;l reaction volume (6&#x2009;&#x3BC;l master mix, 2&#x2009;&#x3BC;l sample/standard and 2&#x2009;&#x3BC;l water) in a 384-well plate. Samples were run on the Roche 480 LightCycler and analyzed using absolute quantification (second derivative maximum method) with the high-sensitivity algorithm. The concentration (nM (fmol&#x2009;&#x3BC;l<sup>&#x2212;1</sup>)) was determined as follows: (mean of sample concentration&#x2009;&#xD7;&#x2009;dilution factor (500)&#x2009;&#xD7;&#x2009;452/573/1,000)&#x2009;&#xD7;&#x2009;adjustment factor (1.5), where 452 represents the size of the standard in bp, 573 is the proxy for the average fragment length of the library in bp and 1,000 is a unit conversion factor. Samples were diluted to the desired fmol amount in 25&#x2009;&#x3BC;l using NFW.</p>
        <p id="Par27">Libraries were subsequently PCR-amplified in a 50-&#x3BC;l reaction volume comprising 25&#x2009;&#x3BC;l of sample, 25&#x2009;&#x3BC;l NEBNext Ultra II Q5 Master Mix and a unique dual index containing PCR primers (dried). The reaction was cycled as follows: step 1, 98&#x2009;&#xB0;C 30&#x2009;s; step 2, 98&#x2009;&#xB0;C 10&#x2009;s; step 3, 65&#x2009;&#xB0;C 75&#x2009;s; step 4, return to step 2 (13 times); step 5, 65&#x2009;&#xB0;C for 5&#x2009;min; step 6, hold at 4&#x2009;&#xB0;C. The number of PCR cycles is dependent on the input (Supplementary Table <xref rid="MOESM4" ref-type="media">18</xref>). The PCR product was subsequently cleaned up using two consecutive 0.7&#xD7; AMPure XP clean-ups. Each sample was quantified using the AccuClear Ultra High Sensitivity dsDNA Quantification kit (Biotium). Hybrid capture was performed using TWIST hybe reagents. Samples were pooled for hybridization with 1&#x2013;4&#x2009;&#x3BC;g of PCR-amplified material per capture reaction.</p>
      </sec>
      <sec id="Sec8">
        <title>DNA sequencing</title>
        <p id="Par28">All DNA sequences were generated on the Illumina NovaSeq sequencing platform, generating paired-end 150&#x2009;bp sequences. Sequences were aligned to the GRCh38 human reference genome using the Burrows&#x2013;Wheeler Aligner-MEM<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Details on the assessment of DNA sequencing quality and sample-to-sample concordance may be found in the <xref rid="MOESM1" ref-type="media">Supplementary Note</xref>.</p>
      </sec>
      <sec id="Sec9">
        <title>Variant calling and filtering</title>
        <p id="Par29">A detailed explanation of variant calling and filtering may be found in the <xref rid="MOESM1" ref-type="media">Supplementary Note</xref>. In brief, for WGS and WES, substitutions were called using CaVEMAN algorithm (v.1.15.1)<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, small InDels with Pindel algorithm (cgpPindel v.3.5.0)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, copy number with both Battenberg (cgpBattenberg v.3.5.3)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and ASCAT (AscatNGS v.4.3.2)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and structural variants with GRIDSS (v.2.9.4)<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. For duplex sequencing, mutations were detected by considering only mutations that were supported by reads from both strands that were not called in the normal sample<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. After filtering, mutations were analyzed using the package dNdScv<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> (v.0.0.1.0). Code for this analysis can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/trwo/nf1_second_hit_normal_tissues">https://github.com/trwo/nf1_second_hit_normal_tissues</ext-link>.</p>
      </sec>
      <sec id="Sec10">
        <title>Driver mutation identification and annotation (WGS and WES): substitutions and InDels</title>
        <p id="Par30">For substitutions and InDels, all mutations resulting in protein-coding changes in genes reported in the COSMIC (v.94) cancer gene census were initially considered<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Driver mutation status was assessed before the application of the exact binomial filter (which determines germline status&#x2014;see above). This circumvented the risk that true driver mutations might be eliminated at a subsequent filtering step, for example, germline driver events. The following two classes of mutations were considered to be candidate drivers: first, missense substitutions or in-frame InDels occurring at hotspots in dominant-acting genes, and second, mutations in recessive-acting cancer genes predicted to result in loss of function, such as nonsense, frameshift or essential splice site variants. Candidate mutations were assigned to tiers, according to their likelihood of acting as a driver. Tier 1 substitution/InDel drivers occurred within genes that were recurrently mutated in a recent meta-analysis of over 1,000 pediatric high-grade gliomas<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. This list of genes included <italic>ACVR1</italic>, <italic>ASXL1</italic>, <italic>ATM</italic>, <italic>ATRX</italic>, <italic>BCOR</italic>, <italic>BRAF</italic>, <italic>CCND2</italic>, <italic>CDK4</italic>, <italic>CDK6</italic>, <italic>CDKN2A</italic>, <italic>CDKN2B</italic>, <italic>EGFR</italic>, <italic>FGFR1</italic>, <italic>H3F3A</italic>, <italic>HIST1H3B</italic>, <italic>HIST1H3C</italic>, <italic>HIST2H3C</italic>, <italic>ID2</italic>, <italic>KDM6B</italic>, <italic>KDR</italic>, <italic>KIT</italic>, <italic>KRAS</italic>, <italic>MET</italic>, <italic>MYC</italic>, <italic>MYCN</italic>, <italic>NF1</italic>, <italic>NTRK1</italic>, <italic>NTRK2</italic>, <italic>NTRK3</italic>, <italic>PDGFRA</italic>, <italic>PIK3CA</italic>, <italic>PIK3R1</italic>, <italic>PPM1D</italic>, <italic>PTEN</italic>, <italic>RB1</italic>, <italic>SETD2</italic>, <italic>TERT</italic>, <italic>TOP3A</italic> and <italic>TP53</italic>. Tier 2 mutations occurred in other supposed cancer genes from the COSMIC (v.94) cancer gene census list.</p>
        <p id="Par31">Mutations in <italic>NF1</italic> itself were considered differently. Inactivating mutations were considered to be probable drivers. Although <italic>NF1</italic> is a recessive cancer gene, it does have residues that are mutated more frequently. Missense mutations that occurred in such loci, defined as &gt;4 mutations of a given residue in COSMIC, were considered as probable driver mutations, and further support for their functional effect was sought from the literature and from predictors of mutational effect<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
      </sec>
      <sec id="Sec11">
        <title>Driver mutation identification and annotation (WGS and WES): copy number changes</title>
        <p id="Par32">Copy number changes were determined to be driver events according to sample ploidy, the genes found on each segment and the segment length. Oncogenes were considered to be amplified if their total copy number was &#x2265;5 when ploidy was &lt;2.7 or &#x2265;9 when ploidy was &#x2265;2.7. For tumor suppressor genes, the total copy number had to equal 0 for &lt;2.7 ploidy and &#x2264; (ploidy&#x2009;&#x2212;&#x2009;2.7) when ploidy was &#x2265;2.7. Copy number aberrations passing these criteria were then annotated as putative tier 1 driver mutations if the oncogene(s) or tumor suppressor gene(s) they contained were found in the list of genes above, the segment width was &#x2264;10&#x2009;Mb wide and this was a recognized oncogenic event for that gene. For example, copy number changes in genes that mediate oncogenesis via fusion events alone were not considered tier 1 drivers. Tier 2 drivers did not meet the criteria outlined for tier 1 variants but had to be found on segments &#x2264;1&#x2009;Mb wide.</p>
      </sec>
      <sec id="Sec12">
        <title>Driver mutation identification and annotation (WGS and WES): structural variants</title>
        <p id="Par33">For a structural variant, independent of copy number state, to be annotated as a driver, it had to either form a fusion gene recognized to be oncogenic, truncate the gene footprint of a tumor suppressor gene or activate an oncogene through intragenic deletion (for example, <italic>PDGFRA</italic>). Once again, tier 1 events occurred in the list of genes used for other variant classes, whereas tier 2 events were plausible drivers that fell outside of these.</p>
      </sec>
      <sec id="Sec13">
        <title>Testing for recent clonal expansions associated with <italic>NF1</italic> null status</title>
        <p id="Par34">A linear mixed effects model comparing the mutation burden derived from WGS of <italic>NF1</italic> null versus <italic>NF1</italic>-heterozygous histologically normal CNS biopsies/microbiopsies was fitted in R using the package nlme. <italic>NF1</italic> null status, whether the sample was derived from bulk sequencing or laser capture microdissection, and coverage were included as fixed effects. The piece of tissue from which the sample was derived was used as a random effect (that is, two microbiopsies from the same piece of tissue should be correlated with one another). Although <italic>NF1</italic> null status was associated with a statistically significant effect, the effect size was only of seven additional mutations. Given that the postnatal somatic mutation rate of most tissues is 10&#x2013;50 mutations per year (including a rate in glia of 27 substitutions per year<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> and a rate in neurons of 17 substitutions per year<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>) and the prenatal rate is usually higher, a recent clonal expansion should result in a mutation burden on the order of 100 mutations even in a child; we, therefore, concluded that <italic>NF1</italic> null status was incompatible with a recent clonal expansion.</p>
      </sec>
      <sec id="Sec14">
        <title>Detecting independent <italic>NF1</italic> null clones in normal tissue: WGS and WES</title>
        <p id="Par35">Driver events within <italic>NF1</italic> were initially identified in the same manner as all other driver mutations. This included a germline essential splice site <italic>NF1</italic> mutation within PD51122 that accounted for their neurofibromatosis type 1. Second loss of function <italic>NF1</italic> mutations in this case were assumed to render the affected cells &#x2018;<italic>NF1</italic> null&#x2019;.</p>
        <p id="Par36">Evidence for any <italic>NF1</italic> driver point mutation that had been identified in the child with neurofibromatosis type 1 was sought in the remaining two cases in the discovery cohort. Similar to the substitution filtering, this provided an approximation of the base sequencing error rate, above which we could determine an <italic>NF1</italic> point mutation to be truly present in the index case. We performed a one-sided Fisher&#x2019;s exact test using the summed variant and total read depth from the two children without <italic>NF1</italic> mutation against those observed in each microdissection and bulk biopsy from the child with neurofibromatosis type 1. After a multiple hypothesis testing correction (Benjamini&#x2013;Hochberg method), the <italic>NF1</italic> point mutation was considered present in a sample if <italic>q</italic>&#x2009;&lt;&#x2009;0.01. All <italic>NF1</italic> driver point mutations that were identified were found in at least one sample without any detectable tumor involvement. No copy number aberrations or structural variants involving <italic>NF1</italic> were detected in normal tissues using standard variant calling.</p>
        <p id="Par37">To increase our sensitivity to detect LOH events in the normal tissue of the child with neurofibromatosis type 1, we phased SNPs to each gene allele. The child&#x2019;s tumor had LOH of the entirety of chromosome 17, leaving only copies of the allele bearing the germline <italic>NF1</italic> mutation. We could phase the heterozygous SNPs identified in the deeply sequenced blood sample (PD51122q) on chromosome 17 according to which allele had the greatest allele frequency in one of the purest bulk tumor samples (PD51122m). These phased SNPs were then profiled in all remaining samples. Only SNPs with &#x2265;10&#xD7; coverage in a sample were kept for its downstream analysis, as few SNPs in noncoding regions would be captured by WES.</p>
        <p id="Par38">To identify samples with possible independent LOH events inactivating <italic>NF1</italic> in both the WGS and WES data, a two-sided exact binomial test was performed. In this test, the number of trials was the sum of total coverage across the heterozygous SNPs found across the gene. The number of successes was the sum of the depth of the alleles that were only found in the tumor. The hypothesized probability of success was the expected aggregate allele fraction. The <italic>NF1</italic> locus was 2&#x2009;+&#x2009;0 in the tumor, while a normal cell would have one copy of each parental allele. The aggregate allele fraction therefore would equal tumor purity&#x2009;+&#x2009;((1&#x2009;&#x2212;&#x2009;tumor purity)&#x2009;&#xD7;&#x2009;0.5). <italic>P</italic> values underwent multiple hypothesis corrections using the Benjamini&#x2013;Hochberg method. To ensure confidence that we were truly detecting these in normal tissue, only samples where <italic>q</italic>&#x2009;&lt;&#x2009;0.01, the median coverage was &#x2265;30&#xD7; and tumor purity was &lt;1% were considered to possess a copy number change to the <italic>NF1</italic> locus that could not be explained by tumor infiltration alone.</p>
        <p id="Par39">Two samples that had significant shifts in the proportion of each <italic>NF1</italic> allele unusually favored the wild-type allele (PD51122s_lo0012 and PD51122u_lo0009). These microdissections of non-neuroectodermal origin are interpreted as containing clones with LOH events that lost the mutant <italic>NF1</italic> allele.</p>
        <p id="Par40">The <italic>NF1</italic> locus had not undergone LOH in the other two children, meaning that a similar analysis could not be performed.</p>
      </sec>
      <sec id="Sec15">
        <title>Assessment of the genetic relationship between tissues that shared a somatic <italic>NF1</italic> variant in PD51122</title>
        <p id="Par41">For a variant to be found in two tissues, either it must have been acquired from a shared ancestor or developed independently. Assuming a comparable rate of mutation acquisition, tissues with a more recent common ancestor will share a greater number of mutations than those that are more distantly related. To determine whether the tissues carrying the same somatic <italic>NF1</italic> mutation were uniquely related, we first needed control to determine how related two tissues would be by chance in this child.</p>
        <p id="Par42">To construct our control data, we used the normal tissues (&lt;1% estimated tumor contamination) without evidence of a second <italic>NF1</italic> hit. Separate comparisons of normal CNS versus normal CNS and normal CNS versus normal mesoderm were made to account for differences in the genetic architecture between germ layers and tissues. A mutation was determined to be shared between tissues if it was identified in both using a Shearwater-like approach (<xref rid="MOESM1" ref-type="media">Supplementary Note</xref>), rather than relying on the calls from the variant caller alone. This improved our sensitivity for detecting low VAF variants and mitigated some of the risk that true shared variants would not be called or erroneously filtered in one sample by our pipeline. All samples in each group were then iteratively compared to the others.</p>
        <p id="Par43">The pairwise comparison was then repeated for tissues that shared a somatic <italic>NF1</italic> variant, and the mean number of shared substitutions per pair was calculated for each mutation (test data). The same number of pairwise comparisons for each mutation were then drawn from the control data at random, without replacement, and the mean was calculated. This was repeated 1,000 times. The <italic>P</italic> value was determined by the number of draws where the control data mean was greater than that observed in the test data (one-sided test).</p>
      </sec>
      <sec id="Sec16">
        <title>Reporting summary</title>
        <p id="Par44">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p>
      </sec>
    </sec>
    <sec id="Sec17" sec-type="materials|methods">
      <title>Online content</title>
      <p id="Par45">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41588-025-02097-2.</p>
    </sec>
    <sec id="Sec19" sec-type="supplementary-material">
      <title>Supplementary information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41588_2025_2097_MOESM1_ESM.pdf"><label>Supplementary Information</label><caption><p>Supplementary Note and Figs. 1&#x2013;3.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41588_2025_2097_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41588_2025_2097_MOESM3_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41588_2025_2097_MOESM4_ESM.xlsx"><label>Supplementary Tables</label><caption><p>Supplementary Tables 1&#x2013;18: Patient and sample characteristics and mutation calls.</p></caption></media></supplementary-material>
</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec18">
          <title>Extended data</title>
          <p id="Par50">
<fig id="Fig4"><label>Extended Data Fig. 1</label><caption><title>Subcutaneous ankle lesion in the child with neurofibromatosis type 1.</title><p><bold>a</bold>,<bold>b</bold>, Representative histological appearances of the tissue are shown. The tissue comprises adipose tissue, bands of fibrous tissue, a Pacinian corpuscle, thick nerve trunks and ganglia. <bold>c</bold>, The light blue outline with a yellow arrowhead indicates the region microdissected that yielded a biallelic loss of <italic>NF1</italic> (PD51122ac_lo0013). It comprises bland spindled cells, embedded in fibrous and fibrillary stroma, that surround a blood vessel. The scale bars represent 1&#x2009;mm, 1&#x2009;mm and 250&#x2009;&#xB5;m, respectively.</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig4_ESM" id="d33e1644"/></fig>
</p>
          <p id="Par51">
<fig id="Fig5"><label>Extended Data Fig. 2</label><caption><title>Mosaic uniparental disomy of chromosome 11p in a nerve from case PD51123.</title><p>Left, a histological image of the slide from which the affected sample was microdissected. Scale bar represents 250&#x2009;&#xB5;m. Right, the coverage of chromosome 11 SNPs and their B-allele fraction (BAF). Gridlines are present for matching to coordinates. The B-allele here is the one inferred to be derived from the major allele within predicted haplotype blocks (red line). The BAF split was not detected by ascatPCA but detected on manual review and the output here is from Battenberg.</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig5_ESM" id="d33e1655"/></fig>
</p>
          <p id="Par52">
<fig id="Fig6"><label>Extended Data Fig. 3</label><caption><title>Histological images of normal tissues with independent <italic>NF1</italic> null clones.</title><p>Where the clone was detected in a microdissected sample, the exact section and area sequenced are shown. For clones found in bulk samples, a representative image from the reference slide is provided. The microdissected and reference sections are 16&#x2009;&#xB5;m and 4&#x2009;&#xB5;m thick. PD51122g_lo0003 was taken from a section that had dried before slide scanning and microdissection, resulting in a suboptimal image. Consequently, the reference slide was used here to provide an overview of the approximate area microdissected. The black outlines on images represent the perimeter of the microdissection. PD51122b_lo0018 is a region of the molecular layer (ML), taken from the cerebellum. The scale bars for the images of microdissected samples represent 250&#x2009;&#xB5;m. The scale bars for PD51122b, PD51122e and PD51122f are 1&#x2009;mm and for PD51122d 500&#x2009;&#xB5;m.</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig6_ESM" id="d33e1670"/></fig>
</p>
          <p id="Par53">
<fig id="Fig7"><label>Extended Data Fig. 4</label><caption><title>Brain MRI at diagnosis from the child with neurofibromatosis type 1.</title><p>FLAIR (top row, left and right images) and axial T2-weighted images (all other images; top row, middle and right images are rotated 90&#xB0; anticlockwise) show typical focal areas of signal intensity (FASI) in the white matter and cerebellar cortex (blue boxes). The presence of tumor (red outline) makes it challenging in some areas to distinguish tumor from FASI (yellow boxes). No convincing FASI was found in the cerebral cortex or spinal cord, suggesting that no close correlation of the <italic>NF1</italic> null clones and FASI could be made. Note that there is hyperintensity of both hippocampi (bottom row, left image).</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig7_ESM" id="d33e1685"/></fig>
</p>
          <p id="Par54">
<fig id="Fig8"><label>Extended Data Fig. 5</label><caption><title>Allele fraction plots for the normal tissues in the child with neurofibromatosis type 1 with the largest <italic>NF1</italic> LOH events.</title><p>Each dot represents a heterozygous SNP that is phased to either the copy of chromosome 17 bearing the germline <italic>NF1</italic> mutation (red) or the wild-type allele (blue). Black arrowheads indicate the approximate location of the breakpoint in each sample.</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig8_ESM" id="d33e1704"/></fig>
</p>
          <p id="Par55">
<fig id="Fig9"><label>Extended Data Fig. 6</label><caption><title>Loss of the germline mutated <italic>NF1</italic> allele in bladder muscle.</title><p>Left, a histological image of the tissue microdissected to generate PD51122s_lo0012. Right, a density plot for the two alleles at heterozygous SNP sites was found across chromosome 17. A two-sided, exact binomial test is applied between the observed chromosome 17 allele fraction bearing the germline mutant <italic>NF1</italic> (red) and the expected fraction (dashed line; <xref rid="Sec2" ref-type="sec">Methods</xref>). The scale bar represents 250&#x2009;&#xB5;m. MP, muscularis propria.</p></caption><graphic position="anchor" xlink:href="41588_2025_2097_Fig9_ESM" id="d33e1726"/></fig>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Thomas R. W. Oliver, Andrew R. J. Lawson, Henry Lee-Six.</p>
      </fn>
      <fn>
        <p>These authors jointly supervised this work: Kieren Allinson, Inigo Martincorena, Thomas S. Jacques, Sam Behjati.</p>
      </fn>
    </fn-group>
    <sec>
      <sec id="FPar1">
        <title>Extended data</title>
        <p id="Par46">is available for this paper at 10.1038/s41588-025-02097-2.</p>
      </sec>
      <sec id="FPar2" sec-type="supplementary-material">
        <title>Supplementary information</title>
        <p id="Par47">The online version contains supplementary material available at 10.1038/s41588-025-02097-2.</p>
      </sec>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>This study was funded by the Wellcome Trust (institutional grant; personal fellowships to T.R.W.O. and S.B.; grants 206194, 108413/A/15/D and 223135/Z/21/Z). T.S.J. is grateful to the Brain Tumour Charity (including the Everest Centre for Low-Grade Paediatric Brain Tumours (GN-000382 and GN-000707) and the INSTINCT program), Great Ormond Street Hospital Children&#x2019;s Charity, Children with Cancer UK, the Olivia Hodson Cancer Fund, Cancer Research UK and the National Institute for Health Research for funding. This research was supported by the National Institute for Health and Care Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre and the NIHR Biomedical Research Centre at The Royal Marsden and the Institute for Cancer Research. Additional funding was received from The Royal National Orthopaedic Research and Development Department (to A.M.F.) and The Bone Cancer Research Trust (to A.M.F.). We thank the Children&#x2019;s Cancer and Leukaemia Group (CCLG) Tissue Bank, the CCLG centers and the Experimental Cancer Medicine Centres Paediatric Network for the collection and provision of tissue samples (project 2016 BS 05). The CCLG Tissue Bank is funded by Cancer Research UK and CCLG. A.M.F. is also separately supported by the National Institute for Health Research, Sarcoma UK, the UCLH Biomedical Research Centre and the UCL Experimental Cancer Centre. Funding from these institutions supported the work of the Biobank where the samples from the adult cohort were stored. H.L.-S. was supported by an NIHR Academic Clinical Fellowship and a Junior Research Fellowship from Trinity College, Cambridge, UK. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We thank the clinical teams of Cambridge University Hospitals and Great Ormond Street Hospital, including the mortuary staff. V. Lee, L. Ward and O. Ogunbiyi from Great Ormond Street Hospital and A. Whyte from Addenbrooke&#x2019;s Hospital helped facilitate the collection and transfer of samples for which we are grateful. We thank G. Caravagna (University of Trieste) for his assistance with copy number calling quality control and A. Maartens (science writer at the Wellcome Sanger Institute) for his critical review of the manuscript. We are indebted to the families who participated in this research.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>S.B. and T.R.W.O. designed the experiment and wrote the manuscript. T.S.J. and K. Allinson conducted the autopsies and provided neuropathological histology expertise. T.R.W.O. performed microdissection, with laboratory support provided by Y.H. and P.A.N., and A.T. provided further technical support. T.R.W.O., A.R.J.L. and H.L.-S. analyzed data, with the assistance of R.S., M.D.Y., T.H.H.C., H.J., T.M.B., S.V.L. and I.C.-C. M.D.Y. provided statistical expertise. G.A.A.B., K. Aquilina, D.H., M.J. and T.D.T. provided clinical expertise and contributed to discussions. U.L. provided radiological expertise. F.A.J. and A.M.F. provided pathological expertise. S.B., T.S.J., I.M. and K. Allinson directed the study.</p>
    </notes>
    <notes notes-type="peer-review">
      <title>Peer review</title>
      <sec id="FPar3">
        <title>Peer review information</title>
        <p id="Par48"><italic>Nature Genetics</italic> thanks Ruben van Boxtel, David Gutmann and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. <xref rid="MOESM3" ref-type="media">Peer reviewer reports</xref> are available.</p>
      </sec>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>WGS and targeted sequencing data are deposited in the European Genome&#x2013;Phenome Archive (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ega/">https://www.ebi.ac.uk/ega/</ext-link>) with accession ID <ext-link ext-link-type="uri" xlink:href="https://ega-archive.org/datasets/EGAD00001015398">EGAD00001015398</ext-link>. Mutation calls are available in Supplementary Tables <xref rid="MOESM4" ref-type="media">1&#x2013;18</xref>. The complete catalog of substitutions identified by WGS has been deposited on Mendeley and can be accessed at 10.17632/hfv45sg3c5.1 (ref. <sup><xref ref-type="bibr" rid="CR16">16</xref></sup>).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Code availability</title>
      <p>Custom R scripts used to analyze the data can be found at <ext-link ext-link-type="uri" xlink:href="https://github.com/trwo/nf1_second_hit_normal_tissues">https://github.com/trwo/nf1_second_hit_normal_tissues</ext-link> (ref. <sup><xref ref-type="bibr" rid="CR41">41</xref></sup>).</p>
    </notes>
    <notes id="FPar4" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par49">I.M. is a cofounder and consultant of Quotient Therapeutics. D.H. provides consultancy to AstraZeneca/MedImmune, Alexion Pharmaceuticals, Bayer, Biodexa, Roche/Genentech and Novartis, as well as expert testimony to AstraZeneca and Novartis, and his expenses are covered by Alexion Pharmaceuticals, Boehringer Ingelheim, Roche/Genentech and Novartis. The other authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><etal/></person-group><article-title>Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1126/science.aaa6806</pub-id><pub-id pub-id-type="pmid">25999502</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. <italic>Science</italic><bold>348</bold>, 880&#x2013;886 (2015).<pub-id pub-id-type="pmid">25999502</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee-Six</surname><given-names>H</given-names></name><etal/></person-group><article-title>The landscape of somatic mutation in normal colorectal epithelial cells</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>532</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1672-7</pub-id><pub-id pub-id-type="pmid">31645730</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal epithelial cells. <italic>Nature</italic><bold>574</bold>, 532&#x2013;537 (2019).<pub-id pub-id-type="pmid">31645730</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>L</given-names></name><etal/></person-group><article-title>The mutational landscape of human somatic and germline cells</article-title><source>Nature</source><year>2021</year><volume>597</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03822-7</pub-id><pub-id pub-id-type="pmid">34433962</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Moore, L. et al. The mutational landscape of human somatic and germline cells. <italic>Nature</italic><bold>597</bold>, 381&#x2013;386 (2021).<pub-id pub-id-type="pmid">34433962</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>ARJ</given-names></name><etal/></person-group><article-title>Extensive heterogeneity in somatic mutation and selection in the human bladder</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1126/science.aba8347</pub-id><pub-id pub-id-type="pmid">33004514</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. <italic>Science</italic><bold>370</bold>, 75&#x2013;82 (2020).<pub-id pub-id-type="pmid">33004514</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation-alternatives>
          <element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Increased somatic mutation burdens in normal human cells due to defective DNA polymerases</article-title><source>Nat. Genet.</source><year>2021</year><volume>53</volume><fpage>1434</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00930-y</pub-id><pub-id pub-id-type="pmid">34594041</pub-id>
</element-citation>
          <mixed-citation id="mc-CR5" publication-type="journal">Robinson, P. S. et al. Increased somatic mutation burdens in normal human cells due to defective DNA polymerases. <italic>Nat. Genet.</italic><bold>53</bold>, 1434&#x2013;1442 (2021).<pub-id pub-id-type="pmid">34594041</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Custers</surname><given-names>L</given-names></name><etal/></person-group><article-title>Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1407</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21675-6</pub-id><pub-id pub-id-type="pmid">33658498</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Custers, L. et al. Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. <italic>Nat. Commun.</italic><bold>12</bold>, 1407 (2021).<pub-id pub-id-type="pmid">33658498</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenbarth</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evidence for the presence of the second allele of the neurofibromatosis type 1 gene in melanocytes derived from cafe au lait macules of NF1 patients</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1997</year><volume>237</volume><fpage>138</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1997.7097</pub-id><pub-id pub-id-type="pmid">9266845</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Eisenbarth, I. et al. Evidence for the presence of the second allele of the neurofibromatosis type 1 gene in melanocytes derived from cafe au lait macules of NF1 patients. <italic>Biochem. Biophys. Res. Commun.</italic><bold>237</bold>, 138&#x2013;141 (1997).<pub-id pub-id-type="pmid">9266845</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>De Schepper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes</article-title><source>J. Invest. Dermatol.</source><year>2008</year><volume>128</volume><fpage>1050</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5701095</pub-id><pub-id pub-id-type="pmid">17914445</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">De Schepper, S. et al. Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. <italic>J. Invest. Dermatol.</italic><bold>128</bold>, 1050&#x2013;1053 (2008).<pub-id pub-id-type="pmid">17914445</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Legius</surname><given-names>E</given-names></name><name><surname>Brems</surname><given-names>H</given-names></name></person-group><article-title>Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism</article-title><source>Childs Nerv. Syst.</source><year>2020</year><volume>36</volume><fpage>2285</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1007/s00381-020-04771-8</pub-id><pub-id pub-id-type="pmid">32601904</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Legius, E. &amp; Brems, H. Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism. <italic>Childs Nerv. Syst.</italic><bold>36</bold>, 2285&#x2013;2295 (2020).<pub-id pub-id-type="pmid">32601904</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gutmann</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Neurofibromatosis type 1</article-title><source>Nat. Rev. Dis. Primers</source><year>2017</year><volume>3</volume><fpage>17004</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.4</pub-id><pub-id pub-id-type="pmid">28230061</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Gutmann, D. H. et al. Neurofibromatosis type 1. <italic>Nat. Rev. Dis. Primers</italic><bold>3</bold>, 17004 (2017).<pub-id pub-id-type="pmid">28230061</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation-alternatives>
          <element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Emmerich</surname><given-names>D</given-names></name><etal/></person-group><article-title>Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient</article-title><source>Eur. J. Hum. Genet.</source><year>2015</year><volume>23</volume><fpage>870</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2014.210</pub-id><pub-id pub-id-type="pmid">25293717</pub-id>
</element-citation>
          <mixed-citation id="mc-CR11" publication-type="journal">Emmerich, D. et al. Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient. <italic>Eur. J. Hum. Genet.</italic><bold>23</bold>, 870&#x2013;873 (2015).<pub-id pub-id-type="pmid">25293717</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation-alternatives>
          <element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)</article-title><source>Acta Neuropathol.</source><year>2021</year><volume>141</volume><fpage>605</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1007/s00401-021-02276-5</pub-id><pub-id pub-id-type="pmid">33585982</pub-id>
</element-citation>
          <mixed-citation id="mc-CR12" publication-type="journal">Fisher, M. J. et al. Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). <italic>Acta Neuropathol.</italic><bold>141</bold>, 605&#x2013;617 (2021).<pub-id pub-id-type="pmid">33585982</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation-alternatives>
          <element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes-Ciriano</surname><given-names>I</given-names></name><etal/></person-group><article-title>Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>654</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0786</pub-id><pub-id pub-id-type="pmid">36598417</pub-id>
</element-citation>
          <mixed-citation id="mc-CR13" publication-type="journal">Cortes-Ciriano, I. et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. <italic>Cancer Discov.</italic><bold>13</bold>, 654&#x2013;671 (2023).<pub-id pub-id-type="pmid">36598417</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation-alternatives>
          <element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>AG</given-names></name></person-group><article-title>Mutation and cancer: statistical study of retinoblastoma</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1971</year><volume>68</volume><fpage>820</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1073/pnas.68.4.820</pub-id><pub-id pub-id-type="pmid">5279523</pub-id>
</element-citation>
          <mixed-citation id="mc-CR14" publication-type="journal">Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. <italic>Proc. Natl Acad. Sci. USA</italic><bold>68</bold>, 820&#x2013;823 (1971).<pub-id pub-id-type="pmid">5279523</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation-alternatives>
          <element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reliable detection of somatic mutations in solid tissues by laser-capture microdissection and low-input DNA sequencing</article-title><source>Nat. Protoc.</source><year>2021</year><volume>16</volume><fpage>841</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-00437-6</pub-id><pub-id pub-id-type="pmid">33318691</pub-id>
</element-citation>
          <mixed-citation id="mc-CR15" publication-type="journal">Ellis, P. et al. Reliable detection of somatic mutations in solid tissues by laser-capture microdissection and low-input DNA sequencing. <italic>Nat. Protoc.</italic><bold>16</bold>, 841&#x2013;871 (2021).<pub-id pub-id-type="pmid">33318691</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Oliver, T. R. W. Cancer-independent somatic mutation of the wild-type NF1 allele in normal tissues in neurofibromatosis type 1. <italic>Mendeley Data</italic>10.17632/hfv45sg3c5.1 (2024).</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation-alternatives>
          <element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><etal/></person-group><article-title>Universal patterns of selection in cancer and somatic tissues</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>1029</fpage><lpage>1041.e21</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id>
</element-citation>
          <mixed-citation id="mc-CR17" publication-type="journal">Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. <italic>Cell</italic><bold>171</bold>, 1029&#x2013;1041.e21 (2017).<pub-id pub-id-type="pmid">29056346</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation-alternatives>
          <element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>A</given-names></name><etal/></person-group><article-title>Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>520</fpage><lpage>537.e5</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.08.017</pub-id><pub-id pub-id-type="pmid">28966033</pub-id>
</element-citation>
          <mixed-citation id="mc-CR18" publication-type="journal">Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. <italic>Cancer Cell</italic><bold>32</bold>, 520&#x2013;537.e5 (2017).<pub-id pub-id-type="pmid">28966033</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation-alternatives>
          <element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Treger</surname><given-names>TD</given-names></name><etal/></person-group><article-title>The genetic changes of Wilms tumour</article-title><source>Nat. Rev. Nephrol.</source><year>2019</year><volume>15</volume><fpage>240</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41581-019-0112-0</pub-id><pub-id pub-id-type="pmid">30705419</pub-id>
</element-citation>
          <mixed-citation id="mc-CR19" publication-type="journal">Treger, T. D. et al. The genetic changes of Wilms tumour. <italic>Nat. Rev. Nephrol.</italic><bold>15</bold>, 240&#x2013;251 (2019).<pub-id pub-id-type="pmid">30705419</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation-alternatives>
          <element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Messiaen</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Exon 10b of the <italic>NF1</italic> gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing</article-title><source>Genet. Med.</source><year>1999</year><volume>1</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1097/00125817-199909000-00002</pub-id><pub-id pub-id-type="pmid">11258625</pub-id>
</element-citation>
          <mixed-citation id="mc-CR20" publication-type="journal">Messiaen, L. M. et al. Exon 10b of the <italic>NF1</italic> gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing. <italic>Genet. Med.</italic><bold>1</bold>, 248&#x2013;253 (1999).<pub-id pub-id-type="pmid">11258625</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation-alternatives>
          <element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Koster</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq</article-title><source>NPJ Genom. Med.</source><year>2021</year><volume>6</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1038/s41525-021-00258-w</pub-id><pub-id pub-id-type="pmid">34782607</pub-id>
</element-citation>
          <mixed-citation id="mc-CR21" publication-type="journal">Koster, R. et al. Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. <italic>NPJ Genom. Med.</italic><bold>6</bold>, 95 (2021).<pub-id pub-id-type="pmid">34782607</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation-alternatives>
          <element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Increased brain apparent diffusion coefficient in children with neurofibromatosis type 1</article-title><source>Radiology</source><year>2001</year><volume>219</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1148/radiology.219.2.r01ap25354</pub-id><pub-id pub-id-type="pmid">11323456</pub-id>
</element-citation>
          <mixed-citation id="mc-CR22" publication-type="journal">Eastwood, J. D. et al. Increased brain apparent diffusion coefficient in children with neurofibromatosis type 1. <italic>Radiology</italic><bold>219</bold>, 354&#x2013;358 (2001).<pub-id pub-id-type="pmid">11323456</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation-alternatives>
          <element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Abascal</surname><given-names>F</given-names></name><etal/></person-group><article-title>Somatic mutation landscapes at single-molecule resolution</article-title><source>Nature</source><year>2021</year><volume>593</volume><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03477-4</pub-id><pub-id pub-id-type="pmid">33911282</pub-id>
</element-citation>
          <mixed-citation id="mc-CR23" publication-type="journal">Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. <italic>Nature</italic><bold>593</bold>, 405&#x2013;410 (2021).<pub-id pub-id-type="pmid">33911282</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Lawson, A. R. J. et al. Somatic mutation and selection at epidemiological scale. Preprint at <italic>medRxiv</italic>10.1101/2024.10.30.24316422 (2024).</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation-alternatives>
          <element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Niemeyer</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)</article-title><source>Blood</source><year>1997</year><volume>89</volume><fpage>3534</fpage><lpage>3543</lpage><pub-id pub-id-type="pmid">9160658</pub-id>
</element-citation>
          <mixed-citation id="mc-CR25" publication-type="journal">Niemeyer, C. M. et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). <italic>Blood</italic><bold>89</bold>, 3534&#x2013;3543 (1997).<pub-id pub-id-type="pmid">9160658</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation-alternatives>
          <element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020</article-title><source>JAMA Netw. Open</source><year>2021</year><volume>4</volume><fpage>e210945</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.0945</pub-id><pub-id pub-id-type="pmid">33734413</pub-id>
</element-citation>
          <mixed-citation id="mc-CR26" publication-type="journal">Landry, J. P. et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. <italic>JAMA Netw. Open</italic><bold>4</bold>, e210945 (2021).<pub-id pub-id-type="pmid">33734413</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation-alternatives>
          <element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Guillamo</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1093/brain/awg016</pub-id><pub-id pub-id-type="pmid">12477702</pub-id>
</element-citation>
          <mixed-citation id="mc-CR27" publication-type="journal">Guillamo, J. S. et al. Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients. <italic>Brain</italic><bold>126</bold>, 152&#x2013;160 (2003).<pub-id pub-id-type="pmid">12477702</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation-alternatives>
          <element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>I</given-names></name><etal/></person-group><article-title>Gene size matters: an analysis of gene length in the human genome</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><fpage>559998</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.559998</pub-id><pub-id pub-id-type="pmid">33643374</pub-id>
</element-citation>
          <mixed-citation id="mc-CR28" publication-type="journal">Lopes, I. et al. Gene size matters: an analysis of gene length in the human genome. <italic>Front. Genet.</italic><bold>12</bold>, 559998 (2021).<pub-id pub-id-type="pmid">33643374</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation-alternatives>
          <element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>T</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name></person-group><article-title>Developmental dysregulation of childhood cancer</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2024</year><volume>14</volume><fpage>a041580</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a041580</pub-id><pub-id pub-id-type="pmid">38692740</pub-id>
</element-citation>
          <mixed-citation id="mc-CR29" publication-type="journal">Oliver, T. &amp; Behjati, S. Developmental dysregulation of childhood cancer. <italic>Cold Spring Harb. Perspect. Med.</italic><bold>14</bold>, a041580 (2024).<pub-id pub-id-type="pmid">38692740</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation-alternatives>
          <element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Giovannini</surname><given-names>M</given-names></name></person-group><article-title>Mouse models of neurofibromatosis 1 and 2</article-title><source>Neoplasia</source><year>2002</year><volume>4</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/sj.neo.7900249</pub-id><pub-id pub-id-type="pmid">12082543</pub-id>
</element-citation>
          <mixed-citation id="mc-CR30" publication-type="journal">Gutmann, D. H. &amp; Giovannini, M. Mouse models of neurofibromatosis 1 and 2. <italic>Neoplasia</italic><bold>4</bold>, 279&#x2013;290 (2002).<pub-id pub-id-type="pmid">12082543</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation-alternatives>
          <element-citation id="ec-CR31" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>McClatchey</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Cichowski</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mouse models of neurofibromatosis</article-title>
            <source>Biochim. Biophys. Acta</source>
            <year>2001</year>
            <volume>1471</volume>
            <fpage>73</fpage>
            <lpage>80</lpage>
          </element-citation>
          <mixed-citation id="mc-CR31" publication-type="journal">McClatchey, A. I. &amp; Cichowski, K. Mouse models of neurofibromatosis. <italic>Biochim. Biophys. Acta</italic><bold>1471</bold>, 73&#x2013;80 (2001).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation-alternatives>
          <element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><article-title>Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmid">19451168</pub-id>
</element-citation>
          <mixed-citation id="mc-CR32" publication-type="journal">Li, H. &amp; Durbin, R. Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. <italic>Bioinformatics</italic><bold>25</bold>, 1754&#x2013;1760 (2009).<pub-id pub-id-type="pmid">19451168</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation-alternatives>
          <element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D</given-names></name><etal/></person-group><article-title>cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data</article-title><source>Curr. Protoc. Bioinformatics</source><year>2016</year><volume>56</volume><fpage>15.10.1</fpage><lpage>15.10.18</lpage><pub-id pub-id-type="doi">10.1002/cpbi.20</pub-id><pub-id pub-id-type="pmid">27930805</pub-id>
</element-citation>
          <mixed-citation id="mc-CR33" publication-type="journal">Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order to detect somatic single nucleotide variants in NGS data. <italic>Curr. Protoc. Bioinformatics</italic><bold>56</bold>, 15.10.1&#x2013;15.10.18 (2016).<pub-id pub-id-type="pmid">27930805</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation-alternatives>
          <element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>2865</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp394</pub-id><pub-id pub-id-type="pmid">19561018</pub-id>
</element-citation>
          <mixed-citation id="mc-CR34" publication-type="journal">Ye, K. et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. <italic>Bioinformatics</italic><bold>25</bold>, 2865&#x2013;2871 (2009).<pub-id pub-id-type="pmid">19561018</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation-alternatives>
          <element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><etal/></person-group><article-title>The life history of 21 breast cancers</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>994</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.023</pub-id><pub-id pub-id-type="pmid">22608083</pub-id>
</element-citation>
          <mixed-citation id="mc-CR35" publication-type="journal">Nik-Zainal, S. et al. The life history of 21 breast cancers. <italic>Cell</italic><bold>149</bold>, 994&#x2013;1007 (2012).<pub-id pub-id-type="pmid">22608083</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation-alternatives>
          <element-citation id="ec-CR36" publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Raine</surname>
                <given-names>KM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data</article-title>
            <source>Curr. Protoc. Bioinformatics</source>
            <year>2016</year>
            <volume>56</volume>
            <fpage>1591</fpage>
            <lpage>1597</lpage>
            <pub-id pub-id-type="doi">10.1002/cpbi.17</pub-id>
          </element-citation>
          <mixed-citation id="mc-CR36" publication-type="journal">Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. <italic>Curr. Protoc. Bioinformatics</italic><bold>56</bold>, 1591&#x2013;1597 (2016).</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation-alternatives>
          <element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>DL</given-names></name><etal/></person-group><article-title>GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly</article-title><source>Genome Res.</source><year>2017</year><volume>27</volume><fpage>2050</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1101/gr.222109.117</pub-id><pub-id pub-id-type="pmid">29097403</pub-id>
</element-citation>
          <mixed-citation id="mc-CR37" publication-type="journal">Cameron, D. L. et al. GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. <italic>Genome Res.</italic><bold>27</bold>, 2050&#x2013;2060 (2017).<pub-id pub-id-type="pmid">29097403</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation-alternatives>
          <element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>JG</given-names></name><etal/></person-group><article-title>COSMIC: the catalogue of somatic mutations in cancer</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id>
</element-citation>
          <mixed-citation id="mc-CR38" publication-type="journal">Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. <italic>Nucleic Acids Res</italic><bold>47</bold>, D941&#x2013;D947 (2019).<pub-id pub-id-type="pmid">30371878</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation-alternatives>
          <element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Tamborero</surname><given-names>D</given-names></name><etal/></person-group><article-title>Support systems to guide clinical decision-making in precision oncology: the Cancer Core Europe Molecular Tumor Board Portal</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>992</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0969-2</pub-id><pub-id pub-id-type="pmid">32632195</pub-id>
</element-citation>
          <mixed-citation id="mc-CR39" publication-type="journal">Tamborero, D. et al. Support systems to guide clinical decision-making in precision oncology: the Cancer Core Europe Molecular Tumor Board Portal. <italic>Nat. Med.</italic><bold>26</bold>, 992&#x2013;994 (2020).<pub-id pub-id-type="pmid">32632195</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation-alternatives>
          <element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>1955</fpage><lpage>1970.e23</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.02.025</pub-id><pub-id pub-id-type="pmid">38503282</pub-id>
</element-citation>
          <mixed-citation id="mc-CR40" publication-type="journal">Ganz, J. et al. Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes. <italic>Cell</italic><bold>187</bold>, 1955&#x2013;1970.e23 (2024).<pub-id pub-id-type="pmid">38503282</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="other">Oliver, T. R. W. trwo/nf1 second hit normal tissues. <italic>GitHub</italic><ext-link ext-link-type="uri" xlink:href="https://github.com/trwo/nf1_second_hit_normal_tissues">github.com/trwo/nf1_second_hit_normal_tissues</ext-link> (2024).</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Int Rep</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Int Rep</journal-id><journal-title-group><journal-title>Kidney International Reports</journal-title></journal-title-group><issn pub-type="epub">2468-0249</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">11935152</article-id><article-id pub-id-type="pii">S2468-0249(24)02007-2</article-id><article-id pub-id-type="doi">10.1016/j.ekir.2024.10.039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Addressing the Multisystemic Impacts of Nephropathic Cystinosis in an Adult</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Jarnes</surname><given-names>Jeanine R.</given-names></name><email>utzx0002@umn.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x2217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Palmer</surname><given-names>Rebekah S.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Whitley</surname><given-names>Chester B.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>University of Minnesota, Department of Pediatrics, Minneapolis, Minnesota, USA</aff><aff id="aff2"><label>2</label>Next Generation of Cystinosis, Ankeny, Iowa, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x2217;</label><bold>Correspondence:</bold> Jeanine R. Jarnes, Department of Pediatrics, University of Minnesota, MMC 446,420 Delaware St SE, Minneapolis, Minnesota 55455, USA. <email>utzx0002@umn.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>04</day><month>3</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>3</month><year>2025</year></pub-date><volume>10</volume><issue>3 Suppl</issue><fpage>S789</fpage><lpage>S793</lpage><history><date date-type="received"><day>7</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; 2024 International Society of Nephrology. Published by Elsevier Inc.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>International Society of Nephrology</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions></article-meta></front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p id="p0010">Infantile nephropathic cystinosis, the most common and severe form of the disease, is an ultrarare autosomal recessive lysosomal storage disorder caused by variants in <italic>CTNS</italic> and characterized by progressive cystine accumulation and multiorgan damage.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> It was once considered a fatal childhood disease; however, kidney transplantation, earlier diagnosis, and cysteamine therapy have transformed its course.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> As life expectancy has increased beyond the age of 50s, an extrarenal phenotype has been revealed, with impacts to nearly all body systems (<xref rid="fig1" ref-type="fig">Figure&#xA0;1</xref>).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Here, we describe the complicated clinical course of an adult with cystinosis and multiple comorbidities, to enrich the understanding of the disease and identify opportunities to support patients in adulthood.<fig id="fig1"><label>Figure&#xA0;1</label><caption><p>Progression of nephropathic cystinosis in untreated and undertreated patients. Each symptom is listed with the age of onset where it most commonly begins. As patients age, symptoms continue advancing, with additional organ systems involved.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p><p>CNS, central nervous system; GI, gastrointestinal.</p></caption><graphic xlink:href="gr1"/></fig></p>
    </sec>
    <sec id="sec2">
      <title>Case Presentation</title>
      <sec id="sec2.1">
        <title>Diagnosis and Initial Management</title>
        <p id="p0015">The patient is a 36-year-old female who was diagnosed with infantile nephropathic cystinosis at the age of 5 years after proteinuria was discovered during a routine well-child visit. Diagnosis was confirmed via slit-lamp eye examination and kidney biopsy; genetic testing later identified 2 pathogenic <italic>CTNS</italic> variants (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). Treatment with oral immediate-release cysteamine bitartrate (Cystagon; Viatris Inc, Canonsburg, PA) commenced upon diagnosis, and cysteamine eye drops were started at the age of 14 years through a clinical trial.<table-wrap position="float" id="tbl1"><label>Table&#xA0;1</label><caption><p>Clinical events, evaluations, and treatment history</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age at Diagnosis, yr</th><th>Complication</th><th>Initial assessment and routine evaluation</th><th>Treatment</th></tr></thead><tbody><tr><td>5</td><td>Proteinuria, photophobia</td><td>Slit-lamp eye exam (cystine crystals); kidney biopsy (cystine crystals); genetic testing (57 kb deletion and c.971-12G&gt;A <italic>CTNS</italic> variants)</td><td>Oral cysteamine, cysteamine eye drops (started at age of 14 yr)</td></tr><tr><td>9</td><td>Hypothyroidism</td><td>Thyroid panel</td><td>Levothyroxine</td></tr><tr><td rowspan="2">11</td><td>GERD</td><td>NA</td><td>Omeprazole, probiotic</td></tr><tr><td>Dysphagia</td><td>Swallowing study (normal); repeated at ages of 21 yrs (normal), 27 yrs (mild hypopharyngeal stasis), 30 yrs (normal), and 33 yrs (normal)</td><td>Speech therapy</td></tr><tr><td rowspan="3">12</td><td>Kidney failure</td><td>NA</td><td>Kidney transplant; prednisone, tacrolimus, calcium, magnesium, vitamin D, ferrous sulfate</td></tr><tr><td>Hypertension</td><td>BP monitoring</td><td>Atenolol</td></tr><tr><td>PTLD (B-cell lymphoma)</td><td>NA</td><td>Chemotherapy</td></tr><tr><td rowspan="3">19</td><td>Migraine</td><td>NA</td><td>Sumatriptan</td></tr><tr><td>Chronic pain</td><td>NA</td><td>Desvenlafaxine</td></tr><tr><td>Chronic fatigue syndrome</td><td>NA</td><td>NA</td></tr><tr><td rowspan="2">20</td><td>Low back pain</td><td>MRI of lumbar spine (normal)</td><td>NA</td></tr><tr><td>Gallstones, biliary colic</td><td>NA</td><td>Cholecystectomy</td></tr><tr><td rowspan="2">21</td><td>Pain in chest wall</td><td>Echocardiogram (mild tricuspid insufficiency); follow-up chest CT at 26 yrs (patchy ground glass attenuation in both lungs; infiltrate cannot be ruled out), exercise stress test at 26 yrs (exercise capacity below average; test terminated early due to fatigue), chest radiograph at 27 yrs (normal), chest CT at 28 yrs (normal), echocardiogram at 31 yrs (mild tricuspid insufficiency), echocardiogram at 35 yrs (normal)</td><td>NA</td></tr><tr><td>Frequent headaches</td><td>Head CT (normal); follow-up brain MRI at 26 yrs (5&#x2013;6 tiny punctate 3&#x2013;5 mm foci of signal abnormality within the subcortical deep white matter of both cerebral hemispheres, including frontal and parietal lobes bilaterally), head CT at 28 yrs (normal), brain MRI at 29 yrs (5&#x2013;6 punctate white matter abnormalities; new T1 bright dentate nuclei and basal ganglia), head CT at 35 yrs (normal)</td><td>NA</td></tr><tr><td rowspan="7">24</td><td>Menorrhagia</td><td>Abdominal CT (normal)</td><td>NA</td></tr><tr><td>Intestinal dysmotility</td><td>NA</td><td>Probiotic</td></tr><tr><td>Diverticulosis</td><td>NA</td><td>Probiotic</td></tr><tr><td>Chronic nausea</td><td>NA</td><td>Ondansetron (discontinued, not effective)</td></tr><tr><td>Dyspepsia</td><td>NA</td><td>Omeprazole</td></tr><tr><td>Impaired night vision</td><td>Eye exam</td><td>Prescription glasses</td></tr><tr><td>Depression/anxiety</td><td>Psychological assessment</td><td>Desvenlafaxine, lorazepam; therapy</td></tr><tr><td rowspan="3">26</td><td>Fibromyalgia</td><td>NA</td><td>NA</td></tr><tr><td>Gastroparesis, abdominal pain, bloating</td><td>Gastric emptying studies (delayed gastric emptying at 4 h); abdominal CT (mild inflammatory changes in LLQ consistent with epiploic appendage); transabdominal and endovaginal US (small amount of fluid in pelvic cul-de-sac); follow-up abdominal CT at 27 yrs (2 cystic lesions of the lateral R native kidney, stable mild transplant caliectasis, isolated sigmoid diverticulum, tiny fat-containing paraumbilical hernia, 2.7 cm functional R ovarian cyst), abdominal radiograph at 28 yrs (normal), abdominal CT at 30 yrs (mild wall thickening and possible inflammation of the bladder, cysts on both ovaries), transabdominal and endovaginal US at 33 yrs (normal), gastric emptying studies at 35 yrs (moderate delay in gastric emptying)</td><td>NA</td></tr><tr><td>Myopathy, bilateral hand numbness, difficulty with squeezing hands, opening jars</td><td>Hand and wrist radiographs (remote fracture of the left ulnar styloid)</td><td>NA</td></tr><tr><td>27</td><td>Lyme disease</td><td>Brain MRI</td><td>Antibiotic protocol</td></tr><tr><td rowspan="2">28</td><td>Abdominal pain, nausea</td><td>Abdominal radiograph (normal)</td><td>NA</td></tr><tr><td>Globus sensation</td><td>Head and neck US (normal)</td><td>NA</td></tr><tr><td>29</td><td>Right shoulder pain</td><td>Shoulder radiograph and MRI (normal)</td><td>NA</td></tr><tr><td>30</td><td>Type 2 diabetes mellitus</td><td>Laboratory testing</td><td>Metformin, glipizide</td></tr><tr><td>31</td><td>Kyphosis of cervical spine</td><td>Radiograph (shallow kyphosis); MRI (no significant findings)</td><td>NA</td></tr></tbody></table><table-wrap-foot><fn><p>BP, blood pressure; CT, computed tomography; GERD, gastroesophageal reflux disease; LLQ, lower left quadrant; MRI, magnetic resonance imaging; NA, not applicable; PTLD, posttransplant lymphoproliferative disorder; R, right; US, ultrasound.</p></fn></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="sec2.2">
        <title>Medical History</title>
        <p id="p0020">The patient experienced gastrointestinal challenges throughout childhood and began reporting mild dysphagia at the age of 11 years. Subsequent swallowing study results were normal. She underwent kidney transplantation at the age of 12 years and later developed hypertension and posttransplant lymphoproliferative disorder (B-cell lymphoma) secondary to immunosuppressive therapy. She experienced various extrarenal complications and underwent additional screening in adulthood, including echocardiograms, brain magnetic resonance imaging, hand and wrist radiographs, gastric emptying or gut transit time studies, and swallowing tests (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>).</p>
      </sec>
      <sec id="sec2.3">
        <title>Cysteamine History</title>
        <p id="p0025">It is unclear how well-controlled this patient&#x2019;s white blood cell (WBC) cystine levels were before the age of 17 years or if there were periods of nonadherence, because this information along with cysteamine history is not available to her current clinic (<xref rid="appsec1" ref-type="fn">Table&#xA0;S1</xref>). She was prescribed immediate-release cysteamine until the age of 29 years; however, she never tolerated the full dosage due to nausea and abdominal pain. She underwent routine WBC cystine level monitoring, which indicated adequate short-term cystine depletion. However, many of these measurements were not true trough levels (taken less than 6 hours after last immediate-release cysteamine dose<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>), making it difficult to assess disease control. At the age of 29 years, the patient switched to delayed-release cysteamine bitartrate (Procysbi; Amgen Inc, Thousand Oaks, CA) to assess the potential effect of every-12-hour dosing on gastrointestinal symptoms. Delayed-release cysteamine was initiated at a low dosage, with the goal of slowly titrating to an appropriate maintenance dosage; gastrointestinal distress continued during the titration process. The patient found that consuming crackers or very low-fat bread with cysteamine minimized her symptoms.</p>
        <p id="p0030">The patient is currently taking 75% of her goal delayed-release cysteamine dosage. Although her last WBC (granulocytes) cystine level was elevated at 5.73 (goal:&#xA0;&lt;1.9 nmol &#xBD; cystine/mg protein), it was drawn 36 hours after the last delayed-release cysteamine dose and was likely not representative of a true trough value.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> In addition to oral and ophthalmic cysteamine, she takes levothyroxine, atenolol, prednisone, tacrolimus, sumatriptan, probiotic, omeprazole, desvenlafaxine, lorazepam, metformin, glipizide, and various supplements.</p>
      </sec>
      <sec id="sec2.4">
        <title>Transition to Adult Care and Multidisciplinary Care</title>
        <p id="p0035">The patient began transitioning from pediatric to adult care at the age of 20 years while attending college out-of-state. She transferred to a metabolic genetics center of excellence for lysosomal storage disorders at the age of 26 years after difficulty finding an adult nephrologist willing to provide comprehensive cystinosis care. She is routinely followed-up with by specialists in genetics, nephrology, internal medicine, oncology, ophthalmology, psychiatry, and dermatology. Additional specialist referrals are handled as needed. The patient was previously evaluated for possible autoimmune diseases by a gastroenterologist, a rheumatologist, and a neurologist.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Results</title>
      <p id="p0040">Due to her physical limitations, the patient is unable to work in a traditional job and relies on disability benefits. Although she maintains her independence and lives alone, her parents are involved in her care and offer continued support. She also has a life partner, who often attends medical appointments. Despite the progressive nature of her multisystemic complications, the patient lives a full life and uses her experiences and skills obtained from postsecondary education to bring awareness to the rare disease community (<xref rid="fig2" ref-type="fig">Figure&#xA0;2</xref>). She is an active volunteer and is highly involved in a patient advocacy group for cystinosis.<fig id="fig2"><label>Figure&#xA0;2</label><caption><p>Resources to support the care of adults with cystinosis. Select education, patient advocacy, and peer support resources for adults with cystinosis and other rare diseases.</p></caption><graphic xlink:href="gr2"/></fig></p>
    </sec>
    <sec id="sec4">
      <title>Discussion</title>
      <p id="p0045">As seen in this case report, the physical manifestations of cystinosis, as well as its treatments, can profoundly impact patients&#x2019; quality of life, professional development, and relationships.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Although this patient has received many diagnoses, her subjective experience more fully captures her true disease severity. She has trouble with ambulation; pain and limited dexterity in her hands; swallowing difficulties; and visual impairment that makes driving difficult, particularly at night. Most notably, she experiences intense generalized pain and fatigue, which have limited her professional and personal aspirations. Although she is well-educated, she is unable to work in a conventional job due to lack of endurance, inability to meet expectations, and the need for frequent sick days.</p>
      <p id="p0050">This patient has undergone extensive testing for her symptoms, which has shown largely normal results. Standard assessments for common symptoms of cystinosis, such as swallowing difficulties, are often not sensitive enough to capture patient-reported abnormalities.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> In addition, certain extrarenal complications, such as gastrointestinal challenges, are multifactorial, making it difficult to determine and address the underlying etiology.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></p>
      <p id="p0055">Oral cysteamine is the only disease-modifying systemic treatment available for cystinosis. It has been shown to delay the time to kidney transplant and limit the extent of extrarenal complications with early and sustained use.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="appsec1" ref-type="fn">S1&#x2013;S3</xref> The importance of prompt cysteamine initiation was confirmed in a natural history study of 86 adults with cystinosis. Patients who began treatment after 5 years of age had a significantly faster progression to kidney failure and greater incidence of other complications, including hypothyroidism, diabetes, neuromuscular challenges, and death, compared to those who started cysteamine earlier.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> More recent publications emphasize the need for even earlier diagnosis and treatment initiation before the onset of glomerular damage to promote optimal patient outcomes.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="appsec1" ref-type="fn">S1</xref></p>
      <p id="p0060">At the age of 5 years, the patient&#x2019;s cystinosis diagnosis was delayed, which may have contributed to worsened overall outcomes. It is also unclear how well-controlled her disease was in childhood. In adulthood, her WBC cystine levels appear to reflect appropriate short-term cystine depletion, although she continues to be unable to tolerate her target cysteamine dosage. Patients with cystinosis require lifelong cysteamine treatment; those who are unable to tolerate the goal dosage should take their maximum tolerated dosage once it has been established. This provides some disease mitigation but may not be optimal.</p>
      <p id="p0065">Cystinosis places a large burden on patients&#x2019; lives, with impacts on physical functioning, relationships, autonomy, and social status.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> In cases like the one described, patients may be blamed for lack of adherence due to their inability to tolerate cysteamine or other factors. To support this patient, the genetics clinic explored alternative dosing techniques to reduce adverse effects, provided and reinforced education on appropriate timing of WBC cystine level testing, and continued to encourage medication adherence while promoting the concept of progress over perfection. In addition, the clinic determined the patient&#x2019;s maximum tolerated cysteamine dosage and slowly titrated to this individualized goal. Clinicians and patient advocacy groups must be willing to navigate the new and evolving landscape of cystinosis care, with the goals of better understanding what it means to live with cystinosis as an adult, and to develop collaborative strategies to address the unmet needs in this patient population (<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>). Considering that the nephrologist must be highly focused on the specialists&#x2019; responsibilities, the broader scope of the patient&#x2019;s multisystem disease may be overlooked unless there is a primary care provider, or clinical geneticist, who takes responsibility for the comprehensive coordination of the patient&#x2019;s complex medical care.<table-wrap position="float" id="tbl2"><label>Table&#xA0;2</label><caption><p>Teaching points</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cystinosis in adulthood</th></tr></thead><tbody><tr><td><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x2022;</label><p id="p0110">Physical health, psychosocial well-being, and overall quality of life are significantly affected for adults with cystinosis due to the multisystemic impacts of the disease and its treatments.</p></list-item></list></td></tr><tr><td><list list-type="simple" id="ulist0015"><list-item id="u0015"><label>&#x2022;</label><p id="p0115">Patients with cystinosis require lifelong cysteamine treatment; those who are unable to tolerate the goal dosage should take their maximum tolerated dosage once it has been established.</p></list-item></list></td></tr><tr><td><list list-type="simple" id="ulist0020"><list-item id="u0020"><label>&#x2022;</label><p id="p0120">Throughout life, in childhood and adulthood, WBC cystine levels should be monitored regularly to assess &#x201C;cystine depletion&#x201D; and the need for cysteamine dosing adjustments; levels must be evaluated against the standardized last dose of IR cysteamine<xref rid="tbl2fna" ref-type="table-fn">a</xref> (6 h) or DR cysteamine<xref rid="tbl2fnb" ref-type="table-fn">b</xref> (12 h) dose to determine the true trough level of cystine.</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn><p>DR, delayed-release; IR, immediate-release; WBC, white blood cell.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0010">Trough level should be obtained approximately 6 h after the last dose of IR cysteamine, but before the next dose.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0015">Trough levels should be obtained 12 to 12.5 h after the last DR cysteamine dose, but before the next dose.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="sec5">
      <title>Disclosure</title>
      <p id="p0070">All the authors declared no conflicting interests.</p>
    </sec>
    <sec id="sec6">
      <title>Patient Consent</title>
      <p id="p0075">The authors declare that they have obtained consent from the patient discussed in this case report.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Gahl</surname><given-names>W.A.</given-names></name><name><surname>Thoene</surname><given-names>J.G.</given-names></name><name><surname>Schneider</surname><given-names>J.A.</given-names></name></person-group><article-title>Cystinosis</article-title><source>N&#xA0;Engl J Med</source><volume>347</volume><year>2002</year><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1056/nejmra020552</pub-id><pub-id pub-id-type="pmid">12110740</pub-id>
</element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Emma</surname><given-names>F.</given-names></name><name><surname>Hoff</surname><given-names>W.V.</given-names></name><name><surname>Hohenfellner</surname><given-names>K.</given-names></name><etal/></person-group><article-title>An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis</article-title><source>Kidney Int</source><volume>100</volume><year>2021</year><fpage>1112</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2021.06.019</pub-id><pub-id pub-id-type="pmid">34237326</pub-id>
</element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Kasimer</surname><given-names>R.N.</given-names></name><name><surname>Langman</surname><given-names>C.B.</given-names></name></person-group><article-title>Adult complications of nephropathic cystinosis: a systematic review</article-title><source>Pediatr Nephrol</source><volume>36</volume><year>2021</year><fpage>223</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s00467-020-04487-6</pub-id><pub-id pub-id-type="pmid">32016627</pub-id>
</element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Langman</surname><given-names>C.B.</given-names></name><name><surname>Barshop</surname><given-names>B.A.</given-names></name><name><surname>Desch&#xEA;nes</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Controversies and research agenda in nephropathic cystinosis: conclusions from a &#x201C;Kidney Disease: improving Global Outcomes&#x201D; (KDIGO) Controversies Conference</article-title><source>Kidney Int</source><volume>89</volume><year>2016</year><fpage>1192</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2016.01.033</pub-id><pub-id pub-id-type="pmid">27181776</pub-id>
</element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Beinart</surname><given-names>N.</given-names></name><name><surname>Hackett</surname><given-names>R.A.</given-names></name><name><surname>Graham</surname><given-names>C.D.</given-names></name><name><surname>Weinman</surname><given-names>J.</given-names></name><name><surname>Ostermann</surname><given-names>M.</given-names></name></person-group><article-title>Mood and illness experiences of adults with cystinosis</article-title><source>Ren Fail</source><volume>37</volume><year>2015</year><fpage>835</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.3109/0886022X.2015.1015391</pub-id><pub-id pub-id-type="pmid">25715639</pub-id>
</element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>S.</given-names></name><name><surname>Grant</surname><given-names>N.</given-names></name><name><surname>Hammond</surname><given-names>C.</given-names></name><name><surname>David</surname><given-names>W.S.</given-names></name><name><surname>Eichler</surname><given-names>F.</given-names></name><name><surname>Sadjadi</surname><given-names>R.</given-names></name></person-group><article-title>Longitudinal dysphagia assessment in adult patients with nephropathic cystinosis using the Modified Barium Swallow Impairment Profile</article-title><source>Muscle Nerve</source><volume>66</volume><year>2022</year><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1002/mus.27642</pub-id><pub-id pub-id-type="pmid">35616433</pub-id>
</element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>M.W.</given-names></name><name><surname>Stein</surname><given-names>D.R.</given-names></name><name><surname>Stein</surname><given-names>A.C.</given-names></name></person-group><article-title>Gastrointestinal challenges in nephropathic cystinosis: clinical perspectives</article-title><source>Pediatr Nephrol</source><volume>39</volume><year>2024</year><fpage>2845</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1007/s00467-023-06211-6</pub-id><pub-id pub-id-type="pmid">38393360</pub-id>
</element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Brodin-Sartorius</surname><given-names>A.</given-names></name><name><surname>T&#xEA;te</surname><given-names>M.J.</given-names></name><name><surname>Niaudet</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults</article-title><source>Kidney Int</source><volume>81</volume><year>2012</year><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.277</pub-id><pub-id pub-id-type="pmid">21900880</pub-id>
</element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Nie&#x3B2;l</surname><given-names>C.</given-names></name><name><surname>Boulesteix</surname><given-names>A.L.</given-names></name><name><surname>Oh</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis</article-title><source>Mol Genet Metab</source><volume>136</volume><year>2022</year><fpage>268</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2022.06.010</pub-id><pub-id pub-id-type="pmid">35835062</pub-id>
</element-citation>
      </ref>
    </ref-list>
    <sec id="appsec2" sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <p id="p0105">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary File (PDF)</title><p><bold>Table&#xA0;S1.</bold> Cysteamine and WBC cystine level history.<bold>Supplementary References.</bold></p></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
</p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgments</title>
      <p id="p0085">The authors thank the patient, who is also co-author RSP. The authors would also like to thank Chelsea Norman, MS, RDN, and Ingrid Wells, MPH, of The Lockwood Group for writing and editorial support. The Lockwood Group&#x2019;s services complied with Good Publication Practice (GPP3) recommendations. This assistance was funded by Amgen Inc (formerly Horizon Therapeutics plc).</p>
      <sec id="sec7">
        <sec id="sec7.1">
          <title>Funding</title>
          <p id="p0080">Funding was provided by <funding-source id="gs1">Amgen Inc</funding-source> (formerly Horizon Therapeutics plc) for writing and editorial support, manuscript submission, and open access. The authors confirm independence from the sponsor; the content of the article has not been influenced by the sponsor. The authors did not receive compensation for the preparation of this manuscript.</p>
        </sec>
      </sec>
    </ack>
    <fn-group>
      <fn id="d36e357">
        <p id="ntpara0010s">This article is part of a sponsored supplement by Amgen Inc.</p>
      </fn>
      <fn id="appsec1" fn-type="supplementary-material">
        <p id="p0090">
<ext-link ext-link-type="doi" xlink:href="10.1016/j.ekir.2024.10.03" id="intref0010">Supplementary File (PDF)</ext-link>
</p>
        <p id="p0095"><bold>Table&#xA0;S1.</bold> Cysteamine and WBC cystine level history</p>
        <p id="p0100">
<bold>Supplementary References.</bold>
</p>
      </fn>
    </fn-group>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Brain</journal-id><journal-id journal-id-type="iso-abbrev">Mol Brain</journal-id><journal-title-group><journal-title>Molecular Brain</journal-title></journal-title-group><issn pub-type="epub">1756-6606</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">11934713</article-id><article-id pub-id-type="publisher-id">1195</article-id><article-id pub-id-type="doi">10.1186/s13041-025-01195-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Micro Report</subject></subj-group></article-categories><title-group><article-title>Functional characterization of a novel de novo<italic> CACNA1C</italic> pathogenic variant in a patient with neurodevelopmental disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0887-7670</contrib-id><name><surname>Stringer</surname><given-names>Robin N.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Xuechen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7931-922X</contrib-id><name><surname>Jurkovicova-Tarabova</surname><given-names>Bohumila</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0985-2299</contrib-id><name><surname>Liedl</surname><given-names>Klaus R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0040-1109</contrib-id><name><surname>Weiss</surname><given-names>Norbert</given-names></name><address><email>nalweiss@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024d6js02</institution-id><institution-id institution-id-type="GRID">grid.4491.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 116X</institution-id><institution>Department of Pathophysiology, Third Faculty of Medicine, </institution><institution>Charles University, </institution></institution-wrap>Prague, Czech Republic </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/054pv6659</institution-id><institution-id institution-id-type="GRID">grid.5771.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 8122</institution-id><institution>Department of General, Inorganic and Theoretical Chemistry, Center for Molecular Bioscience Innsbruck, </institution><institution>University of Innsbruck, </institution></institution-wrap>Innsbruck, Austria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03h7qq074</institution-id><institution-id institution-id-type="GRID">grid.419303.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 9405</institution-id><institution>Center of Biosciences, Institute of Molecular Physiology and Genetics, </institution><institution>Slovak Academy of Sciences, </institution></institution-wrap>Bratislava, Slovakia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05nj8rv48</institution-id><institution-id institution-id-type="GRID">grid.412903.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1212 1596</institution-id><institution>Department of Biology, Faculty of Education, </institution><institution>Trnava University, </institution></institution-wrap>Trnava, Slovakia </aff><aff id="Aff5"><label>5</label>Patient&#x2019;s Family Representative, Kansas City, Missouri USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>18</volume><elocation-id>26</elocation-id><history><date date-type="received"><day>6</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Mutations in <italic>CACNA1C</italic>, the gene encoding Ca<sub>v</sub>1.2 voltage-gated calcium channels, are associated with a spectrum of disorders, including Timothy syndrome and other neurodevelopmental and cardiac conditions. In this study, we report a child with a de novo heterozygous missense variant (c.1973T&#x2009;&gt;&#x2009;C; L658P) in <italic>CACNA1C</italic>, presenting with refractory epilepsy, global developmental delay, hypotonia, and multiple systemic abnormalities, but without overt cardiac dysfunction. Electrophysiological analysis of the recombinant Ca<sub>v</sub>1.2 L658P variant revealed profound gating alterations, most notably a significant hyperpolarizing shift in the voltage dependence of activation and inactivation. Additionally, molecular modeling suggested that the L658P mutation disrupts interactions within the IIS5 transmembrane segment, reducing the energy barrier for state transitions and facilitating channel opening at more negative voltages. These findings establish L658P as a pathogenic <italic>CACNA1C</italic> variant primarily associated with severe neurological dysfunction and expands the phenotypic spectrum of <italic>CACNA1C</italic>-related disorders.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13041-025-01195-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>CACNA1C</italic></kwd><kwd>Ca<sub>v</sub>1.2</kwd><kwd>Calcium channel</kwd><kwd>L658P</kwd><kwd>Channelopathies</kwd><kwd>Electrophysiology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>FWF #10.55776/DOC178</award-id><principal-award-recipient><name><surname>Liedl</surname><given-names>Klaus R.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010783</institution-id><institution>Slovensk&#xE1; Akad&#xE9;mia Vied</institution></institution-wrap></funding-source><award-id>VEGA #2/0073/22</award-id><principal-award-recipient><name><surname>Weiss</surname><given-names>Norbert</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Institute for Research of Metabolic and Cardiovascular Diseases</institution></funding-source><award-id>EXCELES # LX22NPO5104</award-id><principal-award-recipient><name><surname>Weiss</surname><given-names>Norbert</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Min Zhuo, Bong-Kiun Kaang and BioMed central Ltd. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Main text</title>
      <p id="Par6">Ca<sub>v</sub>1.2 calcium channels are highly expressed in the cardiac, neuronal, and endocrine systems, where they play important roles in regulating excitation&#x2013;contraction coupling, neurotransmitter release, hormone secretion, and gene transcription [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. First mutations in the <italic>CACNA1C</italic> gene, which encodes Ca<sub>v</sub>1.2, have been implicated in a multisystem disorder known as Timothy syndrome (TS). TS is characterized by prolonged cardiac QT intervals, life-threatening arrythmias, neurological and developmental abnormalities, and features of autism spectrum disorders [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Since the initial identification of TS-causing mutations, the spectrum of <italic>CACNA1C</italic>-related disease variants has expanded significantly, encompassing a broad range of clinical phenotypes. While some mutations lead to complex, multisystem disorders resembling TS, others result in more localized pathologies, with patients presenting predominantly with either cardiac or neurological symptoms [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p id="Par7">In this study, we report a 2.5-year-old boy presenting with a complex phenotype, including refractory epilepsy, global developmental delay, hypotonia, hypoxemia, oral-pharyngeal dysphagia, restrictive ventilatory defect, hydronephrosis, visual impairment, epileptic encephalopathy, mitochondrial respiratory chain defects, micrognathia, and single transverse palmar crease. Brain MRI revealed diffusely prominent subarachnoid spaces and supratentorial ventricles, consistent with diffuse brain underdevelopment and/or parenchymal volume loss, as well as a simplified gyral pattern indicative of impaired neuronal proliferation. Additionally, small cavities in the left temporal lobe and right cerebellar hemisphere were observed, consistent with encephalomalacia likely resulting from past insults. Despite these systemic abnormalities, electrocardiograms were generally normal. Whole exome sequencing identified a de novo heterozygous missense variant (c.1973T&#x2009;&gt;&#x2009;C) in <italic>CACNA1C</italic>, resulting in the substitution of leucine at position 658 with proline (L658P). This mutation is located within the highly conserved transmembrane IIS5 segment of the Ca<sub>v</sub>1.2 voltage-gated calcium channel (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A and B) [<xref ref-type="bibr" rid="CR6">6</xref>]. This variant has not been reported in the Genome Aggregation Database (gnomAD), but was reported in a cross-section study of the neuropsychiatric phenotypes associated with <italic>CACNA1C</italic>-related disorders [<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, in silico prediction tools have classified this variant as pathogenic [<xref ref-type="bibr" rid="CR8">8</xref>].<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Electrophysiological properties of the Ca<sub>v</sub>1.2 L658P variant. <bold>A</bold> Location of the L658P missense variant (red dot) within the secondary membrane topology of Ca<sub>v</sub>1.2 channel. <bold>B</bold> Amino acid sequence alignment of the IIS5 transmembrane segment showing the conservation of the L658 residue across the 10 human voltage-gated calcium channel isoforms. Alignments were performed using UniProt (Ca<sub>v</sub>1.1 Q13698; Ca<sub>v</sub>1.2 Q13936; Ca<sub>v</sub>1.3 Q01668; Ca<sub>v</sub>1.4 O60840; Ca<sub>v</sub>2.1 O00555; Ca<sub>v</sub>2.2 Q00975; Ca<sub>v</sub>2.3 Q15878; Ca<sub>v</sub>3.1 O43497; Ca<sub>v</sub>3.2 O95180; Ca<sub>v</sub>3.3 Q9P0X4). <bold>C</bold> Representative L-type current traces recorded from tsA-201 cells expressing Ca<sub>v</sub>1.2 wild-type (WT, black traces) and L658P variant channels (red traces), in combination with Ca<sub>v</sub>&#x3B2;<sub>2</sub>, and Ca<sub>v</sub>&#x3B1;<sub>2</sub>&#x3B4;<sub>1</sub>. <bold>D</bold> Corresponding mean current&#x2013;voltage (<italic>I</italic>/<italic>V</italic>) relationship. <bold>E</bold> Mean maximal macroscopic conductance (<italic>G</italic><sub>max</sub>) obtained from the fit of the <italic>I</italic>/<italic>V</italic> curves with the modified Boltzmann Eq.&#xA0;(1). <bold>F</bold> Mean reversal potential (<italic>V</italic><sub>rev</sub>) values. <bold>G</bold> Mean normalized voltage dependence of activation. <bold>H</bold> Mean half-activation potential (<italic>V</italic><sub>0.5</sub> activation) values obtained from the fit of the activation curves with the modified Boltzmann Eq.&#xA0;(2). <bold>I</bold> Mean normalized voltage dependence of steady state inactivation. <bold>J</bold> Mean half-inactivation potential (<italic>V</italic><sub>0.5</sub> inactivation) values obtained from the fit of the inactivation curves with the modified Boltzmann Eq.&#xA0;(3). <bold>K</bold> Mean non-inactivating channel fraction values. <bold>L</bold> Mean window currents calculated from the activation and inactivation curves using the Eq.&#xA0;(4). The squared area shows the window current between &#x2212;&#xA0;70 and &#x2212;&#xA0;55&#xA0;mV, corresponding to a range of neuronal resting membrane potentials. <bold>M</bold> Mean window current values calculated from the area under the curve between &#x2212;&#xA0;70 and &#x2212;&#xA0;55&#xA0;mV. <bold>N</bold> Mean time constant &#x3C4; values of current activation kinetics. <bold>O</bold> Mean time constant &#x3C4; values of current inactivation kinetics. <bold>P</bold> Mean normalized recovery of inactivation kinetics. <bold>Q</bold> Mean time constant &#x3C4; values of recovery from inactivation obtained by fitting the recovery curves with a single-exponential Eq.&#xA0;(5). <bold>R</bold> Dose&#x2013;response of Ca<sub>v</sub>1.2 channels for isradipine. <bold>S</bold> Dose&#x2013;response of Ca<sub>v</sub>1.2 channels for verapamil. <bold>T</bold> Molecular modeling of Ca<sub>v</sub>1.2 showing the impact of the L658P mutation on various superimposed Ca<sub>v</sub>1.2 channel states including resting (cyan), near-open (green), and high-voltage inactivated states (yellow and orange)</p></caption><graphic xlink:href="13041_2025_1195_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par8">To investigate the functional impact of the L658P variant, the mutation was introduced into the human Ca<sub>v</sub>1.2 channel using site-directed mutagenesis. Recombinant wild-type (WT) and L658P channels were heterologoulsy expressed in tsA-201 cells, and patch-clamp recordings were performed to assess their biophysical properties (see Supplementary methods). Both WT and L658P-expressing cells exhibited typical voltage-activated L-type currents (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>C and D). The maximal macroscopic conductance was significantly reduced by 36% (<italic>p</italic>&#x2009;=&#x2009;0.0020) in cells expressing the L658P variant (0.75&#x2009;&#xB1;&#x2009;0.06 nS/pF, n&#x2009;=&#x2009;12) compared to cells expressing the WT channel (1.17&#x2009;&#xB1;&#x2009;0.09 nS/pF, n&#x2009;=&#x2009;17) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>E). Additionally, a hyperpolarizing shift in the reversal potential by &#x2212;14.7&#xA0;mV was observed, from 36.3&#x2009;&#xB1;&#x2009;1.6&#xA0;mV in WT cells to 21.7&#x2009;&#xB1;&#x2009;2.4&#xA0;mV in L658P-expressing cells (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>F). Strikingly, the L658P mutation caused a pronounced hyperpolarizing shift in the voltage dependence of activation of Ca<sub>v</sub>1.2 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>G). Specifically, the mean half-activation potential was shifted by &#x2212;&#xA0;30.4&#xA0;mV (<italic>p</italic>&#x2009;&lt;&#x2009;0.001), from &#x2212;&#xA0;19.3&#x2009;&#xB1;&#x2009;1.7&#xA0;mV (n&#x2009;=&#x2009;16) in WT cells to &#x2212;&#xA0;49.7&#x2009;&#xB1;&#x2009;1.5&#xA0;mV (n&#x2009;=&#x2009;12) in L658P-expresing cells (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>H). Similarly, the voltage dependence of steady state inactivation was shifted by &#x2212;&#xA0;36.5&#xA0;mV, from &#x2212;35.3&#x2009;&#xB1;&#x2009;1.9&#xA0;mV (n&#x2009;=&#x2009;17) in WT cells to &#x2212;&#xA0;71.7&#x2009;&#xB1;&#x2009;1.9&#xA0;mV (n&#x2009;=&#x2009;13) in cells expressing the L658P variant (<italic>p</italic>&#x2009;&lt;&#x2009;0.001) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>I and J). This shift was accompanied by a significant reduction in the non-inactivating channel fraction, from 0.31&#x2009;&#xB1;&#x2009;0.03 (n&#x2009;=&#x2009;17) in WT cells to 0.12&#x2009;&#xB1;&#x2009;0.02 (n&#x2009;=&#x2009;13) in L658P-expressing cells (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>K). Importantly, the pronounced hyperpolarizing shift in activation and inactivation resulted in a hyperpolarizing shift in the window current (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>L). This created a significant window current at hyperpolarized membrane potentials in cells expressing the L658P variant, which was absent in WT cells (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>M). The L658P mutation also slightly accelerated the activation kinetics of the L-type current (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>N), while inactivation kinetics remained largely unaltered (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>O). Notably, our recordings were performed using barium as the charge carrier, preventing the assessment of calcium-dependent inactivation of Ca<sub>v</sub>1.2 [<xref ref-type="bibr" rid="CR9">9</xref>]. Consequently, it is possible that the L658P mutation exhibits a different effect on channel inactivation in the presence of calcium. Furthermore, the L658P variant caused a 2.3-fold reduction in the time constant of recovery from inactivation, from 1.90&#x2009;&#xB1;&#x2009;0.32&#xA0;s (n&#x2009;=&#x2009;5) in WT cells to 0.82&#x2009;&#xB1;&#x2009;0.04&#xA0;s (n&#x2009;=&#x2009;6) (<italic>p</italic>&#x2009;=&#x2009;0.0045) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>P and Q). Lastly, we assessed whether the L658P mutation affected the pharmacological sensitivity of the Ca<sub>v</sub>1.2 channel to therapeutic drugs. No significant differences in the IC50 values for isradipine (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>R) or verapamil (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>S) were observed between WT and L658P channels. Altogether, these findings demonstrate that the L658P mutation induces profound gating alterations in the Ca<sub>v</sub>1.2 channel, most notably characterized by a significant hyperpolarizing shift in the voltage dependence of activation and inactivation. This shift reflects both gain- and loss-of-function effects, respectively, ultimately leading to the emergence of a window current at hyperpolarized membrane potentials.</p>
      <p id="Par9">To begin elucidating the molecular mechanisms by which the L658P mutation induces gating defects, we conducted molecular modeling of the L658P variant in various Ca<sub>v</sub>1.2 channel states (resting, near-open, and post-open) (see Supplementary methods). The combined&#xA0;structural models were aligned based on the voltage-sensing domains in domain II (VSD II) and domain III (VSD III), with the exclusion of the S4 segments to minimize alignment-related influences on the structural divergence points. Structurally, we hypothesized that the&#xA0;L658P mutation facilitates transitions between channel states, contributing to the hyperpolarizing shift in the voltage dependence of activation and inactivation. As shown by the combined view of different Ca<sub>v</sub>1.2 channel states, the L658P variant is located at the structural divergence point of the modeled states (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>T). Specifically, this mutation appears to enhance the mobility of the lower S5 segment and the connecting S4-S5 linker in domain II, effectively lowering the energy barriers for state transitions and enabling channel activation a lower voltage. In the WT channel, the leucine residue at position 658 is tightly anchored by hydrophobic interactions with neighboring residues on IIS6. Replacing this leucine with proline disrupts these interactions, loosening the helix due to the loss of a backbone hydrogen bond. This structural flexibility is likely to reduce the energy required for transitions, thereby enhancing voltage sensitivity. In the WT channel, such transitions would typically require initiation by VSD II, a process that is rendered more energetically favorable by the presence of the proline residue in the L658P mutated channel.</p>
      <p id="Par10">In conclusion, this study identifies the L658P mutation as a pathogenic <italic>CACNA1C</italic> variant with profound effects on Ca<sub>v</sub>1.2 channel gating. The unique biophysical alterations observed emphasise the complex interplay between gain- and loss-of-function mechanism in <italic>CACNA1C</italic>-related disorders. Notably, despite the patient&#x2019;s severe neurological impairment, electrocardiograms remained normal, distinguishing the L658P mutation from variants typically associated with long-QT syndrome [<xref ref-type="bibr" rid="CR7">7</xref>]. The absence of a cardiac phenotype may be attributed to differential expression and regulation of Ca<sub>v</sub>1.2 in neuronal versus cardiac tissues [<xref ref-type="bibr" rid="CR10">10</xref>]. It is also possible that cardiac-specific splicing within the region containing the mutation could explain the lack of a cardiac phenotype. However, the observation that the L658P mutation causes a combined hyperpolarizing shift in both the voltage dependence of activation and inactivation&#x2014;making the channel more likely to be open at resting membrane potentials&#x2014;suggests an overall gain-of-function effect. Further investigations using tissue-specific expression models in both neuronal and cardiac settings will be essential to fully elucidate the impact of the L658P mutation and its exact role in the pathophysiology of <italic>CACNA1C</italic>-related disorders.</p>
    </sec>
    <sec id="Sec2" sec-type="supplementary-material">
      <title>Supplementary Information</title>
      <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13041_2025_1195_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material></p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>MRI</term>
          <def>
            <p id="Par2">Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>TS</term>
          <def>
            <p id="Par3">Timothy syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>VSD</term>
          <def>
            <p id="Par4">Voltage sensing domain</p>
          </def>
        </def-item>
        <def-item>
          <term>WT</term>
          <def>
            <p id="Par5">Wild-type</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Not applicable.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>R.N.S. and B.J.T. conducted patch clamp recordings and analyzed the data. X.T. and K.R.L. conducted the molecular modeling. M.M. is the patient's representative and coordinated information between the patient and the scientists. N.W. wrote the manuscript. All authors critically revised the manuscript and contributed significantly to this work. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>N.W. is supported by a grant from the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences (VEGA #2/0073/22); and the National Institute for Research of Metabolic and Cardiovascular Diseases (Program EXCELES # LX22NPO5104), funded by the European Union &#x2013; Next Generation EU. K.R.L. is supported by a grant from the Austrian Science Fund (FWF #10.55776/DOC178).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All data generated or analyzed during this study are included in this published article.</p>
    </notes>
    <notes>
      <title>Declarations</title>
      <notes id="FPar1">
        <title>Ethics approval and consent to participate</title>
        <p id="Par11">Not applicable.</p>
      </notes>
      <notes id="FPar2">
        <title>Consent for publication</title>
        <p id="Par12">Not applicable.</p>
      </notes>
      <notes id="FPar3" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par13">The authors declare no competing interests.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation-alternatives>
          <element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Zamponi</surname><given-names>GW</given-names></name><name><surname>Striessnig</surname><given-names>J</given-names></name><name><surname>Koschak</surname><given-names>A</given-names></name><name><surname>Dolphin</surname><given-names>AC</given-names></name></person-group><article-title>The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</article-title><source>Pharmacol Rev</source><year>2015</year><volume>67</volume><issue>4</issue><fpage>821</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">26362469</pub-id>
</element-citation>
          <mixed-citation id="mc-CR1" publication-type="journal">Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67(4):821&#x2013;70.<pub-id pub-id-type="pmid">26362469</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation-alternatives>
          <element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Catterall</surname><given-names>WA</given-names></name></person-group><article-title>Voltage gated sodium and calcium channels: discovery, structure, function, and pharmacology</article-title><source>Channels (Austin)</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>2281714</fpage><pub-id pub-id-type="pmid">37983307</pub-id>
</element-citation>
          <mixed-citation id="mc-CR2" publication-type="journal">Catterall WA. Voltage gated sodium and calcium channels: discovery, structure, function, and pharmacology. Channels (Austin). 2023;17(1):2281714.<pub-id pub-id-type="pmid">37983307</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation-alternatives>
          <element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Splawski</surname><given-names>I</given-names></name><name><surname>Timothy</surname><given-names>KW</given-names></name><name><surname>Sharpe</surname><given-names>LM</given-names></name><name><surname>Decher</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Bloise</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism</article-title><source>Cell</source><year>2004</year><volume>119</volume><issue>1</issue><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15454078</pub-id>
</element-citation>
          <mixed-citation id="mc-CR3" publication-type="journal">Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119(1):19&#x2013;31.<pub-id pub-id-type="pmid">15454078</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation-alternatives>
          <element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Rajadhyaksha</surname><given-names>AM</given-names></name></person-group><article-title>L-type calcium channels and neuropsychiatric diseases: Insights into genetic risk variant-associated genomic regulation and impact on brain development</article-title><source>Channels (Austin)</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>2176984</fpage><pub-id pub-id-type="pmid">36803254</pub-id>
</element-citation>
          <mixed-citation id="mc-CR4" publication-type="journal">Baker MR, Lee AS, Rajadhyaksha AM. L-type calcium channels and neuropsychiatric diseases: Insights into genetic risk variant-associated genomic regulation and impact on brain development. Channels (Austin). 2023;17(1):2176984.<pub-id pub-id-type="pmid">36803254</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Herold KG, Hussey JW, Dick IE. CACNA1C-related channelopathies. Handb Exp Pharmacol. 2023</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation-alternatives>
          <element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><article-title>Structural biology of voltage-gated calcium channels</article-title><source>Channels (Austin)</source><year>2024</year><volume>18</volume><issue>1</issue><fpage>2290807</fpage><pub-id pub-id-type="pmid">38062897</pub-id>
</element-citation>
          <mixed-citation id="mc-CR6" publication-type="journal">Yao X, Gao S, Yan N. Structural biology of voltage-gated calcium channels. Channels (Austin). 2024;18(1):2290807.<pub-id pub-id-type="pmid">38062897</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation-alternatives>
          <element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>Timothy</surname><given-names>KW</given-names></name><name><surname>Underwood</surname><given-names>JFG</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Pa&#x219;ca</surname><given-names>SP</given-names></name></person-group><article-title>A cross-sectional study of the neuropsychiatric phenotype of CACNA1C-related disorder</article-title><source>Pediatr Neurol</source><year>2023</year><volume>138</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">36436328</pub-id>
</element-citation>
          <mixed-citation id="mc-CR7" publication-type="journal">Levy RJ, Timothy KW, Underwood JFG, Hall J, Bernstein JA, Pa&#x219;ca SP. A cross-sectional study of the neuropsychiatric phenotype of CACNA1C-related disorder. Pediatr Neurol. 2023;138:101&#x2013;6.<pub-id pub-id-type="pmid">36436328</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation-alternatives>
          <element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Tarnovskaya</surname><given-names>SI</given-names></name><name><surname>Kostareva</surname><given-names>AA</given-names></name><name><surname>Zhorov</surname><given-names>BS</given-names></name></person-group><article-title>L-Type calcium channel: predicting pathogenic/likely pathogenic status for variants of uncertain clinical significance</article-title><source>Membranes (Basel)</source><year>2021</year><volume>11</volume><issue>8</issue><fpage>599</fpage><pub-id pub-id-type="pmid">34436362</pub-id>
</element-citation>
          <mixed-citation id="mc-CR8" publication-type="journal">Tarnovskaya SI, Kostareva AA, Zhorov BS. L-Type calcium channel: predicting pathogenic/likely pathogenic status for variants of uncertain clinical significance. Membranes (Basel). 2021;11(8):599.<pub-id pub-id-type="pmid">34436362</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation-alternatives>
          <element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Arancibia</surname><given-names>F</given-names></name><name><surname>De Giorgis</surname><given-names>D</given-names></name><name><surname>Medina</surname><given-names>F</given-names></name><name><surname>Hermosilla</surname><given-names>T</given-names></name><name><surname>Simon</surname><given-names>F</given-names></name><name><surname>Varela</surname><given-names>D</given-names></name></person-group><article-title>Role of the CaV1.2 distal carboxy terminus in the regulation of L-type current</article-title><source>Channels (Austin)</source><year>2024</year><volume>18</volume><issue>1</issue><fpage>2338782</fpage><pub-id pub-id-type="pmid">38691022</pub-id>
</element-citation>
          <mixed-citation id="mc-CR9" publication-type="journal">Arancibia F, De Giorgis D, Medina F, Hermosilla T, Simon F, Varela D. Role of the CaV1.2 distal carboxy terminus in the regulation of L-type current. Channels (Austin). 2024;18(1):2338782.<pub-id pub-id-type="pmid">38691022</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation-alternatives>
          <element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Bamgboye</surname><given-names>MA</given-names></name><name><surname>Herold</surname><given-names>KG</given-names></name><name><surname>Vieira</surname><given-names>DCO</given-names></name><name><surname>Traficante</surname><given-names>MK</given-names></name><name><surname>Rogers</surname><given-names>PJ</given-names></name><name><surname>Ben-Johny</surname><given-names>M</given-names></name><etal/></person-group><article-title>CaV1.2 channelopathic mutations evoke diverse pathophysiological mechanisms</article-title><source>J Gen Physiol</source><year>2022</year><volume>154</volume><issue>11</issue><fpage>e202213209</fpage><pub-id pub-id-type="pmid">36167061</pub-id>
</element-citation>
          <mixed-citation id="mc-CR10" publication-type="journal">Bamgboye MA, Herold KG, Vieira DCO, Traficante MK, Rogers PJ, Ben-Johny M, et al. CaV1.2 channelopathic mutations evoke diverse pathophysiological mechanisms. J Gen Physiol. 2022;154(11): e202213209.<pub-id pub-id-type="pmid">36167061</pub-id>
</mixed-citation>
        </citation-alternatives>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">11932857</article-id><article-id pub-id-type="doi">10.3389/fonc.2025.1530144</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Integrating quantitative DCE-MRI parameters and radiomic features for improved IDH mutation prediction in gliomas</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ye</surname><given-names>Meiping</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x2020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2898671"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cao</surname><given-names>Zehong</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x2020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2957374"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Zhengyang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2553709"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Sixuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1808602"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jianan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2646481"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Huiquan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2759075"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Luan</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ming</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Chuanshuai</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/343257"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Tianyang</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shi</surname><given-names>Feng</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x2021;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/902305"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Xin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x2021;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1874774"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/445012"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Radiology, Affiliated Hospital of Medical School, Nanjing University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Institute of Medical Imaging and Artificial Intelligence, Nanjing University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Medical Imaging Center, Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Research and Development, United Imaging Intelligence</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Emma Gangemi, Sapienza University of Rome, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Andrea Bianconi, University of Genoa, Italy</p><p>Shiman Wu, Fudan University, China</p></fn><corresp id="fn001">*Correspondence: Xin Zhang, <email xlink:href="mailto:zhangxin@njglyy.com">zhangxin@njglyy.com</email>; Feng Shi, <email xlink:href="mailto:feng.shi@uii-ai.com">feng.shi@uii-ai.com</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x2020;These authors have contributed equally to this work</p></fn><fn fn-type="other" id="fn004"><p>&#x2021;Feng Shi and Xin Zhang jointly supervised this work</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>1530144</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#xA9; 2025 Ye, Cao, Zhu, Chen, Zhou, Yang, Li, Chen, Luan, Li, Tian, Sun, Shi, Zhang and Zhang</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Ye, Cao, Zhu, Chen, Zhou, Yang, Li, Chen, Luan, Li, Tian, Sun, Shi, Zhang and Zhang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objectives</title><p>To develop and validate a multiparametric prognostic model, incorporating dynamic contrast-enhanced (DCE) quantitative parameters and multi-modality radiomic features, for the accurate identification of isocitrate dehydrogenase 1 (IDH1) mutation status from glioma patients.</p></sec><sec><title>Methods</title><p>A total of 152 glioma patient data with confirmed IDH1 mutation status were retrospectively collected. A segmentation neural network was used to measure MRI quantitative parameters compared with the empirically oriented ROI selection. Radiomic features, extracted from conventional MR images (T1CE, T2W, and ADC), and DCE quantitative parameter images were combined with MRI quantitative parameters in our research to predict IDH1 mutation status. We constructed and analyzed Clinical Models 1&#x2013;2 (corresponding to manual and automatic MRI quantitative parameters), Radiomic Feature Models 1&#x2013;3 (corresponding to structural MRI, DCE, and multi-modality respectively), and a Multivariable Combined Model. We tried different usual classifiers and selected logistic regression according to AUC. Fivefold cross-validation was applied for validation.</p></sec><sec><title>Results</title><p>The Multivariable Combined Model showed the best prediction performance (AUC, 0.915; 95% CI: 0.87, 0.96) in the validation cohort. The Multivariable Combined Model performed better than Clinical Model 1 and Radiomic Feature Model 1 (DeLong all p &lt; 0.05), and Radiomic Feature Model 3 performed better than Radiomic Feature Model 1 (DeLong p &lt; 0.05).</p></sec><sec><title>Conclusions</title><p>Compared with the conventional MRI Radiomics and Clinical Models, the Multivariable Combined Model, mainly based on DCE quantitative parameters and multi-modality Radiomics features, is the most promising and deserves attention in the current study.</p></sec></abstract><kwd-group><kwd>glioma</kwd><kwd>dynamic contrast enhanced</kwd><kwd>quantitative parameter</kwd><kwd>radiomics</kwd><kwd>logistic regression</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82330059, 82271965, 82302172); the National Science and Technology Innovation 2030 - Major program of &#x201C;Brain Science and Brain-Like Research&#x201D; (2022ZD0211800); General Project Supported by Medical Science and technology development Foundation; Nanjing Department of Health (YKK22083, YKK23103); the Jiangsu Funding Program for Excellent Postdoctoral Talent (2022ZB694); and Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-LCYJ-PY-15, 2022-LCYJ-MS-03, 2021-LCYJ-PY-36, 2022-LCYJ-MS-25, 2021-LCYJ - PY -20). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="50"/><page-count count="11"/><word-count count="5097"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Imaging and Image-directed Interventions</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Glioma is the most common primary brain tumor, with its most frequent subtype glioblastoma, in particular, being one of the deadliest types of cancer. Brain tumors typically exhibit numerous genetic mutations, spanning several cellular pathways, that open multiple avenues to oncogenesis that no single intervention could conceivably block. The inclusion of mandatory molecular markers for diagnosis in the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) was revised in 2021 (<xref rid="B1" ref-type="bibr">1</xref>), which has made a more rigid definition of prognostically distinct entities. Variations in glioma survival and response to therapy are ascribed to genetic and histological characteristics, particularly the degree of isocitrate dehydrogenase (IDH) mutation, the presence of 1p/19q co-deletion, and the tumor grade (<xref rid="B2" ref-type="bibr">2</xref>&#x2013;<xref rid="B4" ref-type="bibr">4</xref>). IDH is the most critical prognostic marker, and the prognostic value of many other molecular markers (such as 1p/19q codeletion, TERT promoter mutation, and ATRX loss) depends on IDH (<xref rid="B5" ref-type="bibr">5</xref>), whose mutation is a positive prognostic factor. The product of the mutated IDH genes, d-2-hydroxyglutarate (D-2-HG), can induce global DNA hypermethylation and interfere with the immune system, thereby stimulating tumor growth (<xref rid="B6" ref-type="bibr">6</xref>). Previous studies have shown that the IDH1 status was the most prominent single prognostic factor (RR 2.7; 95% CI 1.6&#x2013;4.5) followed by age, histological diagnosis, and MGMT (<xref rid="B7" ref-type="bibr">7</xref>). The survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. IDH1 mutant malignant astrocytomas are more amenable to surgical resection (<xref rid="B8" ref-type="bibr">8</xref>), and IDH1 mutation is associated with improved resection rates, progression-free survival, and overall survival (<xref rid="B9" ref-type="bibr">9</xref>). IDH inhibitors play a crucial role in the targeted therapy of gliomas and are one of the key types of drugs for glioma-targeted treatment. Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to reduce D-2-HG levels and induce cellular differentiation in preclinical models (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). The phase III INDIGO trial has demonstrated that vorasidenib is superior to placebo in patients with non-enhancing grade 2 IDH-mutated gliomas after surgery (<xref rid="B12" ref-type="bibr">12</xref>). IDH mutations can affect tumor immunogenicity leading to the generation of neoantigens and changes in tumor-associated antigens (<xref rid="B13" ref-type="bibr">13</xref>). Second, they can shape the tumor microenvironment creating an immunosuppressive microenvironment and promoting tumor angiogenesis, which provides favorable conditions for tumor cells to escape immune surveillance (<xref rid="B14" ref-type="bibr">14</xref>). IDH mutations can influence immunotherapy targets through epigenetic regulation and can serve as biomarkers for predicting the efficacy of glioma immunotherapy (<xref rid="B15" ref-type="bibr">15</xref>).</p>
      <p>The IDH genotype can be detected by surgery or biopsy, but it suffers from several drawbacks such as invasive operation, sampling error, tumor heterogeneities, and risk of surgical complications. Thus, it is essential to find a non-invasive technique. Conversely, magnetic resonance imaging (MRI), with its non-invasive, rapid, and extensive detection capabilities, and excellent resolution of soft tissue, is considered the most promising option to support clinical practice decisions (<xref rid="B16" ref-type="bibr">16</xref>). Numerous researches have investigated the possibility of using MRI-based Radiomics analysis to noninvasively facilitate the evaluation of prognosis, molecular subtyping, and tumor grading in gliomas (<xref rid="B17" ref-type="bibr">17</xref>&#x2013;<xref rid="B22" ref-type="bibr">22</xref>). The pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to non-invasively predict the microvascular characteristics of tumor (<xref rid="B23" ref-type="bibr">23</xref>), and assess tumor characteristics and stage, providing independent prognostic indicators and enabling risk stratification for cancer patients (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Although DCE biomarkers have been validated through various reference methods and utilized for the assessment of a wide range of tumors, including gliomas (<xref rid="B26" ref-type="bibr">26</xref>), breast cancer (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>), and prostate cancer (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>), the process of manually segmenting DCE to extract image features is time consuming and prone to errors, and adversely impacts reproducibility, which is a significant issue in clinical applications, especially in longitudinal studies. The latest progresses in artificial intelligence (AI), especially deep learning, have demonstrated promising potential for dealing with these challenges (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Trained on extensive datasets of annotated MRI scans, deep learning models are capable of automating the segmentation process (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). They not only bring about speed and high efficiency but also hold the prospect of minimizing human errors. However, integrating deep learning into clinical practice poses numerous technical challenges (such as the need for large, diverse training datasets and the management of imaging variability), as well as broader concerns regarding algorithm validation, integration into clinical workflows, and ethical considerations. To our knowledge, as of now, the research on predicting and evaluating IDH gene typing using a combination of DCE perfusion parameters and radiomic features through machine learning methods has not been explored in the literature. We hope to apply deep learning to mine and analyze glioma imaging data aiming to improve clinical decision making and patient care.</p>
      <p>In this study, we proposed a fully automated method to predict IDH1 mutation in patients with glioma, requiring no user intervention, and proving highly suitable for clinical practice. We employed two methods, manual delineation of regions of interest and fully automated volume segmentation to extract apparent dispersion coefficient (ADC) and DCE perfusion parameters from the tumor core. The Radiomic features were extracted within the tumor core by the fully automated segmentation from DCE quantitative parameter images, ADC, T1CE, and T<sub>2</sub>W. Based on these features and parameters, we all constructed two clinical models, three Radiomic feature models, and a Multivariable Combined Model. We evaluated and compared the stability and predictive performance of these models for IDH genotyping and selected the most promising one.</p>
    </sec>
    <sec sec-type="materials|methods" id="s2">
      <title>Materials and methods</title>
      <p>This retrospective study was approved by the Research Ethics Committee of the Affiliated Nanjing Drum Tower Hospital of Nanjing University and performed in accordance with the Declaration of Helsinki.</p>
      <sec id="s2_1">
        <title>Patients</title>
        <p>Patients were retrospectively enrolled from our hospital between January 2018 and December 2022. The requirement for informed consent was waived due to the retrospective nature of this research. The patient enrollment process is shown in <xref rid="f1" ref-type="fig">
<bold>Figure&#xA0;1</bold>
</xref>. The exclusion criteria were as follows: (1) incomplete images, (2) poor image quality with severe motion or artifacts, and (3) DCE data post-processing failure. According to the above criteria, 152 patients [mean age, 56 years; age range, 22&#x2013;76 years; 42 women (47.3%); IDH1 status (64 mutations and 88 wild type)] were recruited in this research.</p>
        <fig position="float" id="f1">
          <label>Figure&#xA0;1</label>
          <caption>
            <p>Flowchart of patient inclusion and exclusion.</p>
          </caption>
          <graphic xlink:href="fonc-15-1530144-g001" position="float"/>
        </fig>
      </sec>
      <sec id="s2_2">
        <title>Image</title>
        <p>MRI in the enrolled patients was performed on the same 3.0-T system (uMR790, United Imaging Healthcare, Shanghai, China) using a 32-channel phased-array head coil. All patients underwent the same MRI protocol including the following sequences: DWI, T<sub>1</sub>WI, T<sub>2</sub>WI, T<sub>1</sub>CE, and DCE. The DCE sequences consisted of T1 mapping and dynamic scan. For T1 mapping, variable flip-angle scans with flip angles FA 5&#xB0;, 10&#xB0;, 15&#xB0; were acquired and used. Dynamic scan was a T1-gradient echo sequence with the following technical parameters: time of echo, 3.47 ms; time of repetition, 1.9 ms; flip angle, 13&#xB0;; matrix size, 160 &#xD7; 160; field of view, 240 &#xD7; 220 mm<sup>2</sup>; slice thickness, 5 mm. A series of 1,800 images at 90 dynamic phases for 20 axial sections were obtained with a temporal resolution of 4 s for each dynamic phase. The contrast agent (Gadovist, 1 mmol/ml, Bayer Healthcare, Berlin, Germany) was administered (0.1 mmol/kg of bodyweight) through the antecubital vein via a power injector at a rate of 2 ml/s. The protocol details of the morphological sequences (DWI, T<sub>1</sub>WI, T<sub>2</sub>WI, and T<sub>1</sub>CE) are summarized in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S1</bold>
</xref>. The quality of the sequences was assessed by two experienced neuroradiologists (Meiping Ye and SiXuan Chen), with more than 5 years of experience in neuro-oncological radiology.</p>
      </sec>
      <sec id="s2_3">
        <title>Tumor automatic segmentation</title>
        <p>In this study, we used the VB-Net (<xref rid="B35" ref-type="bibr">35</xref>), a segmentation neural work, to obtain the region of interest (the tumor core) according to T<sub>1</sub>CE and T<sub>2</sub>WI. The VB-Net is a modified 3D convolutional neural network, which combines V-Net with innovative bottleneck structures and computes much faster than V-Net (<xref rid="B36" ref-type="bibr">36</xref>). VB-Net, which has been published, is an advanced adaptation of the segmentation-centric V-Net architecture. The improvements in VB-Net include the replacement of traditional convolutional layers in the down- and upsampling modules with a bottleneck structure. This bottleneck structure is designed to optimize parameter efficiency and is composed of three sequential convolutional layers: the first with a kernel size of 1 &#xD7; 1 &#xD7; 1, the second with 3 &#xD7; 3 &#xD7; 3, and the third reverting back to 1 &#xD7; 1 &#xD7; 1. This arrangement reduces redundancy and improves computational efficiency while maintaining performance integrity. Furthermore, VB-Net employs a cascaded framework tailored to accommodate varying regions of interest (ROIs) with multiple sizes. This adaptability ensures its suitability for diverse segmentation tasks providing robust and accurate results. For loss function optimization and enhanced model training, VB-Net integrates a combination of common Dice loss, pixel-class cross-entropy loss, and focal loss. This multi-faceted loss strategy ensures a well-constrained parameter update process contributing to the overall stability and performance of the network. As far as we know, the VB-Net has been successfully applied to the segmentation of multiple organs and lesions in previous researches (<xref rid="B37" ref-type="bibr">37</xref>&#x2013;<xref rid="B39" ref-type="bibr">39</xref>).</p>
        <p>In the segmentation model construction phase, we exclusively used 1,000 cases (comprising T<sub>1</sub>CE and T<sub>2</sub>WI) from the public BraTs2021 dataset (<ext-link xlink:href="http://www.braintumorsegmentation.org" ext-link-type="uri">http://www.braintumorsegmentation.org</ext-link>) for training and validation, and 250 cases were used to test the model&#x2019;s performance. Additionally, we supplemented our analysis by incorporating a private dataset, which consisted of 204 T<sub>1</sub>CE images and 184 T<sub>2</sub>WI images. To construct the segmentation masks, we merged the labels from BraTS2021 based on the defined regions of interest, specifically targeting the whole tumor region in T<sub>2</sub>WI and the tumor core in T<sub>1</sub>CE. Notably, the thickness of all selected images was less than 1 mm ensuring high-resolution data for analysis. Regarding preprocessing, for the private dataset, we applied N4 bias field correction using the SimpleITK package. Subsequently, the T<sub>1</sub>CE images were spatially aligned with the T<sub>2</sub>WI image spacing using the ANTs tool. Finally, all image intensities were normalized to the range [&#x2212;1, 1] enabling consistency across all input data. These preprocessing steps were critical in mitigating imaging artifacts and ensuring uniformity between datasets. Given the distinctions between the two segmentation tasks - whole tumor segmentation in T<sub>2</sub>WI and tumor core segmentation in T<sub>1</sub>CE - separate models were constructed for each. The segmentation models were evaluated using the Dice similarity coefficient (DSC). The DSC of the whole tumor segmentation model in BraTS2021 is 0.83 and 0.70 in the private dataset. Meanwhile, the DSC of the tumor core segmentation model in BraTS2021 is 0.72 and 0.85 in the private dataset. <xref rid="f2" ref-type="fig">
<bold>Figure&#xA0;2</bold>
</xref> shows examples of automated segmentation and co&#x2010;registration with other sequences.</p>
        <fig position="float" id="f2">
          <label>Figure&#xA0;2</label>
          <caption>
            <p>Examples of the automated segmentation and co&#x2010;registration with other sequences. <bold>(a)</bold> a case of glioblastoma. The lesion showed obvious enhancement, and tumor core was automatically segmented based on T1CE. <bold>(b)</bold> a case of diffuse astrocytoma (WHO 2 grade, IDH1-mut). The lesion showed no obvious enhancement, and tumor core was automatically segmented based on T<sub>2</sub>WI.</p>
          </caption>
          <graphic xlink:href="fonc-15-1530144-g002" position="float"/>
        </fig>
      </sec>
      <sec id="s2_4">
        <title>Region of interest analysis and quantitative MRI parameter acquirement</title>
        <p>DCE-MRI data were imported into the United Imaging post-processing workstation for processing (United Imaging Healthcare, Shanghai, China). Arterial input functions were extracted in a manual manner, with the ROI positioned in the middle cerebral artery (<xref rid="B40" ref-type="bibr">40</xref>). Five quantitative pharmacokinetic DCE-MRI parameters (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC) were acquired using the improved Tofts&#x2013;Kermode two&#x2010;compartment model.</p>
        <p>Two kinds of sketching methods of ROI, manual delineation and automatic segmentation, were applied to obtain regional-DCE parameters in our research. For the manual way, first, the quantitative MRI parameter maps (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, iAUC, and ADC maps) were fused with the structural MRI (T1CE or T<sub>2</sub>WI) in the workstation. Then, three manual circular-like ROIs among 20&#x2013;40 mm<sup>2</sup> were drawn by two experienced neuroradiologists (Z.Y.Z. and M.P.Y., with 3 and 8 years of experience in neoro-oncology imaging, respectively) on the significantly enhanced solid area of the tumor on T<sub>1</sub>CE (enhancing lesion), or the hyperintense region on T<sub>2</sub>WI in the central area of the tumor (non-enhancing lesion), at the axial slice with the maximum tumor area. The whole process avoided the peritumoral edema, hemorrhage, cysts, necrosis, calcification, and large vessels (<xref rid="B21" ref-type="bibr">21</xref>). The consistency of the MRI quantitative parameters averaging intensity above 3 ROIs from two neuro-radiologists was evaluated with the Intraclass Correlation Test. Under the condition of good consistency, the data extracted by the neuroradiologists with longer practice time prevailed. For the automatic way, the tumor core segmented by the neural network was consider as the ROI for calculating DCE perfusion parameters and ADC. Then, we compared the MRI quantitative parameters (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, iAUC, and ADC), extracted by manual delineation and automatic segmentation, and clinical index (age) between IDH1-mut and IDH1-wt groups. Parameters with statistically significant differences between groups were selected for input the following prediction models.</p>
      </sec>
      <sec id="s2_5">
        <title>Radiomics feature extraction</title>
        <p>We used uAI Research Portal (Shanghai United Imaging Intelligence, Co., Ltd.) (<xref rid="B41" ref-type="bibr">41</xref>) to extract features from 3D-ROI of automatic segmentation. The uAI Research Portal is a clinical research platform and implemented by Python programming language (version 3.12.1, <ext-link xlink:href="https://www.python.org" ext-link-type="uri">https://www.python.org</ext-link>). The widely used package-PyRadiomics (<ext-link xlink:href="https://pyradiomics.readthedocs.io/en/latest/index.html" ext-link-type="uri">https://pyradiomics.readthedocs.io/en/latest/index.html</ext-link>) was embedded into this platform. The pre-processing of feature extraction included bias field correction, skull stripping, resampling, intensity normalization, and feature normalization. Specifically, the MRI images were resampled to the same spatial resolution, 1&#xD7; 1 &#xD7; 1 mm<sup>3</sup>, and the intensity values of each image were linearly normalized into the range [&#x2212;1, 1]. The Radiomics features were computed from 3D-ROIs based on PyRadiomics. A total of 2,552 features were extracted based on conventional MR images (T<sub>1</sub>CE, T<sub>2</sub>W, and ADC), and 14,220 features were extracted based on DCE parameter images (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC).</p>
      </sec>
      <sec id="s2_6">
        <title>Model construction and evaluation</title>
        <p>The basic setup for the model was a pipeline consisting of four components as follows: a standardizer using Z-score normalization, feature selection using selection operator (LASSO) and the maximum correlation and minimum redundancy method, oversampling using the synthetic minority oversampling technique (SMOTE), and a classifier using logistic regression. The Z-score normalization algorithm was first used to remove the limitations imposed by the units of each feature. Subsequently, the dimension of the features was reduced by lasso regression analysis, then the most relevant features were selected by the maximum correlation and minimum redundancy method. Finally, 7 features were selected from conventional MR Radiomic features (T<sub>1</sub>CE, T<sub>2</sub>W, and ADC), 5 features were selected from DCE Radiomic features (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC), and 9 features were selected from the combination of the abovementioned 12 two kinds of Radiomic features.</p>
        <p>In our research, we used six kinds of different model inputs for data training, including: (a) Clinical Model 1: age, six MRI quantitative parameters obtained by manual extraction; (b) Clinical Model 2: age, six MRI quantitative parameters obtained by automatic extraction; (c) Radiomic Feature Model 1: 7 features selected from conventional MR Radiomic features; (d) Radiomic Feature Model 2: 5 features selected from DCE Radiomic features; (e) Radiomic Feature Model 3: 9 features selected from the above 12 selected Radiomic features; (f) Multivariable Combined Model: 11 features selected from multi-modality features (the above 9 twice-selected Radiomic features, age, and six MRI quantitative parameters by automatic extraction). For maximizing Radiomics algorithm&#x2019;s discrimination, convolutional neural networks (CNN), recurrent neural network (RNN), K near neighbor (KNN), logistic regression (LR), random forest, decision tree, support vector machine (SVM), and Naive Bayes (NB) were implemented for model construction, respectively. Fivefold cross-validation was applied for validation. By trying different classifiers, we finally chose logistic regression according to a comparison of the classification results of the different models. The study workflow is depicted in <xref rid="f3" ref-type="fig">
<bold>Figure&#xA0;3</bold>
</xref>.</p>
        <fig position="float" id="f3">
          <label>Figure&#xA0;3</label>
          <caption>
            <p>A study flow chart for predicting IDH1 mutation in gliomas. Firstly, Region of interest (ROIs) covering the tumor core was delineated according to T1CE or T<sub>2</sub>WI. Secondly, 16472 Radiomic features were totally extracted, seven features from conventional MR Radiomic features (T1CE, T<sub>2</sub>WI, ADC) and five features from DCE Radiomic features (K<sub>trans</sub>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC) were selected among them. Thirdly, two kinds of methods, manual delineation and automatic segmentation, were tried to obtain quantitative MRI parameters. Those parameters with differences between IDH1-mut and IDH1-wt groups were selected to input the following prediction models. Lastly, six models were constructed, the best classifier was selected by trying different usual classifiers and five-fold cross-validation was applied for validation. We compared the classification performance and selected the promising one among these six prediction models.</p>
          </caption>
          <graphic xlink:href="fonc-15-1530144-g003" position="float"/>
        </fig>
      </sec>
      <sec id="s2_7">
        <title>Statistical analysis</title>
        <p>Python (version 3.12.1, <ext-link xlink:href="https://www.python.org" ext-link-type="uri">https://www.python.org</ext-link>). was used for data analyses and visualization in this study. Categorical variables were subjected to Chi-square testing, while continuous variables were analyzed using either the independent samples t-test or the Mann&#x2013;Whitney U test, depending on their distribution characteristics. The intraclass correlation coefficient (ICC) was used to determine the intraobserver and interobserver agreement of ADC and DCE parameters. One&#x2010;way analysis of variance (ANOVA) and Bonferroni <italic>post&#x2010;hoc</italic> tests were used to test the differences in age and MRI quantitative parameters among groups. Values of p less than 0.05 indicated statistical significance. The diagnostic performance of the classification model was measured in terms of accuracy, area under the receiver operating characteristic curve (AUC), using the &#x201C;PRROC&#x201D; R package. The 95% confidence interval (CI) of the AUC was calculated from 2,000 iterations of bootstrapping with the predicted probabilities from the models. The probability threshold for the accuracy calculation was set to 0.5. Thus, a predicted probability of &#x2265;0.5 was classified as an IDH mutation, and other values were classified as IDH wild type. To maximize the recognition rate of the Radiomics algorithm, multiple methods were used to construct models, respectively, such as the Convolutional Neural Network (CNN) and Logistic Regression (LR). The optimal cutoff was determined using Youden&#x2019;s index. AUC comparisons were performed between the various models using Delong&#x2019;s method. We mainly referred to the AUC value to compare the prediction performance of different common classifiers. Finally, we selected LR as the final classifier to compare the performance of different model inputs. Fivefold cross-validation was adopted to ensure the robustness and reliability of these models.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <sec id="s3_1">
        <title>Clinical characteristics</title>
        <p>The baseline demographics and clinical characteristics of the study participants are summarized in <xref rid="T1" ref-type="table">
<bold>Table&#xA0;1</bold>
</xref>. One hundred and fifty-two patients (55.8 &#xB1; 12.0 years; 79 females and 73 males) were included in this retrospective research, including 64 IDH-mutant (IDH1-mut) and 88 IDH1-wild type (IDH1-wt). The study participants were divided into two groups based on IDH1 gene status. Age was statistically significant between groups. For manual delineation, ADC value, K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC were statistically significant between groups. As for automatic segmentation, K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC were statistically significant between groups.</p>
        <table-wrap position="float" id="T1">
          <label>Table&#xA0;1</label>
          <caption>
            <p>Clinical features of patients in the IDH-mut and IDH1-wild groups.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="top" rowspan="2" align="left" colspan="1">Variables</th>
                <th valign="top" colspan="2" align="center" rowspan="1">IDH1 status</th>
                <th valign="top" rowspan="2" align="left" colspan="1">p-Value<sup>*</sup>
</th>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">IDH1-wt type</th>
                <th valign="top" align="left" rowspan="1" colspan="1">IDH1-mut</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">60.88 &#xB1; 8.70</td>
                <td valign="top" align="left" rowspan="1" colspan="1">48.81 &#xB1; 12.46</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt; 0.001</td>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Gender</th>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1">0.225</th>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;Female, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">38 (43.2)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">34 (53.1)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;Male, no. (%)</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">50 (56.8)</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">30 (46.9)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Histology</th>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1">NA</th>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;Glioblastoma, IDH-wild, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">88 (100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;Astrocytoma, IDH-mut, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">45 (70)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;Oligodendroglioma, IDH-mut, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">19 (30)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Grade</th>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1">NA</th>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;G2, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">32 (50)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;G3, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">16 (25)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;G4, no. (%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">88 (100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">16 (25)</td>
                <td valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Automatic segmentation</th>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;ADC<sub>0,1000</sub> (mm<sup>2</sup>/s)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">1,206.37 &#xB1; 224.08</td>
                <td valign="top" align="left" rowspan="1" colspan="1">1,229.56 &#xB1; 269.00</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.564</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;K<sup>trans</sup> (/min/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">68.82 (49.42, 93.15)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">31.99 (13.53, 52.93)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;K<sub>ep</sub> (/min/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">338.15 (279.00, 422.31)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">572.04 (355.92, 1433.20)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;V<sub>e</sub> (/100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">238.23 (171.37, 353.27)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">68.32 (17.36, 164.70)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;V<sub>p</sub> (ml/100 g/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">4.59 (2.47, 8.67)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">2.85 (1.53, 6.25)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.004</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;iAUC (minmmol/L/100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">20.99 (15.42, 29.60)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">8.24 (3.36, 15.38)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Manual delineation</th>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
                <th valign="top" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;ADC<sub>0,1000</sub> (mm<sup>2</sup>/s)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">1,009.30 &#xB1; 217.37</td>
                <td valign="top" align="left" rowspan="1" colspan="1">1,156.06 &#xB1; 283.11</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;K<sup>trans</sup> (/min/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">74.45 (48.55, 105.85)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">29.05 (11.40, 55.23)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;K<sub>ep</sub> (/min/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">342.95 (235.40, 507.03)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">729.20 (358.78, 1750.28)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;V<sub>e</sub> (/100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">228.20 (139.70, 419.23)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">48.30 (12.20, 216.33)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;V<sub>p</sub> (ml/100 g/1,000)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">6.30 (1.65, 16.25)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">2.95 (1.10, 6.08)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.005</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;iAUC (minmmol/L/100)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">25.70 (19.13, 47.28)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">8.30 (3.43, 23.58)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">&lt; 0.001</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Data are presented as mean &#xB1; standard deviation, number with percentage in parentheses, or median with interquartile range in parentheses. *Calculated using chi-square test for categorical variables, either independent t test or Mann&#x2013;Whitney U test for continuous variables depending on their normality distribution. G2, grade 2; G3, grade 3; G4, grade 4; ADC<sub>0,1000</sub>, apparent diffusion coefficient, calculated based on b0 and b1000; K<sup>trans</sup>, volume transfer constant; K<sub>ep</sub>, rate constant between the extravascular extracellular space and blood plasma; V<sub>e</sub>, volume of extravascular/extracellular space per unit volume of tissue; V<sub>p</sub>, fractional blood plasma volume; iAUC, initial area under the curve.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3_2">
        <title>Radiomic feature extraction and feature selection</title>
        <p>A total of 2,552 features were extracted based on conventional MR images (T<sub>1</sub>CE, T<sub>2</sub>W, and ADC), and 14,220 features were extracted based on DCE parameter images (K<sup>trans</sup>, K<sub>ep</sub>, V<sub>e</sub>, V<sub>p</sub>, and iAUC). After applying logistic regression and the maximum correlation and minimum redundancy method, seven key Radiomic features were selected from conventional MR Radiomic features, and five features were selected from DCE Radiomic features.</p>
      </sec>
      <sec id="s3_3">
        <title>Model validation, evaluation, and comparison</title>
        <p>We mainly referred to the AUC value to compare the prediction performance among different usual classifiers. Finally, we selected LR as the final classifier to compare the performance of different model inputs. Five-old cross-validation was applied to ensure the robustness and reliability of these models. The results showed that the AUCs in the validation cohort of Clinical models 1&#x2013;2, Radiomic feature models 1&#x2013;3, and Multivariable Combined Model were 0.849 (95% CI: 0.79, 0.91), 0.881 (95% CI: 0.81, 0.91), 0.867 (95% CI: 0.81, 0.92), 0.906 (95% CI: 0.86, 0.95), 0.908 (95% CI: 0.86, 0.95), and 0.915 (95% CI: 0.87, 0.96), respectively. The accuracy in the validation cohort of the above models were 0.803, 0.849, 0.803, 0.836, 0.855 and 0.862, respectively. More details are summarized in <xref rid="T2" ref-type="table">
<bold>Table&#xA0;2</bold>
</xref>; <xref rid="f4" ref-type="fig">
<bold>Figure&#xA0;4</bold>
</xref>. The Multivariable Combined Model showed the best classification performance. There was no significant difference between Clinical Model 1 and Clinical Model 2, Radiomic Feature Model 2 and Radiomic Feature Model 1 in the validation cohort (DeLong p &gt; 0.05), whereas Radiomic Feature Model 3 performed better than Radiomic Feature Model 1 (DeLong p &lt; 0.05). Multivariable Combined Model performed better than Clinical Model 1 and Radiomic Feature Model 1 (DeLong p all &lt; 0.05). More details are summarized in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S2</bold>
</xref>.</p>
        <table-wrap position="float" id="T2">
          <label>Table&#xA0;2</label>
          <caption>
            <p>The classification performance of the different diagnostic models.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Models</th>
                <th valign="top" align="left" rowspan="1" colspan="1">Features (no.)</th>
                <th valign="top" align="left" rowspan="1" colspan="1">Cohort</th>
                <th valign="top" align="left" rowspan="1" colspan="1">AUC</th>
                <th valign="top" align="left" rowspan="1" colspan="1">ACC</th>
                <th valign="top" align="left" rowspan="1" colspan="1">SEN</th>
                <th valign="top" align="left" rowspan="1" colspan="1">SPE</th>
                <th valign="top" align="left" rowspan="1" colspan="1">F1-score</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Clinical Model 1</td>
                <td valign="top" rowspan="2" align="left" colspan="1">7</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.871</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.829</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.719</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.909</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.780</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.849</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.803</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.688</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.886</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.739</td>
              </tr>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Clinical Model 2</td>
                <td valign="top" rowspan="2" align="left" colspan="1">7</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.893</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.847</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.734</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.929</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.802</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.881</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.849</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.703</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.932</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.790</td>
              </tr>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Radiomic Feature Model 1</td>
                <td valign="top" rowspan="2" align="left" colspan="1">7</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.884</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.816</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.734</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.875</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.770</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.867</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.803</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.719</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.864</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.748</td>
              </tr>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Radiomic Feature Model 2</td>
                <td valign="top" rowspan="2" align="left" colspan="1">5</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.908</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.842</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.809</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.867</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.812</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.906</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.836</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.797</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.864</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.802</td>
              </tr>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Radiomic Feature Model 3</td>
                <td valign="top" rowspan="2" align="left" colspan="1">9</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.914</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.862</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.801</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.906</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.830</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.908</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.855</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.781</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.909</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.814</td>
              </tr>
              <tr>
                <td valign="top" rowspan="2" align="left" colspan="1">Multivariable Combined Model</td>
                <td valign="top" rowspan="2" align="left" colspan="1">11</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Training</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.917</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.857</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.789</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.906</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.823</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Validation</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.915</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.862</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.797</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.909</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.824</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>AUC, area under the curve; ACC, accuracy; SEN, sensitivity; SPE, specificity.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" id="f4">
          <label>Figure&#xA0;4</label>
          <caption>
            <p>Evaluation of the different diagnosis model. <bold>(a)</bold> Decision curve analysis for six diagnosis models, the x-axis represents the threshold probability, and the y-axis measures the net benefit. <bold>(b)</bold> the ROC curve of different diagnosis model in the validation cohort. <bold>(c)</bold> the calibration curves for assessment of the clinical diagnosis models.</p>
          </caption>
          <graphic xlink:href="fonc-15-1530144-g004" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <p>We developed and validated a multiparametric prognostic model to predict IDH mutation status in glioma using MR Radiomics features combined with clinical factor (age) and MRI quantitative parameters (DCE and ADC), which showed improved performance over the model using only conventional MRI or mono-modality radiomic features. Compared with the independent Radiomics and Clinical Models, the Multivariable Combined Model could be the most promising, and in the current study, its advantages are deserved for attention. First, we provided a binary classifier to preoperatively predict IDH mutation of glioma with satisfactory performance. Second, our model made full use of DCE quantitative parameters and their Radiomics features to explore the value of MRI perfusion imaging in predicting IDH-mut glioma. Third, we compared the differences between MRI quantitative parameters extracted by manual 2D-ROI and automatic 3D- ROI.</p>
      <p>The IDH1/2 mutation plays a crucial role in glioma in glioma diagnosis, treatment, and prognosis (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Previous studies have shown that IDH1/2 gene mutation can cause &#x3B1;-ketoglutaric acid reduction and 2-hydroxyglutaric acid increase, indirectly affect angiogenesis, hypoxia stress, cell maturation and differentiation, and other physiological and pathological processes, and interfere with the expression of vascular endothelial growth factor and other tumor-related genes (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Lusien et&#xA0;al. (<xref rid="B45" ref-type="bibr">45</xref>) concluded that gliomas with different IDH genotypes had unique vascular gene expression patterns related to vascular remodeling. Yue Hu et&#xA0;al. (<xref rid="B46" ref-type="bibr">46</xref>) showed that IDH1-wt gliomas expressed significantly higher vascular endothelial growth factor (VEGF) expression and perfusion metrics in contrast to IDH-mut gliomas. Multiple studies have shown that perfusion features obtained by perfusion-weighted MRI could predict glioma survival/progression and the critical tumor characteristics of glioma such as genetic mutations (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Yue Hu et&#xA0;al. (<xref rid="B46" ref-type="bibr">46</xref>) demonstrated that histogram analysis of DCE-MRI could non-invasively predict IDH mutation. In addition, histogram DCE-MRI also showed good diagnostic performance in predicting O6-methylguanine-DNA methyltransferase (MGMT), telomere reverse transcriptase (TERT), and evaluating the prognosis of glioma (<xref rid="B49" ref-type="bibr">49</xref>). These insights in phenotype and genotype account for the application of perfusion MRI to predict IDH mutation. It is also valuable and persuasive to use multi-modality Radiomic features including DCE to predict IDH genotype.</p>
      <p>Zhang et&#xA0;al. found that the histogram DCE-MRI demonstrated good diagnostic performance in identifying IDH1 mutation (<xref rid="B49" ref-type="bibr">49</xref>). We found that the values of K<sup>trans</sup>, V<sub>e</sub>, and iAUC in IDH wild-type gliomas were higher than those of IDH mutant gliomas, and the values of K<sub>ep</sub> were lower than those of IDH mutant gliomas. Furthermore, the difference between groups of ADC values obtained by automatic extraction was inconsistent with manual extraction, which should be related to the heterogeneity of gliomas and the delineated area of ROI. Ignoring this difference, we included six quantitative MRI parameters and age to predict glioma IDH mutation in two clinical models. We hope to explore the effect of MRI quantitative parameters obtained by two different ROI extraction methods on the prediction of IDH mutation in clinical models. We found that the AUC of Clinical Model 2 (automatic extraction) was higher than that of Clinical Model 1 (manual extraction) in the testing cohort (DeLong p &gt; 0.05). We consider that the influence of different ROI sketching methods on quantitative MRI studies could be ignored.</p>
      <p>In the following research, we constructed three Radiomic feature models and one Multivariable Combined Model. We found that the classification performance of the Radiomic feature model of DCE quantitative parameters was higher than the model of traditional MRI image features (DeLong p &gt; 0.05), and lower than the combination model of these two kinds of Radiomic features (DeLong p &gt; 0.05). Among these models, the Multivariable Combined Model showed the best classification performance. We considered the quantitative MRI parameters may not have obvious influence on the classification results of the Multivariable Combined Model, and the difference between the model of Radiomic features and the model of quantitative MRI parameters was not significant (p &gt; 0.05). The AUC of the Multivariable Combined Model in testing cohort was 0.915 and the accuracy was 0.862, which deserved people&#x2019;s concern while comparing with previous researches. Wang et&#xA0;al. found the Radiomics model based on DCE-MRI and DWI had a considerable effect on the evaluation of IDH1 mutation (<xref rid="B50" ref-type="bibr">50</xref>), and the AUC and accuracy of the combined model in testing cohort was 0.909,0.833 separately. Hitherto, there are no studies focusing on the estimation of IDH1 mutation using the Radiomics analysis of DCE-MRI and quantitative MRI parameters of DCE. In addition, 3D-ROI was also used in this study to automatically segment the entire lesion and extract DCE quantitative parameters, which was not been tried in previous studies. Our study demonstrated that the LR model based on multivariable combined parameters showed good diagnostic performance in estimating IDH1 mutation in gliomas.</p>
      <p>The present study has several limitations. First, the study was retrospective, limited radiomic features restricted further improvement of the model performance. Second, the radiomic model may not perform well in multi-centered and future applications because to the sensitivity of radiomic characteristics to parameters and systems. Our next research topic is multicenter radiomic, whose harmonization can improve the generalizability of the model. Third, the time-consuming, multi-staged workflow discourages the application of the Multivariable Combined Model in clinical practice. In conclusion, we developed and validated a multiparametric prognostic model to predict IDH mutation status in glioma using MR Radiomics features combined with clinical factor and MRI quantitative parameters, which showed improved performance over the model using only conventional MRI or Radiomic features.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <title>Abbreviations</title>
      <fn fn-type="abbr" id="abbrev1">
        <p>DCE, dynamic contrast enhanced; IDH1, isocitrate dehydrogenase 1; LR, logistic regression; AUC, area under the receiver operating characteristic curve; TERT, telomerase reverse transcriptase; ATRX, alpha thalassemia retardation syndrome X-linked; MRI, magnetic resonance imaging; ROI, region of interest; ADC, apparent dispersion coefficient.</p>
      </fn>
    </fn-group>
    <sec sec-type="data-availability" id="s5">
      <title>Data availability statement</title>
      <p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
    </sec>
    <sec sec-type="ethics-statement" id="s6">
      <title>Ethics statement</title>
      <p>The studies involving humans were approved by the Medical Ethics Committee of the Affiliated Drum Tower Hospital of Medical School, Nanjing University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
    </sec>
    <sec sec-type="author-contributions" id="s7">
      <title>Author contributions</title>
      <p>MY: Data curation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. ZC: Data curation, Formal analysis, Methodology, Software, Supervision, Validation, Visualization, Writing &#x2013; review &amp; editing. ZZ: Conceptualization, Data curation, Formal analysis, Writing &#x2013; review &amp; editing. SC: Data curation, Formal analysis, Writing&#xA0;&#x2013;&#xA0;review &amp; editing. JZ: Data curation, Formal analysis, Writing &#x2013; review &amp; editing. HY: Conceptualization, Formal analysis, Writing &#x2013; review &amp; editing. XL: Data curation, Formal analysis, Writing &#x2013; review &amp; editing. QC: Data curation, Formal&#xA0;analysis, Writing &#x2013; review &amp; editing. WL: Data curation, Writing &#x2013; review &amp; editing. ML: Data curation, Writing &#x2013; review &amp; editing. CT: Data curation, Writing &#x2013; review &amp; editing. TS: Methodology, Software, Writing &#x2013; review &amp; editing. FS: Conceptualization, Formal analysis, Methodology, Software, Supervision, Validation, Writing &#x2013; review &amp; editing. XZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Writing &#x2013; review &amp; editing. BZ: Conceptualization, Funding acquisition, Resources, Writing &#x2013; review &amp; editing.</p>
    </sec>
    <sec sec-type="COI-statement" id="s9">
      <title>Conflict of interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
    <sec sec-type="ai-statement" id="s10">
      <title>Generative AI statement</title>
      <p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
    </sec>
    <sec sec-type="disclaimer" id="s11">
      <title>Publisher&#x2019;s note</title>
      <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
    </sec>
    <sec sec-type="supplementary-material" id="s12">
      <title>Supplementary material</title>
      <p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2025.1530144/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fonc.2025.1530144/full#supplementary-material</ext-link>
</p>
      <supplementary-material id="SM1" position="float" content-type="local-data">
        <media xlink:href="DataSheet1.docx"/>
      </supplementary-material>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Cree</surname><given-names>IA</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The 2021 WHO classification of tumors of the central nervous system: a summary</article-title>. <source>Neuro-Oncology</source>. (<year>2021</year>) <volume>23</volume>:<page-range>1231&#x2013;51</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/noab106</pub-id>
</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iorgulescu</surname><given-names>JB</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Neff</surname><given-names>C</given-names></name><name><surname>Cioffi</surname><given-names>G</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Kruchko</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States</article-title>. <source>Neuro-Oncology</source>. (<year>2022</year>) <volume>24</volume>:<fpage>1989</fpage>&#x2013;<lpage>2000</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/noac113</pub-id>
<pub-id pub-id-type="pmid">35460555</pub-id>
</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>JJ</given-names></name><name><surname>Gonzalez Castro</surname><given-names>LN</given-names></name><name><surname>McBrayer</surname><given-names>S</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Cloughesy</surname><given-names>T</given-names></name><name><surname>Portnow</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions</article-title>. <source>Neuro Oncol</source>. (<year>2023</year>) <volume>25</volume>:<fpage>4</fpage>&#x2013;<lpage>25</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/noac207</pub-id>
<pub-id pub-id-type="pmid">36239925</pub-id>
</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kong</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Thin-slice magnetic resonance imaging-based radiomics signature predicts chromosomal 1p/19q co-deletion status in grade II and III gliomas</article-title>. <source>Front Neurol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>551771</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fneur.2020.551771</pub-id>
<pub-id pub-id-type="pmid">33192984</pub-id>
</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berger</surname><given-names>TR</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Lang-Orsini</surname><given-names>M</given-names></name><name><surname>Chukwueke</surname><given-names>UN</given-names></name></person-group>. <article-title>World health organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: A review</article-title>. <source>JAMA Oncol</source>. (<year>2022</year>) <volume>8</volume>:<page-range>1493&#x2013;501</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2844</pub-id>
</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>Lowery</surname><given-names>MA</given-names></name><name><surname>Shih</surname><given-names>AH</given-names></name><name><surname>Schvartzman</surname><given-names>JM</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Famulare</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition</article-title>. <source>Cancer Discovery</source>. (<year>2018</year>) <volume>8</volume>:<page-range>1540&#x2013;7</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0877</pub-id>
</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>C</given-names></name><name><surname>Hentschel</surname><given-names>B</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Capper</surname><given-names>D</given-names></name><name><surname>Felsberg</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas</article-title>. <source>Acta Neuropathol</source>. (<year>2010</year>) <volume>120</volume>:<page-range>707&#x2013;18</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/s00401-010-0781-z</pub-id>
</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beiko</surname><given-names>J</given-names></name><name><surname>Suki</surname><given-names>D</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Fox</surname><given-names>BD</given-names></name><name><surname>Cheung</surname><given-names>V</given-names></name><name><surname>Cabral</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>IDH1 mutant Malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection</article-title>. <source>Neuro Oncol</source>. (<year>2014</year>) <volume>16</volume>:<fpage>81</fpage>&#x2013;<lpage>91</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/not159</pub-id>
<pub-id pub-id-type="pmid">24305719</pub-id>
</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahmeti</surname><given-names>H</given-names></name><name><surname>Kiese</surname><given-names>D</given-names></name><name><surname>Freitag-Wolf</surname><given-names>S</given-names></name><name><surname>Kalab</surname><given-names>M</given-names></name><name><surname>R&#xF6;cken</surname><given-names>C</given-names></name><name><surname>Jansen</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas</article-title>. <source>J Neurooncol</source>. (<year>2024</year>) <volume>169</volume>:<page-range>423&#x2013;35</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/s11060-024-04743-x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Taylor</surname><given-names>JW</given-names></name><name><surname>Maher</surname><given-names>EA</given-names></name><name><surname>Arrillaga-Romany</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial</article-title>. <source>Nat Med</source>. (<year>2023</year>) <volume>29</volume>:<page-range>615&#x2013;22</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41591-022-02141-2</pub-id>
</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Penas-Prado</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>KB</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Maher</surname><given-names>EA</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial</article-title>. <source>Clin Cancer Res</source>. (<year>2021</year>) <volume>27</volume>:<page-range>4491&#x2013;9</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-0611</pub-id>
</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Blumenthal</surname><given-names>DT</given-names></name><name><surname>Touat</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>KB</given-names></name><name><surname>Clarke</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Vorasidenib in IDH1- or IDH2-mutant low-grade glioma</article-title>. <source>N Engl J Med</source>. (<year>2023</year>) <volume>389</volume>:<fpage>589</fpage>&#x2013;<lpage>601</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1056/NEJMoa2304194</pub-id>
<pub-id pub-id-type="pmid">37272516</pub-id>
</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>O</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name></person-group>. <article-title>IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review</article-title>. <source>Mol Oncol</source>. (<year>2024</year>) <volume>18</volume>:<page-range>2822&#x2013;41</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1002/1878-0261.13598</pub-id>
</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name></person-group>. <article-title>Advances in immune microenvironment and immunotherapy of isocitrate dehydrogenase mutated glioma</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>914618</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.914618</pub-id>
<pub-id pub-id-type="pmid">35769466</pub-id>
</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Glioma targeted therapy: insight into future of molecular approaches</article-title>. <source>Mol Cancer</source>. (<year>2022</year>) <volume>21</volume>:<fpage>39</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/s12943-022-01513-z</pub-id>
<pub-id pub-id-type="pmid">35135556</pub-id>
</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haubold</surname><given-names>J</given-names></name><name><surname>Hosch</surname><given-names>R</given-names></name><name><surname>Parmar</surname><given-names>V</given-names></name><name><surname>Glas</surname><given-names>M</given-names></name><name><surname>Guberina</surname><given-names>N</given-names></name><name><surname>Catalano</surname><given-names>OA</given-names></name><etal/></person-group>. <article-title>Fully automated MR based virtual biopsy of cerebral gliomas</article-title>. <source>Cancers</source>. (<year>2021</year>) <volume>13</volume>:<elocation-id>6186</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/cancers13246186</pub-id>
<pub-id pub-id-type="pmid">34944806</pub-id>
</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sha</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group>. <article-title>Prediction of the molecular subtype of IDH mutation combined with MGMT promoter methylation in gliomas via radiomics based on preoperative MRI</article-title>. <source>Cancers</source>. (<year>2023</year>) <volume>15</volume>:<fpage>1440</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/cancers15051440</pub-id>
<pub-id pub-id-type="pmid">36900232</pub-id>
</mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>F</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Diffusion tensor imaging-based machine learning for IDH wild-type glioblastoma stratification to reveal the biological underpinning of radiomic features</article-title>. <source>CNS Neurosci Ther</source>. (<year>2023</year>) <volume>29</volume>:<page-range>3339&#x2013;50</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1111/cns.14263</pub-id>
</mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>Y-H</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Hsu</surname><given-names>Y-C</given-names></name><etal/></person-group>. <article-title>Convolutional neural network to predict IDH mutation status in glioma from chemical exchange saturation transfer imaging at 7 Tesla</article-title>. <source>Front Oncol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1134626</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fonc.2023.1134626</pub-id>
<pub-id pub-id-type="pmid">37223677</pub-id>
</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Guan</surname><given-names>F</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas</article-title>. <source>Eur Radiol</source>. (<year>2023</year>) <volume>33</volume>:<page-range>3455&#x2013;66</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/s00330-023-09459-6</pub-id>
</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Niu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Quantitative and qualitative parameters of DCE-MRI predict CDKN2A/B homozygous deletion in gliomas</article-title>. <source>Acad Radiol</source>. (<year>2024</year>) <volume>31</volume>:<page-range>3355&#x2013;65</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.acra.2024.02.017</pub-id>
</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Radiomics for predicting grades, isocitrate dehydrogenase mutation, and oxygen 6-methylguanine-DNA methyltransferase promoter methylation of adult diffuse gliomas: combination of structural MRI, apparent diffusion coefficient, and susceptibility-weighted imaging</article-title>. <source>Quant Imaging Med Surg</source>. (<year>2024</year>) <volume>14</volume>:<page-range>9276&#x2013;89</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.21037/qims-24-1110</pub-id>
</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hangel</surname><given-names>G</given-names></name><name><surname>Schmitz-Abecassis</surname><given-names>B</given-names></name><name><surname>Sollmann</surname><given-names>N</given-names></name><name><surname>Pinto</surname><given-names>J</given-names></name><name><surname>Arzanforoosh</surname><given-names>F</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Advanced MR techniques for preoperative glioma characterization: part 2</article-title>. <source>J magnetic resonance imaging: JMRI</source>. (<year>2023</year>) <volume>57</volume>:<page-range>1676&#x2013;95</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1002/jmri.28663</pub-id>
</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nalepa</surname><given-names>J</given-names></name><name><surname>Ribalta Lorenzo</surname><given-names>P</given-names></name><name><surname>Marcinkiewicz</surname><given-names>M</given-names></name><name><surname>Bobek-Billewicz</surname><given-names>B</given-names></name><name><surname>Wawrzyniak</surname><given-names>P</given-names></name><name><surname>Walczak</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Fully-automated deep learning-powered system for DCE-MRI analysis of brain tumors</article-title>. <source>Artif Intell Med</source>. (<year>2020</year>) <volume>102</volume>:<elocation-id>101769</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.artmed.2019.101769</pub-id>
<pub-id pub-id-type="pmid">31980106</pub-id>
</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Diagnostic values of DCE-MRI and DSC-MRI for differentiation between high-grade and low-grade gliomas: A comprehensive meta-analysis</article-title>. <source>Acad Radiol</source>. (<year>2018</year>) <volume>25</volume>:<page-range>338&#x2013;48</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.acra.2017.10.001</pub-id>
</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parvaze</surname><given-names>S</given-names></name><name><surname>Bhattacharjee</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Ahlawat</surname><given-names>S</given-names></name><name><surname>Patir</surname><given-names>R</given-names></name><name><surname>Vaishya</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Radiomics-based evaluation and possible characterization of dynamic contrast enhanced (DCE) perfusion derived different sub-regions of Glioblastoma</article-title>. <source>Eur J Radiol</source>. (<year>2023</year>) <volume>159</volume>:<elocation-id>110655</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.ejrad.2022.110655</pub-id>
<pub-id pub-id-type="pmid">36577183</pub-id>
</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Breast tumor segmentation in DCE-MRI with tumor sensitive synthesis</article-title>. <source>IEEE Trans Neural Networks Learn Syst</source>. (<year>2023</year>) <volume>34</volume>:<fpage>4990</fpage>&#x2013;<lpage>5001</lpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1109/TNNLS.2021.3129781</pub-id>
</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>BreastDM: A DCE-MRI dataset for breast tumor image segmentation and classification</article-title>. <source>Comput Biol Med</source>. (<year>2023</year>) <volume>164</volume>:<elocation-id>107255</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107255</pub-id>
<pub-id pub-id-type="pmid">37499296</pub-id>
</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tavakoli</surname><given-names>AA</given-names></name><name><surname>Hielscher</surname><given-names>T</given-names></name><name><surname>Badura</surname><given-names>P</given-names></name><name><surname>G&#xF6;rtz</surname><given-names>M</given-names></name><name><surname>Kuder</surname><given-names>TA</given-names></name><name><surname>Gnirs</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Contribution of dynamic contrast-enhanced and diffusion MRI to PI-RADS for detecting clinically significant prostate cancer</article-title>. <source>Radiology</source>. (<year>2023</year>) <volume>306</volume>:<page-range>186&#x2013;99</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1148/radiol.212692</pub-id>
</mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breit</surname><given-names>HC</given-names></name><name><surname>Block</surname><given-names>TK</given-names></name><name><surname>Winkel</surname><given-names>DJ</given-names></name><name><surname>Gehweiler</surname><given-names>JE</given-names></name><name><surname>Glessgen</surname><given-names>CG</given-names></name><name><surname>Seifert</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Revisiting DCE-MRI: classification of prostate tissue using descriptive signal enhancement features derived from DCE-MRI acquisition with high spatiotemporal resolution</article-title>. <source>Invest Radiol</source>. (<year>2021</year>) <volume>56</volume>:<page-range>553&#x2013;62</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1097/RLI.0000000000000772</pub-id>
</mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonada</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>LF</given-names></name><name><surname>Carone</surname><given-names>G</given-names></name><name><surname>Panico</surname><given-names>F</given-names></name><name><surname>Cofano</surname><given-names>F</given-names></name><name><surname>Fiaschi</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Deep learning for MRI segmentation and molecular subtyping in glioblastoma: critical aspects from an emerging field</article-title>. <source>Biomedicines</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>1878</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/biomedicines12081878</pub-id>
<pub-id pub-id-type="pmid">39200342</pub-id>
</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bianconi</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>LF</given-names></name><name><surname>Bonada</surname><given-names>M</given-names></name><name><surname>Zeppa</surname><given-names>P</given-names></name><name><surname>Nico</surname><given-names>E</given-names></name><name><surname>De Marco</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Deep learning-based algorithm for postoperative glioblastoma MRI segmentation: a promising new tool for tumor burden assessment</article-title>. <source>Brain Inform</source>. (<year>2023</year>) <volume>10</volume>:<fpage>26</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/s40708-023-00207-6</pub-id>
<pub-id pub-id-type="pmid">37801128</pub-id>
</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Voort</surname><given-names>SR</given-names></name><name><surname>Incekara</surname><given-names>F</given-names></name><name><surname>Wijnenga</surname><given-names>MMJ</given-names></name><name><surname>Kapsas</surname><given-names>G</given-names></name><name><surname>Gahrmann</surname><given-names>R</given-names></name><name><surname>Schouten</surname><given-names>JW</given-names></name><etal/></person-group>. <article-title>Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning</article-title>. <source>Neuro-oncol</source>. (<year>2023</year>) <volume>25</volume>:<page-range>279&#x2013;89</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/noac166</pub-id>
</mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Mo</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>D</given-names></name></person-group>. <article-title>Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma</article-title>. <source>Semin Cancer Biol</source>. (<year>2023</year>) <volume>91</volume>:<page-range>110&#x2013;23</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2023.03.006</pub-id>
</mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Deep learning empowered volume delineation of whole-body organs-at-risk for accelerated radiotherapy</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>6566</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41467-022-34257-x</pub-id>
<pub-id pub-id-type="pmid">36323677</pub-id>
</mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Milletari</surname><given-names>F</given-names></name><name><surname>Navab</surname><given-names>N</given-names></name><name><surname>Ahmadi</surname><given-names>S-A</given-names></name></person-group>. (<year>2016</year>). <article-title>V-net: fully convolutional neural networks for volumetric medical image segmentation</article-title>, in: <conf-name>2016 Fourth International Conference on 3D Vision (3DV), California, 2016</conf-name>. <publisher-loc>the USA</publisher-loc>: <publisher-name>IEEE</publisher-name>. pp. <page-range>565&#x2013;71</page-range>.</mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma</article-title>. <source>Precis Clin Med</source>. (<year>2023</year>) <volume>6</volume>:<elocation-id>pbad019</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/pcmedi/pbad019</pub-id>
<pub-id pub-id-type="pmid">38025974</pub-id>
</mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Automatic segmentation of white matter hyperintensities in routine clinical brain MRI by 2D VB-Net: A large-scale study</article-title>. <source>Front Aging Neurosci</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>915009</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fnagi.2022.915009</pub-id>
<pub-id pub-id-type="pmid">35966772</pub-id>
</mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>MRI-based automatic identification and segmentation of extrahepatic cholangiocarcinoma using deep learning network</article-title>. <source>BMC Cancer</source>. (<year>2023</year>) <volume>23</volume>:<fpage>1089</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/s12885-023-11575-x</pub-id>
<pub-id pub-id-type="pmid">37950207</pub-id>
</mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C-H</given-names></name><name><surname>Jaspers</surname><given-names>J</given-names></name><name><surname>Romero</surname><given-names>AM</given-names></name><name><surname>Wielopolski</surname><given-names>P</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name><name><surname>van Osch</surname><given-names>MJP</given-names></name><etal/></person-group>. <article-title>Improved reliability of perfusion estimation in dynamic susceptibility contrast MRI by using the arterial input function from dynamic contrast enhanced MRI</article-title>. <source>Nmr BioMed</source>. (<year>2024</year>) <volume>37</volume>:<elocation-id>e5038</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1002/nbm.5038</pub-id>
<pub-id pub-id-type="pmid">37712359</pub-id>
</mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Innanje</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>uRP: An integrated research platform for one-stop analysis of medical images</article-title>. <source>Front Radiol</source>. (<year>2023</year>) <volume>3</volume>:<elocation-id>1153784</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fradi.2023.1153784</pub-id>
<pub-id pub-id-type="pmid">37492386</pub-id>
</mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>&#x15A;ledzi&#x144;ska</surname><given-names>P</given-names></name><name><surname>Bebyn</surname><given-names>MG</given-names></name><name><surname>Furtak</surname><given-names>J</given-names></name><name><surname>Kowalewski</surname><given-names>J</given-names></name><name><surname>Lewandowska</surname><given-names>MA</given-names></name></person-group>. <article-title>Prognostic and predictive biomarkers in gliomas</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>10373</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3390/ijms221910373</pub-id>
<pub-id pub-id-type="pmid">34638714</pub-id>
</mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>SJ</given-names></name><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Larion</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>IDH mutation in glioma: molecular mechanisms and potential therapeutic targets</article-title>. <source>Br J Cancer</source>. (<year>2020</year>) <volume>122</volume>:<page-range>1580&#x2013;9</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1038/s41416-020-0814-x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Shih</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title>. <source>Cancer Cell</source>. (<year>2010</year>) <volume>18</volume>:<page-range>553&#x2013;67</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.015</pub-id>
</mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Santwijk</surname><given-names>L</given-names></name><name><surname>Kouwenberg</surname><given-names>V</given-names></name><name><surname>Meijer</surname><given-names>F</given-names></name><name><surname>Smits</surname><given-names>M</given-names></name><name><surname>Henssen</surname><given-names>D</given-names></name></person-group>. <article-title>A systematic review and meta-analysis on the differentiation of glioma grade and mutational status by use of perfusion-based magnetic resonance imaging</article-title>. <source>Insights into Imaging</source>. (<year>2022</year>) <volume>13</volume>:<fpage>102</fpage>. doi:&#xA0;<pub-id pub-id-type="doi">10.1186/s13244-022-01230-7</pub-id>
<pub-id pub-id-type="pmid">35670981</pub-id>
</mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>JJ</given-names></name><name><surname>Shen</surname><given-names>DD</given-names></name><name><surname>Jia</surname><given-names>ZZ</given-names></name></person-group>. <article-title>Non-invasive estimation of glioma IDH1 mutation and VEGF expression by histogram analysis of dynamic contrast-enhanced MRI</article-title>. <source>Front Oncol</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>593102</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.3389/fonc.2020.593102</pub-id>
<pub-id pub-id-type="pmid">33425744</pub-id>
</mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>B</given-names></name></person-group>. <article-title>Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network</article-title>. <source>Neuro Oncol</source>. (<year>2019</year>) <volume>21</volume>:<page-range>1197&#x2013;209</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1093/neuonc/noz095</pub-id>
</mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Jo</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Nam</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma</article-title>. <source>Eur Radiol</source>. (<year>2020</year>) <volume>30</volume>:<page-range>2142&#x2013;51</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1007/s00330-019-06548-3</pub-id>
</mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H-W</given-names></name><name><surname>Lyu</surname><given-names>G-W</given-names></name><name><surname>He</surname><given-names>W-J</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>M-Z</given-names></name><etal/></person-group>. <article-title>DSC and DCE histogram analyses of glioma biomarkers, including IDH, MGMT, and TERT, on differentiation and survival</article-title>. <source>Acad Radiol</source>. (<year>2020</year>) <volume>27</volume>:<page-range>e263&#x2013;71</page-range>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.acra.2019.12.010</pub-id>
</mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas</article-title>. <source>Eur J Radiol</source>. (<year>2022</year>) <volume>147</volume>:<elocation-id>110141</elocation-id>. doi:&#xA0;<pub-id pub-id-type="doi">10.1016/j.ejrad.2021.110141</pub-id>
<pub-id pub-id-type="pmid">34995947</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<Reply Id="2" error="The following PMCID is not available: 2"/><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Invest Ophthalmol Vis Sci</journal-id><journal-id journal-id-type="iso-abbrev">Invest Ophthalmol Vis Sci</journal-id><journal-id journal-id-type="publisher-id">IOVS</journal-id><journal-title-group><journal-title>Investigative Ophthalmology &amp; Visual Science</journal-title></journal-title-group><issn pub-type="ppub">0146-0404</issn><issn pub-type="epub">1552-5783</issn><publisher><publisher-name>The Association for Research in Vision and Ophthalmology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40100204</article-id><article-id pub-id-type="pmc">11932423</article-id>
<article-id pub-id-type="doi">10.1167/iovs.66.3.34</article-id><article-id pub-id-type="publisher-id">IOVS-24-41454</article-id><article-categories><subj-group subj-group-type="heading"><subject>Multidisciplinary Ophthalmic Imaging</subject></subj-group><subj-group subj-group-type="category"><subject>Multidisciplinary Ophthalmic Imaging</subject></subj-group></article-categories><title-group><article-title>Three-Dimensional &#x3B2;-Amyloid Burden Correlation Between the Eye and Brain in Alzheimer's Disease Mice Using Light-Sheet Fluorescence Microscopy</article-title><alt-title alt-title-type="runhead">3D Amyloid Correlation in Eye and Brain Using LSFM</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Son</surname><given-names>Hye Joo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seonok</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name specific-use="Kim SY"><surname>Kim</surname><given-names>Seog-Young</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Jin Hwa</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Suk Hyun</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Soo-Jong</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chanwoo</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hahn</surname><given-names>Alice</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><aff id="aff1"><label>1</label>Department of Nuclear Medicine, Dankook University Medical Center, Dankook University College of Medicine, Cheonan, Chungnam, Republic of Korea</aff><aff id="aff2"><label>2</label>Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea</aff><aff id="aff3"><label>3</label>Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea</aff><aff id="aff4"><label>4</label>Convergence Medicine Research Center, Asan Medical Center, Seoul, Republic of Korea</aff><aff id="aff5"><label>5</label>Department of Radiology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea</aff><aff id="aff6"><label>6</label>Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States</aff><aff id="aff7"><label>7</label>Department of Nuclear Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Republic of Korea</aff><aff id="aff8"><label>8</label>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States</aff></contrib-group><author-notes><corresp id="cor1">
<label>*</label>Correspondence: Hye Joo Son, Department of Nuclear Medicine, Dankook University Medical Center, Dankook University College of Medicine, Cheonan 31116, Republic of Korea; <email>neuroscience@dankook.ac.kr</email>.</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>66</volume><issue>3</issue><elocation-id>34</elocation-id><history><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date><date date-type="received"><day>21</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>Copyright 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="iovs-66-3-34.pdf"/><abstract><sec><title>Purpose</title><p>Recent studies have highlighted the significance of peripheral &#x3B2;-amyloid (A&#x3B2;) deposition, identifying the eye as a potential early detection site for Alzheimer's disease (AD). However, previous two-dimensional AD ocular studies have been unable to establish a clear correlation between the three-dimensional A&#x3B2; accumulation in the entire eyeball and brain while preserving structural integrity. This study employed a combined brain amyloid positron emission tomography/magnetic resonance (PET/MR) and light-sheet fluorescence microscopy (LSFM) platform to assess whether the three-dimensionally measured A&#x3B2; burden in the eyeball correlates with that in the brain.</p></sec><sec><title>Methods</title><p>Thirteen eyeballs (6 AD, 7 control) and 17 brains (10 AD, 7 control) were collected from ten 44-week-old 5xFAD and seven control mice. The samples underwent tissue clearing and staining with thioflavin S (A&#x3B2;), anti-CD11b (microglia), and anti&#x2013;ACSA-2 (astrocytes) for LSFM imaging and quantified via 3D surface volume. Standardized uptake value ratios from [<sup>18</sup>F]Flutemetamol PET/MR were also calculated.</p></sec><sec><title>Results</title><p>AD eyeballs presented significantly greater plaque-like surface volumes (median, 51,091,002 &#xB5;m&#xB3; [interquartile range, 38,488,272&#x2013;64,869,828]) than controls (229,293 &#xB5;m&#xB3; [115,863&#x2013;311,5320]; <italic toggle="yes">P</italic> = 0.001). AD brains exhibited higher [<sup>18</sup>F]Flutemetamol uptake and greater plaque-like surface volumes (898,634,368 &#xB5;m&#xB3; [556,263,488&#x2013;1,105,326,720]) than controls (33,320,178 &#xB5;m&#xB3; [26,842,538&#x2013;62,716,956]; <italic toggle="yes">P</italic> &lt; 0.001). A strong positive correlation was observed between the plaque-like surface volumes in the brain and that in the eyeball (<italic toggle="yes">r</italic> = 0.810, <italic toggle="yes">P</italic> = 0.001). No significant correlations were found in other morphologic parameters.</p></sec><sec><title>Conclusions</title><p>Our observation of a strong correlation between the three-dimensional A&#x3B2; burden in the whole eyeball and brain advances our understanding of the systemic nature of A&#x3B2; pathology and suggests ocular A&#x3B2; as a potential independent predictor of brain A&#x3B2; burden.</p></sec></abstract><kwd-group><kwd>alzheimer's disease</kwd><kwd>amyloid</kwd><kwd>eye</kwd><kwd>light-sheet microscope</kwd><kwd>tissue clearing</kwd></kwd-group><counts><page-count count="11"/></counts></article-meta></front>
  <body>
    <p>With the accelerated development of Alzheimer's disease (AD) therapies, exemplified by the phase III trial of lecanemab,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> a growing focus on establishing disease-specific screening biomarkers for early diagnosis in the preclinical stage (pathology positive, clinical negative) has been noted, aiming for secondary prevention by reducing early-stage AD pathology accumulation and delaying symptom onset. Recently, the focus of AD research has undergone a paradigmatic shift, extending beyond the traditional confines of central nervous system (CNS) pathology. The eye, an extension of the CNS with a shared embryologic origin and structural, functional, and immunologic systems, presents an opportunity for the noninvasive assessment of neural integrity.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> retinal ganglion cell axons forming the optic nerve extend to the lateral geniculate nucleus and the superior colliculus, facilitating the transport of amyloid precursor protein (APP) produced by retinal ganglion cells.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p>
    <p>In several neurodegenerative disorders, ocular manifestations precede conventional CNS-based diagnoses.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Patients with AD exhibit visual manifestations, including decreased visual acuity, contrast sensitivity, and poor color discrimination.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Current advances in noninvasive, high-resolution ophthalmologic technologies such as optical coherence tomography (OCT) and blue-light autofluorescence have significantly enhanced the early detection of subtle neuropathologic changes in the eyes of patients with preclinical AD.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Ocular AD biomarkers are recognized as cost-effective and widely acceptable screening tools for early dementia diagnosis, owing to their direct accessibility.</p>
    <p>Although ocular amyloid-beta (A&#x3B2;) deposition has been reported in several human and animal studies,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>&#x2013;</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> no previous studies have established a correlation between the quantitative parameters for three-dimensional (3D) A&#x3B2; accumulation in the whole intact eyeball and the whole-brain A&#x3B2; load. In a previous study analyzing human A&#x3B2; (hA&#x3B2;) expression in homogenate fractions of lenses and brain from Tg2576 mice by anti-hA&#x3B2; immunoblot and enzyme-linked immunosorbent assay (ELISA), the average total hA&#x3B2; concentration increased with age in both tissues.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> In another study of APPswe/PS1dE9 transgenic mice, ELISA measurements revealed a significant correlation between A&#x3B2; levels in the retina and cerebrum (<italic toggle="yes">r</italic> = 0.7291, <italic toggle="yes">P</italic> = 0.0014), although curcumin's inhibitory effect on A&#x3B2; attenuated this association.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> However, these earlier studies focused predominantly on the retina and posterior regions of the eye, hindering a comprehensive assessment of the entire eyeball, and relied on traditional experimental techniques<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>&#x2013;</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> that involved homogenized samples or thin, two-dimensional (2D) sections of localized subregions. Such approaches disrupt the intrinsic spherical structure of the whole eyeball and limit the ability to comprehensively assess the 3D spatial distribution of A&#x3B2; particles within intact ocular structures. Given the diverse 3D morphologic profiles of A&#x3B2;&#x2014;each playing distinct roles in neurotoxicity and disease progression&#x2014;quantification based on 2D sections fails to accurately reflect these 3D A&#x3B2; features. Light-sheet fluorescence microscope (LSFM), combined with tissue-clearing technologies, enables in-depth 3D visualization of neuropathologic networks within the fully transparent, whole eyeball&#x2014;a level of detail previously unattainable with conventional techniques.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref></p>
    <p>In this study, we aimed to investigate the correlation between A&#x3B2; burden in the whole eyeball and the brain using an innovative platform that integrates amyloid brain positron emission tomography (PET)/magnetic resonance (MR) and LSFM. Specifically, we focused on the 3D spatial distribution of AD-related pathology in the chemically cleared eyeballs and brains of 5xFAD transgenic AD mice to support our hypothesis that A&#x3B2; burden measured in the whole eyeball significantly correlates with that in the brain.</p>
    <sec sec-type="methods" id="sec2">
      <title>Methods</title>
      <sec id="sec2-1">
        <title>Animal</title>
        <p>We assembled a cohort of ten 44-week-old female 5xFAD mice (Jackson Laboratory, Bar Harbor, ME, USA) and seven 31-week-old female C57BL/6J mice as controls. The choice of 31-week-old control mice was determined by practical considerations, including animal availability and the scheduling requirements for MR and PET imaging. The 5xFAD model overexpresses five familial AD mutations in human APP (the Swedish [K670N, M671L], Florida [I716V], and London [V7171]) and PSEN1 (M146L and L286V), driven by the neural-specific Thy1 promoter.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> We selected the 44-week (approximately 11-month) time point for our cohort of female 5xFAD mice because the purpose of our study was to evaluate the correlation between A&#x3B2; burden in the whole eyeball and that in the brain, and sufficient accumulation of A&#x3B2; plaques in both tissues at this stage was essential to allow for a meaningful assessment of this correlation. By 2&#xA0;months of age, the 5xFAD model exhibits extracellular A&#x3B2; formation in the subiculum and cortical layer V, which is accompanied by astrogliosis and microgliosis.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Widespread A&#x3B2; plaques and significant neuronal loss occur by 6 and 9&#xA0;months, respectively.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> In a previous study investigating the relationship between brain and retinal A&#x3B2; plaque deposition in 5xFAD mice at 6, 12, and &#x2265;14&#xA0;months of age, A&#x3B2; plaque loads increased significantly and sharply between 6 and 12&#xA0;months of age in the retina, hippocampus, and cortex.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Another study examining age-related patterns of soluble and insoluble A&#x3B2; deposition and their impact on retinal structure and function in the 5xFAD mouse model reported that at 6&#xA0;months of age, A&#x3B2; labeling was confined to the inner retinal layers, with no detectable immunoreactivity in the outer retina.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> However, by 12 and 17&#xA0;months, positive A&#x3B2; staining was observed in the ganglion cell layer, inner plexiform layer, outer plexiform layer, inner nuclear layer, and outer nuclear layer of the retina.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> By 9 to 10&#xA0;months, 5xFAD mice show well-established A&#x3B2; plaques and associated neuropathology in both the brain and retina. All mice were housed in temperature-controlled conditions (22 &#xB1; 2&#xB0;C, 55% &#xB1; 10% humidity) with a 12-hour light/dark cycle. This study adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All animal experiments were approved by the Dankook Institutional Animal Care and Use Committee (DKU-22-080).</p>
      </sec>
      <sec id="sec2-2">
        <title>Brain Amyloid PET/MRI Acquisition and Analysis</title>
        <p>Brain [<sup>18</sup>F]Flutemetamol PET/MR imaging (MRI) was performed using a nanoScan PET/MRI (1T; Mediso, Budapest, Hungary). The mice were anesthetized (1.5% isoflurane in 100% O<sub>2</sub> gas) and intravenously injected with [<sup>18</sup>F]Flutemetamol (0.3&#x2013;0.4 mCi) through the tail vein. PET static images were acquired for 20&#xA0;minutes (20&#x2013;40&#xA0;minutes postinjection) and reconstructed in Tera-Tomo 3D using full detector mode. T1-weighted gradient-echo 3D sequences and T2-weighted fast spin-echo MR images were acquired for anatomic reference and attenuation correction. The 7T T2-weighted brain MR images were used for template generation of PET/MR images. For quantification, we used an in-house amyloid-specific mouse brain PET template for spatial normalization. We manually performed skull-stripping on the control mice using ITK-SNAP to create brain masks on individual T2 MR images.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> These masks were then applied to the MRIs and spatially normalized to the mouse brain T2 template. The coregistered PET images were normalized to the template space using MRI normalization parameters, and a final template was generated by averaging and smoothing these normalized images. For both groups, spatial normalization was performed by cropping the whole-body PET scans to preserve only the head region and to align the scans with the mouse brain PET template. These head-region images were first aligned to the in-house mouse brain PET template using rigid body registration and then spatially normalized to the template space. Finally, the mouse atlas in PMOD Biomedical Image Quantification and Kinetic Modeling Software (Version 4.3; PMOD Technologies LLC, Zurich, Switzerland) was used for region-of-interest (ROI)&#x2013;based quantitative analysis of the spatially normalized PET images. We used standardized uptake value ratios (SUVRs) for the relative quantification of [<sup>18</sup>F]Flutemetamol PET scans. The whole cerebellum served as the reference region for this quantification (detailed description in <xref rid="iovs-66-3-34_s005" ref-type="supplementary-material">Supplementary Method</xref>).<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p>
      </sec>
      <sec id="sec2-3">
        <title>Hydrophilic Tissue Clearing and LSFM Imaging</title>
        <p>After transcranial perfusion, extracted brains and eyeballs were fixed in 4% paraformaldehyde solution in PBS. The brains were then dissected into 1-mm sagittal sections targeting the CA1 hippocampal region, while the eyeballs remained intact. Tissue clearing was performed using the hydrophilic Binaree Tissue Clearing Kit (HRTI-012; Binaree, Daegu, Korea). After three 20-minute washes with 1&#xD7; PBS at 4&#xB0;C, samples were incubated in 10 mL of starting solution at 37&#xB0;C for 48&#xA0;hours, shaking at 50 rpm. The solution was then replaced with 10 mL of Tissue Clearing Solution A, and the samples were incubated at 42&#xB0;C with shaking at 50 rpm for 2&#xA0;days (48&#xA0;hours) to achieve initial clearing. Following this, the clearing solution was removed, and the samples were transferred to a tube containing 5 mL of triple-distilled water (TDW) to perform a washing step. Since the clearing solution is highly viscous, the samples were carefully retrieved using forceps to avoid damage. The washing was conducted at 10&#xB0;C with shaking at 50 rpm for 1&#xA0;hour, and this process was repeated four times, with fresh TDW added for each wash. Despite careful handling, the repeated solution exchanges and mechanical stress during these steps may have further contributed to tissue damage, particularly in partially cleared eye globes. After completing the washing steps, the TDW was replaced with 3 mL of Tissue Clearing Solution B, and the samples were incubated at 42&#xB0;C with shaking at 50 rpm for 2&#xA0;days (48&#xA0;hours). Finally, a 48-hour permeabilization step was performed at 37&#xB0;C with shaking at 50 rpm using 3 mL of a solution containing 0.2% Triton X-100 and 10% dimethyl sulfoxide in 0.1&#xD7; PBS to facilitate subsequent antibody penetration. Among the 17 eyeballs collected (1 eyeball per mouse: 10 AD and 7 control mice), 4 AD mouse eyeballs were damaged during the clearing process. Consequently, the final steps were conducted on 6 AD eyeballs, 7 control eyeballs, 10 AD brains, and 7 control brains. Subsequently, the samples were treated with thioflavin-S (488&#x202F;nm, A&#x3B2;) at a concentration of 1 &#xD7; 10&#x207B;&#x2075;%, selected as optimal based on both published data<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> and preliminary testing over a range of 1% to 1 &#xD7; 10&#x207B;&#x2078;%. At the higher concentration (1%), plaques were readily visualized, but excessive background fluorescence obscured finer details; at 1 &#xD7; 10&#x207B;&#x2078;%, background fluorescence was negligible, but plaque visibility was diminished. By balancing plaque signal intensity against nonspecific fluorescence, we identified 1 &#xD7; 10&#x207B;&#x2075;% as providing &#x201C;specific&#x201D; staining through an optimal ratio of bright plaque labeling to minimal background fluorescence. The samples were then stained with anti-mouse ACSA-2 antibody (647&#x202F;nm) for astrocytes and anti-mouse CD11b antibody (561&#x202F;nm) for microglia.</p>
        <p>High-resolution LSFM imaging of ex vivo brain and eyeball samples was performed using a Zeiss Lightsheet Z.1 microscope (Carl Zeiss Meditec, Oberkochen, Germany) with a 5&#xD7; illumination lens (0.1 NA) and a 5&#xD7; objective lens (EC Plan-Neofluar, 0.16 NA; Carl Zeiss AG, Oberkochen, Germany) at a 0.71&#xD7; zoom factor. The system was calibrated for three excitation wavelengths: 647&#xA0;nm for astrocytes, 555&#xA0;nm for microglia, and 488&#xA0;nm for A&#x3B2; detection. Single-illumination mode was used to enhance the signal-to-noise ratio and image clarity. The 3D surface models for each wavelength were generated using Imaris software (Version 7.2.3, Bitplane AG, Zurich, Switzerland). To designate a computational surface model of individual amyloid particle of interest, the Surface creation tool was used to generate a ROI. To ensure reproducibility and minimize user bias, we employed the automated thresholding functionalities integrated into the Imaris software, which algorithmically determined thresholds using standardized parameters without manual adjustments. The initial threshold was determined using Gaussian filtering, background subtraction, and auto-local thresholding, which standardized segmentation by enhancing the signal-to-noise ratio, reducing noise, and preserving structural integrity.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>&#x2013;</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Surface smoothing was performed using a 4-&#xB5;m grain size, corresponding to the smallest discernible cellular markers in slice-mode observations, to define amyloid particle borders.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Background subtraction (local contrast) in Imaris isolated foreground particles from the background by calculating a variable baseline intensity for each voxel and subtracting it from the original intensity.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Auto-local thresholding enhanced segmentation accuracy by dynamically adjusting intensity thresholds based on local image characteristics, with the Niblack method effectively handling uneven illumination and noise by calculating thresholds from the local mean and standard deviation.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>&#x2013;</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> While automated thresholding was the primary method, a subsequent manual correction step addressed errors such as misidentifying noncellular particles (e.g., fibrous dust), ensuring a refined semiautomated process that balanced accuracy and consistency. Furthermore, to minimize bias, all data were anonymized, and analysts performed thresholding and manual corrections while blinded to the animals&#x2019; genotypes, PET results, and experimental conditions. Finally, volumetric data extraction of each particle was performed using the &#x201C;Statistics&#x201D; function in the &#x201C;Surpass&#x201D; tab of the Imaris interface, selecting the &#x201C;Volume&#x201D; metric from the available measurement parameters. Additionally, unique identifiers were assigned to individual particles using the &#x201C;Object ID&#x201D; feature, allowing calculation of each amyloid particle's surface area and volume, which were then summed to obtain the total surface area and volume. Statistical validation was performed by applying a 95% confidence interval to the voxel dimensions, accurately determining the volumetric characteristics of the surface models.</p>
      </sec>
      <sec id="sec2-4">
        <title>Statistics</title>
        <p>Data are presented as the medians [interquartile range (IQR)]. The right-skewed variables (total surface volume [&#xB5;m<sup>3</sup>] of ocular amyloid, brain microglia, and astrocytes; total number of plaque-like features, total surface area [&#xB5;m&#xB2;]; and individual surface area [&#xB5;m&#xB2;] of ocular plaque-like features) were analyzed after log transformation. A <italic toggle="yes">t</italic>-test or Wilcoxon rank-sum test was used to assess differences in quantitative parameters between groups. After log transformation, normality was assessed using the Shapiro&#x2013;Wilk test. If normality was satisfied, comparisons were made using the <italic toggle="yes">t</italic>-test; otherwise, the Wilcoxon rank-sum test was applied. Pearson's or Spearman's correlation analyses were conducted to evaluate the correlation between various A&#x3B2; quantitative and morphologic parameters in the brain and the eyeball. A two-sided <italic toggle="yes">P</italic> value &lt;0.05 was considered statistically significant. All the statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 4.2.2 (<ext-link xlink:href="https://cran.r-project.org/" ext-link-type="uri">https://cran.r-project.org/</ext-link>).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3">
      <title>Results</title>
      <sec id="sec3-1">
        <title>Three-Dimensional A&#x3B2; Distribution in Eyes and Brains of 5xFAD Mice Via LSFM Imaging</title>
        <p>Using advanced LSFM with tissue clearing, we investigated the 3D distribution of key neuropathological markers&#x2014;thioflavin-S for A&#x3B2;, CD11b for microglia, and ACSA-2 for astrocytes&#x2014;in the eyeballs and brains of AD and control mice. In the visual comparison, AD mice exhibited significantly greater accumulation of A&#x3B2; plaque-like features in the eyes compared to the controls. Within the eyeball, the accumulation of A&#x3B2; plaque-like features was predominantly distributed in the retina and optic nerve, as well as in the anterior regions, including the iris, limbus, and lens (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>, <xref rid="iovs-66-3-34_s005" ref-type="supplementary-material">Supplementary Fig. S1</xref>, <xref rid="iovs-66-3-34_s001" ref-type="supplementary-material">Supplementary Videos S1</xref> and <xref rid="iovs-66-3-34_s002" ref-type="supplementary-material">S2</xref>). Similarly, the brain tissues of AD mice showed more extensive deposition of A&#x3B2; plaque-like features compared to the controls (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>B, <xref rid="iovs-66-3-34_s003" ref-type="supplementary-material">Supplementary Video S3</xref>).</p>
        <fig position="float" id="fig1">
          <label>Figure 1.</label>
          <caption>
            <p>Light-sheet fluorescence images of &#x3B2;-amyloid in AD and control mouse eyeball. (<bold>A</bold>) Representative images of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume staining using thioflavin-S (488&#xA0;nm, green channel) for &#x3B2;-amyloid in the eyeballs of 44-week-old 5xFAD mice. (<bold>B</bold>) Imaris-based volume rendering surface model for &#x3B2;-amyloid in the eyeballs of AD mice. (<bold>C</bold>) Representative images of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume staining using thioflavin-S (488&#xA0;nm, green channel) for &#x3B2;-amyloid in the eyeballs of control mice.</p>
          </caption>
          <graphic xlink:href="iovs-66-3-34-f001" position="float"/>
        </fig>
        <fig position="float" id="fig2">
          <label>Figure 2.</label>
          <caption>
            <p>Evaluation of brain &#x3B2;-amyloid accumulation using both light-sheet fluorescence microscopy and [<sup>18</sup>F]Flutemetamol PET/MR imaging. (<bold>A</bold>) Representative images of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume immunostaining of the brain of 44-week-old 5xFAD mice (merged image). (<bold>B</bold>) Green channel (488&#xA0;nm) with volume staining for thioflavin-S, a specific marker for amyloid. (<bold>C</bold>) Purple channel (647&#xA0;nm) with volume immunostaining with anti&#x2013;ACSA-2, a specific marker for astrocytes. (<bold>D</bold>) Red channel (561&#xA0;nm) with volume immunostaining with anti-CD11b, a specific marker for microglia. (<bold>E</bold>) Visual comparison [<sup>18</sup>F]Flutemetamol brain PET/MR imaging in representative AD and control mice. Note: The color bar for SUVR ranges from 0 to 2.5. (<bold>F</bold>) Quantitative group comparison of cortical SUVR between the AD and control groups.</p>
          </caption>
          <graphic xlink:href="iovs-66-3-34-f002" position="float"/>
        </fig>
      </sec>
      <sec id="sec3-2">
        <title>Comparison of Quantitative and Morphologic Parameters of Ocular A&#x3B2; Plaque-Like Features Between AD and Control Groups</title>
        <p>With respect to the total ocular amyloid load, the eyeballs of AD mice presented a significantly greater total number (AD: median, 7747 [IQR, 2612&#x2013;9866]; control: 1286 [659&#x2013;1680]; <italic toggle="yes">P</italic> = 0.019), total surface area (AD: 11,189,654&#xA0;&#xB5;m&#xB2; [4,491,474&#x2013;14,954,527]; control: 147,599&#xA0;&#xB5;m&#xB2; [124,661&#x2013;1,261,400]; <italic toggle="yes">P</italic> = 0.003), and total surface volume (AD: 51,091,002 &#xB5;m&#xB3; [38,488,272&#x2013;64,869,828]; control: 229,293 &#xB5;m&#xB3; [115,863&#x2013;3,115,320]; <italic toggle="yes">P</italic> = 0.001) of plaque-like feature accumulation than did those of control mice. Regarding individual particle size, the eyeballs of AD mice also presented significantly greater individual surface areas (AD: 1481&#xA0;&#xB5;m&#xB2; [646&#x2013;1720]; control: 186&#xA0;&#xB5;m&#xB2; [161&#x2013;648]; <italic toggle="yes">P</italic> = 0.003) and individual surface volumes (AD: 5900 &#xB5;m&#xB3; [1663&#x2013;8995]; control: 261 &#xB5;m&#xB3; [190&#x2013;1697]; <italic toggle="yes">P</italic> = 0.001) of plaque-like feature accumulation than the control mice. Assigning unique identifiers to individual plaque-like particles within each mouse's eyeball facilitated the quantification of their volume (&#xB5;m&#xB3;) and allowed 3D visualization of the total number and distribution of plaque-like features. This revealed significant intraindividual variability in the surface volume of individual plaque-like features within the same specimen and notable interindividual variability in both the total number of plaque-like features and the individual volume distribution among different samples within the same AD group (<xref rid="fig4" ref-type="fig">Fig.&#xA0;4</xref>, <xref rid="iovs-66-3-34_s004" ref-type="supplementary-material">Supplementary Video S4</xref>). Furthermore, there were no statistically significant differences in the morphologic shape parameters of individual plaque-like features, such as oblate/prolate ellipticity, prolate ellipticity, and sphericity (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>).</p>
        <table-wrap position="float" content-type="4col" id="tbl1">
          <label>Table 1.</label>
          <caption>
            <p>Comparison of the Quantitative and Morphologic Parameters of Ocular and Brain Amyloid Between AD and Control Groups</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Organ and Quantitative Parameter</th>
                <th rowspan="1" colspan="1">AD, Median [IQR]</th>
                <th rowspan="1" colspan="1">Control, Median [IQR]</th>
                <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Eyeball</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid total plaque number<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">7747 [2612&#x2013;9866]</td>
                <td rowspan="1" colspan="1">1286 [659&#x2013;1680]</td>
                <td rowspan="1" colspan="1">0.019<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid total plaque surface area (&#xB5;m<sup>2</sup>)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">11,189,654 [4,491,474&#x2013;14,954,527]</td>
                <td rowspan="1" colspan="1">147,599 [124,661&#x2013;1,261,400]</td>
                <td rowspan="1" colspan="1">0.003<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid total surface volume (&#xB5;m&#xB3;)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">51,091,002 [38,488,272&#x2013;64,869,828]</td>
                <td rowspan="1" colspan="1">229,293 [115,862&#x2013;3,115,320]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid individual plaque area (&#xB5;m<sup>2</sup>)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">1481 [646&#x2013;1720]</td>
                <td rowspan="1" colspan="1">186 [161&#x2013;648]</td>
                <td rowspan="1" colspan="1">0.002<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid individual plaque volume (&#xB5;m&#xB3;)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">5900 [1663&#x2013;8995]</td>
                <td rowspan="1" colspan="1">261 [190&#x2013;1697]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid ellipticity (oblate)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">0.18 [0.18&#x2013;0.19]</td>
                <td rowspan="1" colspan="1">0.17 [0.16&#x2013;0.19]</td>
                <td rowspan="1" colspan="1">0.708</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid ellipticity (prolate)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">0.75 [0.74&#x2013;0.76]</td>
                <td rowspan="1" colspan="1">0.77 [0.76&#x2013;0.79]</td>
                <td rowspan="1" colspan="1">0.643</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Ocular amyloid sphericity<xref rid="tb1fn3" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.69 [0.67&#x2013;0.69]</td>
                <td rowspan="1" colspan="1">0.69 [0.68&#x2013;0.69]</td>
                <td rowspan="1" colspan="1">0.567</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Brain</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid total plaque number<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref><sup>,</sup><xref rid="tb1fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">58,326 [53,324&#x2013;64,346]</td>
                <td rowspan="1" colspan="1">175,241 [151,035&#x2013;232,121]</td>
                <td rowspan="1" colspan="1">&lt;0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid total plaque surface area (&#xB5;m<sup>2</sup>)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">179,019,864 [117,849,088&#x2013;213,864,800]</td>
                <td rowspan="1" colspan="1">33,627,468 [26,550,408&#x2013;43,610,360]</td>
                <td rowspan="1" colspan="1">&lt;0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid total surface volume (&#xB5;m&#xB3;)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">898,634,368 [556,263,488&#x2013;1,105,326,720]</td>
                <td rowspan="1" colspan="1">33,320,178 [26,842,538&#x2013;62,716,956]</td>
                <td rowspan="1" colspan="1">&lt;0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid individual plaque area (&#xB5;m<sup>2</sup>)<xref rid="tb1fn3" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">3685 [3014&#x2013;3755]</td>
                <td rowspan="1" colspan="1">154 [136&#x2013;237]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid individual plaque volume (&#xB5;m&#xB3;)<xref rid="tb1fn3" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">17,211 [12,682&#x2013;17,828]</td>
                <td rowspan="1" colspan="1">155 [124&#x2013;327]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid ellipticity (oblate)<xref rid="tb1fn3" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.31 [0.30&#x2013;0.32]</td>
                <td rowspan="1" colspan="1">0.14 [0.13&#x2013;0.15]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid ellipticity (prolate)<xref rid="tb1fn3" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.48 [0.47&#x2013;0.50]</td>
                <td rowspan="1" colspan="1">0.82 [0.81&#x2013;0.84]</td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb1fn1" ref-type="table-fn">*</xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid sphericity<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref><sup>,</sup><xref rid="tb1fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.84 [0.83&#x2013;0.85]</td>
                <td rowspan="1" colspan="1">0.68 [0.67&#x2013;0.69]</td>
                <td rowspan="1" colspan="1">&lt;0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain amyloid PET SUVR<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref><sup>,</sup><xref rid="tb1fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">1.12 [1.04&#x2013;1.27]</td>
                <td rowspan="1" colspan="1">1.00 [0.97&#x2013;1.08]</td>
                <td rowspan="1" colspan="1">0.167</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain astrocyte total surface volume (&#xB5;m&#xB3;)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref><sup>,</sup><xref rid="tb1fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">59,064,360 [39,531,352&#x2013;108,245,992]</td>
                <td rowspan="1" colspan="1">20,272,722 [12,365,537&#x2013;26,177,505]</td>
                <td rowspan="1" colspan="1">0.005<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x2003;Brain microglia total surface volume (&#xB5;m&#xB3;)<xref rid="tb1fn2" ref-type="table-fn"><sup>&#x2020;</sup></xref><sup>,</sup><xref rid="tb1fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">51,210,100 [41,950,104&#x2013;56,498,836]</td>
                <td rowspan="1" colspan="1">23,461,594 [17,099,503&#x2013;27,573,731]</td>
                <td rowspan="1" colspan="1">&lt;0.001<xref rid="tb1fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tb1fn1">
              <label>*</label>
              <p><italic toggle="yes">P</italic> &lt; 0.05 was considered statistically significant.</p>
            </fn>
            <fn id="tb1fn2">
              <label>&#x2020;</label>
              <p><italic toggle="yes">t</italic>-test.</p>
            </fn>
            <fn id="tb1fn3">
              <label>&#x2021;</label>
              <p>Wilcoxon rank-sum test.</p>
            </fn>
            <fn id="tb1fn4">
              <label>&#xA7;</label>
              <p>The right-skewed variables were analyzed after log transformation.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="sec3-3">
        <title>Comparison of [<sup>18</sup>F]Flutemetamol PET/MR and LSFM Brain A&#x3B2; Imaging Parameters Between AD and Control</title>
        <p>In the LSFM images, although the AD mice had significantly fewer total plaque-like numbers (AD: 58,326 [53,324&#x2013;64,346]; control: 175,241 [151,035&#x2013;232,121]; <italic toggle="yes">P</italic> &lt; 0.001), their brains exhibited a significantly greater total surface area (AD: 179,019,864 &#xB5;m&#xB2; [117,849,088&#x2013;213,864,800]; control: 33,627,468 &#xB5;m&#xB2; [26,550,408&#x2013;43,610,360]; <italic toggle="yes">P</italic> &lt; 0.001) and a significantly greater total surface volume (AD: 898,634,368 &#xB5;m&#xB3; [556,263,488&#x2013;1,105,326,720]; control: 33,320,178 &#xB5;m&#xB3; [26,842,538&#x2013;62,716,956]; <italic toggle="yes">P</italic> &lt; 0.001) of plaque-like features compared to controls (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref><xref rid="fig4" ref-type="fig"><sup>4</sup></xref>B,&#xA0;<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). Individual plaque-like features in the brains of AD mice also showed significantly larger surface areas (AD: 3685&#xA0;&#xB5;m&#xB2; [3014&#x2013;3755]; control: 154&#xA0;&#xB5;m&#xB2; [136&#x2013;237]; <italic toggle="yes">P</italic> = 0.001) and surface volumes (AD: 17,211&#xA0;&#xB5;m&#xB3; [12,682&#x2013;17,828]; control: 155&#xA0;&#xB5;m&#xB3; [124&#x2013;327]; <italic toggle="yes">P</italic> = 0.001). Additionally, significant differences were found in morphologic shape parameters such as oblate ellipticity (AD: 0.31 [0.30&#x2013;0.32]; control: 0.14 [0.13&#x2013;0.15]; <italic toggle="yes">P</italic> = 0.001), prolate ellipticity (AD: 0.48 [0.47&#x2013;0.50]; control: 0.82 [0.81&#x2013;0.84]; <italic toggle="yes">P</italic> = 0.001), and sphericity (AD: 0.84 [0.83&#x2013;0.85]; control: 0.68 [0.67&#x2013;0.69]; <italic toggle="yes">P</italic> &lt; 0.001) (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). In [<sup>18</sup>F]Flutemetamol brain PET/MR visual analysis, AD mice showed higher &#x3B2;-amyloid uptake than controls (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>E), although the cortical SUVR difference was not statistically significant (AD: 1.12 [1.04&#x2013;1.27]; control: 1.00 [0.97&#x2013;1.08]; <italic toggle="yes">P</italic> = 0.167) (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>F).</p>
        <fig position="float" id="fig3">
          <label>Figure 3.</label>
          <caption>
            <p>Comparison of total amyloid load in the eyeball and brain between AD and control groups. (<bold>A</bold>) Comparison of the log-transformed ocular amyloid total surface volume between the AD (<italic toggle="yes">n</italic> = 6) group and the control group (<italic toggle="yes">n</italic> = 7). (<bold>B</bold>) Comparison of the brain amyloid total surface volume between the AD (<italic toggle="yes">n</italic> = 10) group and the control group (<italic toggle="yes">n</italic> = 7).</p>
          </caption>
          <graphic xlink:href="iovs-66-3-34-f003" position="float"/>
        </fig>
        <fig position="float" id="fig4">
          <label>Figure 4.</label>
          <caption>
            <p>Visualization of intra- and inter-individual variability in amyloid particle count and volume distribution in eyeballs. Visualization of intraindividual variability in the surface volume of each amyloid particle throughout the entire eyeball architecture within the same specimen and interindividual variability concerning both the total plaque number and the individual plaque volume distribution among different specimens within the same disease group (total <italic toggle="yes">n</italic> = 13, AD = 6, control = 7). The x-axis corresponds to distinct mouse IDs in both the AD and control groups. The y-axis indicates the unique IDs of individual amyloid particles within each mouse's eyeball, whereas the z-axis quantifies the volume of individual amyloid particles (&#xB5;m&#xB3;).</p>
          </caption>
          <graphic xlink:href="iovs-66-3-34-f004" position="float"/>
        </fig>
      </sec>
      <sec id="sec3-4">
        <title>Correlation Between A&#x3B2; Plaque-Like Feature Quantitative and Morphologic Parameters in the Brain and Eyeball</title>
        <p>Regarding total plaque-like feature load, we observed a strong positive correlation between total surface volume in the eyeball and that in the brain (<italic toggle="yes">r</italic> = 0.810, <italic toggle="yes">P</italic> = 0.001) (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>A, <xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>), and total surface area in the brain was also strongly correlated with that in the eyeball (<italic toggle="yes">r</italic> = 0.722, <italic toggle="yes">P</italic> = 0.005) (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>B,&#xA0;<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>). At the level of individual plaque-like features, total surface volume (<italic toggle="yes">r</italic> = 0.824, <italic toggle="yes">P</italic> = 0.001) and surface area (<italic toggle="yes">r</italic> = 0.808, <italic toggle="yes">P</italic> = 0.001) in the brain correlated with those in the eyeball (<xref rid="fig5" ref-type="fig">Figs.&#xA0;5</xref>C,&#xA0;<xref rid="fig5" ref-type="fig">5</xref>D,&#xA0;<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>). However, there were no significant correlations between morphologic shape parameters, such as ellipticity or sphericity, in the brain and eyeball (<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>). Additionally, there was no significant correlation between total surface volume in the eyeball and brain [<sup>18</sup>F]Flutemetamol PET/MR cortex SUVR (<italic toggle="yes">r</italic> = 0.399, <italic toggle="yes">P</italic> = 0.199) (<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>).</p>
        <fig position="float" id="fig5">
          <label>Figure 5.</label>
          <caption>
            <p>Correlation between quantitative and morphologic parameters of amyloid accumulation in the brain and eyeball. (<bold>A</bold>) Correlation between the log-transformed total surface volume (&#xB5;m<sup>3</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>) of ocular &#x3B2;-amyloid and the total surface volume (&#xB5;m<sup>3</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>) of brain &#x3B2;-amyloid (<italic toggle="yes">r</italic> = 0.810, <italic toggle="yes">P</italic> = 0.001) (total <italic toggle="yes">n</italic> = 13, AD = 6, control = 7). (<bold>B</bold>) Correlation between the log-transformed total surface area (&#xB5;m&#xB2;) of ocular &#x3B2;-amyloid and the total surface area (&#xB5;m&#xB2;) of brain &#x3B2;-amyloid (<italic toggle="yes">r</italic> = 0.722, <italic toggle="yes">P</italic> = 0.005). (<bold>C</bold>) Correlation between the log-transformed surface volume (&#xB5;m<sup>3</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>) of individual ocular &#x3B2;-amyloid particle and the surface volume (&#xB5;m<sup>3</sup>) of individual brain &#x3B2;-amyloid particle (<italic toggle="yes">r</italic> = 0.824, <italic toggle="yes">P</italic> = 0.001). (<bold>D</bold>) Correlation between the log-transformed surface area (&#xB5;m&#xB2;) of individual ocular &#x3B2;-amyloid particle and the surface area (&#xB5;m&#xB2;) of individual brain &#x3B2;-amyloid particle (<italic toggle="yes">r</italic> = 0.808, <italic toggle="yes">P</italic> = 0.001).</p>
          </caption>
          <graphic xlink:href="iovs-66-3-34-f005" position="float"/>
        </fig>
        <table-wrap position="float" content-type="5col" id="tbl2">
          <label>Table 2.</label>
          <caption>
            <p>Correlation Between Quantitative and Morphologic Parameters of Amyloid Accumulation in the Brain and Eyeball</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1">Parameter</th>
                <th align="center" rowspan="1" colspan="1">Parameter</th>
                <th rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th>
                <th align="center" rowspan="1" colspan="1">
<italic toggle="yes">r</italic>
</th>
                <th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value<xref rid="tb2fn1" ref-type="table-fn"><sup>*</sup></xref></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Ocular amyloid total surface volume (&#xB5;m&#xB3;)<xref rid="tb2fn4" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">Brain amyloid total surface volume (&#xB5;m&#xB3;)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.810<xref rid="tb2fn2" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb2fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular amyloid total plaque surface area (&#xB5;m&#xB2;)<xref rid="tb2fn4" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">Brain amyloid total plaque surface area (&#xB5;m&#xB2;)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.722<xref rid="tb2fn2" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.005<xref rid="tb2fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular amyloid individual plaque area (&#xB5;m&#xB2;)<xref rid="tb2fn4" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">Brain amyloid individual plaque area (&#xB5;m&#xB2;)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.808<xref rid="tb2fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb2fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular amyloid individual plaque volume (&#xB5;m&#xB3;)<xref rid="tb2fn4" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">Brain amyloid individual plaque volume (&#xB5;m&#xB3;)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.824<xref rid="tb2fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.001<xref rid="tb2fn1" ref-type="table-fn"><sup>*</sup></xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular amyloid total surface volume (&#xB5;m&#xB3;)<xref rid="tb2fn4" ref-type="table-fn"><sup>&#x2020;</sup></xref></td>
                <td rowspan="1" colspan="1">Amyloid PET SUVR</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.399<xref rid="tb2fn2" ref-type="table-fn"><sup>&#x2021;</sup></xref></td>
                <td rowspan="1" colspan="1">0.199</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular ellipticity (oblate)</td>
                <td rowspan="1" colspan="1">Brain ellipticity (oblate)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.420<xref rid="tb2fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.153</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular ellipticity (prolate)</td>
                <td rowspan="1" colspan="1">Brain ellipticity (prolate)</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">0.531<xref rid="tb2fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.062</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ocular sphericity</td>
                <td rowspan="1" colspan="1">Brain sphericity</td>
                <td rowspan="1" colspan="1">13</td>
                <td rowspan="1" colspan="1">&#x2212;0.061<xref rid="tb2fn4" ref-type="table-fn"><sup>&#xA7;</sup></xref></td>
                <td rowspan="1" colspan="1">0.844</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tb2fn1">
              <label>*</label>
              <p>
<italic toggle="yes">P</italic> &lt; 0.05 was considered statistically significant.</p>
            </fn>
            <fn id="tb2fn2">
              <label>&#x2020;</label>
              <p>The right-skewed variables were analyzed after log transformation.</p>
            </fn>
            <fn id="tb2fn3">
              <label>&#x2021;</label>
              <p>Pearson correlation coefficients.</p>
            </fn>
            <fn id="tb2fn4">
              <label>&#xA7;</label>
              <p>Spearman rank correlation coefficients.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="sec3-5">
        <title>Increased Astrocyte and Microglial Expression in AD Mouse Brains but Not in Eyeballs</title>
        <p>In AD brains, neuroinflammation was marked by higher expression of CD11b in microglia (AD: 51,210,100 &#xB5;m&#xB3; vs. control: 23,461,594 &#xB5;m&#xB3;; <italic toggle="yes">P</italic> &lt; 0.001) and ACSA-2 in astrocytes (AD: 59,064,360 &#xB5;m&#xB3; vs. control: 20,272,722 &#xB5;m&#xB3;; <italic toggle="yes">P</italic> = 0.005) compared to controls (<xref rid="fig2" ref-type="fig">Figs.&#xA0;2</xref>C,&#xA0;<xref rid="fig2" ref-type="fig">2</xref>D,&#xA0;<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). However, no astrocyte or microglial expression of these proteins was detected in the AD eyeballs (<xref rid="iovs-66-3-34_s005" ref-type="supplementary-material">Supplementary Fig. S2</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4">
      <title>Discussion</title>
      <p>Using LSFM and brain amyloid PET/MR, we conducted a comprehensive 3D spatial visualization of AD-associated neuropathology in transparent, intact 5xFAD mouse eyeballs and brains. AD mice exhibited greater accumulation of A&#x3B2; plaque-like features in both the brain and eyeball, with notable distribution not only in the retina and optic nerve but also in the more externally accessible anterior regions, including the iris, limbus, and lens, in contrast to previous studies<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>&#x2013;</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> focusing on the retina. Furthermore, we observed a strong positive correlation between the accumulation of A&#x3B2; plaque-like features in the brain and the eyeball.</p>
      <p>Research on AD ocular biomarkers spans three major areas: (1) retinal structural changes (e.g., retinal nerve fiber layer [RNFL] and ganglion cell&#x2013;inner plexiform layer thinning), (2) A&#x3B2;/tau proteinopathies, and (3) vascular alterations.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Among these, early detection of ocular A&#x3B2; and tau is crucial for developing a sensitive, cost-effective biomarker for screening A&#x3B2;/tau-positive, asymptomatic individuals at risk of AD. In the mouse retina, A&#x3B2; is detected in the inner and outer nuclear layer, inner plexiform layer, and ganglion cell layer, whereas APP spans the ganglion cell layer to inner nuclear layers.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> In previous investigations of the physiologic roles of A&#x3B2; and APP in the normal visual functions,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> APP is essential for retinal synaptogenesis, glial differentiation, angiogenesis, and neuronal survival in rodents.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Genetic and AD risk factors, such as apolipoprotein E and iron overload, can disrupt retinal APP processing, leading to A&#x3B2; plaque overproduction.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> A&#x3B2; has been detected in both mouse and human retinas, although inconsistencies across studies may reflect differences in species, age, sex, genetics, disease severity, sample size, or staining methods. Williams et al.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> found no evidence of tau, A&#x3B2;, TDP-43, ubiquitin, or &#x3B1;-synuclein in the eyes of 17 patients with AD, regardless of disease severity. In contrast, a postmortem cohort from the Netherlands Brain Bank identified A&#x3B2;-positive structures in the human retina, including aggregates in vessel walls, globular deposits in the photoreceptor layer, and cytoplasmic granular deposits in ganglion cells.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> While the co-occurrence of pathological proteins observed in the brain is only partially reflected in the retina, these findings nonetheless support the presence of hallmark neurodegenerative disease proteins in retinal tissue.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Histologic studies of postmortem human eyes have identified neuritic plaques in the retinas of patients with AD using Gallyas silver and 6E10 antibody staining.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> Similarly, Moncaster et al.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> demonstrated A&#x3B2; pathology in the lenses of both patients with AD and Tg2576 transgenic mice, highlighting its potential as an accessible biomarker for early detection and monitoring of AD. Supporting this, fluorescent ligand eye scanning successfully distinguished patients with AD from healthy individuals with 85% sensitivity and 95% specificity by detecting exogenous ligands bound to lens A&#x3B2;.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Koronyo-Hamaoui et al.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> identified retinal A&#x3B2; with high diagnostic accuracy in postmortem samples from patients with AD (sensitivity = 1.00, specificity = 1.00, diagnostic odds ratio &#x2265; 187.00). In vivo imaging of transgenic APPSWE/PS1&#x394;E9 mice treated with curcumin and A&#x3B2; antibody clones further suggested that retinal A&#x3B2; plaque formation precedes brain deposition.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Sampani et al.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> reported higher concentrations of AD biomarkers in ocular fluids compared to plasma, with significant correlations between the two compartments.</p>
      <p>Our study is the first to demonstrate that total plaque-like feature load, measured three-dimensionally by total surface volume across the entire eyeball, shows a strong positive correlation (<italic toggle="yes">r</italic> = 0.810, <italic toggle="yes">P</italic> = 0.001) with the whole-brain plaque-like feature load&#x2014;a relationship that previous studies could not adequately assess due to limitations in measurement techniques. We also observed a strong correlation between the individual surface area and volume of plaque-like features in the eyeball and brain. In the meta-analysis, the limited number of eligible studies has hindered a clear elucidation of the interaction between retinal A&#x3B2; and brain A&#x3B2;.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Although Koronyo-Hamaoui et al.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> assessed A&#x3B2; in both the brain and the retina, their evaluation was limited to qualitative visual detection of the concurrent presence of A&#x3B2; in both tissues without providing quantitative correlation data on A&#x3B2; levels. Their 2D cross-sectional analysis of retinal flat mounts measured plaque count and area but excluded certain amyloid particles due to sectioning angles and lacked the ability to differentiate between a few large plaques and numerous smaller ones, limiting the precision of total amyloid burden assessments. Using Imaris-based 3D surface models,<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> we quantified the total surface volume of plaque-like features within the intact spherical ocular structure by summing the 3D-rendered individual volumes, providing a more accurate representation of amyloid load. We selected total surface volume as the representative measure of ocular plaque-like features, as volumetric assessments provide a more comprehensive reflection of the true pathological burden compared to particle counts alone.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref></p>
      <p>Although complex 3D amyloid patterns (TAPs, three-dimensional amyloid patterns) have been identified in human AD brain tissue,<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> no prior studies have investigated the morphologic correlation between plaque-like features in the brain and eye. In our study, we found no significant correlation between these morphologic parameters, indicating that plaque-like features in the eye may differ morphologically from those in the brain. By assigning unique identifiers to each individual plaque-like feature, we not only quantified the total plaque-like feature load in the entire eyeball but also measured 3D morphologic features, such as ellipticity and sphericity. Our analysis demonstrated significant intraindividual variability in the surface volumes of plaque-like features within the same specimen and interindividual differences in the number and volume distribution among different AD mice. For example, mouse 1 exhibited a total surface volume of 44,786,904 &#xB5;m&#xB3;, with fewer but larger plaque-like features (average volume: 4915 &#xB5;m&#xB3;; total particle number: 9113), while mouse 3 had a total surface volume of 38,488,272 &#xB5;m&#xB3; but a greater number of smaller particles (average volume: 1663 &#xB5;m&#xB3;; total particle number: 23,143). Previous investigations into the structure&#x2012;toxicity relationship of A&#x3B2;<sub>1-42</sub> aggregates suggested a correlation between various conformational entities of A&#x3B2; and neurotoxicity in AD.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Although they share an identical amino acid sequence, more regular and longer A&#x3B2; fibrils exhibit intrinsic toxicity.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></p>
      <p>Although our findings do not definitively identify whether the total number, volume, size, or shape of plaque-like features holds the greatest prognostic value, they may provide valuable insights into the relationship between 3D amyloid morphology and the treatment outcome of more effective structure-based AD therapies in future studies.</p>
      <p>Our visual analysis of [<sup>18</sup>F]Flutemetamol brain PET/MRI showed greater amyloid uptake in AD mice compared to controls, although cortical SUVR differences were not statistically significant. Ocular uptake in PET imaging was likely due to nonspecific radiopharmaceutical binding, which interfered with the accuracy of measurements, making quantitative analysis in the eyeball infeasible. This nonspecific uptake can occur when radiopharmaceuticals bind to nontarget tissues or are distributed unexpectedly within the body, complicating data interpretation.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Although amyloid PET imaging is crucial in clinical settings for noninvasive early AD detection, quantifying amyloid PET imaging in preclinical mouse studies presents several challenges. The lower spatial resolution of small-animal PET complicates the precise measurement of plaque location and quantity, limiting accurate tracking in specific brain regions. Additionally, nonspecific binding in PET imaging complicates accurate amyloid burden quantification, causing discrepancies between preclinical mouse data and clinical findings.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> Addressing these limitations is crucial for improving the translational relevance of amyloid PET imaging in preclinical studies and enhancing the evaluation of potential AD treatments. We believe that the 3D analytical method tested in this study can provide meaningful information in preclinical settings, offering great potential as a robust tool for efficacy evaluation in future drug development.</p>
      <p>Although neuroinflammation was not observed in our eyeball samples, previous reports have documented its presence in the eyes of patients with AD. Glial fibrillary acidic protein (GFAP) immunoreactivity is elevated in the retinal ganglion cell layer in patients with AD.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> Given that early-stage neuroinflammation precedes later-stage neurodegeneration,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> the absence of astrocytes and microglia in our AD eyeball samples might reflect early neuroinflammation not detectable in 44-week-old AD mouse eyeballs. Alternatively, it could be due to limitations in antibody efficacy, including poor penetration or nonspecific surface labeling.</p>
      <p>Regarding study limitation, our data provide a cross-sectional snapshot of ocular and brain A&#x3B2; pathology in 44-week-old 5xFAD mice, lacking a longitudinal perspective on disease progression over the life span. An umbrella review of 14 meta-analyses underscored the limitations of cross-sectional designs, showing poor to moderate accuracy in detecting AD through OCT metrics such as RNFL thickness and prosaccade latency in a cross-sectional setting.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> Future well-designed longitudinal studies are necessary to track ocular A&#x3B2; pathology over the life span, from the very early stages to severe AD, and determine if these changes could better predict AD onset. Additionally, future research should comprehensively assess relationships among ocular and brain pathology, evaluate visual and cognitive function, and perform intraregional correlation analyses between brain and eye subregions. Furthermore, discrepancies between LSFM and PET imaging outcomes may partly reflect an overestimation of amyloid pathology by LSFM. Thioflavin-S staining, widely used to detect A&#x3B2; plaque-like features, has limitations due to its nonspecific binding to other &#x3B2;-sheet&#x2013;rich structures, such as p-tau aggregates, necessitating caution when using thioflavin-S as an A&#x3B2;-detecting probe in 5xFAD mice. Despite these challenges, thioflavin-S was chosen over anti-A&#x3B2; antibodies in this study due to the challenges of antibody penetration in thick, whole-organ samples because its small-molecule properties allow for consistent and uniform staining. However, prior studies have reported that thioflavin-S&#x2013;labeled protein aggregates in the cortical and hippocampal regions of 5xFAD mice did not correspond to anti-A&#x3B2; antibody staining.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> High dye concentrations have also been associated with nonspecific staining and red-shifted fluorescence, underscoring the need to optimize thioflavin-S protocols.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> These findings emphasize the importance of using complementary techniques, such as A&#x3B2; antibody colabeling, ELISA, Western blotting, or mass spectrometry, to achieve a more accurate and balanced interpretation of amyloid pathology.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Nonetheless, we optimized the staining protocol to minimize potential overestimation. Although thioflavin-S staining result may still lead to some overestimation of the absolute A&#x3B2; burden, the use of a uniform staining protocol for both brain and ocular tissues ensures that any resulting overestimation remains proportionate, thereby preserving the strength and significance of the observed correlation.</p>
      <p>Our novel observation of a robust positive correlation between 3D-measured A&#x3B2; plaque-like feature burden in the whole eyeball and its concurrent presence in the brain, particularly in accessible regions like the iris and lens, highlights the systemic nature of A&#x3B2; pathology. Our results raise the possibility that ocular A&#x3B2; levels could serve as independent predictors of brain A&#x3B2; burden. Given the routine nature of ophthalmologic exams for adults older than 50&#xA0;years, incorporating ocular A&#x3B2; biomarkers into primary care may offer a practical and accessible alternative to advanced neuroimaging, particularly in resource-limited settings, and could potentially aid in identifying candidates for early preventive AD interventions.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material id="iovs-66-3-34_s001" position="float" content-type="local-data">
        <caption>
          <title>Supplement 1</title>
        </caption>
        <media xlink:href="iovs-66-3-34_s001.mp4" id="d67e1298" position="anchor" mimetype="video" mime-subtype="mp4"/>
      </supplementary-material>
      <supplementary-material id="iovs-66-3-34_s002" position="float" content-type="local-data">
        <caption>
          <title>Supplement 2</title>
        </caption>
        <media xlink:href="iovs-66-3-34_s002.mp4" id="d67e1302" position="anchor" mimetype="video" mime-subtype="mp4"/>
      </supplementary-material>
      <supplementary-material id="iovs-66-3-34_s003" position="float" content-type="local-data">
        <caption>
          <title>Supplement 3</title>
        </caption>
        <media xlink:href="iovs-66-3-34_s003.mp4" id="d67e1306" position="anchor" mimetype="video" mime-subtype="mp4"/>
      </supplementary-material>
      <supplementary-material id="iovs-66-3-34_s004" position="float" content-type="local-data">
        <caption>
          <title>Supplement 4</title>
        </caption>
        <media xlink:href="iovs-66-3-34_s004.mp4" id="d67e1310" position="anchor" mimetype="video" mime-subtype="mp4"/>
      </supplementary-material>
      <supplementary-material id="iovs-66-3-34_s005" position="float" content-type="local-data">
        <caption>
          <title>Supplement 5</title>
        </caption>
        <media xlink:href="iovs-66-3-34_s005.pdf" id="d67e1314" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors thank the PET core of the Convergence Medicine Research Center at the Asan Institute for Life Sciences, Asan Medical Center (Director: Prof. Jae Seung Kim) for their assistance with [<sup>18</sup>F]Flutemetamol brain PET/MR imaging. They also thank the MRI core of the Convergence Medicine Research Center for their support in acquiring 7T brain MRI images for amyloid PET template creation and Seonghyun Kim for his valuable contributions to animal care, tissue clearing, and immunostain.</p>
      <p>Supported by the research fund of Dankook University in 2025.</p>
      <p content-type="COI-statement">Disclosure: <bold>H.J. Son</bold>, None; <bold>S. Kim</bold>, None; <bold>S.-Y. Kim</bold>, None; <bold>J.H. Jung</bold>, None; <bold>S.H. Lee</bold>, None; <bold>S.-J. Kim</bold>, None; <bold>C. Kim</bold>, None; <bold>A. Hahn</bold>, None</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Park</surname>
<given-names>KW.</given-names></string-name>
</person-group>
<article-title>Anti-amyloid antibody therapies for Alzheimer's disease</article-title>. <source><italic toggle="yes">Nucl Med Mol Imaging</italic></source>. <year>2024</year>; <volume>58</volume>: <fpage>227</fpage>&#x2013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">38932758</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Van Dyck</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Swanson</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Aisen</surname>
<given-names>P</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Lecanemab in early Alzheimer's disease</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2023</year>; <volume>388</volume>: <fpage>9</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>London</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Benhar</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Schwartz</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>The retina as a window to the brain-from eye research to CNS disorders</article-title>. <source><italic toggle="yes">Nat Rev Neurol</italic></source>. <year>2013</year>; <volume>9</volume>: <fpage>44</fpage>&#x2013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">23165340</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sadun</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Bassi</surname>
<given-names>CJ.</given-names></string-name></person-group>
<article-title>Optic nerve damage in Alzheimer's disease</article-title>. <source><italic toggle="yes">Ophthalmology</italic></source>. <year>1990</year>; <volume>97</volume>: <fpage>9</fpage>&#x2013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">2314849</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koronyo-Hamaoui</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Koronyo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ljubimov</surname>
<given-names>AV</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model</article-title>. <source><italic toggle="yes">Neuroimage</italic></source>. <year>2011</year>; <volume>54</volume>: <fpage>S204</fpage>&#x2013;<lpage>S217</lpage>.<pub-id pub-id-type="pmid">20550967</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>La Morgia</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Ross-Cisneros</surname>
<given-names>FN</given-names></string-name>, <string-name><surname>Koronyo</surname>
<given-names>Y</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Melanopsin retinal ganglion cell loss in Alzheimer disease</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2016</year>; <volume>79</volume>: <fpage>90</fpage>&#x2013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">26505992</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ning</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>J</given-names></string-name>, <string-name><surname>To</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ashe</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Matsubara</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Amyloid-&#x3B2; deposits lead to retinal degeneration in a mouse model of Alzheimer disease</article-title>. <source><italic toggle="yes">Invest Ophthalmol Vis Sci</italic></source>. <year>2008</year>; <volume>49</volume>: <fpage>5136</fpage>&#x2013;<lpage>5143</lpage>.<pub-id pub-id-type="pmid">18566467</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Moncaster</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Moir</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Burton</surname>
<given-names>MA</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Alzheimer's disease amyloid-&#x3B2; pathology in the lens of the eye</article-title>. <source><italic toggle="yes">Exp Eye Res</italic></source>. <year>2022</year>; <volume>221</volume>: <fpage>108974</fpage>.<pub-id pub-id-type="pmid">35202705</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mei</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>L</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Retinal levels of amyloid beta correlate with cerebral levels of amyloid beta in young APPswe/PS1dE9 transgenic mice before onset of Alzheimer's disease</article-title>. <source><italic toggle="yes">Behav Neurol</italic></source>. <year>2020</year>; <volume>2020</volume>: <fpage>1574816</fpage>.<pub-id pub-id-type="pmid">33029254</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Huisken</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Swoger</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Del Bene</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wittbrodt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stelzer</surname>
<given-names>EH.</given-names></string-name></person-group>
<article-title>Optical sectioning deep inside live embryos by selective plane illumination microscopy</article-title>. <source><italic toggle="yes">Science</italic></source>. <year>2004</year>; <volume>305</volume>: <fpage>1007</fpage>&#x2013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">15310904</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oakley</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Cole</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Logan</surname>
<given-names>S</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Intraneuronal &#x3B2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2006</year>; <volume>26</volume>: <fpage>10129</fpage>&#x2013;<lpage>10140</lpage>.<pub-id pub-id-type="pmid">17021169</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Habiba</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Merlin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>JKH</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Age-specific retinal and cerebral immunodetection of amyloid-&#x3B2; plaques and oligomers in a rodent model of Alzheimer's disease</article-title>. <source><italic toggle="yes">J Alzheimers Dis</italic></source>. <year>2020</year>; <volume>76</volume>: <fpage>1135</fpage>&#x2013;<lpage>1150</lpage>.<pub-id pub-id-type="pmid">32597800</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lim</surname>
<given-names>JKH</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>QX</given-names></string-name>, <string-name><surname>He</surname>
<given-names>Z</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Retinal functional and structural changes in the 5xFAD mouse model of Alzheimer's disease</article-title>. <source><italic toggle="yes">Front Neurosci</italic></source>. <year>2020</year>; <volume>14</volume>: <fpage>862</fpage>.<pub-id pub-id-type="pmid">32903645</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Mirrione</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Schiffer</surname>
<given-names>WK</given-names></string-name>, <string-name><surname>Fowler</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Alexoff</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Dewey</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Tsirka</surname>
<given-names>SE.</given-names></string-name></person-group>
<article-title>A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator</article-title>. <source><italic toggle="yes">Neuroimage</italic></source>. <year>2007</year>; <volume>38</volume>: <fpage>34</fpage>&#x2013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">17707126</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ma</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hof</surname>
<given-names>PR</given-names></string-name>, <string-name><surname>Grant</surname>
<given-names>SC</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy</article-title>. <source><italic toggle="yes">Neuroscience</italic></source>. <year>2005</year>; <volume>135</volume>: <fpage>1203</fpage>&#x2013;<lpage>1215</lpage>.<pub-id pub-id-type="pmid">16165303</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>MacKeigan</surname>
<given-names>TP</given-names></string-name>, <string-name><surname>Morgan</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Stys</surname>
<given-names>PK.</given-names></string-name></person-group>
<article-title>Quantitation of tissue amyloid via fluorescence spectroscopy using controlled concentrations of thioflavin-S</article-title>. <source><italic toggle="yes">Molecules</italic></source>. <year>2023</year>; <volume>28</volume>(<issue>11</issue>): <fpage>4483</fpage>.<pub-id pub-id-type="pmid">37298959</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ridler</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Calvard</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Picture thresholding using an iterative selection method</article-title>. <source><italic toggle="yes">IEEE Trans Syst Man Cybern</italic></source>. <year>1978</year>; <volume>8</volume>: <fpage>630</fpage>&#x2013;<lpage>632</lpage>.</mixed-citation>
      </ref>
      <ref id="bib18">
        <label>18.</label>
        <mixed-citation publication-type="book">
<collab>Bitplane</collab>. <article-title>Imaris Reference Manual</article-title>. <publisher-loc>Concord, MA</publisher-loc>: Bitplane; <year>2017</year>.</mixed-citation>
      </ref>
      <ref id="bib19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Oberholzer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ostreicher</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Christen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Br&#xFC;hlmann</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Methods in quantitative image analysis</article-title>. <source><italic toggle="yes">Histochem Cell Biol</italic></source>. <year>1996</year>; <volume>105</volume>: <fpage>333</fpage>&#x2013;<lpage>355</lpage>.<pub-id pub-id-type="pmid">8781988</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pham</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Prince</surname>
<given-names>JL.</given-names></string-name></person-group>
<article-title>Current methods in medical image segmentation</article-title>. <source><italic toggle="yes">Annu Rev Biomed Eng</italic></source>. <year>2000</year>; <volume>2</volume>: <fpage>315</fpage>&#x2013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">11701515</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Otsu</surname>
<given-names>N.</given-names></string-name>
</person-group>
<article-title>A threshold selection method from gray-level histograms</article-title>. <source><italic toggle="yes">Automatica</italic></source>. <year>1975</year>; <volume>11</volume>: <fpage>23</fpage>&#x2013;<lpage>27</lpage>.</mixed-citation>
      </ref>
      <ref id="bib22">
        <label>22.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Niblack</surname>
<given-names>W.</given-names></string-name>
</person-group>
<source><italic toggle="yes">An Introduction to Digital Image Processing</italic></source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Strandberg Publishing Company</publisher-name>; <year>1985</year>.</mixed-citation>
      </ref>
      <ref id="bib23">
        <label>23.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Stockman</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Shapiro</surname>
<given-names>LG.</given-names></string-name></person-group>
<source><italic toggle="yes">Computer Vision</italic></source>. <publisher-loc>Upper Saddle River, NJ</publisher-loc>: <publisher-name>Prentice Hall PTR</publisher-name>; <year>2001</year>.</mixed-citation>
      </ref>
      <ref id="bib24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chaubey</surname>
<given-names>AK.</given-names></string-name>
</person-group>
<article-title>Comparison of the local and global thresholding methods in image segmentation</article-title>. <source><italic toggle="yes">World J Res Rev</italic></source>. <year>2016</year>; <volume>2</volume>: <fpage>1</fpage>&#x2013;<lpage>4</lpage>.</mixed-citation>
      </ref>
      <ref id="bib25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Alber</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Goldfarb</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>LI</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Developing retinal biomarkers for the earliest stages of Alzheimer's disease: what we know, what we don't, and how to move forward</article-title>. <source><italic toggle="yes">Alzheimers Dement</italic></source>. <year>2020</year>; <volume>16</volume>: <fpage>229</fpage>&#x2013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">31914225</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Javaid</surname>
<given-names>FZ</given-names></string-name>, <string-name><surname>Brenton</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cordeiro</surname>
<given-names>MF.</given-names></string-name></person-group>
<article-title>Visual and ocular manifestations of Alzheimer's disease and their use as biomarkers for diagnosis and progression</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2016</year>; <volume>7</volume>: <fpage>55</fpage>.<pub-id pub-id-type="pmid">27148157</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hern&#xE1;ndez-Zimbr&#xF3;n</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Perez-Hern&#xE1;ndez</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Torres-Romero</surname>
<given-names>A</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Markers of Alzheimer's disease in primary visual cortex in normal aging in mice</article-title>. <source><italic toggle="yes">Biomed Res Int</italic></source>. <year>2017</year>; <volume>2017</volume>: <fpage>3706018</fpage>.<pub-id pub-id-type="pmid">29138750</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib28">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Garey</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Jen</surname>
<given-names>LS.</given-names></string-name></person-group>
<article-title>Expression of &#x3B2;b-amyloid precursor protein immunoreactivity in the retina of the rat during normal development and after neonatal optic tract lesion</article-title>. <source><italic toggle="yes">Neuroreport</italic></source>. <year>1997</year>; <volume>8</volume>: <fpage>713</fpage>&#x2013;<lpage>717</lpage>.<pub-id pub-id-type="pmid">9106753</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib29">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ho</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Vessey</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Cappai</surname>
<given-names>R</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Amyloid precursor protein is required for normal function of the rod and cone pathways in the mouse retina</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2012</year>; <volume>7</volume>: <fpage>e29892</fpage>.<pub-id pub-id-type="pmid">22279552</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib30">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shah</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Gupta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chatterjee</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Martins</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease</article-title>. <source><italic toggle="yes">Mol Psychiatry</italic></source>. <year>2017</year>; <volume>22</volume>: <fpage>353</fpage>&#x2013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">28093567</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib31">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Williams</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>McGuone</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Frosch</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Hyman</surname>
<given-names>BT</given-names></string-name>, <string-name><surname>Laver</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Stemmer-Rachamimov</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease</article-title>. <source><italic toggle="yes">J Neuropathol Exp Neurol</italic></source>. <year>2017</year>; <volume>76</volume>: <fpage>376</fpage>&#x2013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">28379416</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib32">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hart de Ruyter</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Evers</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Morrema</surname>
<given-names>THJ</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases</article-title>. <source><italic toggle="yes">Acta Neuropathol</italic></source>. <year>2024</year>; <volume>148</volume>: <fpage>24</fpage>.<pub-id pub-id-type="pmid">39160362</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib33">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Koronyo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Biggs</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Barron</surname>
<given-names>E</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease</article-title>. <source><italic toggle="yes">JCI Insight</italic></source>. <year>2017</year>; <volume>2</volume>(<issue>16</issue>): <fpage>e93717</fpage>.</mixed-citation>
      </ref>
      <ref id="bib34">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Tsai</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ljubimov</surname>
<given-names>AV</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Ocular changes in TgF344-AD rat model of Alzheimer's disease</article-title>. <source><italic toggle="yes">Invest Ophthalmol Vis Sci</italic></source>. <year>2014</year>; <volume>55</volume>: <fpage>523</fpage>&#x2013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">24398104</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib35">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kerbage</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Sadowsky</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Tariot</surname>
<given-names>PN</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Detection of amyloid &#x3B2; signature in the lens and its correlation in the brain to aid in the diagnosis of Alzheimer's disease</article-title>. <source><italic toggle="yes">Am J Alzheimers Dis Other Demen</italic></source>. <year>2015</year>; <volume>30</volume>: <fpage>738</fpage>&#x2013;<lpage>745</lpage>.<pub-id pub-id-type="pmid">24526759</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib36">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sampani</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ness</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tuz-Zahra</surname>
<given-names>F</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study</article-title>. <source><italic toggle="yes">Alzheimers Res Ther</italic></source>. <year>2024</year>; <volume>16</volume>: <fpage>192</fpage>.<pub-id pub-id-type="pmid">39187891</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib37">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Jiang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Amyloid plaques in retina for diagnosis in Alzheimer's patients: a meta-analysis</article-title>. <source><italic toggle="yes">Front Aging Neurosci</italic></source>. <year>2016</year>; <volume>8</volume>: <fpage>267</fpage>.<pub-id pub-id-type="pmid">27891091</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib38">
        <label>38.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Crassin</surname>
<given-names>C.</given-names></string-name>
</person-group>
<source><italic toggle="yes">GigaVoxels: A Voxel-Based Rendering Pipeline for Efficient Exploration of Large and Detailed Scenes</italic></source>. <publisher-loc>Grenoble, France</publisher-loc>: <publisher-name>Universit&#xE9; de Grenoble</publisher-name>; <year>2011</year>.</mixed-citation>
      </ref>
      <ref id="bib39">
        <label>39.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Demir</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Westermann</surname>
<given-names>R.</given-names></string-name></person-group>
<source><italic toggle="yes">Vector-to-Closest-Point Octree for Surface Ray-Casting</italic></source>. <publisher-loc>Nicosia, Cyprus</publisher-loc>: <publisher-name>The Eurographics Association</publisher-name>; <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="bib40">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Liebmann</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Renier</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bettayeb</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Greengard</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Tessier-Lavigne</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Flajolet</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Three-dimensional study of Alzheimer's disease hallmarks using the iDISCO clearing method</article-title>. <source><italic toggle="yes">Cell Rep</italic></source>. <year>2016</year>; <volume>16</volume>: <fpage>1138</fpage>&#x2013;<lpage>1152</lpage>.<pub-id pub-id-type="pmid">27425620</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib41">
        <label>41.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>L&#xFC;hrs</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ritter</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Adrian</surname>
<given-names>M</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>3D structure of Alzheimer's amyloid-&#x3B2;<sub>1-42</sub> fibrils</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci USA</italic></source>. <year>2005</year>; <volume>102</volume>: <fpage>17342</fpage>&#x2013;<lpage>17347</lpage>.<pub-id pub-id-type="pmid">16293696</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib42">
        <label>42.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kristensen</surname>
<given-names>LK</given-names></string-name>, <string-name><surname>Christensen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jensen</surname>
<given-names>MM</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Site-specifically labeled (89)Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model</article-title>. <source><italic toggle="yes">Theranostics</italic></source>. <year>2019</year>; <volume>9</volume>: <fpage>4409</fpage>&#x2013;<lpage>4420</lpage>.<pub-id pub-id-type="pmid">31285769</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib43">
        <label>43.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Frost</surname>
<given-names>GR</given-names></string-name>, <string-name><surname>Longo</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer's disease mouse model</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2020</year>; <volume>10</volume>: <fpage>10379</fpage>.<pub-id pub-id-type="pmid">32587315</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib44">
        <label>44.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Blanks</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Torigoe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Porrello</surname>
<given-names>KV</given-names></string-name>, <string-name><surname>Hinton</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Blanks</surname>
<given-names>RH.</given-names></string-name></person-group>
<article-title>Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL</article-title>. <source><italic toggle="yes">Neurobiol Aging</italic></source>. <year>1996</year>; <volume>17</volume>: <fpage>385</fpage>&#x2013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">8725900</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib45">
        <label>45.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Ryu</surname>
<given-names>YH.</given-names></string-name></person-group>
<article-title>The development status of PET radiotracers for evaluating neuroinflammation</article-title>. <source><italic toggle="yes">Nucl Med Mol Imaging</italic></source>. <year>2024</year>; <volume>58</volume>: <fpage>160</fpage>&#x2013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">38932754</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib46">
        <label>46.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Nam</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Na</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Justin Lee</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yun</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>A key mediator and imaging target in Alzheimer's disease: unlocking the role of reactive astrogliosis through MAOB</article-title>. <source><italic toggle="yes">Nucl Med Mol Imaging</italic></source>. <year>2024</year>; <volume>58</volume>: <fpage>177</fpage>&#x2013;<lpage>184</lpage>.<pub-id pub-id-type="pmid">38932762</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib47">
        <label>47.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Costanzo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lengyel</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Parravano</surname>
<given-names>M</given-names></string-name>, <etal>et al</etal>.</person-group>
<article-title>Ocular biomarkers for Alzheimer disease dementia: an umbrella review of systematic reviews and meta-analyses</article-title>. <source><italic toggle="yes">JAMA Ophthalmol</italic></source>. <year>2023</year>; <volume>141</volume>: <fpage>84</fpage>&#x2013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">36394831</pub-id>
</mixed-citation>
      </ref>
      <ref id="bib48">
        <label>48.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>Y.</given-names></string-name></person-group>
<article-title>Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2021</year>; <volume>11</volume>: <fpage>1617</fpage>.<pub-id pub-id-type="pmid">33452414</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
    <app-group>
      <app id="app1">
        <title>Supplementary Material</title>
        <p><xref rid="iovs-66-3-34_s001" ref-type="supplementary-material"><sc><bold>Supplementary Video S1.</bold></sc></xref>&#x2003;Representative light-sheet fluorescence microscope image of &#x3B2;-amyloid in the eyeballs of 5xFAD mice. Representative image of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume staining using thioflavin-S (488&#xA0;nm, green channel) for &#x3B2;-amyloid in the eyeballs of 5xFAD mice.</p>
        <p><xref rid="iovs-66-3-34_s002" ref-type="supplementary-material"><sc><bold>Supplementary Video S2.</bold></sc></xref>&#x2003;Representative light-sheet fluorescence microscope image of &#x3B2;-amyloid in the eyeballs of control mice. Representative image of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume staining using thioflavin-S (488&#xA0;nm, green channel) for &#x3B2;-amyloid in the eyeballs of control mice.</p>
        <p><xref rid="iovs-66-3-34_s003" ref-type="supplementary-material"><sc><bold>Supplementary Video S3.</bold></sc></xref>&#x2003;Representative light-sheet fluorescence microscope images of &#x3B2;-amyloid, astrocyte, and microglia in the brains of 5xFAD mice. Representative images of light-sheet fluorescence microscope imaging with hydrophilic tissue clearing and volume immunostaining of the brains of 44-week-old 5xFAD mice. Green channel (488&#xA0;nm) with volume staining with thioflavin-S, a specific marker for amyloid. Purple channel (647&#xA0;nm) with volume immunostaining with anti&#x2013;ACSA-2, a specific marker for astrocytes. Red channel (561&#xA0;nm) with volume immunostaining with anti-CD11b, a specific marker for microglia.</p>
        <p><xref rid="iovs-66-3-34_s004" ref-type="supplementary-material"><sc><bold>Supplementary Video S4.</bold></sc></xref>&#x2003;Interindividual variability concerning the number and surface volume of each individual amyloid particle throughout the entire eyeball architecture among mice (total <italic toggle="yes">n</italic> = 13, AD = 6, control = 7). The x-axis corresponds to distinct mouse IDs in both the AD and control groups. The y-axis indicates the unique IDs of individual amyloid particles within each mouse's eyeball, whereas the z-axis quantifies the volumes of individual amyloid particles (&#xB5;m&#xB3;).</p>
      </app>
    </app-group>
  </back>
</article>
</pmc-articleset>